<SEC-DOCUMENT>0001047469-17-003061.txt : 20170428
<SEC-HEADER>0001047469-17-003061.hdr.sgml : 20170428
<ACCEPTANCE-DATETIME>20170428164852
ACCESSION NUMBER:		0001047469-17-003061
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20170621
FILED AS OF DATE:		20170428
DATE AS OF CHANGE:		20170428
EFFECTIVENESS DATE:		20170428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		17796474

	BUSINESS ADDRESS:	
		STREET 1:		101 PARK DRIVE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		101 PARK DRIVE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2231999zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg78701_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>PROXY STATEMENT PURSUANT TO SECTION 14(A) OF<BR>
THE SECURITIES EXCHANGE ACT OF 1934  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B> ADAPTIMMUNE THERAPEUTICS PLC</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=881017,FOLIO='blank',FILE='DISK122:[17ZBH1.17ZBH78701]BA78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g1039423.jpg" ALT="LOGO" WIDTH="285" HEIGHT="52">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Adaptimmune Therapeutics&nbsp;PLC<BR>  </B></FONT><FONT SIZE=2><B>101 Park Drive, Milton Park<BR>
Abingdon, Oxfordshire OX14&nbsp;4RY, U.K.<BR>
Registered Company No.&nbsp;09338148  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>April 28, 2017 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Dear
Shareholder: </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Annual General Meeting of Adaptimmune Therapeutics&nbsp;plc (the "AGM")  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This letter, the notice of the AGM set out in this document (</FONT><FONT SIZE=2><B>"the Notice"</B></FONT><FONT SIZE=2>) and associated
materials for the AGM are being sent to you because, as of April&nbsp;26, 2017 (being the latest practicable date before the circulation of this document), you are registered as a holder of ordinary
shares in the register of members of the Company. However, this letter, the Notice and associated materials will also be available to holders of American Depositary Shares
(</FONT><FONT SIZE=2><B>"ADS"</B></FONT><FONT SIZE=2>) and contain information relevant to holders of ADSs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
am pleased to confirm that our AGM will take place at </FONT><FONT SIZE=2><B>11&nbsp;a.m. London time (6&nbsp;a.m. Eastern Standard Time) on Wednesday, June&nbsp;21, 2017 at 60
Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14&nbsp;4RX.</B></FONT><FONT SIZE=2> The Notice is set out in this document and it contains the resolutions to be proposed at the AGM (the </FONT> <FONT SIZE=2><B>"Resolutions"</B></FONT><FONT
SIZE=2>). </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Action to be taken by holders of ordinary shares in the Company  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a holder of ordinary shares in the Company and are planning to attend the AGM in person (or by way of corporate representative) it
would be helpful if you could inform Margaret Henry, Company Secretary, on email: margaret.henry@adaptimmune.com, tel: +44 (0)1235 430036 or mobile:&nbsp;+44 (0)7710 304249. If you are a holder of
American Depositary Shares (</FONT><FONT SIZE=2><B>"ADSs"</B></FONT><FONT SIZE=2>), please ignore the rest of this section and refer instead to the section
below&#151;"</FONT><FONT SIZE=2><I>Holders of American Depositary Shares</I></FONT><FONT SIZE=2>". </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are unable to attend the AGM, you can still vote on the Resolutions by appointing a proxy. A form of proxy for use at the AGM is enclosed. You are advised to complete and return
the form of proxy in accordance with the instructions printed on it and so as to arrive at the Company's registrar, Computershare Investor Services&nbsp;PLC, The Pavilions, Bridgwater Road, Bristol,
BS99&nbsp;6ZY, England as soon as possible but in any event by no later than </FONT><FONT SIZE=2><B>11 a.m. London time (6&nbsp;a.m. Eastern Standard Time) on Monday, June&nbsp;19,
2017</B></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may also submit your proxy vote online at www.investorcentre.co.uk/eproxy (see instructions on form of proxy) to arrive by no later than </FONT><FONT SIZE=2><B>11&nbsp;a.m. London
time (6&nbsp;a.m. Eastern Standard Time) on Monday, June&nbsp;19, 2017.</B></FONT><FONT SIZE=2> The return of a form of proxy or the electronic appointment of a proxy does not preclude you from
attending and voting at the AGM if you so wish. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to attend and vote at the AGM as an ordinary shareholder, you must continue to be registered as a holder of ordinary shares in the Company's register of members as of
5&nbsp;p.m. London time (12&nbsp;noon Eastern Standard Time) on Monday, June&nbsp;19, 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Therefore,
if you sell or transfer your ordinary shares in the Company prior to June&nbsp;19, 2017, your form of proxy can no longer be used and if submitted (whether before or after
you sell or transfer your ordinary shares) will be treated as invalid. Please pass this document together with the accompanying form of proxy to the person who arranged the sale or transfer for
delivery to the purchaser or transferee. The purchaser or transferee should contact Margaret Henry, Company Secretary, to request a new form of proxy for its use. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=96190,FOLIO='blank',FILE='DISK122:[17ZBH1.17ZBH78701]BC78701A.;18',USER='PJAMES',CD='26-APR-2017;19:27' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should
you elect to convert your holding of ordinary shares in the capital of the Company into an interest in the capital of the Company represented by ADSs before the AGM, you will
cease to be a holder of ordinary shares in your own name and will not be entitled to attend and vote at the AGM as an ordinary shareholder. You will also not be able to use the enclosed form of proxy.
However, you may be able to exercise your vote as a holder of an interest in the capital of the Company represented by American Depositary Shares&#151;please refer to the next
section&#151;"</FONT><FONT SIZE=2><I>Holders of American Depositary Shares</I></FONT><FONT SIZE=2>". </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Holders of American Depositary Shares  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to exercise your vote as a holder of an interest in the capital of the Company represented by American Depositary Shares ("ADSs"), you
or your bank or broker or nominee must be registered as a holder of ADSs in the ADS register </FONT><FONT SIZE=2><B>by 5&nbsp;p.m. Eastern Standard Time on Thursday, May&nbsp;4, 2017 (the record
date for ADS holders).</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you hold ADSs through a bank, broker or nominee on May&nbsp;4, 2017, the AGM documentation, including the ADS proxy card, will be sent to your broker who should forward the
materials to you. Please reach out to your broker to provide your voting instructions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
note that ADS proxy cards submitted by ADS holders must be received by Citibank </FONT><FONT SIZE=2><B>no later than 10&nbsp;a.m. Eastern Standard Time on Wednesday,
June&nbsp;14, 2017</B></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contacts for ADS holders  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you have queries about how you can deliver voting instructions, please contact Citibank, N.A.&#151;ADR Shareholder Services at tel:
+1-877-248-4237 (toll free within the United States) or&nbsp;+1-781-575-4555 (for international callers) or by email: citibank@shareholders-online.com or at Citibank Shareholder Services,
P.O.&nbsp;Box&nbsp;43077, Providence, RI 02940-3077. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
at any point you require guidance, please contact Margaret Henry, Company Secretary, on email: margaret.henry@adaptimmune.com, tel: +44(0)1235 430036 or cell: +44 (0)7710 304249. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You will find an explanatory note in relation to each of the Resolutions in the attached proxy statement. Your Directors consider that each
Resolution is in the best interests of the Company and its shareholders as a whole and is likely to promote the success of the Company. Accordingly, your Directors unanimously recommend that you vote
in favour of the Resolutions as each of the Directors with personal holdings of shares in the Company intends to do in respect of their own beneficial holdings of shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thank
you for your ongoing support of Adaptimmune. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="4pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>Yours sincerely,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><BR><FONT SIZE=2> /s/&nbsp;DAVID M. MOTT<BR></FONT> <FONT SIZE=2><B>David M. Mott</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2><B><I>Chairman</I></B></FONT><FONT SIZE=2><B>, Adaptimmune Therapeutics&nbsp;plc</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=3,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=418257,FOLIO='blank',FILE='DISK122:[17ZBH1.17ZBH78701]BC78701A.;18',USER='PJAMES',CD='26-APR-2017;19:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g1039423.jpg" ALT="LOGO" WIDTH="285" HEIGHT="52">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Adaptimmune Therapeutics&nbsp;PLC<BR>  </B></FONT><FONT SIZE=2><B>101 Park Drive, Milton Park<BR>
Abingdon, Oxfordshire OX14&nbsp;4RY, U.K.<BR>
Registered Company No.&nbsp;09338148  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTICE OF 2017 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON WEDNESDAY, JUNE&nbsp;21, 2017  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>NOTICE</B></FONT><FONT SIZE=2> is hereby given that the Annual General Meeting of Adaptimmune Therapeutics&nbsp;plc, a public limited
company incorporated under the laws of England and Wales (referred to herein as the "Company," "we," "us" and "our"), will be held on Wednesday, June&nbsp;21, 2017, at 11:00&nbsp;a.m. London
time (6:00&nbsp;a.m. Eastern Standard time), at 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14&nbsp;4RX, for transaction of the following business: </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Ordinary resolutions</U>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
re-elect as a director, Barbara Duncan, who retires in accordance with the Articles of Association. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
re-elect as a director, Giles Kerr, who retires in accordance with the Articles of Association. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
re-elect as a director, Tal Zaks, who retires in accordance with the Articles of Association. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
re-elect as a director, Ali Behbahani, who retires by rotation in accordance with the Articles of Association. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
re-elect as a director, Peter Thompson, who retires by rotation in accordance with the Articles of Association. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
re-appoint KPMG&nbsp;LLP as our U.K. statutory auditors under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of
shareholders at which the U.K. statutory accounts and reports are presented. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
authorize the Audit Committee to determine our U.K. statutory auditors' remuneration for the fiscal year ended December&nbsp;31, 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
receive the U.K. statutory annual accounts and reports for the fiscal year ended December&nbsp;31, 2016 and to note that the Directors do not recommend the payment
of any dividend for the year ended December&nbsp;31, 2016. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
receive and approve our U.K. statutory directors' remuneration report for the year ended December&nbsp;31, 2016, which is set forth as </FONT> <FONT SIZE=2><I>Annex&nbsp;A</I></FONT><FONT SIZE=2> to the attached proxy statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;&nbsp;&nbsp;To
authorize the directors, in accordance with section&nbsp;551 of the U.K. Companies Act 2006, generally and unconditionally, to exercise all powers of the Company to
allot ordinary shares of &pound;0.001 nominal value each in the Company (</FONT><FONT SIZE=2><B>"ordinary shares"</B></FONT><FONT SIZE=2>) or grant rights to subscribe for or to convert any
security into ordinary shares up to a maximum aggregate nominal amount of &pound;140,000.00 provided that this authority shall, (unless renewed, varied or revoked from time to time by the
Company in general meeting) expire on June&nbsp;20, 2022; provided, however, that if the Company makes offers or agreements prior to the expiration of the granted authority that will require
allotment of ordinary shares or grant of rights to subscribe for or to convert any security into ordinary shares after such expiration, the directors may allot ordinary shares or grant rights to
subscribe for or convert any security into ordinary shares pursuant to such offer or agreement notwithstanding the expiration of authority conferred by this resolution. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=802728,FOLIO='blank',FILE='DISK122:[17ZBH1.17ZBH78701]BE78701A.;26',USER='LBURNET',CD='28-APR-2017;10:05' -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
authority is in substitution for all previous authorities conferred on the directors in accordance with section&nbsp;551 of the U.K. Companies Act 2006 but without prejudice to
any allotment of ordinary shares or grant of rights to subscribe for or convert any security into ordinary shares made or offered or agreed to be made pursuant to such authorities prior to the date of
this resolution. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Special resolution</U>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;&nbsp;&nbsp;To
generally empower the directors, subject to the passing of resolution 10 and in accordance with section&nbsp;570 of the U.K. Companies Act 2006, to allot ordinary
shares for cash or to grant rights to subscribe for or to convert any security into ordinary shares pursuant to the authority conferred by resolution 10, as if section&nbsp;561(1) of the U.K.
Companies Act 2006 did not apply to any such allotment. This power shall (i)&nbsp;be limited to the allotment of ordinary shares for cash or grant of rights to subscribe for or convert any security
into ordinary shares up to a maximum aggregate nominal amount of &pound;140,000.00; and (ii)&nbsp;expire on the conclusion of the annual general meeting of shareholders to be held in 2019
(unless renewed, varied or revoked by the Company prior to or on such date); provided, however, that if the Company makes offers or agreements prior to the expiration of the granted authority that
will require allotment of ordinary shares or grant of rights to subscribe for or to convert any security into ordinary shares after such expiration, the directors may allot ordinary shares or grant
rights to subscribe for or convert any security into ordinary shares pursuant to such offer or agreement notwithstanding the expiration of authority conferred by this resolution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
resolution revokes and replaces all unexercised powers previously granted to our Board of Directors to allot ordinary shares or rights to subscribe for or convert any security into
ordinary shares as if section&nbsp;561(1) of the U.K. Companies Act 2006 did not apply but without prejudice to any allotment made or agreed to be made pursuant to such authorities prior to the date
of this resolution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposals
1 through 10 will be proposed as ordinary resolutions and under English law, assuming that a quorum is present, an ordinary resolution is passed on a show of hands if it is
approved by a simple majority (more than 50%) of the votes cast by shareholders present (in person or by proxy) at the meeting and entitled to vote. If a poll is demanded, an ordinary resolution is
passed if it is approved by holders representing a simple majority of the total voting rights of shareholders present (in person or by proxy) who (being entitled to vote) vote on the resolution.
Proposal 11 will be proposed as a special resolution. Special resolutions require the affirmative vote of not less than 75% of the votes cast by shareholders present (in person or by proxy) at the
meeting and entitled to vote. On a poll, a special resolution is passed if it is approved by holders representing not less than 75% of the total voting rights of shareholders present (in person or by
proxy) who (being entitled to vote) vote on the resolution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
result of the shareholder votes on the ordinary resolutions in proposals 8 and 9 regarding receipt of our U.K. statutory annual accounts and reports for the year ended
December&nbsp;31, 2016 and approval of our U.K. statutory directors' annual report on remuneration for the year ended December&nbsp;31, 2016 will not require our Board of Directors or any
committee thereof to take any action. Our Board of Directors values the opinions of our shareholders as expressed through such votes and will carefully consider the outcome of the votes on proposals 8
and 9. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results of any polls taken on the resolutions at the Meeting and any other information required by the U.K. Companies Act 2006 will be made available on our website as soon as
reasonably practicable following the Meeting and for the required period thereafter. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="234pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>BY ORDER OF THE BOARD</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B> Registered Office</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;MARGARET HENRY&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101 Park Drive, Milton Park,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Margaret Henry</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Abingdon,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><I>Company Secretary</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Oxfordshire OX14&nbsp;4RY, United Kingdom</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>April&nbsp;28, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Registered in England and Wales</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>No 09338148</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=243273,FOLIO='blank',FILE='DISK122:[17ZBH1.17ZBH78701]BE78701A.;26',USER='LBURNET',CD='28-APR-2017;10:05' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notes  </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Only
those members registered in the register of members of the Company at 5p.m. London time (12.00 noon Eastern Standard Time) on June&nbsp;19, 2017 will be
entitled to attend and vote at the AGM in respect of the number of ordinary shares registered in their name at the time. Changes to entries on the relevant register after that deadline will be
disregarded in determining the rights of any person to attend and vote at the AGM. Should the AGM be adjourned to a time not more than 48&nbsp;hours after the deadline, the same deadline will also
apply for the purpose of determining the entitlement of members to attend and vote (and for the purpose of determining the number of votes they may cast) at the adjourned AGM. Should the AGM be
adjourned for a longer period, then to be so entitled, members must be entered on the Register at the time which is 48&nbsp;hours before the time fixed for the adjourned AGM or, if the Company gives
notice of the adjourned AGM, at the time specified in the notice.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Any
member may appoint a proxy to attend, speak and vote on his/her behalf. A member may appoint more than one proxy in relation to the AGM provided that each proxy
is appointed to exercise the rights attached to a different share or shares of the member. A proxy need not be a member, but must attend the meeting in person. Proxy forms should be lodged with the
Company's Registrar (Computershare) not later than 11a.m. London time (6a.m. Eastern Standard Time) on June&nbsp;19, 2017. Completion and return of the appropriate proxy form does not prevent a
member from attending and voting in person if he/she is entitled to do so and so wishes. The attached proxy statement explains proxy voting and the matters to be voted on in more detail. Please read
the proxy statement carefully. For specific information regarding the voting of your ordinary shares, please refer to the proxy statement under the section entitled "</FONT><FONT SIZE=2><I>Questions
and Answers About Voting</I></FONT><FONT SIZE=2>."
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Any
corporation which is a member can appoint one or more corporate representatives who may exercise on its behalf all of its powers as a member provided that they
do not do so in relation to the same shares.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(d)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
the case of joint holders, the vote of the senior who tenders the vote whether in person or by proxy will be accepted to the exclusion of the votes of any other
joint holders. For these purposes, seniority shall be determined by the order in which the names stand in the Company's relevant register or members for the certificated or uncertificated shares of
the Company (as the case may be) in respect of the joint holding.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(e)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>CREST
members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for the AGM and any adjournments of it by using
the procedures described in the CREST Manual. CREST personal members or other CREST sponsored members, and those CREST members who have appointed voting service providers, should refer to their
sponsors or voting service providers, who will be able to take the appropriate action on their behalf. </FONT></DD></DL>

<UL>

<P style="font-family:times;"><FONT SIZE=2>For
a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a </FONT><FONT SIZE=2><B>"CREST Proxy Instruction"</B></FONT><FONT SIZE=2>) must be
properly authenticated in accordance with Euroclear's specifications and must contain the information required for those instructions as described in the CREST Manual (available via
www.euroclear.com). The message, regardless of whether it relates to the appointment of a proxy or to an amendment to the instruction given to the previously appointed proxy, must, to be valid, be
transmitted so as to be received by the Company's agent 3RA50 by the latest time for receipt of proxy appointments specified in the Notice. For this purpose, the time of receipt will be taken to be
the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the Company's agent is able to retrieve the message by enquiry to CREST in the manner
prescribed by CREST. After this time, any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means. </FONT></P>

</UL>
</UL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=609852,FOLIO='blank',FILE='DISK122:[17ZBH1.17ZBH78701]BE78701A.;26',USER='LBURNET',CD='28-APR-2017;10:05' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>CREST
members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear UK does not make available special procedures in CREST for any particular messages.
Normal system timings and limitations will, therefore, apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST
member is a CREST personal member or sponsored member or has appointed voting service providers, to procure that its CREST sponsors or voting service providers take) such action as shall be necessary
to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers
are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation&nbsp;35(5)(a) of the Uncertificated Securities Regulations&nbsp;2001.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(f)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>As
of April&nbsp;26, 2017 (being the last practicable date before circulation of this Notice), the Company's issued ordinary share capital consisted of 560,976,430
ordinary shares, carrying one vote each. Therefore, the total voting rights in the Company as of that date are 560,976,430.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(g)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Under
s527 Companies Act 2006, members meeting the threshold requirement set out in that section have the right to require the Company to publish on a website a
statement setting out any matter relating to: (i)&nbsp;the audit of the Company's accounts (including the auditor's report and the conduct of the audit) that are to be laid before the AGM; or
(ii)&nbsp;any circumstance connected with an auditor of the Company ceasing to hold office since the previous meeting at which annual accounts and reports were laid in accordance with s437 Companies
Act 2006. The Company may not require the shareholders requesting any such website publication to pay its expenses in complying with ss527 or 528 Companies Act 2006. Where the Company is required to
place a statement on a website under s527 Companies Act 2006, it must forward the statement to the Company's auditor not later than the time when it makes the statement available on the website. The
business which may be dealt with at the AGM includes any statement that the Company has been required, under s527 Companies Act 2006, to publish on a website.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(h)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Except
as set out in the notes to this Notice, any communication with the Company in relation to the AGM, including in relation to proxies, should be sent to the
Company's Registrar, Computershare Investor Services&nbsp;PLC, The Pavilions, Bridgwater Road, Bristol, BS99&nbsp;6ZY, England. No other means of communication will be accepted. In particular, you
may not use any electronic address provided either in this notice or in any related documents to communicate with the Company for any purpose other than those expressly stated.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Copies
of the service agreement for our executive director and of the letters of appointment for our non-executive directors will be available for inspection at the
registered office of the Company during normal business hours on any week day (public holidays excepted) from the date of this Notice of AGM until the date of the AGM, and at the place of the AGM for
one hour before the meeting and at the meeting itself. </FONT></DD></DL>
</UL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=498024,FOLIO='blank',FILE='DISK122:[17ZBH1.17ZBH78701]BE78701A.;26',USER='LBURNET',CD='28-APR-2017;10:05' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg78701_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG78701A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg78701_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG78701_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da78701_information_concerning_proxy_solicitation_and_voting"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INFORMATION CONCERNING PROXY SOLICITATION AND VOTING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da78701_information_concerning_proxy_solicitation_and_voting"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da78701_questions_and_answers_about_voting"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>QUESTIONS AND ANSWERS ABOUT VOTING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da78701_questions_and_answers_about_voting"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc78701_election_of_directors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ELECTION OF DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc78701_election_of_directors"><FONT SIZE=2>8</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc78701_proposal_1_#151;re-election_of__pro02437"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 1&#151;RE-ELECTION OF BARBARA DUNCAN TO THE BOARD OF
DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc78701_proposal_1_#151;re-election_of__pro02437"><FONT SIZE=2>9</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc78701_proposal_2_#151;re-election_of__pro02318"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 2&#151;RE-ELECTION OF GILES KERR TO THE BOARD OF
DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc78701_proposal_2_#151;re-election_of__pro02318"><FONT SIZE=2>10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc78701_proposal_3_#151;re-election_of__pro02243"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 3&#151;RE-ELECTION OF TAL ZAKS TO THE BOARD OF
DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc78701_proposal_3_#151;re-election_of__pro02243"><FONT SIZE=2>11</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc78701_proposal_4_#151;re-election_of__pro02381"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 4&#151;RE-ELECTION OF ALI BEHBAHANI TO THE BOARD OF
DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc78701_proposal_4_#151;re-election_of__pro02381"><FONT SIZE=2>12</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc78701_proposal_5_#151;re-election_of__pro02525"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 5&#151;RE-ELECTION OF PETER THOMPSON TO THE BOARD OF
DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc78701_proposal_5_#151;re-election_of__pro02525"><FONT SIZE=2>13</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de1"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSALS 6 AND 7&#151;RE-APPOINTMENT OF KPMG AS OUR U.K. STATUTORY AUDITORS AND AUTHORIZATION OF THE AUDIT COMMITTEE TO
DETERMINE OUR U.K. AUDITOR'S REMUNERATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de1"><FONT SIZE=2>14</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de78701_proposal_8_#151;resolution_to___pro03507"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 8&#151;RESOLUTION TO RECEIVE THE COMPANY'S U.K. STATUTORY ANNUAL
ACCOUNTS AND REPORTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de78701_proposal_8_#151;resolution_to___pro03507"><FONT SIZE=2>15</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de78701_proposal_9_#151;approval_of_ou__pro03238"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL 9&#151;APPROVAL OF OUR U.K. STATUTORY DIRECTORS' ANNUAL REPORT ON
REMUNERATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de78701_proposal_9_#151;approval_of_ou__pro03238"><FONT SIZE=2>16</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de2"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSALS 10 AND 11&#151;AUTHORIZATION OF ALLOTMENT OF SHARES AND DISAPPLICATION OF PRE-EMPTION RIGHTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de2"><FONT SIZE=2>18</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg78701_board_of_directors_and_corporate_governance"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg78701_board_of_directors_and_corporate_governance"><FONT SIZE=2>19</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di78701_director_remuneration_and_attendance"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DIRECTOR REMUNERATION AND ATTENDANCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di78701_director_remuneration_and_attendance"><FONT SIZE=2>26</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di78701_security_ownership_of_certain___sec02525"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di78701_security_ownership_of_certain___sec02525"><FONT SIZE=2>29</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di78701_section_16(a)_benefici__di702035"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di78701_section_16(a)_benefici__di702035"><FONT SIZE=2>32</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk78701_executive_officers_of_the_company"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXECUTIVE OFFICERS OF THE COMPANY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk78701_executive_officers_of_the_company"><FONT SIZE=2>33</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk78701_executive_compensation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXECUTIVE COMPENSATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk78701_executive_compensation"><FONT SIZE=2>35</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dm78701_transactions_with_related_persons"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>TRANSACTIONS WITH RELATED PERSONS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dm78701_transactions_with_related_persons"><FONT SIZE=2>41</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dm78701_audit_committee_report"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>AUDIT COMMITTEE REPORT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dm78701_audit_committee_report"><FONT SIZE=2>43</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dm78701_delivery_of_proxy_materials"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DELIVERY OF PROXY MATERIALS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dm78701_delivery_of_proxy_materials"><FONT SIZE=2>45</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dm78701_additional_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ADDITIONAL INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dm78701_additional_information"><FONT SIZE=2>46</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FORM OF PROXY FOR ORDINARY SHAREHOLDERS</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=8,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=673033,FOLIO='i',FILE='DISK122:[17ZBH1.17ZBH78701]BG78701A.;8',USER='PJAMES',CD='26-APR-2017;19:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da78701_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Adaptimmune Therapeutics&nbsp;PLC<BR>  </B></FONT><FONT SIZE=2><B>101 Park Drive, Milton Park<BR>
Abingdon, Oxfordshire OX14&nbsp;4RY, U.K.<BR>
Registered Company No.&nbsp;09338148  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROXY STATEMENT FOR THE 2017 ANNUAL GENERAL MEETING OF SHAREHOLDERS<BR>  </B></FONT><FONT SIZE=2><B>TO BE HELD ON JUNE 21, 2017  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="da78701_information_concerning_proxy_solicitation_and_voting"> </A>
<A NAME="toc_da78701_1"> </A>
<BR>  INFORMATION CONCERNING PROXY SOLICITATION AND VOTING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have sent you this proxy statement and the enclosed form of proxy because the Board of Directors of Adaptimmune Therapeutics&nbsp;plc
(referred to herein as the "Company", "we", "us" or "our") is soliciting your proxy to vote at our annual general meeting of shareholders (referred
to herein as the "Meeting" or the "AGM") to be held on Wednesday, June&nbsp;21, 2017, at 11:00&nbsp;a.m. London time (6:00&nbsp;a.m. Eastern Standard time), at 60 Jubilee Avenue, Milton Park,
Abingdon, Oxfordshire&nbsp;OX14&nbsp;4RX. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> This proxy statement summarizes information about the proposals to be considered at the Meeting and other information you may find useful in
determining how to vote. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The form of proxy is the means by which you actually authorize another person to vote your shares in accordance with your instructions. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to solicitations by mail, our directors, officers and regular employees, without additional remuneration, may solicit proxies by telephone, e-mail and personal interviews.
All costs of solicitation of proxies will be covered by us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are mailing the Notice of 2017 AGM, this proxy statement and the form of proxy to our ordinary shareholders of record as of April&nbsp;26, 2017 (being the latest practicable date
before the circulation of this document) for the first time on or about April&nbsp;28, 2017. In this mailing, we are also including our U.K. statutory annual accounts and reports for the year ended
December&nbsp;31, 2016 ("2016 U.K. Annual Report") and our annual report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016 (the "Annual Report on Form&nbsp;10-K"). In addition, we
have provided brokers, dealers, bankers, and their nominees, at our expense, with additional copies of our proxy materials, the 2016 U.K. Annual Report and the Annual Report on Form&nbsp;10-K so
that our record holders can supply these materials to the beneficial owners of our ordinary shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whilst
this document is being sent to our ordinary shareholders of record, this document will also be sent to holders of American Depositary Shares
(</FONT><FONT SIZE=2><B>"ADSs"</B></FONT><FONT SIZE=2>) and contains information relevant to holders of ADSs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da78701_important_notice_regarding_the__imp04369"> </A>
<A NAME="toc_da78701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to be Held on June&nbsp;21, 2017    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Notice of 2017 AGM, this proxy statement, the Annual Report on Form&nbsp;10-K, our 2016 U.K. Annual Report and our form of proxy are
available in the Investors section of our website at http://www.adaptimmune.com. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da78701_questions_and_answers_about_voting"> </A>
<A NAME="toc_da78701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  QUESTIONS AND ANSWERS ABOUT VOTING    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Why am I receiving these materials?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have sent you this proxy statement and the enclosed form of proxy because you are an ordinary shareholder of record and our Board is
soliciting your proxy to vote at the Meeting, including at any adjournments or postponements of the Meeting. You are invited to attend the Meeting to vote </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=605261,FOLIO='1',FILE='DISK122:[17ZBH1.17ZBH78701]DA78701A.;14',USER='LBURNET',CD='28-APR-2017;10:06' -->
<A NAME="page_da78701_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>on
the proposals described in this proxy statement. However, you do not need to attend the Meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed form of proxy.
Alternatively, please submit your proxy online at www.investorcentre.co.uk/eproxy (see instructions on form of proxy), in any event to arrive by no later than </FONT><FONT SIZE=2><B>11&nbsp;a.m.
London time (6&nbsp;a.m. Eastern Standard Time) on Monday, June&nbsp;19, 2017.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to mail this proxy statement and the accompanying form of proxy on or about April&nbsp;28, 2017 to all ordinary shareholders of record entitled to vote at the Meeting. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Materials
for ADS holders of record, including this proxy statement, the Annual Report on Form&nbsp;10-K and an ADS proxy card, will be mailed on or about May&nbsp;8, 2017 to all ADS
holders, including banks, brokers and nominees, who are registered as holders of ADSs in the ADS register by 5.p.m. Eastern Standard Time on May, 4, 2017 (the record date for ADS holders). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who can vote at the Meeting?  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ordinary shareholders  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only ordinary shareholders of record registered in the register of members at 5&nbsp;p.m. London time (12&nbsp;noon Eastern Standard Time)
on Monday, June&nbsp;19, 2017 will be entitled to vote at the Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of April&nbsp;26, 2017 (being the last practicable date before the circulation of this proxy statement) there were 560,976,430 ordinary shares issued and outstanding and entitled to
vote. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
or not you plan to attend the Meeting, we urge you to fill out and return the enclosed form of proxy to ensure your vote is counted. Alternatively, please submit your proxy
online at www.investorcentre.co.uk/eproxy (see instructions on form of proxy) to arrive by no later than </FONT><FONT SIZE=2><B>11&nbsp;a.m. London time (6&nbsp;a.m. Eastern Standard Time) on
Monday, June&nbsp;19, 2017.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you sell or transfer your ordinary shares in the Company prior to June&nbsp;19, 2017, your form of proxy can no longer be used and if submitted (whether before or after you sell or
transfer your ordinary shares) will be treated as invalid. Please pass this document together with the accompanying form of proxy to the person who arranged the sale or transfer for delivery to the
purchaser or transferee. The purchaser or transferee should contact Margaret Henry, Company Secretary, to request a new form of proxy for its use. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Beneficial owners of ordinary shares which are registered in the name of a broker, bank or other agent  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, on April&nbsp;26, 2017, your ordinary shares were held in an account at a brokerage firm, bank or other similar organization and you are
the beneficial owner of shares, these proxy materials should be forwarded to you by that organization. The organization holding your account is considered the shareholder of record for purposes of
voting at the Meeting. As a beneficial owner, you may have the right to direct your broker or other agent on how to vote the shares in your account. You are also invited to attend the Meeting.
However, because you are not the shareholder of record, you may not vote your shares in person at the Meeting and you are encouraged to provide voting instructions to your broker or other agent so
that they may submit a proxy. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Holders of American Depositary Shares  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You are entitled to exercise your vote as a holder of an interest in the capital of the Company represented by ADSs if you or your brokerage
firm, bank or nominee is registered as a holder of ADSs in the ADS register </FONT><FONT SIZE=2><B>by 5&nbsp;p.m. Eastern Standard Time on Thursday, May&nbsp;4, 2017 (the record date for ADS
holders).</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you hold ADSs through a brokerage firm, bank or nominee on May&nbsp;4, 2017, the materials for ADS holders, including the ADS proxy card, will be sent to that organization. The
organization holding </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=10,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=458023,FOLIO='2',FILE='DISK122:[17ZBH1.17ZBH78701]DA78701A.;14',USER='LBURNET',CD='28-APR-2017;10:06' -->
<A NAME="page_da78701_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>your
account is considered the ADS holder of record. Please reach out to that organization to provide your voting instructions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
note that ADS proxy cards submitted by ADS holders must be received by Citibank, N.A. </FONT><FONT SIZE=2><B>no later than 10&nbsp;a.m. Eastern Standard Time on Wednesday,
June&nbsp;14, 2017</B></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Citibank,
N.A. will collate all votes properly submitted by ADS holders and submit a vote on behalf of all ADS holders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contacts for ADS holders  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you have queries about how you can deliver voting instructions, please contact Citibank, N.A.&#151;ADR Shareholder Services at tel:
+1-877-248-4237 (toll free within the United States) or +1-781-575-4555 (for international callers) or by email: citibank@shareholders-online.com or at Citibank Shareholder Services,
P.O.&nbsp;Box&nbsp;43077, Providence, RI 02940-3077. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
at any point you require guidance, please contact Margaret Henry, Company Secretary, on email: margaret.henry@adaptimmune.com, tel: +44(0)1235 430036 or cell: +44 (0)7710 304249. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What are the requirements to elect the directors and approve each of the proposals?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may cast your vote for or against proposals 1 through 11 or abstain from voting your shares on one or more of these proposals. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposals
1 through 10 will be proposed as ordinary resolutions. Proposal 11 will be proposed as a special resolution. Under English law, assuming that a quorum is present, an ordinary
resolution is passed on a show of hands if it is approved by a simple majority (more than 50%) of the votes cast by shareholders present (in person or by proxy) at the Meeting and entitled to vote. If
a poll is demanded, an ordinary resolution is passed if it is approved by holders representing a simple majority of the total voting rights of shareholders present (in person or by proxy) who (being
entitled to vote) vote on the resolution. Special resolutions require the affirmative vote of not less than 75% of the votes cast by shareholders present (in person or by proxy) at the Meeting and
entitled to vote. On a poll, a special resolution is passed if it is approved by holders representing not less than 75% of the total voting rights of shareholders present (in person or by proxy) who
(being entitled to vote) vote on the resolution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
regard to proposals 8 and 9 regarding receipt of our U.K. statutory annual accounts and reports for the year ended December&nbsp;31, 2016 and approval of our U.K. statutory
directors' annual report on remuneration for the year ended December&nbsp;31, 2016, the votes on these proposals will not require our Board of Directors or any committee to take any action.
Nonetheless, our Board of Directors values
the opinions of our shareholders as expressed through such votes and will carefully consider the outcome of the votes on these proposals. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=11,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=231998,FOLIO='3',FILE='DISK122:[17ZBH1.17ZBH78701]DA78701A.;14',USER='LBURNET',CD='28-APR-2017;10:06' -->
<A NAME="page_da78701_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What are the voting recommendations of our Board regarding the election of directors and other
proposals?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the items that will be brought for a vote of our shareholders at the Meeting, along with the Board's voting
recommendations. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="81pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Proposal

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description of Proposal </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Board's<BR>
Recommendation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Re-election of Barbara Duncan as a director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Re-election of Giles Kerr as a director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Re-election of Tal Zaks as a director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Re-election of Ali Behbahani as a director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Re-election of Peter Thompson as a director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Re-appointment of KPMG&nbsp;LLP as our U.K. statutory auditors under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting at which the U.K. statutory accounts and reports are
presented</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Authorization for the Audit Committee to determine our U.K. statutory auditors' remuneration for the fiscal year ended December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>To receive the U.K. statutory annual accounts and reports for the fiscal year ended December&nbsp;31, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Approval of our U.K. statutory directors' annual report on remuneration, which is set forth in Annex&nbsp;A, for the year ended December&nbsp;31, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Authorization for the Board of Directors to allot ordinary shares and grant rights over ordinary shares up to a maximum aggregate nominal amount of &pound;140,000.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Authorization for the disapplication of U.K. statutory rights of preemption with respect to the allotment of ordinary shares and grant of rights over ordinary shares referred to in Resolution 10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B> FOR</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What constitutes a quorum?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of the Meeting, a quorum will be present if members holding at least one-third in number of the issued ordinary shares of the
Company and entitled to vote are present in person or represented by proxy at the Meeting. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are an ordinary shareholder of record, your shares will be counted towards the quorum only if you are present in person or represented by proxy at the Meeting. If you are a
beneficial owner of ordinary shares held in an account at a brokerage firm, bank or other similar organization your shares will be counted towards the quorum if your broker or nominee submits a proxy
for those shares and the proxy represents the holder at the Meeting. A member represented by a proxy at the Meeting will be counted towards the quorum requirement even where the proxy abstains from
voting. If a form of proxy does not instruct the proxy how to vote, the proxy may vote as he or she sees fit or abstain in relation to any business of the Meeting, but the member represented by that
proxy at the Meeting will be counted towards the quorum requirement. If there is no quorum, the Meeting will stand adjourned to such time, date and place as may be fixed by the chairperson of the
Meeting (being not less than 10&nbsp;days later), and, if a quorum is not present at the adjourned meeting, the Meeting will be dissolved. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How do I vote my shares?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>If you are an ordinary "shareholder of record</I></FONT><FONT SIZE=2>," you may attend the Meeting in person or you may
appoint a proxy to vote on your behalf:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> By completing and signing the form of proxy and returning it in the envelope provided; or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=12,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=457171,FOLIO='4',FILE='DISK122:[17ZBH1.17ZBH78701]DA78701A.;14',USER='LBURNET',CD='28-APR-2017;10:06' -->
<A NAME="page_da78701_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> By submitting your proxy online at www.investorcentre.co.uk/eproxy (see instructions on form of proxy) to arrive by no later than </FONT> <FONT SIZE=2><B>11&nbsp;a.m. London time (6&nbsp;a.m.
Eastern Standard Time) on Monday, June&nbsp;19, 2017.</B></FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you properly give instructions as to your proxy appointment by executing and returning a form of proxy, or by submitting your proxy online, and your proxy appointment is not
subsequently revoked, your shares will be voted in accordance with your instructions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>If your ordinary shares are held in an account at a brokerage firm, bank or similar organization,</I></FONT><FONT SIZE=2> you should follow directions provided by
your broker, bank or other nominee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How will my shares be voted if I do not specify how they should be voted?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you sign and send your form of proxy but do not indicate how you want your shares to be voted, your shares may be voted by the person that
you appoint as your proxy as he or she sees fit or such person may abstain in relation to any business of the Meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Can I change my vote or revoke a proxy?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A registered shareholder can revoke his or her proxy before the time of voting at the Meeting in several ways by: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>mailing
a revised form of proxy dated later than the prior form of proxy;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>voting
in person at the Meeting; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>notifying
our Company Secretary in writing that you are revoking your proxy. Your revocation must be received before the Meeting to be effective. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your ordinary shares are held in an account at a brokerage firm, bank or similar organization, you may change or revoke your voting instructions by contacting the broker, bank or
other nominee holding the shares or by your broker, bank or other nominee validly appointing you as proxy to attend at the Meeting. See also "What if I plan to attend the Meeting?" </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who counts the votes?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Computershare Investor Services&nbsp;PLC ("Computershare") has been engaged as our independent agent to tabulate shareholder votes. If you are
an ordinary shareholder of record, you can return your executed form of proxy to Computershare for tabulation or directly submit your proxy online to Computershare at www.investorcentre.co.uk/eproxy
(see instructions on form of proxy). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you hold your ordinary shares through a broker, your broker will return the form of proxy to Computershare or directly submit your proxy to Computershare online. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are a holder of record of ADSs, you can return your executed ADS proxy card to Citibank, N.A. for tabulation. If you hold your ADSs through a broker, bank or other organization,
that organization can return the ADS proxy card to Citibank, N.A. following your instruction. Citibank, N.A. will submit your votes to Computershare for tabulation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How are votes counted?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes will be counted by Computershare, who will separately count "for" and "against" votes, and "votes withheld" or abstentions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=13,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=139175,FOLIO='5',FILE='DISK122:[17ZBH1.17ZBH78701]DA78701A.;14',USER='LBURNET',CD='28-APR-2017;10:06' -->
<A NAME="page_da78701_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How many votes do I have?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On a show of hands, each ordinary shareholder of record present in person, and each duly authorised representative present in person of a
shareholder that is a corporation, has one vote. On a show of hands, each proxy present in person who has been duly appointed by one or more shareholders has one vote, but a proxy has one vote for and
one vote against a resolution if, in certain circumstances, the proxy is instructed by more than one shareholder to vote in different ways on a resolution. On a poll, each shareholder present in
person or by proxy or (being a corporation) by a duly authorised representative has one vote for each share held by the shareholder. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What if I plan to attend the Meeting?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attendance at the Meeting will be limited to ordinary shareholders of record and beneficial owners of ordinary shares as of 5&nbsp;p.m. London
time (12&nbsp;noon Eastern Standard Time) on Monday, June&nbsp;19, 2017. In order to obtain admittance to the Meeting each shareholder may be asked to present valid picture identification, such as
a driver's license or passport. If your ordinary shares are held through brokerage accounts or by a bank or other nominee you may be able to attend at the discretion of the Chairman. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How do you solicit proxies?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will solicit proxies and will bear the entire cost of this solicitation. The initial solicitation of proxies may be supplemented by
additional mail communications and by telephone, fax, e-mail, internet and personal solicitation by our directors, officers or other employees. No additional compensation for soliciting proxies will
be paid to our directors, officers or other employees for their proxy solicitation efforts. We also reimburse Citibank, N.A. for their expenses in sending materials, including ADS proxy cards, to ADS
holders of record. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What do I do if I receive more than one notice or form of proxy?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you hold your ordinary shares in more than one account, you will receive a form of proxy for each account. To ensure that all of your shares
are voted, please sign, date and return all forms of proxy. Please be sure to vote all of your shares. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Will there be any other business conducted at the Meeting?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No. In accordance with our Articles of Association, no matters other than proposals 1 through 11 may be presented at this Meeting. We have not
been notified of, and our Board is not aware of, any other matters to be presented for action at the Meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What is Computershare's role?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Computershare is our registrar. All communications concerning ordinary shareholder of record accounts, including address changes, name changes,
ordinary share transfer requirements and similar issues can be handled by contacting Computershare at tel: +44 (0)&nbsp;370&nbsp;702 0000 or by writing to Computershare Investor
Services&nbsp;PLC, The Pavilions, Bridgwater Road, Bristol, BS99&nbsp;6ZY, England. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Communications
concerning ADS holder of record accounts can be handled by contacting Citibank, N.A.&#151;ADR Shareholder Services at tel: +1-877-248-4237 (toll free within the
United States) or +1-781-575-4555 (for international callers) or by email: citibank@shareholders-online.com or at Citibank Shareholder Services, P.O.&nbsp;Box&nbsp;43077, Providence, RI
02940-3077. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=14,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=241106,FOLIO='6',FILE='DISK122:[17ZBH1.17ZBH78701]DA78701A.;14',USER='LBURNET',CD='28-APR-2017;10:06' -->
<A NAME="page_da78701_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How can I find out the results of the voting at the Meeting?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting results will be announced by the filing of a current report on Form&nbsp;8-K within four business days after the Meeting. If final
voting results are unavailable at that time, we will file an amended current report on Form&nbsp;8-K within four business days of the day the final results are available. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What are the implications of being an "emerging growth company"?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an "emerging growth company" as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply
with certain reduced public company reporting requirements. As a result of this election we are providing in this 2017 Proxy Statement the scaled disclosure permitted for emerging growth companies,
including the scaled executive compensation disclosure. In addition, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our Named Executive Officers
(as defined herein) or the frequency with which such votes must be conducted. We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year
(a)&nbsp;following May&nbsp;11, 2020, the fifth anniversary of the completion of our initial public offering, (b)&nbsp;in which we have total annual gross revenue of at least
$1.07&nbsp;billion, or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our ordinary shares that are held by non-affiliates exceeds
$700&nbsp;million as of the prior June&nbsp;30<SUP>th</SUP>&nbsp;, and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt during the prior
three-year period. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directions to Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directions to our Meeting, which is to be held at 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14&nbsp;4RX, are available at:
www.adaptimmune.com </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=15,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=594697,FOLIO='7',FILE='DISK122:[17ZBH1.17ZBH78701]DA78701A.;14',USER='LBURNET',CD='28-APR-2017;10:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc78701_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc78701_election_of_directors"> </A>
<A NAME="toc_dc78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ELECTION OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors currently consists of nine directors. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Articles of Association require that those directors who were appointed since our 2016 Annual General Meeting must retire from office and offer themselves for re-election.
Accordingly, Ms.&nbsp;Barbara Duncan, Mr.&nbsp;Giles Kerr and Dr.&nbsp;Tal Zaks, will retire from office and offer themselves for re-election by our shareholders at the 2017 AGM. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
our Articles of Association require one-third (or such number nearest to but not exceeding one-third) of our remaining directors who are subject to retirement by rotation
to retire from office at each annual general meeting effective from the 2016 Annual General Meeting, commencing with the longest-serving directors. In the case of equal tenure, retirement is by
agreement. Of the six
directors subject to retirement by rotation, Dr.&nbsp;Ali Behbahani and Dr.&nbsp;Peter Thompson, will, on this occasion, retire from office and stand for re-election by our shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Having
carried out an evaluation of the individual performance of each of Ms.&nbsp;Duncan, Mr.&nbsp;Kerr, Dr.&nbsp;Zaks, Dr.&nbsp;Behbahani and Dr.&nbsp;Thompson, with the
support of the Corporate Governance and Nominating Committee, the Board is satisfied that their performance continues to be effective and that they continue to demonstrate commitment to their roles.
The Board considers that it is entirely appropriate for of each of Ms.&nbsp;Duncan, Mr.&nbsp;Kerr, Dr.&nbsp;Zaks, Dr.&nbsp;Behbahani and Dr.&nbsp;Thompson, to seek re-election at the AGM. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of the above directors has been nominated for re-election and no other nominees for directors have been presented. Therefore, it is anticipated that following the AGM, if all of the
above directors are re-elected, the Board of Directors will be comprised of nine members. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with proposals 1 through 5, we set forth the biographical information for the nominees to our Board of Directors. For biographical information for the other directors see </FONT> <FONT SIZE=2><I>Board of Directors and Corporate
Governance</I></FONT><FONT SIZE=2>. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=16,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=682255,FOLIO='8',FILE='DISK122:[17ZBH1.17ZBH78701]DC78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dc78701_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc78701_proposal_1_#151;re-election_of__pro02437"> </A>
<A NAME="toc_dc78701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 1&#151;RE-ELECTION OF BARBARA DUNCAN TO THE BOARD OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ms.&nbsp;Barbara Duncan is currently a member of our Board of Directors and has been nominated for re-election as a director. If elected, she
will hold office from the date of her election until the next annual general meeting of shareholders where she must retire by rotation and offer herself for re-election, or until her earlier death,
resignation or removal. Ms.&nbsp;Duncan has agreed to serve if elected, and we have no reason to believe that she will be unable to serve. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ms.&nbsp;Duncan,
52, has served as a Non-Executive Director since June 2016 and also serves as a member of our Audit Committee. She has over 15&nbsp;years of experience in the life
sciences industry and served as Chief Financial Officer and Treasurer at Intercept Pharmaceuticals,&nbsp;Inc. (NASDAQ: ICPT) from 2009 to 2016 and as Chief Financial Officer and then Chief Executive
Officer at DOV Pharmaceuticals,&nbsp;Inc.
from 2001 to 2009. Prior to joining DOV, Ms.&nbsp;Duncan served as Vice President of Corporate Finance&#151;Global Healthcare at Lehman Brothers&nbsp;Inc. from 1998 to 2001, and as Director
of Corporate Finance at SBC Warburg Dillon Read&nbsp;Inc. from 1994 to 1998. She also worked for PepsiCo,&nbsp;Inc. from 1989 to 1992 in its international audit division, and was a certified
public accountant in the audit division of Deloitte&nbsp;&amp; Touche&nbsp;LLP from 1986 to 1989. Ms.&nbsp;Duncan currently serves as a director for public companies Aevi Genomic Medicine (NASDAQ:
GNMX), Jounce Therapeutics,&nbsp;Inc. (NASDAQ: JNCE), Innoviva,&nbsp;Inc. (NASDAQ: INVA) and ObsEva&nbsp;SA (NASDAQ: OBSV). She holds an MBA from the Wharton School of the University of
Pennsylvania and a Bachelor of Business Administration from Louisiana State University. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors believes Ms.&nbsp;Duncan's qualifications to serve as a member of our board include her financial expertise, her extensive experience in the healthcare industry
and her years of experience in her leadership roles as a director and executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on her extensive experience as a senior executive and member of the board of directors of public companies in the pharmaceutical and healthcare sectors, as well as her substantial
background as a public company chief financial officer, our Corporate Governance and Nominating Committee concluded that Ms.&nbsp;Duncan should be nominated for re-election to our Board of
Directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>  </B></FONT><FONT SIZE=2><B><I><U>FOR</U></I></B></FONT><FONT SIZE=2><B> THE RE-ELECTION OF BARBARA DUNCAN TO THE BOARD OF DIRECTORS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=17,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=907576,FOLIO='9',FILE='DISK122:[17ZBH1.17ZBH78701]DC78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dc78701_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="dc78701_proposal_2_#151;re-election_of__pro02318"> </A>
<A NAME="toc_dc78701_3"> </A>
<BR>  PROPOSAL 2&#151;RE-ELECTION OF GILES KERR TO THE BOARD OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Giles Kerr is currently a member of our Board of Directors and has been nominated for re-election as a director. If elected, he will
hold office from the date of his election until the next annual general meeting of shareholders where he must retire by rotation and offer himself for re-election, or until his earlier death,
resignation or removal. Mr.&nbsp;Kerr has agreed to serve if elected, and we have no reason to believe that he will be unable to serve. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Kerr,
57, has served as a Non-Executive Director since November 2016 and also serves as a member of our Audit Committee and of our Corporate Governance and Nominating
Committee. He has substantial commercial and financial experience gained from service on numerous public and private company boards and as an audit partner. Mr.&nbsp;Kerr has served as Director of
Finance of the University of Oxford since 2005. He also currently serves as a Board member and Audit Committee member of public companies BTG&nbsp;plc (LSE:&nbsp;BTG), Paypoint&nbsp;plc
(LSE:&nbsp;PAY) and Senior&nbsp;plc (LSE:&nbsp;SNR) as well as on the boards of several private companies, including Quanta Dialysis Technologies&nbsp;Ltd, Oxford Sciences
Innovation&nbsp;plc and Oxford Capital Fund. Mr.&nbsp;Kerr previously served in roles of increasing seniority at Amersham&nbsp;plc since 1990, including as Chief Financial Officer and a Board
member from 1997 to 2004, when the company was acquired by GE Healthcare, and as a director of Victrex&nbsp;plc and of Elan Corporation&nbsp;Inc. Prior to his role at Amersham, Mr.&nbsp;Kerr was
a National Partner with Arthur Andersen. He is a Fellow of the Institute of Chartered Accountants of England and Wales and holds a B.A. degree in Economics from the University of York, U.K. Our Board
of Directors believes Dr.&nbsp;Kerr's qualifications to serve as a member of our board include his financial expertise, his extensive experience in the healthcare industry and his years of
experience in his leadership roles as a director and executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on his extensive experience as a senior executive and member of the board of directors of numerous public companies in the pharmaceutical and healthcare sectors, as well as his
substantial background as a public company chief financial officer, the Corporate Governance and Nominating Committee concluded that Mr.&nbsp;Kerr is qualified to serve on our Board of Directors.
Mr.&nbsp;Kerr recused himself from the Corporate Governance and Nominating Committee's deliberations concerning his nomination. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>  </B></FONT><FONT SIZE=2><B><I><U>FOR</U></I></B></FONT><FONT SIZE=2><B> THE RE-ELECTION OF GILES KERR TO THE BOARD OF DIRECTORS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=18,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=1240,FOLIO='10',FILE='DISK122:[17ZBH1.17ZBH78701]DC78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dc78701_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="dc78701_proposal_3_#151;re-election_of__pro02243"> </A>
<A NAME="toc_dc78701_4"> </A>
<BR>  PROPOSAL 3&#151;RE-ELECTION OF TAL ZAKS TO THE BOARD OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Tal Zaks is currently a member of our Board of Directors and has been nominated for re-election as a director. If elected, he will
hold office from the date of his election until the next annual general meeting of shareholders where he must retire by rotation and offer himself for
re-election, or until his earlier death, resignation or removal. Dr.&nbsp;Zaks has agreed to serve if elected, and we have no reason to believe that he will be unable to serve. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Zaks,
51, has served as a Non-Executive Director since November 2016 and also serves as a member of our Remuneration Committee. He has substantial research, development and
commercialization experience gained from service in industry and academia. Dr.&nbsp;Zaks has served as the Chief Medical Officer of Moderna Therapeutics,&nbsp;Inc. since March 2015. He previously
served as Senior Vice President and Head of Global Oncology at Sanofi Inc, where he was responsible for all aspects of oncology drug discovery, development and commercialization. Dr.&nbsp;Zaks began
his industry career at GlaxoSmithKline in the genetics research group, where he built the oncology translational medicine team and led translational research on lapatinib as well as the in-licensing
and clinical development of foretinib. In addition to his industry work, Dr.&nbsp;Zaks is an Adjunct Associate Professor of Medicine at the University of Pennsylvania and has served as a volunteer
physician at the Philadelphia Veterans Administration Medical Center, treating patients with genitourinary cancers. Dr.&nbsp;Zaks received his M.D. and Ph.D. degrees from the Ben Gurion University
in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship
in medical oncology at the University of Pennsylvania. Our Board of Directors believes Dr.&nbsp;Zaks' qualifications to serve as a member of our board include his extensive experience in the
biopharmaceutical industry and his years of experience in his leadership roles as an executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on his extensive experience as a senior executive in the pharmaceutical and healthcare sectors, the Corporate Governance and Nominating Committee concluded that Dr.&nbsp;Zaks is
qualified to serve on our Board of Directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>  </B></FONT><FONT SIZE=2><B><I><U>FOR</U></I></B></FONT><FONT SIZE=2><B> THE RE-ELECTION OF TAL ZAKS TO THE BOARD OF DIRECTORS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=19,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=124082,FOLIO='11',FILE='DISK122:[17ZBH1.17ZBH78701]DC78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dc78701_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="dc78701_proposal_4_#151;re-election_of__pro02381"> </A>
<A NAME="toc_dc78701_5"> </A>
<BR>  PROPOSAL 4&#151;RE-ELECTION OF ALI BEHBAHANI TO THE BOARD OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Ali Behbahani is currently a member of our Board of Directors and has been nominated for re-election as a director. If elected, he
will hold office from the date of his election until the next annual general meeting of shareholders where he must retire by rotation and offer himself for re-election, or until his earlier death,
resignation or removal. Dr.&nbsp;Behbahani has agreed to serve if elected, and we have no reason to believe that he will be unable to serve. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Behbahani,
40, has served as a Non-Executive Director since February 2015 and also serves as a member of our Corporate Governance and Nominating Committee. He formerly served
as a Non-Executive Director of Adaptimmune Limited since September 2014, initially in a capacity as a nominee of New Enterprise Associates ("NEA"), one of our shareholders. Dr.&nbsp;Behbahani has
been a Partner on the healthcare team at NEA since 2013, having worked for the fund since 2007, specializing in investments in the biopharmaceutical, medical device, specialty pharmaceutical and
healthcare services sectors. He is also currently a member of the board of directors of Nevro Corp. and CRISPR Therapeutics AG. He also serves on the board of directors of several private companies,
including Solace Therapeutics,&nbsp;Inc., ClarVista Medical,&nbsp;Inc. and NKarta,&nbsp;Inc. He has previously worked as a consultant in business development at The Medicines Company and held
positions as a Venture Associate at Morgan Stanley Venture Partners from 2000 to 2002 and as a Healthcare Investment Banking Analyst at Lehman Brothers from 1998 to 2000. Dr.&nbsp;Behbahani
conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. He holds an M.D. degree from The
University of Pennsylvania School of Medicine and an MBA from the Wharton School of the University of Pennsylvania. Our Board of Directors believes Dr.&nbsp;Behbahani's qualifications to serve as a
member of our board include his financial expertise, his experience as a venture capital investor, his extensive experience in the healthcare industry and his years of experience in his leadership
roles as a director and executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on his extensive experience as a senior executive and board member in the pharmaceutical and healthcare sectors, the Corporate Governance and Nominating Committee concluded that
Dr.&nbsp;Behbahani is qualified to serve on our Board of Directors. Dr.&nbsp;Behbahani recused himself from the Corporate Governance and Nominating Committee's deliberations concerning his
nomination. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>  </B></FONT><FONT SIZE=2><B><I><U>FOR</U></I></B></FONT><FONT SIZE=2><B> THE RE-ELECTION OF ALI BEHBAHANI TO THE BOARD OF DIRECTORS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=5,SEQ=20,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=507537,FOLIO='12',FILE='DISK122:[17ZBH1.17ZBH78701]DC78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dc78701_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="dc78701_proposal_5_#151;re-election_of__pro02525"> </A>
<A NAME="toc_dc78701_6"> </A>
<BR>  PROPOSAL 5&#151;RE-ELECTION OF PETER THOMPSON TO THE BOARD OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Peter Thompson is currently a member of our Board of Directors and has been nominated for re-election as a director. If elected, he
will hold office from the date of his election until the next annual general meeting of shareholders where he must retire by rotation and offer himself for re-election, or until his earlier death,
resignation or removal. Dr.&nbsp;Thompson has agreed to serve if elected, and we have no reason to believe that he will be unable to serve. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Thompson,
57, has served as a Non-Executive Director since February 2015 and also serves as a member of our Remuneration Committee. He formerly served as a Non-Executive
Director of Adaptimmune Limited since September 2014, initially in his capacity as a nominee of OrbiMed Private Investments V,&nbsp;L.P. ("OrbiMed"), one of our shareholders. Dr.&nbsp;Thompson is
currently a Private Equity Partner with OrbiMed who brings over 25&nbsp;years of industry experience. He co-founded and was Chief Executive Officer of Trubion Pharmaceuticals from 2002 to 2009
(NASDAQ: TRBN), co-founded Cleave BioSciences and Corvus Pharmaceuticals (NASDAQ:CRVS), and was previously an executive of Chiron Corporation and Becton Dickinson. Dr.&nbsp;Thompson also serves as a
Director on several public and private company Boards including Cardioxyl Pharmaceuticals,&nbsp;Inc., Cleave Biosciences, PMV Pharmaceuticals,&nbsp;Inc., Principia BioPharma, ProNai
Therapeutics,&nbsp;Inc., Response BioMedical Corp, and OxOnc Development&nbsp;Inc. He is also an Ernst&nbsp;&amp; Young Entrepreneur of the Year awardee and an Affiliate Professor of Neurosurgery at
the University of Washington. He is the inventor on numerous patents, is a board-certified internist and oncologist and was on the staff at the National Cancer Institute following his internal
medicine training at Yale University. Our Board of Directors believes Dr.&nbsp;Thompson's qualifications to serve as a member of our board include his financial expertise, his experience as a
venture capital investor, his extensive experience in the pharmaceutical industry and his years of experience in his leadership roles as a director and executive officer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on his extensive experience as a senior executive in the pharmaceutical and healthcare sectors, and his financial expertise and experience as a venture capital investor, the
Corporate Governance and Nominating Committee concluded that Dr.&nbsp;Thompson is qualified to serve on our Board of Directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>  </B></FONT><FONT SIZE=2><B><I><U>FOR</U></I></B></FONT><FONT SIZE=2><B> THE RE-ELECTION OF PETER THOMPSON TO THE BOARD OF DIRECTORS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=21,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=910106,FOLIO='13',FILE='DISK122:[17ZBH1.17ZBH78701]DC78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de78701_1_14"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="de1"></A>PROPOSAL 6&#151;RE-APPOINTMENT OF KPMG&nbsp;LLP AS OUR U.K. STATUTORY AUDITORS<BR>
UNDER THE U.K. COMPANIES ACT 2006, TO HOLD OFFICE UNTIL THE CONCLUSION OF<BR>
THE NEXT GENERAL MEETING AT WHICH THE U.K. STATUTORY ACCOUNTS ARE<BR>
PRESENTED  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de78701_proposal_7_#151;authorization___pro04089"> </A>
<A NAME="toc_de78701_1"> </A></FONT> <FONT SIZE=2><B>  PROPOSAL 7&#151;AUTHORIZATION FOR THE AUDIT COMMITTEE TO DETERMINE THE U.K.<BR>  STATUTORY AUDITORS' REMUNERATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposal 6 seeks your approval of the re-appointment of KPMG&nbsp;LLP to serve as our U.K. statutory auditor, to hold office until the
conclusion of the next general meeting at which the U.K. statutory accounts are presented to you. In the event this proposal does not receive the affirmative vote of the holders of a majority of the
shares entitled to vote and present in person or represented by proxy at the Meeting, the Board of Directors may appoint an auditor to fill the vacancy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proposal
7 authorizes the Audit Committee to determine our U.K. statutory auditors' remuneration. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>THE BOARD OF DIRECTORS AND AUDIT COMMITTEE RECOMMEND A VOTE<BR>
<U>FOR</U>:</I></B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>PROPOSAL 6 TO RE-APPOINT KPMG&nbsp;LLP AS OUR U.K. STATUTORY AUDITORS UNDER THE U.K. COMPANIES ACT 2006, TO HOLD
OFFICE UNTIL THE CONCLUSION OF THE NEXT ANNUAL GENERAL MEETING AT WHICH OUR STATUTORY ACCOUNTS ARE PRESENTED</B></FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>PROPOSAL 7 TO AUTHORIZE OUR AUDIT COMMITTEE TO DETERMINE OUR U.K. STATUTORY AUDITORS'
REMUNERATION</B></FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=22,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=474920,FOLIO='14',FILE='DISK122:[17ZBH1.17ZBH78701]DE78701A.;22',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_de78701_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de78701_proposal_8_#151;resolution_to___pro03507"> </A>
<A NAME="toc_de78701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 8&#151;RESOLUTION TO RECEIVE THE COMPANY'S U.K. STATUTORY ANNUAL<BR>  ACCOUNTS AND REPORTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Meeting, our Board of Directors will present our U.K. statutory annual accounts and reports for the period January&nbsp;1, 2016 through
December&nbsp;31, 2016, which includes the audited portion of the directors' annual report on remuneration. We will provide our shareholders with an opportunity to receive the U.K. statutory annual
accounts and reports to raise questions in relation to them. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>THE BOARD OF DIRECTORS AND AUDIT COMMITTEE RECOMMEND A VOTE<BR>
<U>FOR</U> THE RESOLUTION TO RECEIVE THE COMPANY'S U.K. STATUTORY ANNUAL ACCOUNTS AND<BR>
REPORTS</I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=23,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=375422,FOLIO='15',FILE='DISK122:[17ZBH1.17ZBH78701]DE78701A.;22',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_de78701_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de78701_proposal_9_#151;approval_of_ou__pro03238"> </A>
<A NAME="toc_de78701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 9&#151;APPROVAL OF OUR U.K. STATUTORY DIRECTORS' ANNUAL REPORT ON<BR>  REMUNERATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our U.K. statutory directors' remuneration report is set forth as </FONT><FONT SIZE=2><I>Annex&nbsp;A</I></FONT><FONT SIZE=2> to this proxy
statement. The directors' remuneration report includes the annual report on remuneration. This document describes in detail our remuneration policies and procedures and explains how these policies and
procedures help to achieve our compensation objectives with regard to our directors and the retention of high-quality directors. Our Board of Directors and the Remuneration Committee believe that the
policies and procedures as articulated in the directors' remuneration report are effective and that as a result of these policies and procedures we have and will continue to have high-quality
directors. Our Board of Directors has approved and signed the report in accordance with English law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Meeting, the shareholders will vote on the annual report on remuneration. This vote is advisory and non-binding. Although non-binding, our Board of Directors and Remuneration
Committee will review and consider the voting results when making future decisions regarding our director remuneration program. Following the Meeting, and as required under English law, the directors'
annual report on remuneration will be delivered to the U.K. Registrar of Companies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>THE BOARD RECOMMENDS YOU VOTE<BR>
<U>FOR</U> APPROVAL OF OUR U.K. STATUTORY DIRECTORS' ANNUAL REPORT ON REMUNERATION<BR>
SET FORTH IN ANNEX A</I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=24,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=955514,FOLIO='16',FILE='DISK122:[17ZBH1.17ZBH78701]DE78701A.;22',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_de78701_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de78701_background_to_proposals_10_and_11"> </A>
<A NAME="toc_de78701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  BACKGROUND TO PROPOSALS 10 AND 11    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the U.K. Companies Act 2006, our Board of Directors may only allot ordinary shares or grant rights over ordinary shares if
authorized to do so by our shareholders. If so authorized, the U.K. Companies Act 2006 requires us, where the allotment is for cash, to offer them in the first instance to our existing ordinary
shareholders in proportion to their holdings, unless the shareholders have sanctioned the disapplication of their statutory rights of pre-emption in respect of such allotment or grant of rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors anticipates that there may be occasions when they need flexibility to finance business opportunities and growth, or otherwise act in the best interests of the
Company, by the issuance of ordinary shares or grant of rights over ordinary shares without a pre-emptive offer to existing shareholders. To ensure our continued ability to respond to market
conditions and address business needs, our Board of Directors considers it appropriate that they be granted additional authority to allot ordinary shares or grant rights over ordinary shares up to an
aggregate nominal amount of &pound;140,000.00 on a non-preemptive basis. These authorities will replace all of the existing authorities granted by our shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
proposals are fully compliant with U.K. company law, consistent with U.S. capital markets practice and governance standards, and if approved, will keep us on an equal footing with
our peer
companies who are incorporated in the U.S.A. We are asking you to approve these proposals to allow us to continue to execute on our business and growth strategy in a timely and competitive manner. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
full details of the proposals are set forth below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=25,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=663567,FOLIO='17',FILE='DISK122:[17ZBH1.17ZBH78701]DE78701A.;22',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_de78701_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="de2"></A>PROPOSAL 10&#151;AUTHORIZATION OF ALLOTMENT OF SHARES  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the U.K. Companies Act 2006, our Board of Directors cannot allot shares in the Company (other than pursuant to an employee share scheme)
unless they are authorised to do so by the Company in general meeting. The Directors currently have an existing authority to allot shares in the Company and to grant rights to subscribe for or convert
securities into shares in the Company. This authority was granted to the Directors on December&nbsp;17, 2015 and was in respect of a maximum aggregate nominal amount of &pound;150,000.00,
which represented approximately 35% of the then issued ordinary share capital of the Company, and it remains unexercised in respect of approximately 1.32% of the Company's issued ordinary share
capital. Resolution 10 is an ordinary resolution to seek a new authority, which will replace the existing authority. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Resolution
10 proposes that the Directors are granted authority to allot new ordinary shares or to grant rights to subscribe for or to convert any security into ordinary shares in the
Company up to a maximum aggregate nominal amount of &pound;140,000.00. This amount represents approximately 25% of the issued ordinary share capital of the Company as of April&nbsp;26, 2017.
If approved by shareholders, this authority will run for five years and will expire on June&nbsp;20, 2022. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Directors have no present intention of exercising this authority, except in relation to the Company's share incentive schemes, but believe it is in the interests of shareholders for
the Directors to have this flexibility to allot shares otherwise than just in relation to the Company's share incentive schemes should circumstances and their intentions change. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>  </B></FONT><FONT SIZE=2><B><I><U>FOR</U></I></B></FONT><FONT SIZE=2><B> THE APPROVAL OF PROPOSAL 10</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de78701_proposal_11_#151;disap__de701790"> </A>
<A NAME="toc_de78701_5"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 11&#151;DISAPPLICATION OF PRE-EMPTION RIGHTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Resolution seeks a disapplication of pre-emption rights for cash issues of up to a certain proportion of the Company's issued ordinary
share capital. Our Board of Directors currently has a power to allot shares as if the rights of pre-emption applicable under the U.K. Companies Act did not apply for cash issues. This power was
granted to the Directors pursuant to shareholder resolutions passed on December&nbsp;17, 2015 and was in respect of a maximum aggregate nominal amount of &pound;150,000.00, which represented
approximately 35% of the then issued ordinary share capital of the Company, and it remains unexercised in respect of approximately 1.32% of the Company's issued ordinary share capital. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Directors have decided to seek to renew the disapplication of pre-emption rights for cash issues to replace the existing power. This Resolution will, if passed, give the Directors
power, pursuant to the authority to allot granted by Resolution 10, to allot ordinary shares for cash or to grant rights to subscribe for or to convert any security into ordinary shares without first
offering them to existing shareholders in proportion to their existing holdings up to an aggregate maximum nominal amount of &pound;140,000.00, which represents approximately 25% of the
Company's issued ordinary share capital as of April&nbsp;26, 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Resolution will be required to be passed as a special resolution and, if passed, this power will expire at the end of the AGM of the Company to be held in 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Directors have no present intention of exercising this power, except in relation to the Company's share incentive schemes, but believe it is in the interests of shareholders for the
Directors to have this flexibility to allot shares for cash otherwise than just in relation to the Company's share incentive schemes should circumstances and their intentions change. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE<BR>  </B></FONT><FONT SIZE=2><B><I><U>FOR</U></I></B></FONT><FONT SIZE=2><B> THE APPROVAL OF PROPOSAL 11</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=26,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=830690,FOLIO='18',FILE='DISK122:[17ZBH1.17ZBH78701]DE78701A.;22',USER='PJAMES',CD='26-APR-2017;19:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg78701_1_19"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg78701_board_of_directors_and_corporate_governance"> </A>
<A NAME="toc_dg78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  BOARD OF DIRECTORS AND CORPORATE GOVERNANCE    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


BOARD OF DIRECTORS  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directors  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="210pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David M. Mott</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chairman of the Board of Directors</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence M. Alleva</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ali Behbahani, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Barbara Duncan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Giles Kerr</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elliott Sigal, Ph.D, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Thompson, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tal Zaks, Ph.D, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Non-Executive Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Executive Officer and Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors currently consists of nine directors. The biographical information for Barbara Duncan, Giles Kerr, Dr.&nbsp;Tal Zaks, Dr.&nbsp;Ali Behbahani and
Dr.&nbsp;Peter Thompson, the nominees to our Board of Directors, is provided in "Proposal 1&#151;Re-Election of Barbara Duncan to the Board of Directors", "Proposal 2&#151;Re-Election
of Giles Kerr to the Board of Directors", "Proposal 3&#151;Re-Election of Tal Zaks to the Board of Directors", "Proposal 4&#151;Re-Election of Ali Behbahani to the Board of Directors"
and "Proposal 5&#151;Re-Election of Peter Thompson to the Board of Directors" respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below
is biographical information for those directors who are not standing for re-election at this Meeting and who will remain seated following the Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>David M. Mott</I></FONT><FONT SIZE=2> has served as our Chairman since January 2017 and as a Board member since February 2015. He also serves as Chairman of our
Remuneration Committee and of our Corporate Governance and Nominating Committee. Mr.&nbsp;Mott formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014, initially in a
capacity as a nominee of NEA, one of our shareholders. Mr.&nbsp;Mott has served as a General Partner of NEA, an investment firm focused on venture capital and growth equity investments, since 2008,
and leads its healthcare investing practice. He was formerly President and Chief Executive Officer of MedImmune&nbsp;LLC, a subsidiary of AstraZeneca&nbsp;Plc, and Executive Vice President of
AstraZeneca&nbsp;Plc. From 1992 to 2008, Mr.&nbsp;Mott worked at MedImmune and served in roles including Chief Operating Officer, Chief Financial Officer, President and Chief Executive Officer.
Prior to joining MedImmune, Mr.&nbsp;Mott was a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham&nbsp;&amp;&nbsp;Co.,&nbsp;Inc. He is currently a member of
the board of directors of Ardelyx, Epizyme and Tesaro, as well as several private companies, including 3-V Biosciences and Cydan, and has previously served on numerous public and private company
boards in the biopharmaceutical industry, including Shire Pharmaceuticals, Ambit Pharmaceuticals, Onthera Pharmaceuticals, Prosensa Holding&nbsp;BV, Zyngenia and Conceptis. Mr.&nbsp;Mott received
a bachelor of arts degree from Dartmouth College. Our Board of Directors believes Mr.&nbsp;Mott's qualifications to serve as a member of our board include his financial expertise, his experience as
a venture capital investor, his extensive experience in the pharmaceutical industry and his years of experience in his leadership roles as a director and executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>James Noble</I></FONT><FONT SIZE=2> has served as our full-time Chief Executive Officer since March 2014 and part-time CEO from July 2008 to March 2014 and is one
of our co-founders. From July 2008 until March 2014, Mr.&nbsp;Noble was also part-time CEO of Immunocore Limited. Mr.&nbsp;Noble has 24&nbsp;years of experience in the biotech industry. He has
held numerous non-executive director positions including at CuraGen Corporation, PowderJect Pharmaceuticals&nbsp;plc, Oxford GlycoSciences&nbsp;plc, MediGene AG, and Advanced Medical
Solutions&nbsp;plc. Mr.&nbsp;Noble is also Deputy Chairman of GW Pharmaceuticals&nbsp;plc </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=27,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=375558,FOLIO='19',FILE='DISK122:[17ZBH1.17ZBH78701]DG78701A.;7',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dg78701_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>(NASDAQ:&nbsp;GWPH).
Mr.&nbsp;Noble qualified as a chartered accountant with PwC and spent seven years at the investment bank Kleinwort Benson Limited, where he became a director in 1990. He then
joined British Biotech&nbsp;plc as Chief Financial Officer from 1990 to 1997. Mr.&nbsp;Noble was previously Chief Executive Officer of Avidex Limited, a privately held biotechnology company that
was our predecessor, from 2000 to 2006. Mr.&nbsp;Noble holds an MA from the University of Oxford. Our Board of Directors believes Mr.&nbsp;Noble's qualifications to serve as a member of our board
include his financial expertise, his extensive experience in the biopharmaceutical industry and his years of experience in his leadership roles as a director and executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Lawrence M. Alleva</I></FONT><FONT SIZE=2> has served as a Non-Executive Director since March 2015 and also serves as Chairman of our Audit Committee.
Mr.&nbsp;Alleva is a former partner with PricewaterhouseCoopers&nbsp;LLP (PwC), where he worked for 39&nbsp;years from 1971 until his retirement in June 2010, including 28&nbsp;years' service
as a partner. Mr.&nbsp;Alleva worked with numerous pharmaceutical and biotechnology companies as clients and, additionally, served PwC in a variety of office, regional and national practice
leadership roles, most recently as the U.S. Ethics and Compliance Leader for the firm's Assurance Practice from 2006 until 2010. Mr.&nbsp;Alleva currently serves as a director for public companies
Tesaro&nbsp;Inc. (NASDAQ:&nbsp;TSRO), Bright Horizons Family Solutions&nbsp;Inc. (NYSE: BFAM) and Mirna Therapeutics&nbsp;Inc. (NYSE:&nbsp;MIRN), and chairs the audit committee for those
companies. He previously served on the board of GlobalLogic,&nbsp;Inc. through the sale of the company in 2013 and also chaired the audit committee. Mr.&nbsp;Alleva is a Certified Public
Accountant (inactive). He received a B.S. degree in Accounting from Ithaca College and attended Columbia University's Executive MBA non-degree program. Our Board of Directors believes
Mr.&nbsp;Alleva's qualifications to serve as a member of our board include his financial expertise, his extensive experience working with public companies on corporate finance and accounting matters
as a Certified Public Accountant (inactive), his experience serving as a director on other corporate boards and his experience in a senior leadership role at PwC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Elliott Sigal</I></FONT><FONT SIZE=2> has served as a Non-Executive Director since February 2015 and also serves as a member of our Corporate Governance and
Nominating Committee. He formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014. Dr.&nbsp;Sigal is a former Executive Vice President and member of the Board of
Directors of Bristol-Myers Squibb. He joined BMS in 1997 as head of Applied Genomics, went on to head Discovery Research followed by clinical development and ultimately served as Chief Scientific
Officer and President of R&amp;D from 2004 until 2013. Dr.&nbsp;Sigal serves as a board member for the Mead Johnson Nutrition Company, Spark Therapeutics and the Melanoma Research Alliance. He also
serves as a senior advisor to the healthcare team of NEA and consults for several biotechnology companies. Dr.&nbsp;Sigal holds an M.D. from the University of Chicago and trained in Internal
Medicine and Pulmonary Medicine at the University of California, San Francisco, where he was on faculty from 1988 to 1992. He also holds a B.S., M.S, and Ph.D. in engineering from Purdue University.
Our Board of Directors believes Dr.&nbsp;Sigal's qualifications to serve as a member of our board include his extensive experience in the pharmaceutical industry and his years of experience in his
leadership roles as a director and executive officer. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CORPORATE GOVERNANCE  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Structure of our Board of Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The leadership structure of our current Board of Directors separates the positions of Chief Executive Officer and Chairman of the Board in order
to ensure independent leadership of the Board. Our Board believes that this separation is appropriate for the Company at this time because it allows for a division of responsibilities, with our CEO
focused on leading the Company while the Chairman can focus on leading the Board in overseeing management, and for a sharing of ideas between individuals having different perspectives. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=28,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=767841,FOLIO='20',FILE='DISK122:[17ZBH1.17ZBH78701]DG78701A.;7',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dg78701_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Independence of our Board of Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has determined that all of our directors, other than James Noble, qualify as "independent" directors in accordance with
the independence requirements under the applicable listing standards of The NASDAQ Global Market as well as applicable rules promulgated by the SEC. Mr.&nbsp;Noble is not considered independent
because he is an employee of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors has made a subjective determination as to each independent director that no relationships exist that would interfere with the exercise of independent judgment in
carrying out the responsibilities of a director. In making these determinations, our Board of Directors reviewed and discussed information provided by the directors and us with regard to each
director's business and personal activities and relationships as they may relate to us and our management. There are no family relationships among any of our directors or executive officers. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
independent directors meet in regularly scheduled executive sessions at which only independent directors are present. All of the committees of our Board of Directors are comprised
entirely of directors determined by the Board of Directors to be independent. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Committees of our Board of Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has three standing committees: the Audit Committee; the Remuneration Committee; and the Corporate Governance and
Nominating Committee. The charters for each of these committees can be found on our website at http://www.adaptimmune.com </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Audit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Remuneration </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Corporate<BR>
Governance<BR>
and Nominating </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David M. Mott</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chair</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chair</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence M. Alleva</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chair</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ali Behbahani, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Barbara Duncan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Giles Kerr</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elliott Sigal, Ph.D, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Thompson, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tal Zaks, Ph.D, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Audit Committee is currently composed of Mr.&nbsp;Alleva, Ms.&nbsp;Duncan and Mr.&nbsp;Kerr, with Mr.&nbsp;Alleva serving as
chairman of the committee. Our Board of Directors has determined that each member of the Audit Committee meets the independence requirements of Rule&nbsp;10A-3 under the Exchange Act and the
applicable listing standards of The NASDAQ Global Market. Our Board of Directors has determined that each of Mr.&nbsp;Alleva, Ms.&nbsp;Duncan and Mr.&nbsp;Kerr is an "audit committee financial
expert" within the meaning of SEC regulations and the applicable listing standards of The NASDAQ Global Market. The Audit Committee held eight meetings during 2016. The Audit Committee's
responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing and reviewing our internal controls, accounting policies and financial reporting and provide a forum through which our independent
registered public accounting firm reports; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> meeting at least once a year with our independent registered public accounting firm without executive Board members present; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=29,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=148326,FOLIO='21',FILE='DISK122:[17ZBH1.17ZBH78701]DG78701A.;7',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dg78701_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the activities of our independent registered public accounting firm, including their appointment, reappointment or removal, as well
as monitoring of their objectivity and independence; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> considering the fees paid to the independent registered public accounting firm and determine whether the fee levels for non-audit services,
individually and in aggregate, relative to the audit fee are appropriate to enable an effective and high quality audit to be conducted; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maintaining oversight over related person transactions to ensure that they are appropriately disclosed and to make recommendations to the Board
of Directors regarding authorization, and for considering noteworthy questions of possible conflicts of interest involving directors. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Remuneration Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Remuneration Committee is currently composed of Mr.&nbsp;Mott, Dr.&nbsp;Thompson and Dr.&nbsp;Zaks, with Mr.&nbsp;Mott serving as
chairman of the committee. Our Board of Directors has determined that each member of the Remuneration Committee is "independent" as defined under the applicable listing standards of The NASDAQ Global
Market. The Remuneration Committee held five meetings during 2016. The Remuneration Committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing corporate goals and objectives relevant to the compensation of our senior executive officers and making recommendations concerning
such objectives to the Board of Directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appointing, compensating and overseeing the work of any compensation consultant or other advisor retained by the Remuneration Committee; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing the performance of our senior executive officers and our Chief Executive Officer who is our sole executive director; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> setting the policy for the remuneration of the senior executive officers and executive directors and the basis of their service and employment
agreements with due regard to the interests of the shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving the compensation of our senior executive officers other than our Chief Executive Officer; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making recommendations to the Board of Directors with respect to the compensation of the Chief Executive Officer and the Non-Executive
Directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> determining the allocation of awards under our share option schemes to our senior executive officers, making recommendations to the Board of
Directors with respect to the allocation of option awards to our Chief Executive Officer and setting the overall allocation of option awards to our employees and consultants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> producing a directors' remuneration policy and an annual directors' remuneration report to be included in our U.K. statutory annual report and
financial statements; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> producing a remuneration committee report on executive compensation when required by the rules of the SEC to be included in our annual proxy
statement. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
individual will participate in discussion or decisions concerning his or her own remuneration. None of the members of our Remuneration Committee has at any time during the prior three
years been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year
has served, as a member of our Remuneration Committee or the remuneration committee of any entity that has one or more executive officers serving on our Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
noted above, our Board of Directors has delegated to the Remuneration Committee the authority to determine the remuneration for our executive officers with the exception of our Chief </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=30,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=484488,FOLIO='22',FILE='DISK122:[17ZBH1.17ZBH78701]DG78701A.;7',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dg78701_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Executive
Officer who is also our sole executive director. Executive and non-executive director remuneration is recommended by our Remuneration Committee to the Board of Directors for approval. Our
Chief Executive Officer may participate in general discussions with our Remuneration Committee and Board of Directors about these remuneration matters but he does not participate in discussions during
which his individual remuneration is being considered and approved. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2016, the Committee retained Willis Towers Watson, a remuneration consultant, to assist the Committee in ensuring that our remuneration arrangements for the Executive Director and
senior executives are competitive for the calendar year commencing January&nbsp;1, 2017. Willis Towers Watson provided data from comparable publicly traded biopharmaceutical companies and otherwise
assisted the Committee in its design of competitive remuneration for our senior executives. The Committee expects to continue to use remuneration consultants to assist the Committee in determining
competitive levels of executive remuneration and specific design elements of our remuneration program. After review and consultation with Willis Towers Watson, the Committee determined that Willis
Towers Watson is independent and that there is no conflict of interest resulting from retaining Willis Towers Watson currently or in 2017. In reaching these conclusions, our Remuneration Committee
considered the factors set forth in the SEC rules and the applicable listing standards of The NASDAQ Global Market. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Committee also retained Radford, an Aon Hewitt company, to conduct market research and analysis and to advise the Committee concerning compensation for our Non-Executive Directors.
As anticipated in our U.K. Directors' Report on Remuneration for the period ended December&nbsp;31, 2015, we revised our remuneration arrangements for Non-Executive Directors during 2016 to comprise
an award of a fixed number of share options, plus an additional number of share options or cash payment at the director's election. The option awards and cash payments were established at competitive
levels taking into account peer data from comparable companies provided in a benchmarking survey undertaken by Radford. After review and consultation with Radford, the Remuneration Committee
determined that Radford is independent and that there is no conflict of interest resulting from retaining Radford currently or in 2017. In reaching these conclusions, our Remuneration Committee
considered the factors set forth in the SEC rules and the applicable listing standards of The NASDAQ Global Market. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Governance and Nominating Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Corporate Governance and Nominating Committee is composed of Mr.&nbsp;Mott, Dr.&nbsp;Behbahani, Mr.&nbsp;Kerr and Dr.&nbsp;Sigal,
with Mr.&nbsp;Mott serving as chairman of the committee. Our Board of Directors has determined that each member of the Corporate Governance and Nominating Committee is "independent" as defined under
the applicable listing standards of The NASDAQ Global Market. The Corporate Governance and Nominating Committee held four meetings during 2016. The Nominating and Corporate Governance Committee's
responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing the structure, size and composition of the Board of Directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recommending to our Board of Directors individuals to be nominated for election as directors and to each of the committees of our Board; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> supervising the selection and appointment process of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making recommendations to the Board of Directors with regard to any changes and using an external search consultant if considered appropriate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appointing, compensating and overseeing the work of any search firm or other advisor retained by the Committee; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making final recommendations to the Board of Directors with respect to new appointments, which includes meeting the candidate prior to
approving the appointment; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=31,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=745305,FOLIO='23',FILE='DISK122:[17ZBH1.17ZBH78701]DG78701A.;7',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dg78701_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the induction of new directors and providing appropriate training to the Board of Directors during the course of the year in order
to ensure that they have the knowledge and skills necessary to operate effectively; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> evaluating the performance of the Board of Directors, both on an individual basis and for the Board of Directors as a whole, taking into
account such factors as attendance record, contribution during board meetings and the amount of time that has been dedicated to board matters during the course of the year. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Oversight of Risk Management  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management is primarily responsible for assessing and managing risk, while our Board of Directors is responsible for overseeing management's
execution of its responsibilities. Our Board of Directors is supported by its committees in fulfillment of this responsibility. For example, our Audit Committee focuses on our overall financial risk
by evaluating our internal controls and disclosure policies as well as ensuring the integrity of our financial statements and periodic reports. Our Remuneration Committee strives to create incentives
that encourage an appropriate level of risk-taking consistent with our business strategy. Finally, our Corporate Governance and Nominating Committee ensures that our governance policies and procedures
are appropriate in light of the risks we face. Our Chief Executive Officer, Mr.&nbsp;Noble, serves on our Board of Directors; however, he does not serve as Chairman of the Board of Directors.
Mr.&nbsp;Mott serves as Chairman of the Board of Directors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Nomination Process  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Corporate Governance and Nominating Committee of the Board of Directors reviews possible candidates for the Board and recommends the
nominees for Directors to the Board for approval. The criteria that the Corporate Governance and Nominating and Committee and the Board of Directors look for in determining candidates for election to
the Board, include, among others:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the highest personal and professional ethics, integrity and values; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> commitment to representing the long-term interests of the Company's shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> independence under the standards promulgated by The NASDAQ Global Market; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ability to dedicate the time and resources sufficient to ensure the diligent performance of his or her duties on our behalf, including
attending all Board of Directors and applicable committee meetings. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we do not have a standalone diversity policy, diversity is among the critical factors that the Board of Directors considers when evaluating its composition. It is the Corporate
Governance and Nominating Committee's policy that the composition of the Board of Directors reflect a range of talents, ages, skills, character, diversity and expertise, particularly in the areas of
accounting and finance, management, domestic and international markets, leadership, corporate governance, and biotechnology and related industries, sufficient to provide sound and prudent guidance
with respect to the operations and interests of the Company. The independent directors of our Board of Directors believe that the current members of the Board of Directors reflect an appropriate
diversity of gender,
age, race, geographical background and experience but are committed to continuing to consider diversity issues in evaluating the composition of the Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Nominating and Corporate Governance Committee's policy does not contemplate any disparate treatment of management nominees versus those put forth by our shareholders. To date, the
Committee has worked with Egon Zehnder, an independent global board and executive search firm, to assist in identifying and evaluating potential nominees against role specifications. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=32,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=640,FOLIO='24',FILE='DISK122:[17ZBH1.17ZBH78701]DG78701A.;7',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dg78701_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shareholder Recommendations and Nominees  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is the policy of our Board of Directors that the Nominating and Corporate Governance Committee consider both recommendations and nominations
for candidates to the Board from shareholders so long as such recommendations and nominations comply with our Articles of Association and applicable laws, including the rules and regulations of the
SEC. Shareholders may recommend director nominees for consideration by the Corporate Governance and Nominating Committee by writing to our Company Secretary at the address below, or the Company's
registered office address from time to time, and providing evidence of the shareholder's ownership of our ordinary shares and/or ADSs, the nominee's name, home and business address and other contact
information, as well as the nominee's detailed biographical data and qualifications for board membership, and information regarding any relationships between the recommended candidate and the Company
within the last three fiscal years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
verification of the shareholder status of the person submitting the recommendation, all properly submitted recommendations will be promptly brought to the attention of the
Corporate Governance and Nominating Committee. Shareholders who desire to nominate persons directly for election to the Board at an annual general meeting of shareholders must meet the deadlines and
other requirements set forth under "Additional Information&#151;Shareholder Proposals for 2018 Annual General Meeting." Any vacancies on the Board of Directors occurring between our annual
general meetings of shareholders may be filled by persons selected by a majority of the directors then in office, in which case any director so elected will serve until the next annual general meeting
of shareholders when such director will offer himself/herself for re-election, or by persons elected by an ordinary resolution of the shareholders of the Company. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may write to the Corporate Governance and Nominating Committee at: </FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>c/o
Margaret Henry<BR>
Company Secretary<BR>
Adaptimmune Therapeutics&nbsp;plc<BR>
101 Park Drive<BR>
Abingdon<BR>
Oxfordshire OX14&nbsp;4RY<BR>
United Kingdom </FONT></P>

</UL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of Business Conduct and Ethics  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a Code of Business Conduct and Ethics applicable to all of our directors, officers and employees. The Code of Business Conduct
and Ethics is available on our website at http://www.adaptimmune.com. We expect that any amendments to this code or any waivers of its requirements will be disclosed on our website. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shareholder Communication with the Board of Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is the policy of our Board of Directors to allow shareholders to communicate with its members. Communications may be addressed to the entire
board or to any individual director. All such communications will initially be received and processed by our Company Secretary. Spam, junk mail, advertisements and threatening, hostile, illegal and
similar unsuitable communications will not be delivered to the Board. Shareholders can contact members of the Board Directors by writing care of our Company Secretary at the Company's registered
office address. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=33,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=11106,FOLIO='25',FILE='DISK122:[17ZBH1.17ZBH78701]DG78701A.;7',USER='PJAMES',CD='26-APR-2017;19:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di78701_1_26"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di78701_director_remuneration_and_attendance"> </A>
<A NAME="toc_di78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DIRECTOR REMUNERATION AND ATTENDANCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under our Directors' Remuneration Policy, the Board has the discretion to pay our Non-Executive Directors for their Board and committee service
in the form of cash fees or share options or a mixture of cash fees and share options. Our remuneration arrangements for Non-Executive Directors during 2016 comprised an award of a fixed number of
share options, plus an additional number of share options or cash payment at the director's election. The option awards and cash payments were established at competitive levels taking into account
peer data from comparable companies provided in a benchmarking survey undertaken by Radford consultants and are compliant with the last Directors' Remuneration policy approved by our shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Non-Executive Directors may earn the following annual cash compensation or they may make an election to receive such compensation in the form of an additional number of share
options. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 Cash<BR>
Compensation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Board of Directors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chairman (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Committee Chair (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Remuneration Committee Chair (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Governance and Nominating Committee Chair (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Committee member/non-Chair (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Remuneration Committee member/non-Chair (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Governance and Nominating Committee member/non-Chair (additional retainer)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
cash payments are payable monthly in arrears at the end of each month during which such individual served as a director (with prorated payments for service during a portion of such
month). Non-Executive Directors are also entitled to receive reimbursement of expenses incurred in the course of performing services to the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Non-Executive Directors do not receive any pension from the Company nor do they participate in any performance-related incentive plans. Our Non-Executive Directors participate in the
Group's long-term incentive plans on terms similar to those used for our executive directors and officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
joining the Board, Non-Executive Directors are eligible to receive an initial award of share options covering 288,000 of our ordinary shares and, at their election, either cash
compensation, as set forth above, or additional options of equivalent value. All such options vest in three annual installments over three years. Subsequently, all Non-Executive Directors are eligible
to receive an annual award of share options covering 144,000 of our ordinary shares, at their election, and either cash compensation, as set forth above, or additional options of equivalent value. All
options awarded annually are exercisable on the first anniversary of the date of grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
2016, all Non-Executive Directors (except for Barbara Duncan, Giles Kerr and Tal Zaks) were granted an annual award of share options on August&nbsp;11, 2016. Ms.&nbsp;Duncan,
Mr.&nbsp;Kerr and Dr.&nbsp;Zaks were awarded share options on joining the Board of Directors and relevant committees during 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining option awards, the Board of Directors works within benchmarking guidelines provided by remuneration consultants. All options are granted with an exercise price that is no
lower than the fair market value of an ordinary share on the date prior to the date of grant. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=34,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=776391,FOLIO='26',FILE='DISK122:[17ZBH1.17ZBH78701]DI78701A.;10',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_di78701_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2016 Director Compensation Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below shows the compensation paid to our Non-Executive Directors during the year ended December&nbsp;31, 2016. The compensation paid
to James Noble, our Chief Executive Officer and an executive director is set forth in "</FONT><FONT SIZE=2><I>Executive Compensation</I></FONT><FONT SIZE=2>" below. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees<BR>
Earned or<BR>
paid in<BR>
cash$(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
awards($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David M. Mott(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>141,063</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>141,063</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence Alleva(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>144,945</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>144,945</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ali Behbahani(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>136,016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>136,016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Barbara Duncan(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>295,099</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>295,099</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Giles Kerr(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,166</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>134,489</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>141,655</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jonathan Knowles(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>160,085</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>160,085</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ian Laing(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,209</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>106,123</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>123,332</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elliott Sigal(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>136,016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>136,016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Thompson(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>137,180</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>137,180</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tal Zaks(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,217</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>134,489</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>139,706</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
fees paid to Mr.&nbsp;Kerr and Mr.&nbsp;Laing were denominated in pounds sterling. For purposes of this table, the 2016 amounts paid to those Directors have
been converted based on the pound sterling/U.S. dollar exchange rate in effect as of December&nbsp;31, 2016(&pound;1/$1.233). All fees paid represent pro-rata amounts as Mr.&nbsp;Kerr joined
the Board on November&nbsp;1, 2016, Dr.&nbsp;Zaks joined the Board on November&nbsp;16, 2016 and Mr.&nbsp;Laing was paid effective from August&nbsp;11, 2016 and stood down from the Board on
December&nbsp;31, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>See
Item&nbsp;7&#151;"Share based compensation" and Note&nbsp;2 (r)&nbsp;and Note&nbsp;10 "Share based compensation" to our audited consolidated
financial statements, in our Form&nbsp;10-K for an explanation of the assumptions used in the calculation of these amounts.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Mott
received an annual option award covering 191,410 ordinary shares on August&nbsp;11, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Alleva
received an annual option award covering 196,678 ordinary shares on August&nbsp;11, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Behbahani
received an annual option award covering 184,562 ordinary shares on August&nbsp;11, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ms.&nbsp;Duncan
received an initial option award covering 332,776 ordinary shares on June&nbsp;23, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Kerr
received an initial option award covering 288,000 ordinary shares on November&nbsp;29, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Knowles
received an annual option award covering 217,222 ordinary shares on August&nbsp;11, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Laing
received an annual option award covering 144,000 ordinary shares on August&nbsp;11, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Sigal
received an annual option award covering 184,562 ordinary shares on August&nbsp;11, 2016. </FONT></DD></DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=35,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=256264,FOLIO='27',FILE='DISK122:[17ZBH1.17ZBH78701]DI78701A.;10',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_di78701_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Thompson
received an annual option award covering 186,142 ordinary shares on August&nbsp;11, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Zaks
received an initial option award covering 288,000 ordinary shares on November&nbsp;29, 2016.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2016, our Board of Directors met 14 times. With the exception of Ms.&nbsp;Duncan, Mr.&nbsp;Kerr and Dr.&nbsp;Zaks, all of our directors attended a minimum of 75% of the meetings
of our Board of Directors and its committees in&nbsp;2016. Ms.&nbsp;Duncan was first appointed in late June and has attended six meetings in 2016. Mr.&nbsp;Kerr was appointed on
November&nbsp;1, 2016, and attended one meeting in 2016. Dr.&nbsp;Zaks was appointed on November&nbsp;14, 2016, and was unable to attend the final board meeting of 2016; however, he has attended
board and Remuneration Committee meetings in January through March 2017. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Deeds of Indemnification  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have any third party indemnification provisions in place for the benefit of one or more of our directors. However, we agree to use all
reasonable endeavors to provide and maintain appropriate directors' and officers' liability insurance (including ensuring that premiums are properly paid) for their benefit for so long as any claims
may lawfully be brought against them. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Executive Director Appointment Letters  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into letters of appointment with each of our Non-Executive Directors. These letters set forth the main terms on which each of
our Non-Executive Directors serve on our Board of Directors. Continued appointment under the letter is contingent on continued satisfactory performance as a member of the Board of Directors and as a
member of a committee, if relevant, as well as being re-elected at the annual general meetings in accordance with the Articles of Association of the Company. The appointment may be terminated by the
Company or the Non-Executive Director with a three months' prior written notice. Upon termination, the
Non-Executive Director is entitled to a pro-rata amount of the annual fee (if applicable) that is outstanding and payable up to the date of termination, and reimbursement in the normal way of any
expenses properly incurred before that date. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=36,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=767852,FOLIO='28',FILE='DISK122:[17ZBH1.17ZBH78701]DI78701A.;10',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_di78701_1_29"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di78701_security_ownership_of_certain___sec02525"> </A>
<A NAME="toc_di78701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table and related footnotes set forth information with respect to the beneficial ownership of our ordinary shares, as of
April&nbsp;10, 2017, by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each beneficial owner of more than 5% of our ordinary shares </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our named executive officers and directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of our executive officers and directors as a group. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership is determined in accordance with the rules and regulations of the SEC. Under these rules, beneficial ownership includes any shares as to which a person has sole or
shared voting power or investment power. In computing the number of ordinary shares beneficially owned by a person and the percentage ownership of that person, ordinary shares subject to options, or
other rights held by such person that are currently exercisable or will become exercisable within 60&nbsp;days of April&nbsp;10, 2017 are considered outstanding. These ordinary shares, however,
are not included in the computation
of the percentage ownership of any other person. Applicable percentage ownership is based on 560,976,430 ordinary shares outstanding as of April&nbsp;10, 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise indicated, the address for each of the shareholders listed in the table below is c/o&nbsp;Adaptimmune Therapeutics&nbsp;plc, 101 Park Drive, Milton Park, Oxfordshire
OX14&nbsp;4RY, United Kingdom. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Ordinary Shares<BR>
Beneficially Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Greater than 5% Shareholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New Enterprise Associates(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>72,156,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12.86</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FMR&nbsp;LLC(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>42,391,084</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.56</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Matrix Capital Management Master Fund L.P(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>42,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capital World Investors(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,756,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OrbiMed Private Investments V,&nbsp;L.P.(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>36,896,260</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ian Laing(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29,346,675</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nicholas Cross(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29,322,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Named Executive Officers and Directors</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,466,404</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.76</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado, M.D.(9).&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,359,315</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.42</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe(10)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,263,315</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Mott(11)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>72,319,229</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ali Behbahani, M.D.(12)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>72,311,682</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Thompson, M.D.(13)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>37,051,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.60</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elliott Sigal, M.D., Ph.D.(14)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>673,012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence M. Alleva(15)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>382,707</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Barbara Duncan(16)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Giles Kerr(16)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tal Zaks, Ph.D.(16)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>All Executive Officers and Directors as a Group (14 persons</I></FONT><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
137,142,305</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
24.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of (i)&nbsp;72,139,000 ordinary shares directly held by New Enterprise Associates&nbsp;14,&nbsp;L.P., or NEA 14 and (ii)&nbsp;17,000 ordinary shares
directly held by NEA Ventures&nbsp;14,&nbsp;L.P., or NEA Ven 14. These ordinary shares are represented by ADSs. The shares directly held by NEA 14 are indirectly held by NEA Partners
14,&nbsp;L.P., or NEA </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=37,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=804676,FOLIO='29',FILE='DISK122:[17ZBH1.17ZBH78701]DI78701A.;10',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_di78701_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>Partners&nbsp;14,
the sole general partner of NEA&nbsp;14, NEA 14&nbsp;GP,&nbsp;LTD, or NEA&nbsp;14&nbsp;LTD, the sole general partner of NEA Partners 14 and each of the individual
Directors of NEA&nbsp;14&nbsp;LTD. The individual Directors, or collectively, the Directors of NEA&nbsp;14&nbsp;LTD, are M.&nbsp;James Barrett, Peter J. Barris, Forest Baskett, Ryan D.
Drant, Anthony A. Florence,&nbsp;Jr., Patrick J. Kerins, Krishna "Kittu" Kolluri, C. Richard Kramlich, David M. Mott (a member of our Board), Scott D. Sandell, Peter Sonsini, Ravi Viswanathan and
Harry R. Weller. The shares directly held by NEA Ven 14 are indirectly held by Karen P. Welsh, the general partner of NEA Ven 14. All indirect holders of the above referenced
shares disclaim beneficial ownership of all applicable shares except to the extent of their actual pecuniary interest therein. The principal business address of New Enterprise Associates,&nbsp;Inc.
is 1954 Greenspring Drive, Suite&nbsp;600, Timonium, MD 21093.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>FMR&nbsp;LLC
holds these shares in the form of ADSs on behalf of certain of its direct and indirect subsidiaries and has sole voting power and sole dispositive
power over these shares. The registered office of FMR,&nbsp;LLC is 245 Summer Street, Boston, MA 02210, United States.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Matrix
Capital Management Master Fund&nbsp;L.P. holds these shares in the form of ADSs. The registered office of Matrix Capital Management Master Fund&nbsp;L.P.
is c/o Matrix Capital Management&nbsp;L.P., 1000 Winter Street, Suite&nbsp;4500, Waltham, MA 02451.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Capital
World Investors, a division of Capital Research and Management Company (CRMC), a U.S.-based investment management company, holds these shares in the form of
ADSs. The Capital Group Companies,&nbsp;Inc. is the parent company of CRMC. The business address for CRMC is 333 South Hope Street, Los Angeles, CA 90071.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>OrbiMed
Capital&nbsp;GP V&nbsp;LLC ("GP V") is the sole general partner of OPI V. OrbiMed Advisors&nbsp;LLC ("OrbiMed Advisors") is the managing member
of&nbsp;GP V.&nbsp;GP V and OrbiMed Advisors may be deemed to have beneficial ownership of the shares held by OPI V. Samuel D. Isaly is the managing member of and owner of a controlling interest
in OrbiMed Advisors and as such may be deemed to have beneficial ownership of the shares held by OPI V. Peter Thompson, one of our directors, is employed as a Private Equity Partner at OrbiMed
Advisors. Each of&nbsp;GP V, OrbiMed Advisors, Mr.&nbsp;Isaly and Dr.&nbsp;Thompson disclaims beneficial ownership of the shares held by OPI V except to the extent of its or his pecuniary
interest therein, if any. The address for these entities is 601&nbsp;Lexington Avenue, 54<SUP>th</SUP>&nbsp;floor, New York, New York 10022.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
options held by Mr.&nbsp;Laing to purchase 303,875 ordinary shares that are exercisable immediately.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
279,378 ordinary shares represented by 46,563 ADSs.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of (i)&nbsp;9,972,600 ordinary shares; (ii)&nbsp;1,200,000 ordinary shares represented by 200,000 ADSs and (ii)&nbsp;options to purchase 4,293,804
ordinary shares that are or will be exercisable within 60&nbsp;days of April&nbsp;10, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of (i)&nbsp;96,000 ordinary shares represented by 16,000 ADSs and (ii)&nbsp;options to purchase 2,263,315 ordinary shares that are or will be
exercisable within 60&nbsp;days of April&nbsp;10, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of options to purchase 2,263,315 ordinary shares that are or will be exercisable within 60&nbsp;days of April&nbsp;10, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
the shares set forth in footnote (1)&nbsp;above and options held by Mr.&nbsp;Mott to purchase 163,229 ordinary shares that are exercisable immediately.
Mr.&nbsp;Mott is a member of the Board at NEA 14&nbsp;GP,&nbsp;LTD, which has ultimate voting and investment power over </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=38,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=570363,FOLIO='30',FILE='DISK122:[17ZBH1.17ZBH78701]DI78701A.;10',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_di78701_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
<UL>

<P style="font-family:times;"><FONT SIZE=2>shares
held of record by New Enterprise Associates 14, Limited Partnership. He disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
the shares set forth in footnote (1)&nbsp;above and options held by Dr.&nbsp;Behbahani to purchase 155,682 ordinary shares that are exercisable
immediately. Dr.&nbsp;Behbahani is a partner of New Enterprise Associates,&nbsp;Inc., which has ultimate voting and investment power over shares held of record by New Enterprise Associates 14,
Limited Partnership.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
the shares set forth in footnote (5)&nbsp;above and options held by Dr.&nbsp;Thompson to purchase 155,682 ordinary shares that are exercisable
immediately. Dr.&nbsp;Thompson is an employee of Orbimed Advisors&nbsp;LLC, which has ultimate voting and investment power over shares held of record by Orbimed Private Investments V,&nbsp;L.P.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
shares held by Sigal Family Investments,&nbsp;LLC, and options held by Dr.&nbsp;Sigal to purchase 305,974 ordinary shares that are or will be
exercisable within 60&nbsp;days of April&nbsp;10, 2017. Dr.&nbsp;Sigal is a manager of Sigal Family Investments,&nbsp;LLC. Dr.&nbsp;Sigal may be deemed to have voting and investment power
over the shares held by Sigal Family Investments,&nbsp;LLC. Dr.&nbsp;Sigal disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Also included in
the ordinary shares beneficially owned are 52,938 ordinary shares represented by 8,823 ADSs that Dr.&nbsp;Sigal purchased during the IPO.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(15)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of options held by Mr.&nbsp;Alleva to purchase 312,123 ordinary shares that are or will be exercisable within 60&nbsp;days of April&nbsp;10, 2017 and
70,584 ordinary shares represented by 11,764 ADSs that Mr.&nbsp;Alleva purchased during the IPO.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(16)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
options held by Barbara Duncan, Giles Kerr and Tal Zaks are not exercisable within 60&nbsp;days of April&nbsp;10, 2017.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=39,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=1037150,FOLIO='31',FILE='DISK122:[17ZBH1.17ZBH78701]DI78701A.;10',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_di78701_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di78701_section_16(a)_benefici__di702035"> </A>
<A NAME="toc_di78701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our directors, executive officers and any greater than 10&nbsp;percent shareholders are required by Section&nbsp;16(a) of the
Exchange Act to file with the SEC initial reports of ownership and reports of changes in ownership of shares and to furnish us with copies of such reports. Based on a review of those reports and
written representations that no other reports were required, we believe that our Section&nbsp;16 directors and officers complied with all of their applicable Section&nbsp;16(a) filing
requirements. The one exception to this was a Form&nbsp;3 for Dr.&nbsp;Tal Zaks that was inadvertently filed outside of the time frame prescribed by Section&nbsp;16. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=40,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=601775,FOLIO='32',FILE='DISK122:[17ZBH1.17ZBH78701]DI78701A.;10',USER='PJAMES',CD='26-APR-2017;19:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk78701_1_33"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk78701_executive_officers_of_the_company"> </A>
<A NAME="toc_dk78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE OFFICERS OF THE COMPANY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below is a list of our executive officers as of the date of this proxy statement. There are no family relationships between any of our executive
officers, and there is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was selected. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="258pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Bertrand</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Operating Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Helen Tayton-Martin, Ph.D</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Business Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Financial Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gwendolyn Binder-Scholl, Ph.D</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Technology Officer, Adaptimmune&nbsp;LLC</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;James Noble.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For biographical information regarding Mr.&nbsp;Noble, refer to the discussion under</FONT><FONT SIZE=2><I> Board of
Directors</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;William Bertrand.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Bertrand has served as our Chief Operating Officer since March 2017 and is responsible for a range of
operational
functions including compliance, risk management, human resources and legal/IP. Mr.&nbsp;Bertrand's prior experience includes a 12&nbsp;year tenure at MedImmune, where he served as its first
General Counsel and Chief Compliance Officer, along with holding a variety of operational and corporate strategy roles. He has also formerly served as Executive Vice President, General Counsel for
Infinity Pharmaceuticals,&nbsp;Inc., and as Senior Vice President, Acting Chief Operating Officer and General Counsel for Salix Pharmaceuticals, where he remained as General Manager to help finalize
the integration of the company's $14&nbsp;billion acquisition by Valeant Pharmaceuticals in April 2015. He is currently a member of the board of directors of Ardelyx,&nbsp;Inc.
(NASDAQ: ARDX) and has served as a member of the board of directors of several private companies including Trustwave and Inotek Pharmaceuticals. Mr.&nbsp;Bertrand received a J.D. from the University
of Wisconsin and a B.S. in biology from Wayne State University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Helen Tayton-Martin, Ph.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Tayton-Martin transitioned to become Adaptimmune's Chief Business Officer in March 2017, having
served as Chief
Operating Officer since 2008. She is responsible for optimizing the strategic and commercial opportunity for the Company's assets, leading on business development and commercial activities. Her role
encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management, commercial planning and partnerships, including our strategic partnership
with GSK. Dr.&nbsp;Tayton-Martin has 25&nbsp;years of experience working within the pharmaceutical, biotech and consulting environment in disciplines across preclinical and clinical development,
outsourcing, strategic planning, due diligence and business development. She co-founded Adaptimmune from Avidex Limited (subsequently Medigene), where she was responsible for commercial development of
the soluble TCR program in cancer and HIV therapy from 2005 to 2008. Dr.&nbsp;Tayton-Martin holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London
Business School. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rafael Amado, M.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Amado has served as our Chief Medical Officer since March 2015 and has 12&nbsp;years of experience within
the biotech
and pharmaceutical industries. Dr.&nbsp;Amado leads our clinical strategy and is responsible for our clinical trials across the U.S. and Europe under our strategic collaboration with GSK (LSE/NYSE:
GSK), as well as leading the development of our pipeline of wholly-owned research programs. He formerly served as Senior Vice President and Head of Oncology R&amp;D at GSK, where he was responsible for
integrating oncology R&amp;D activities, from drug target identification to clinical development and registration globally. Dr.&nbsp;Amado joined GSK in 2008 as Vice President of Clinical Development,
and served in positions of increasing responsibility, including Senior Vice President and Head of Oncology Clinical Development. He oversaw the development and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=41,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=686695,FOLIO='33',FILE='DISK122:[17ZBH1.17ZBH78701]DK78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dk78701_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>registration
globally of over fifteen novel indications across six products and led the development of a pipeline of products in novel areas of cancer biology. Prior to joining GSK, Dr.&nbsp;Amado
was Executive Director of Therapeutic Oncology at Amgen from 2003 to 2008 where he was responsible for development activities of several assets. Dr.&nbsp;Amado trained as a Hematologist/Oncologist
at the University of California, Los Angeles, where he remained as faculty for eight years until joining Amgen in 2003. He holds an M.D. from the University of Seville School of Medicine, and
performed his residency in Internal Medicine at Michael Reese Hospital, a University of Chicago Affiliated Hospital, and his fellowship in Hematology/Oncology at the University of California, Los
Angeles. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adrian Rawcliffe.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Rawcliffe has served as our Chief Financial Officer since March 2015 and leads our financial strategy and
operations, as
well as Investor Relations, corporate communications, global IT and facilities. He has 17&nbsp;years of experience within the pharmaceutical industry and most recently served as Senior Vice
President, Finance of GSK's North American Pharmaceuticals business. Mr.&nbsp;Rawcliffe currently serves as a non-executive director of WAVE Life Sciences (NASDAQ: WVE). Mr.&nbsp;Rawcliffe joined
GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&amp;D Finance, where he was responsible for all business development and finance
activities for GSK's Pharmaceuticals R&amp;D business and Managing Partner and President of SR One&nbsp;Ltd, GSK's venture-capital business. Mr.&nbsp;Rawcliffe qualified as a chartered accountant with
PwC and holds a B.Sc. degree in Natural Sciences from the University of Durham, U.K.. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gwendolyn Binder-Scholl, Ph.D.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Binder-Scholl has served as our Chief Technology Officer since February 2016. Prior to assuming
this
position, Dr.&nbsp;Binder-Scholl was Executive Vice President of Adaptimmune&nbsp;LLC and Head of Translational Sciences. She has also previously served in senior clinical, regulatory and
operational roles in the company since March 2011. As CTO, Dr.&nbsp;Binder-Scholl leads our Manufacturing Development and Translational Science operations and oversees the UK research team. Her
strategic focus is on optimizing the therapeutic potential of Adaptimmune's product through directed translational research across correlative clinical and manufacturing development. As well as her
leadership of manufacturing operations, she oversees process development and the co-ordination of Research operations more broadly, integrating pipeline and second generation T-cell research with
clinical outcomes. Dr.&nbsp;Binder-Scholl has 14&nbsp;years of industry and academic experience in cellular and gene therapy translational research and development, with prior roles including
Director of Translational Research Operations at the University of Pennsylvania from 2006 to 2011 and Director of Scientific Affairs at Virxsys Corporation. Dr.&nbsp;Binder-Scholl is a biochemistry
and molecular biology graduate of Wells College with a Ph.D. in cellular and molecular medicine from Johns Hopkins University. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=42,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=946314,FOLIO='34',FILE='DISK122:[17ZBH1.17ZBH78701]DK78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dk78701_1_35"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk78701_executive_compensation"> </A>
<A NAME="toc_dk78701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Compensation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section discusses the material components of the executive compensation program offered to our named executive officers, or NEOs,
identified below. For the year ended December&nbsp;31, 2016, these NEOs were:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> James Noble, Chief Executive Officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Adrian Rawcliffe, Chief Financial Officer; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Rafael Amado, Chief Medical Officer. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are an "emerging growth company" as that term is used in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and have elected to comply with the reduced compensation
disclosure requirements available to emerging growth companies under the JOBS Act. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2016 Summary Compensation Table  </I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
awards<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Non-equity<BR>
incentive plan<BR>
compensation<BR>
($)(5) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All other<BR>
compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 James Noble(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>388,395</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,411,405</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>97,099</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,465</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,917,364</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Executive Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>442,080</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>294,720</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>761,421</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
435,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
674,104</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
117,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
34,262</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,260,816</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Financial Officer</I></FONT><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>336,452</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,379,693</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>151,403</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42,387</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,909,935</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Rafael Amado</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
430,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
674,104</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
116,100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
20,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,240,494</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Medical Officer(2)</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>331,358</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,379,693</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>149,111</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31,949</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,892,111</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Noble
also serves as a director but receives no additional compensation for this service.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Rawcliffe
and Dr.&nbsp;Amado commenced employment with us on March&nbsp;16, 2015. The 2015 salary shown for Mr.&nbsp;Rawcliffe represents the
pro-rated amount of his base salary of $425,000 and the 2015 salary shown from Dr.&nbsp;Amado represents the pro-rated amount of his base salary of $418,200. The 2015 non-equity incentive plan
compensation amounts shown for Mr.&nbsp;Rawcliffe and Dr.&nbsp;Amado are based on 45% of their pro-rated 2015 base salaries.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Compensation
paid to Mr.&nbsp;Noble is denominated in Pounds Sterling. For purposes of this table, all 2016 amounts have been converted based on the Pound
Sterling/U.S. Dollar exchange rate in effect as of December&nbsp;31, 2016 (&pound;1/$1.233) and all 2015 amounts have been converted based on the Pound Sterling/U.S. Dollar exchange rate in
effect as of December&nbsp;31, 2015 (&pound;1/$1.4736).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>See
Item&nbsp;7&#151;"Share based compensation", and Note&nbsp;2 (r)&nbsp;and Note&nbsp;10 "Share based compensation" to our audited consolidated
financial statements, in our Form&nbsp;10-K for an explanation of the assumptions used in the calculation of these amounts.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Amount
represents sums paid under our annual cash bonus program.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of Company payments in the amount of (i)&nbsp;$16,962.14 to subsidize city of Philadelphia taxes, (ii)&nbsp;$5,300 in matching contributions under the
401(k) plan and (iii)&nbsp;$12,000 to private health care insurance on behalf of Mr.&nbsp;Rawcliffe.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of Company payments in the amount of (i)&nbsp;$13,188.94 to subsidize city of Philadelphia taxes, (ii)&nbsp;$20,198 in matching contributions under the
401(k) plan and (iii)&nbsp;$9,000 to private health care insurance on behalf of Mr.&nbsp;Rawcliffe. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=43,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=140821,FOLIO='35',FILE='DISK122:[17ZBH1.17ZBH78701]DK78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dk78701_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of Company payments in the amount of (i)&nbsp;$14,989.90 to subsidize city of Philadelphia taxes and $5,300 in matching contributions under the 401(k)
plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of Company payments in the amount of (i)&nbsp;$11,750.66 to subsidize city of Philadelphia taxes and (ii)&nbsp;$20,198 in matching contributions under
the 401(k) plan.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Narrative Disclosure to Summary Compensation Table  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The primary elements of compensation for our NEOs are base salary, annual cash bonuses and long-term, equity-based compensation awards. Our NEOs
also participate in employee benefit plans and programs that we offer to our other full-time employees on the same basis and have from time to time received relocation or other expense reimbursements
from us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base Salary.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our NEOs receive base salary to compensate them for the satisfactory performance of duties to our company. The base salary
payable to
each NEO is intended to provide a fixed component of compensation reflecting the executive's skill set, experience, role and responsibilities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Remuneration Committee periodically reviews NEO base salaries in consultation with management and Willis Towers Watson, an independent compensation consultant, to determine whether
any adjustments are necessary or appropriate. The following table shows the annual base salaries of our NEOs for 2016 and 2017. All annual base salary increases were effective January&nbsp;1 of the
given year. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 Annual<BR>
Base Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 Annual<BR>
Base Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>388,395</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>502,854</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>435,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>443,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>430,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>442,900</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Compensation
paid to Mr.&nbsp;Noble is denominated in pounds sterling. For purposes of this table, 2016 and 2017 amounts for Mr.&nbsp;Noble in the table above
have been converted based on the pound sterling/U.S. dollar exchange rate in effect as of December&nbsp;31, 2016 (&pound;1/$1.233).  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Annual Cash Bonuses.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our NEOs have the opportunity to earn annual performance bonuses based on
the achievement of short-term performance goals, and which are expressed as a percentage of base salary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Remuneration Committee generally determines annual bonuses for our NEOs, and the Board determines the annual bonus for our CEO, subject to: (i)&nbsp;objective criteria set forth by
the Board of Directors or an authorized delegate thereof on an annual basis; and (ii)&nbsp;the overall performance of the Company and the Group. The initial target annual bonus with effect from
January&nbsp;1, 2017 for Mr.&nbsp;Noble is fifty percent (50%) of his base salary and for each of Mr.&nbsp;Rawcliffe and Dr.&nbsp;Amado is forty-five percent (45%) of his base salary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity-Based Compensation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We have historically offered share options to our employees, including our NEOs, as the long-term incentive
component of
our compensation program. We typically grant options to employees as soon as practicable after they commence employment with us and may thereafter grant additional options in the discretion of our
Board of Directors or Remuneration Committee. Our share options allow employees to purchase our ordinary shares at a price equal to the fair market value of our ordinary shares on the date prior to
the grant date. Our share options typically vest as to 25% of the shares subject to the option on the first anniversary of the grant date and in monthly installments during the three-year period
thereafter, subject to the holder's continued service </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=44,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=1030150,FOLIO='36',FILE='DISK122:[17ZBH1.17ZBH78701]DK78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dk78701_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>with
us. From time to time, our Board of Directors or Remuneration Committee may also construct alternate vesting schedules as it determines in its sole discretion. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
awarded share options to our NEOs during 2016 in the following amounts and subject to vesting in accordance with our standard time-based vesting schedule described above: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Named Executive Officer

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 Options<BR>
Granted (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,968,016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>939,948</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rafael Amado</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>939,948</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retirement, Health, Welfare and Additional Benefits.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our NEOs are eligible to participate in our employee benefit plans and programs,
including
medical and dental benefits and life insurance, to the same extent as our other full-time employees, subject to the terms and eligibility requirements of those plans. We also sponsor a 401(k) defined
contribution plan in which our NEOs based in the United States may participate, subject to limits imposed by the Internal Revenue Code, to the same extent as all of our other full-time employees.
During 2016, we made discretionary employer matching contributions equal to 50% of the first 4% of the elective contributions made by participants in the 401(k) plan. These matching contributions are
subject to a vesting schedule. In addition, we made a 3% discretionary Safe Harbor match which is fully vested as of the date on which the contribution is made. We believe that providing a vehicle for
tax-deferred retirement savings through our 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our NEOs, in accordance
with our compensation policies. We do not typically provide any perquisites or special personal benefits to our NEOs, but have from time to time reimbursed amounts associated with relocation and other
expenses for our NEOs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at 2016 Fiscal Year-End  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding equity awards held by our named executive officers as of December&nbsp;31, 2016. All
options are options to purchase ordinary shares. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="77pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>First date some<BR>
or all options<BR>
are exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
securities<BR>
underlying<BR>
unexercised<BR>
options (#)<BR>
exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
securities<BR>
underlying<BR>
unexercised<BR>
options(#)<BR>
unexercisable(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
exercise<BR>
Price<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
expiration<BR>
date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 James Noble</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/31/2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,055,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>280,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.1671</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>03/30/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/31/2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>219,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>219,100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.1671</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>03/30/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/19/2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,749,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,750,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.5308</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/19/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,968,016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.2717</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adrian Rawcliffe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
03/16/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,575,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2,025,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
0.74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
03/16/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>939,948</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.2717</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Rafael Amado</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
03/16/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,575,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2,025,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
0.74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
03/16/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>939,948</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.2717</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>01/18/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Vesting
of all options is subject to continued service through the applicable vesting date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
exercise price was converted from pounds sterling to U.S. dollars based on the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on
the date of grant. The actual exercise price will be the pounds sterling amount regardless of the exchange rate on the date of grant or of exercise. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=45,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=583639,FOLIO='37',FILE='DISK122:[17ZBH1.17ZBH78701]DK78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dk78701_1_38"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was partially vested and the remainder will vest in annual installments on the thirty first of March from March&nbsp;31, 2017 through March&nbsp;31,
2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was partially vested and 109,500 ordinary shares will vest on April&nbsp;14, 2017 and 190,600 ordinary shares will vest on April&nbsp;14, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was partially vested and the remainder will vest in monthly installments of 72,900 ordinary shares on the nineteenth of each month from March&nbsp;19,
2017 through November&nbsp;19, 2018, and in one installment of 73,500 ordinary shares on December&nbsp;19, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option partially vests as to 492,004 ordinary shares on January&nbsp;18, 2017 and the remainder will vest in monthly installments of 41,000 ordinary shares on
the eighteenth of each month from February&nbsp;18, 2017 through December&nbsp;18, 2019, and in one installment of 41,012 ordinary shares on January&nbsp;18, 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was partially vested and the remainder will vest in monthly installments of 75,000 ordinary shares on the sixteenth of each month from April&nbsp;16,
2016 through March&nbsp;16, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option partially vests as to 234,987 ordinary shares on January&nbsp;18, 2017, and the remainder will vest in monthly installments of 19,582 ordinary shares
on the eighteenth of each month from February&nbsp;18, 2017 through December&nbsp;18, 2019, and in one installment of 19,591 ordinary shares on January&nbsp;18, 2020.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into a service agreement with our Chief Executive Officer and employment agreements with each of our NEOs. Certain key terms of
those agreements and our executive severance policy are described below. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


James Noble  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into a service agreement with Mr.&nbsp;Noble dated March&nbsp;10, 2017 that sets forth the terms and conditions under which
Mr.&nbsp;Noble serves as our Chief Executive Officer and as a director. The employment shall continue until terminated by either party giving no less than nine months' written notice.
Mr.&nbsp;Noble's current annual base salary, effective January&nbsp;1, 2017, is &pound;407,830, subject to review, and Mr.&nbsp;Noble is eligible for an annual bonus at the discretion of
the Company subject to the achievement of certain performance criteria. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we may terminate the agreement immediately by notice if Mr.&nbsp;Noble (i)&nbsp;commits a material breach under the agreement, (ii)&nbsp;is guilty of conduct tending
to bring him or the company into disrepute, (iii)&nbsp;becomes bankrupt, (iv)&nbsp;fails to perform his duties to a satisfactory standard, (v)&nbsp;is disqualified from being a director by
reason of any order made under the Companies Directors Disqualification Act 1986 or any other enactment, or (vi)&nbsp;is convicted of an offence under any statutory enactment or regulation
(including the criminal offence of insider dealing under the Criminal Justice Act 1993 or any similar conviction in the United States, but excluding a motoring offence for which no custodial sentence
is given). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Noble
is eligible to participate in the Company's share option schemes, Group Personal Pension Scheme and in the private health care scheme and permanent health insurance
schemes which the Company or any Group Company may maintain for the benefit of its senior executives. Mr.&nbsp;Noble's service agreement contains non-solicitation and non-competition provisions for
a twelve month period as well as confidentiality provisions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=46,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=155672,FOLIO='38',FILE='DISK122:[17ZBH1.17ZBH78701]DK78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dk78701_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adrian Rawcliffe and Rafael Amado  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The employment agreements for Mr.&nbsp;Rawcliffe and Dr.&nbsp;Amado were entered into on March&nbsp;10, 2017. The agreements have no
specific term and establish an at-will employment relationship. Mr.&nbsp;Rawcliffe's current annual base salary, effective January&nbsp;1, 2017, is $443,700 and Dr.&nbsp;Amado's current annual
base salary, effective January&nbsp;1, 2017, is $442,900, subject to periodic review and adjustment by the Company, and their annual target bonus opportunities are 45% of their annual base salaries
subject to the achievement of certain performance criteria. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Rawcliffe
and Dr.&nbsp;Amado are eligible to participate in the equity plans sponsored and/or maintained by the Company and its affiliates from time to time, in accordance
with the terms of any such plans, at the sole and absolute discretion of the Company and the Board of Directors. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company may terminate either of their employment with or without cause and without notice, but Mr.&nbsp;Rawcliffe and Dr.&nbsp;Amado are required to provide at least
60&nbsp;days' advance written notice to us if he is terminating his employment. In the event of a termination of his employment by the Company without cause or by Mr.&nbsp;Rawcliffe or
Dr.&nbsp;Amado for good reason, any portion of his initial award of 3,600,000 share options that was granted on March&nbsp;16, 2015, which is unvested as of the date of
termination shall vest and immediately become exercisable on the date of termination. The agreements contain non-solicitation and non-competition provisions for a twelve month period as well as
standard confidentiality provisions. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Severance Policy  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's executive severance policy is applicable in relation to our NEOs. If the employment of any of our NEOs is terminated by the
Company without cause, or if he resigns for good reason, then the NEO will be entitled under his employment agreement and the executive severance policy to receive a severance payment equal to his
annual base salary for nine months and to payment of premiums for continuation of healthcare benefits for a period of nine months following such termination. In addition, at the sole discretion of the
Board (or an authorized committee thereof), the NEO may be paid a lump sum cash amount equal to his target annual performance bonus for the year of termination, prorated based on the number of
calendar days he was employed during the year. Furthermore, if the employment of any of our NEOs is terminated without cause or he resigns for good reason within 12&nbsp;months following a change in
control, he will be entitled to receive a severance payment equal to his annual base salary for 12&nbsp;months, payment of premiums for continuation of healthcare benefits for a period of
12&nbsp;months, a lump sum cash amount equal to the full target performance bonus for the year of termination, and accelerated vesting of any unvested and outstanding equity awards. In order to
receive severance benefits under the employment agreement and executive severance policy, the NEO is required to execute a release of claims in favor of the Company and comply with certain other
post-employment covenants set forth in his employment agreement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Retirement Plans  </I></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


401(k) Plan  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain a tax-qualified retirement plan for our U.S.-based employees that provides eligible employees with an opportunity to save for
retirement on a tax-advantaged basis. We make discretionary employer matching contributions equal to 50% of the first 4% of the elective contributions made by participants in the 401(k) plan. These
company matching contributions are subject to a vesting schedule. In addition, we make a 3% discretionary Safe Harbor matching
contribution, which is fully vested as of the date of the contribution. Pre-tax contributions are allocated to each participant's individual account and are then invested in selected investment
alternatives according to the participant's directions. The 401(k) plan is intended to qualify under Sections&nbsp;401(a) and 501(a) of the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=47,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=67812,FOLIO='39',FILE='DISK122:[17ZBH1.17ZBH78701]DK78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_dk78701_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Internal
Revenue Code. As a tax-qualified retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) plan. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


U.K. Defined Contribution Plan  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the U.K., we maintain a defined contribution plan that provides employees with an opportunity to contribute a portion of their monthly salary
into the plan. If an employee elects to participate in the plan, there is a minimum employee contribution of 5% of monthly salary; there is no maximum limit to the employee contribution. The employee
contribution to this plan is matched by us up to a maximum of 5% of monthly salary. All U.K. employees are eligible to participate in this plan. The method by which our U.K. employees participate is
through a so-called "salary exchange" pursuant to which employees agree to a reduction in monthly salary in an amount equal to the defined contribution plan election. The amount of the reduction,
together with the tax and national insurance savings to the employee and us as a result of the salary reduction, are contributed into the plan in addition to the 5% matching contribution described
above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity Compensation Plan Information  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information on our equity compensation plans as of December&nbsp;31, 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="108pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Plan Category


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities to be<BR>
Issued Upon<BR>
Exercise of<BR>
Outstanding<BR>
Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise Price<BR>
of Outstanding<BR>
Options $ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Securities<BR>
Available for<BR>
Future Issuance<BR>
Under Equity<BR>
Compensation Plans(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>49,237,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.72</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33,128,439</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>49,237,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.72</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33,128,439</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this table, the Weighted Average Exercise Price of Outstanding Options has been converted from &pound;0.58 based on the pound sterling/U.S. dollar exchange rate in
effect as of December&nbsp;31, 2016 (&pound;1/$1.233). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company grants options over ordinary shares in Adaptimmune Therapeutics&nbsp;plc under the following option plans: (i)&nbsp;the Adaptimmune Therapeutics&nbsp;plc Employee Share
Option Scheme (adopted 14&nbsp;January 2016), (ii)&nbsp;the Adaptimmune Therapeutics&nbsp;plc 2015 Share Option Scheme and (adopted March&nbsp;16, 2015) (ii)&nbsp;the Adaptimmune
Therapeutics&nbsp;plc Company Share Option Plan (adopted March&nbsp;16, 2015). The maximum aggregate number of options which may be granted under these plans and any incentive plans adopted by the
Company cannot exceed a scheme limit that equates to 8% of the initial fully diluted share capital of the Company immediately following our IPO plus an automatic annual increase of an amount
equivalent to 4% of the issued share capital on each 30&nbsp;June (or such lower number as the Board, or an appropriate committee of the Board, may determine). The automatic increase is effective
from July&nbsp;1, 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to December&nbsp;31, 2014, the Company granted options to purchase ordinary shares in Adaptimmune Limited under three option schemes: (i)&nbsp;the Adaptimmune Limited Share
Option Scheme (adopted May&nbsp;30, 2008), (ii)&nbsp;the Adaptimmune Limited 2014 Share Option Scheme (adopted April&nbsp;11, 2014 and (iii)&nbsp;the Adaptimmune Limited Company Share Option
Plan (adopted December&nbsp;16, 2014). As part of the corporate reorganization in connection with our IPO, the holders of options granted under these schemes over ordinary shares of Adaptimmune
Limited were granted equivalent options on substantially the same terms over ordinary shares of Adaptimmune Therapeutics&nbsp;plc ("Replacement Options") in exchange for the release of these
options. The Company does not intend to grant any further options under these schemes. Further details of our option plans are set forth in Note&nbsp;10 titled "Share based compensation" in our
audited consolidated financial statements in our Form&nbsp;10-K. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=48,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=855692,FOLIO='40',FILE='DISK122:[17ZBH1.17ZBH78701]DK78701A.;6',USER='PJAMES',CD='26-APR-2017;19:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dm78701_1_41"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm78701_transactions_with_related_persons"> </A>
<A NAME="toc_dm78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  TRANSACTIONS WITH RELATED PERSONS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Certain Relationships and Related Party Transactions  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Related Person Transactions Policy  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a policy with respect to the review, approval and ratification of related party transactions. Under the policy, our Audit
Committee will be responsible for reviewing and approving related person transactions. In the course of its review and approval of related person transactions, our Audit Committee will consider the
relevant facts and circumstances to decide whether to approve such transactions. In particular, our policy will require our Audit Committee to consider, among other factors it deems
appropriate:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person's relationship to us and interest in the transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the interests, direct or indirect, of any related person in the transaction in sufficient detail so as to enable the Audit Committee to assess
such interests; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the materials facts of the proposed related-person transaction, including the proposed aggregate value of such transaction, or, in the case of
indebtedness, that amount of principal that would be involved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the benefits to us of the proposed transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an assessment of whether the proposed transaction is on terms that are comparable to the terms available to an unrelated third party or to
employees generally; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> management's recommendation with respect to the proposed related-person transaction. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee may only approve those transactions that are in, or are not inconsistent with, our best interests and those of our shareholders, as the Audit Committee determines in
good faith. If Audit Committee review and approval would be inappropriate, the relevant related party transaction will be referred to another independent body of our Board for review, consideration,
approval or ratification. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Certain Related Person Transactions  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a description of transactions since January&nbsp;1, 2016 through the date of this proxy statement in which (a)&nbsp;we were
a participant, (b)&nbsp;the amount involved exceeded $120,000 and (c)&nbsp;one or more of our executive officers, directors, director nominees or 5% shareholders, or their immediate family
members, each of whom we refer to as a "related person," had a direct or indirect material interest. We refer to these as "related person transactions." The information below excludes compensation
arrangements with directors and executive officers, which are described above elsewhere in this proxy statement under "Director Remuneration" and "Executive Compensation." </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> On September&nbsp;12, 2016, we entered into a letter agreement with Immunocore Limited ("Immunocore") that became effective
November&nbsp;8, 2016, recording our mutual agreement to terminate the target collaboration agreement with the termination effective on March&nbsp;1, 2017. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The board overlap between us and Immunocore ended on December&nbsp;31, 2016 when Dr.&nbsp;Jonathan Knowles and Ian Laing resigned from our
board of directors. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We and Immunocore have invoiced each other in respect of a transitional services agreement (under which certain staff resources and other
administration services are supplied by each company to the other company for a transitional period). Additionally, during the periods presented Immunocore has invoiced the Company in respect of
services provided under a target collaboration agreement (under which certain target identification services were provided by </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=49,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=938270,FOLIO='41',FILE='DISK122:[17ZBH1.17ZBH78701]DM78701A.;14',USER='DSLOAN',CD='27-APR-2017;16:55' -->
<A NAME="page_dm78701_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Immunocore),
costs related to joint patents and in respect of property rent. The amount payable by the Company to Immunocore at December&nbsp;31, 2016 was $365,000. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> As of the closing of the Company's registered direct offering of its ADSs on April&nbsp;10, 2017, Immunocore ceased to hold 5% or more of our
shares. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Investors Rights Agreement  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are party to an investors rights agreement entered into on February&nbsp;23, 2015, with certain of our shareholders, including New
Enterprise Associates 14,&nbsp;L.P., NEA Ventures 2014,&nbsp;L.P., OrbiMed Private Investments V,&nbsp;L.P. and Sigal Family Investments,&nbsp;LLC pursuant to which certain of our
shareholders, including certain holders with beneficial ownership of five percent or more of our ordinary shares and entities affiliated with certain of our directors, have the right to demand that we
file&nbsp;a registration statement for their ordinary shares or request that their ordinary shares be covered by a registration statement that we are otherwise filing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=50,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=325880,FOLIO='42',FILE='DISK122:[17ZBH1.17ZBH78701]DM78701A.;14',USER='DSLOAN',CD='27-APR-2017;16:55' -->
<A NAME="page_dm78701_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm78701_audit_committee_report"> </A>
<A NAME="toc_dm78701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  AUDIT COMMITTEE REPORT    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Review of the Company's Audited Financial Statements for the Year ended December&nbsp;31, 2016  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Audit Committee has reviewed and discussed with management our audited consolidated financial statements for the year ended
December&nbsp;31, 2016. Our Audit Committee has also discussed with KPMG&nbsp;LLP, our independent registered public accounting firm, the matters required to be discussed by Statement on Auditing
Standards No.&nbsp;61, as amended, regarding communication with audit committees, as adopted by the Public Company Accounting Oversight Board ("PCAOB") in Rule&nbsp;3200T. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Audit Committee has also received the written disclosures and the letter from KPMG&nbsp;LLP required by the applicable requirements of the PCAOB regarding communications with the
audit committee concerning independence, and our Audit Committee has discussed with KPMG&nbsp;LLP its independence from management and the Company. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on our Audit Committee's review and discussions with management and the independent auditors, and subject to the limitations of the Audit Committee's role and responsibilities
referred to above and in the Audit Committee charter, our Audit Committee recommended to the Board of Directors that our audited consolidated financial statements be included in our Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2016 for filing with the SEC. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I> The Audit Committee of the Board of Directors</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence M. Alleva, Chairman<BR>
Barbara Duncan<BR>
Giles Kerr</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><I>The foregoing report of the Audit Committee shall not be deemed incorporated by reference by any general statement incorporating by reference this proxy statement into any
filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates this information by
reference, and shall not otherwise be deemed filed under such acts.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee approves KPMG&nbsp;LLP's and its affiliates audit and non-audit services in advance as required under Sarbanes-Oxley and SEC rules. Before the commencement of each
fiscal year, the Audit Committee appoints the independent auditor to perform audit services that we expect to be performed for the fiscal year and appoints the auditor to perform audit-related, tax
and other permitted non-audit services. In addition, our Audit Committee approves the terms of the engagement letter to be entered into by us with the independent auditor. The Audit Committee has also
delegated to its chairman the authority, from time to time, to pre-approve audit-related and non-audit services not prohibited by law to be performed by our independent auditors and associated fees,
provided that the chairman shall report any decisions to pre-approve such audit-related and non-audit services and fees to our full Audit Committee at its next regular meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
table below sets forth the fees paid to KPMG&nbsp;LLP over the past two years in connection with its work for us, including our subsidiary, Adaptimmune&nbsp;LLC. All such audit,
audit-related and tax services were pre-approved by the Audit Committee, which concluded that the provision of such services by KPMG&nbsp;LLP was compatible with the maintenance of that firm's
independence in the conduct of its auditing functions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=51,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=946624,FOLIO='43',FILE='DISK122:[17ZBH1.17ZBH78701]DM78701A.;14',USER='DSLOAN',CD='27-APR-2017;16:55' -->
<A NAME="page_dm78701_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fees
billed by KPMG&nbsp;LLP in 2015 and 2016 were as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Fees

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six month period<BR>
ended<BR>
December&nbsp;31, 2015<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2016<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>212,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>360,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-related Fees(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>151,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>352,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>373,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>712,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>During
2015 we changed our fiscal year from June&nbsp;30 to a calendar fiscal year. The fees for the period ending December&nbsp;31, 2015 in the table above have
been calculated by adding the fees paid for the six months ended June&nbsp;30, 2015 and the six months ended December&nbsp;31, 2015. Fees paid for the six months ended June&nbsp;30, 2015 have
been calculated by prorating the amounts paid for the year by the six month period.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit
Fees consist of fees billed for the audit of our annual consolidated financial statements, the review of the interim consolidated financial statements, and
related services that are normally provided in connection with registration statements, including the registration statement for our IPO. Included in the 2015 audit fees are the fees billed in
connection with our IPO in May 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit-related
Fees incurred were $352,000 and $151,000 in 2016 and 2015 respectively.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Tax
Fees consist of fees for professional services, including tax consulting and compliance. There were no such fees incurred in 2016 or 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>All
Other Fees incurred were $10,000 in 2015 and we did not incur any such fees in 2016.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=52,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=796433,FOLIO='44',FILE='DISK122:[17ZBH1.17ZBH78701]DM78701A.;14',USER='DSLOAN',CD='27-APR-2017;16:55' -->
<A NAME="page_dm78701_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm78701_delivery_of_proxy_materials"> </A>
<A NAME="toc_dm78701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DELIVERY OF PROXY MATERIALS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2016, including audited financial statements, accompanies
this Proxy Statement. Copies of our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2016 and the exhibits thereto are available from the Company without charge upon
written request of a shareholder. Copies of these materials are also available online through the SEC at </FONT><FONT SIZE=2><I>www.sec.gov</I></FONT><FONT SIZE=2>. The Company may satisfy SEC rules
regarding delivery of proxy materials, including this Proxy Statement and the Annual Report, by delivering a single set of proxy materials to an address shared by two or more Company shareholders or
ADS holders. This delivery method can result in meaningful cost savings for the Company. In order to take advantage of this opportunity, the Company may deliver only a single set of proxy materials to
multiple shareholders or ADS holders who share an address, unless contrary instructions are received prior to the mailing date. Similarly, if you share an address with another shareholder or ADS
holders and have received multiple copies of our proxy materials, you may write or call us at the address and phone number below to request delivery of a single copy of the proxy materials in the
future. We undertake to deliver promptly upon written or oral request a separate copy of the proxy materials, as requested, to a shareholder or ADS holders at a shared address to which a single copy
of the proxy materials was delivered. If you are an ordinary shareholder of record and prefer to receive separate copies of proxy materials either now or in the future, please contact Margaret Henry,
Company Secretary, Adaptimmune Therapeutics&nbsp;plc, 101 Park Drive, Milton Park, Abingdon, Oxfordshire OX 14 4RY United Kingdom or by telephone at +(44) 1235 430036. If you hold ADSs and you
prefer to receive separate copies of proxy materials either now or in the future, please contact the Depositary, your brokerage firm or bank, as applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>EACH SHAREHOLDER IS URGED TO COMPLETE, DATE, SIGN<BR>
AND PROMPTLY RETURN THE ENCLOSED FORM OF PROXY OR TO SUBMIT<BR>
YOUR PROXY ONLINE.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>EACH ADS HOLDER IS URGED TO COMPLETE, DATE, SIGN AND PROMPTLY RETURN<BR>
THE ADS PROXY CARD TO CITIBANK, N.A., THE DEPOSITARY FOR THE ADSs.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=53,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=213995,FOLIO='45',FILE='DISK122:[17ZBH1.17ZBH78701]DM78701A.;14',USER='DSLOAN',CD='27-APR-2017;16:55' -->
<A NAME="page_dm78701_1_46"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="dm78701_additional_information"> </A>
<A NAME="toc_dm78701_4"> </A>
<BR>  ADDITIONAL INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


U.K. Statutory Annual Accounts and Reports of the Board of Directors and Auditors of Adaptimmune
Therapeutics&nbsp;plc for the year ended December&nbsp;31, 2016  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent with its obligations under the U.K. Companies Act 2006, our Board of Directors will present at the Meeting our U.K. statutory annual
accounts and reports for the year ended December&nbsp;31, 2016. Accordingly, our Board of Directors will lay before the Company at the Meeting the Company's U.K. statutory annual accounts and
reports for the year ended December&nbsp;31, 2016, which have been approved by and, where appropriate, signed on behalf of our Board of Directors and will be delivered to the Registrar of Companies
in the United Kingdom following the Meeting. A copy of our U.K. statutory directors' remuneration report, including the annual report on remuneration, is included as Annex&nbsp;A to this proxy
statement. A complete copy of our U.K. statutory annual accounts and reports, including the statutory Board of Directors report, strategic report, and auditor's report on our U.K. accounts will be
sent separately to you no less than 21&nbsp;days prior to the Meeting. You will be provided an opportunity to raise questions in relation to such accounts and reports at the Meeting. Full accounts
and reports will be available for inspection prior to and during the Meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shareholders' Rights to Call a General Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our shareholders have the right to call a meeting of our shareholders. The U.K. Companies Act 2006 generally requires the directors to call a
general meeting once we have received requests to do so from shareholders representing at least 5% of our paid-up shares entitled to vote at a general meeting. The U.K. Companies Act 2006 generally
prohibits shareholders of a U.K. public limited company from passing written resolutions. However, significant shareholders would, in any case, still have the power to call a general meeting and
propose resolutions. These provisions are mandatory under the U.K. Companies Act 2006 and cannot be waived by our shareholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shareholder Proposals for 2018 Annual General Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to be considered for inclusion in our proxy statement for our 2018 annual general meeting of shareholders, shareholder proposals must
be received by the Company at the Office of the Company Secretary, 101 Park Drive, Milton Park, Abingdon, Oxfordshire OX14&nbsp;4RY no later than 120&nbsp;days before the anniversary of the date
on which we sent our proxy materials for the Meeting, or December&nbsp;28, 2017. However, if the date of such annual general meeting is more than 30 calendar days from the date of the anniversary of
the Meeting, then the notice must be received by our Company Secretary a reasonable time before we begin to print and send our proxy materials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shareholder
proposals submitted for consideration at our 2018 annual general meeting of shareholders, but not submitted for inclusion in our proxy statement for our 2018 annual general
meeting of shareholders, must be received by the Company at the Office of the Company Secretary, 101 Park Drive, Milton Park, Abingdon, Oxfordshire OX14&nbsp;4RY no later than 45&nbsp;days before
the anniversary of the date of the Meeting, or May&nbsp;5, 2018. However, if the date of the 2018 annual general meeting is changed by more than 30 calendar days from the date of the anniversary of
the Meeting, the notice must be received by our Company Secretary at least 45&nbsp;days prior to the date we intend to distribute our proxy materials with respect to the 2018 annual general meeting.
If a shareholder does not timely provide notice as described above, proxies solicited on behalf of our management for the 2018 annual general meeting will confer discretionary authority to vote with
respect to any such matter, as permitted by the proxy rules of the SEC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
section&nbsp;338 of the U.K. Companies Act (2006), shareholders representing at least 5% of holders entitled to vote on a resolution at an annual general meeting may require the
Company to include such resolution in its notice of an annual general meeting. Provided the applicable thresholds are met, notice of the resolution must be received by the Company at the Office of the
Company </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=54,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=869330,FOLIO='46',FILE='DISK122:[17ZBH1.17ZBH78701]DM78701A.;14',USER='DSLOAN',CD='27-APR-2017;16:55' -->
<A NAME="page_dm78701_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Secretary,
101 Park Drive, Milton Park, Abingdon, Oxfordshire OX14&nbsp;4RY at least six weeks prior to the date of the annual general meeting, or, if later, at the time notice of the annual general
meeting is delivered to shareholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Questions?  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you have any questions or need more information about the Meeting please write to us at: </FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Margaret
Henry<BR>
Company Secretary<BR>
Adaptimmune Therapeutics&nbsp;plc<BR>
101 Park Drive<BR>
Milton Park<BR>
Abingdon<BR>
Oxfordshire OX14&nbsp;4RY<BR>
United Kingdom </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=55,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=619581,FOLIO='47',FILE='DISK122:[17ZBH1.17ZBH78701]DM78701A.;14',USER='DSLOAN',CD='27-APR-2017;16:55' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_lc78701_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="lc78701_annex_a_to_proxy_statement"> </A>
<A NAME="toc_lc78701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ANNEX A TO PROXY STATEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directors' Remuneration Report  </B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Remuneration Committee Chairman's Statement  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On behalf of the Board of Directors of Adaptimmune Therapeutics&nbsp;plc, I am pleased to present the Directors' Remuneration Report for the
year ended 31&nbsp;December 2016. Shareholders will be invited to approve the Report on Remuneration (which will be a non-binding advisory vote) at the Annual General Meeting of shareholders to be
held on 21&nbsp;June 2017. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Period Covered by the Directors' Remuneration Report  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Directors' Remuneration Report that follows is for the full year period from 1&nbsp;January 2016 to 31&nbsp;December 2016 except where
otherwise stated. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Remuneration Committee  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Committee is responsible for reviewing and establishing our executive remuneration policy and philosophy, including making recommendations
regarding the remuneration of our Chief Executive Officer ("CEO") to the Board for its approval, and determining and approving the remuneration of other senior executive officers. While the Board sets
the remuneration of our CEO, who is our sole Executive Director, the Committee makes recommendations on such matters to the Board. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Philosophy  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We seek to attract and retain outstanding employees who have the potential to support the growth of the Group and to attract and retain
Non-Executive Directors who can substantially contribute to our success as an innovative, clinical-stage biopharmaceutical company. As the Group has operations in the United Kingdom and the United
States, our senior executives and our Non-Executive Directors live and work in the U.K. and the U.S., and we are listed on a U.S. stock
exchange, we assess the competitiveness of our policies against both European and U.S. benchmarks and practices, with an increasing focus on U.S. benchmarks and practices. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Business Strategy during 2016  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our primary goal in 2016 was to progress the development of the Group including executing on key elements of our pipeline development
programmes, progressing our clinical trials programmes and opening additional INDs, as well as delivering new alliances from business development activities and continuing toward establishing the
manufacturing and laboratory facilities required for the next development phase. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Activities and major decisions  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Committee's activities during the year included a benchmarking review of executive compensation, which was undertaken to ensure that
remuneration for the senior executive team remains competitive for the retention and engagement of key talent. The Committee engaged Willis Towers Watson as independent advisors to benchmark executive
compensation against a selected peer group consisting of comparable U.S.-listed and U.K. and European-listed biopharmaceutical companies, and to provide recommendations for base salaries, equity based
awards and the structure of bonus incentive awards for 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result of this benchmarking exercise, our CEO and senior executive officers received increased base salary awards at levels that remain compliant with the last approved Directors' </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=56,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=544664,FOLIO='A-1',FILE='DISK122:[17ZBH1.17ZBH78701]LC78701A.;7',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_lc78701_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Remuneration
Policy and are aligned with the 50<SUP>th</SUP>&nbsp;percentile of peer group comparator data. For our CEO, this resulted in a base salary award of &pound;407,830 effective
from 1&nbsp;January 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2017 the Committee also considered the extent of achievement of 2016 calendar year objectives by the executive team and determined the level of bonus incentive awards payable
in respect of the 2016 calendar year. The awards made to our CEO and senior executive officers recognised that some of our corporate objectives for 2016 had been achieved, with our CEO receiving a
bonus award at 50% of the potential target bonus amount. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the same time, the Committee approved the objectives to be achieved by the executive team during 2017. These are considered to be commercially sensitive and will not be disclosed in
detail, but are linked to our business strategies which include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the advancement of our clinical trials for our AFP, MAGE-A10 and MAGE-A4 SPEAR T-cells, as well as of our clinical studies with our NY-ESO
SPEAR T-cell beyond the setting of synovial sarcoma where preliminary evidence of efficacy and safety is established; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuing to use our SPEAR T-cell platform to generate SPEAR T-cells for cancers where existing therapeutic approaches are limited; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuing to understand, further enhance and improve the effectiveness and persistence of our SPEAR T-cell therapies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the optimisation and expansion of our process development and manufacturing capabilities to maintain our leadership position in the TCR space;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the continued expansion of our intellectual property portfolio. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
the remuneration arrangements adopted in 2017 recognise the greater demands placed on our CEO and senior executive team to deliver on our strategy and create value for our
shareholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally,
under the last approved Directors' Remuneration policy, the Board has discretion to pay Non-Executive Directors in the form of a mixture of cash and equity. As anticipated in
the Remuneration Report for the period ended 31&nbsp;December 2015, we implemented revised remuneration arrangements for Non-Executive Directors during 2016 so that such remuneration now comprises
an award of a fixed number of share options, plus an additional number of share options or cash payment at the Director's election. The option awards and cash payments were established at competitive
levels based on peer group data from comparable companies provided in a benchmarking survey undertaken by Radford consultants. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;text-align:left;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;DAVID M. MOTT<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> David M Mott<BR></FONT> <FONT SIZE=2><I>Director and Chairman of Remuneration Committee</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> 10&nbsp;March 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=57,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=765889,FOLIO='A-2',FILE='DISK122:[17ZBH1.17ZBH78701]LC78701A.;7',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_lc78701_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PART I&#151;REPORT ON REMUNERATION  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The information provided in this part of the Directors' Remuneration Report is subject to audit.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Remuneration Committee presents the Report on Remuneration for the year ended 31&nbsp;December 2016, which will be put to shareholders for
a non-binding vote at the Annual General Meeting to be held on 21&nbsp;June 2017. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Single Total Figure of Remuneration for each Director  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows the remuneration received by the Directors for the year ended 31&nbsp;December 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
reference only, the table also shows the remuneration received by the Directors for the six months ended 31&nbsp;December 2015, which information was included in the Company's
annual report and financial statements for the period ended 31&nbsp;December 2015 and approved by shareholders at the Annual General Meeting held on 16&nbsp;June 2016. The annual bonus amount is
shown for the 12&nbsp;months ended 31&nbsp;December 2015. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="34pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="34pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=17 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the year ended 31&nbsp;December 2016: </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=17 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>For the six months ended 31&nbsp;December 2015: </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Variable Pay(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Variable Pay(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fixed Pay(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fixed Pay(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity-<BR>
Based<BR>
Awards(6)<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity-<BR>
Based<BR>
Awards(6)<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Director

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
and fees<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Taxable<BR>
benefits<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Annual<BR>
bonus<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pension<BR>
allowance<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
and fees<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Taxable<BR>
benefits<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Annual<BR>
bonus<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pension<BR>
contributions<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
&pound; </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><B><I>Executive</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>James Noble,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>315,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>848</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>78,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>410,348</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>150,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>854</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>200,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>358,354</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:12pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>CEO</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><B><I>Non-executives</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Jonathan Knowles</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Lawrence Alleva</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Ali Behbahani</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Barbara Duncan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Giles Kerr</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,812</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ian Laing</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>David Mott</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Elliott Sigal</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Peter Thompson</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:6pt;text-indent:-6pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Tal Zaks</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,231</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
majority of the remuneration was set and paid in pounds sterling (&pound;). For the purpose of this table, the fees paid in U.S. dollars to Dr&nbsp;Tal
Zaks have been translated into pounds sterling based on the U.S. dollar/pound sterling exchange rate at 31&nbsp;December 2016 ($1.233 to &pound;1).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
base salary levels of our CEO and all other employees of the Group are reviewed and, to the extent deemed necessary, adjusted to be effective from
1&nbsp;January in each year. The salary amount paid to Mr&nbsp;Noble for the six months ended 31&nbsp;December 2015, shown in the table, represents 50% of his annual salary of
&pound;300,000 (effective from 1&nbsp;January 2015) for the year ended 31&nbsp;December 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Taxable
benefits comprise medical and life insurance. Generally, Mr&nbsp;Noble participates in the same benefits as we offer to all our employees in the United
Kingdom where Mr&nbsp;Noble resides.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
annual bonus amount shown for the year ended 31&nbsp;December 2016 represents the total bonus payment that related to performance in 2016. The annual bonus
amount shown for the six months ended 31&nbsp;December 2015 represents the total bonus payment that related to performance in the 12&nbsp;months ended 31&nbsp;December 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
pension allowance for the year ended 31&nbsp;December 2016 represents an amount equating to 5% of the base salary for that period. The pension contributions
for the six months ended 31&nbsp;December 2015 represent 50% of the total contributions for 2015 into a money purchase plan at the rate of 5% of base salary. 5% is the maximum employer matching
contribution to each employee's participation in the basic defined contribution pension scheme.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
valuation of equity-based awards is based on the market value of underlying shares given at the time that performance conditions were met, less the applicable
exercise price. In the year ended 31&nbsp;December 2016, the valuation of all options granted was nil because it was based on the market value of the underlying shares. There were no performance
obligations linked to the equity-based awards other than service obligations and therefore, for the purposes of this valuation, all performance conditions are considered to be met at the award date.
No equity-based awards were made to Directors during the six months ended 31&nbsp;December 2015. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Bonus  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The annual bonus for the year ended 31&nbsp;December 2016 shown in the table above for Mr&nbsp;Noble, our CEO, was based on the achievement
of objectives primarily linked to progression with the development of the Group including executing on key elements of our pipeline development </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=58,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=769552,FOLIO='A-3',FILE='DISK122:[17ZBH1.17ZBH78701]LC78701A.;7',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_lc78701_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>programmes,
progressing our clinical trials programmes and opening additional INDs, delivering new alliances from business development activities and continuing toward establishing manufacturing and
laboratory facilities required for the next development phase. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board has considered whether it would be in the best interests of the Company and its shareholders to disclose the precise targets agreed for the performance measures in 2016. As the
specific objectives for a single year are based on the Group's long-term strategies, the Board has concluded that disclosing such targets would necessarily involve divulging competitively sensitive
information that we believe would be detrimental to our commercial performance going forward and, therefore, we are providing the categories of objectives, rather than the precise targets. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Statement of Directors' Shareholdings and Share Interests  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below shows, for each Director, the total number of shares owned, the total number of share options held and the number of share
options vested as at 31&nbsp;December 2016. No Director exercised any share options during the year ended 31&nbsp;December 2016. The table only reflects shares held individually by each Director,
or a family investment vehicle, and does not include shares held by any investment fund with which the Director is affiliated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Director

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total share<BR>
options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Vested share<BR>
options(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Options exercised<BR>
during year<BR>
ended<BR>
31&nbsp;December 2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Executive Director</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,172,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,241,116</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,023,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Non-Executive Directors</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence Alleva</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70,584</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>746,904</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>258,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ali Behbahani</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>340,244</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>155,682</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Barbara Duncan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>332,776</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Giles Kerr</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>288,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jonathan Knowles</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,138,184</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>393,028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>393,028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ian Laing</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,042,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>303,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>303,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Mott</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>354,639</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>163,229</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elliott Sigal</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>367,038</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>728,639</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>251,864</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Thompson</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>341,824</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>155,682</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tal Zaks</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>288,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>All
share options that were outstanding as at 31&nbsp;December 2016 use time-based vesting and are not subject to performance targets other than continued service
until the date of vesting.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
1,200,000 Ordinary shares represented by 200,000 ADSs that Mr&nbsp;Noble purchased in October 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 70,584 Ordinary shares represented by 11,764 ADSs that Mr&nbsp;Alleva purchased during the IPO.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
70,584 Ordinary shares represented by 11,764 ADSs that Dr&nbsp;Knowles purchased during the IPO.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
254,100 Ordinary shares held by Sigal Family Investments&nbsp;LLC, as well as 52,938 Ordinary shares represented by 8,823 ADSs that Dr&nbsp;Sigal
purchased during the IPO and 60,000 Ordinary shares represented by 10,000 ADSs purchased by Sigal Family Investments&nbsp;LLC in May 2016.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=59,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=102405,FOLIO='A-4',FILE='DISK122:[17ZBH1.17ZBH78701]LC78701A.;7',USER='PJAMES',CD='26-APR-2017;19:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_le78701_1_5"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy on Shareholding Requirements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not currently have a policy requiring our Directors to hold a certain number or value of our shares. However, we encourage our Executive
Director and senior executive officers to have a shareholding in the Company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directors' Equity-based Awards Held at 31&nbsp;December 2016  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below presents the interests of the Directors in options to acquire our Ordinary shares with a nominal value of &pound;0.001 per
share as at 31&nbsp;December 2016. 4,181,368 options were granted to Directors during the year ended 31&nbsp;December 2016. None of our Directors exercised any options during the year ended
31&nbsp;December 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="110pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Director

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Options<BR>
Held </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant<BR>
date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Start date<BR>
for vesting </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercise<BR>
price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>First date of exercise of<BR>
some or all options(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date of<BR>
expiry </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B><I>Executive Director</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Noble(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,335,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20/03/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31/03/14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.1120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31/03/14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30/03/24</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>438,100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20/03/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31/03/14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.1120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31/03/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30/03/24</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,500,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20/03/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19/12/14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.3557</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19/12/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19/12/24</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,968,016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18/01/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18/01/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.89</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18/01/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18/01/26 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Total </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>7,241,116</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B><I>Non-Executive Directors</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lawrence Alleva(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>519,481</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16/03/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16/03/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.5000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16/03/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16/03/25</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,745</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/25</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>196,678</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/26 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Total </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>746,904</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ali Behbahani</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>155,682</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/25</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>184,562</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/26 </FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Total </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>340,244</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Barbara Duncan(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>332,776</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23/06/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23/06/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23/06/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23/06/26</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Giles Kerr(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
288,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>29/11/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>29/11/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
0.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>29/11/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>29/11/26</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jonathan Knowles(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
175,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>31/12/18</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>217,222</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30/12/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31/12/18 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Total </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>393,028</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ian Laing(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>159,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31/12/18</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>144,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30/12/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31/12/18 </FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Total </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>303,875</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Mott</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>163,229</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/25</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>191,410</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/26 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Total </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>354,639</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Elliott Sigal(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>519,481</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16/03/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16/03/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.5000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16/03/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16/03/25</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,596</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/25</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>184,562</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/26 </FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Total </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>728,639</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Peter Thompson</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>155,682</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/05/25</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>186,142</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/08/26 </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Total </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>341,824</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Tal Zaks(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>288,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29/11/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29/11/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
&pound;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29/11/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29/11/26</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:times;"><FONT SIZE=2>Notes
to table of Directors' Equity-based Awards Held at 31&nbsp;December 2016  </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>All
share options awarded to Directors that were outstanding as at 31&nbsp;December 2016 use time-based vesting and are not subject to performance targets other
than continued service until the date of vesting. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=60,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=748344,FOLIO='A-5',FILE='DISK122:[17ZBH1.17ZBH78701]LE78701A.;8',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_le78701_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>All
options granted to James Noble on 20&nbsp;March 2015 were granted as replacement options in exchange for options formerly held over Ordinary shares of
Adaptimmune Limited. Generally, these replacement options vest and become exercisable as follows: 25% on the first anniversary of the grant date of the original options and 75% in monthly instalments
over the following three years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>519,481
options granted to Lawrence Alleva and 519,481 options granted to Dr&nbsp;Elliott Sigal vest and become exercisable as follows: 25% on the first
anniversary of the grant date and 75% in monthly instalments over the following three years. All options granted to Non-Executive Directors on 11&nbsp;May 2015 vested and became exercisable on
11&nbsp;May 2015. All options granted to Non-Executive Directors on 11&nbsp;August 2016 vest and become exercisable on 11&nbsp;August 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Options
granted to Barbara Duncan, Giles Kerr and Tal Zaks were awarded on appointment as new Directors, and vest and become exercisable as follows: 25% on the first
anniversary of the grant date and 75% in monthly instalments over the following two years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
recognition of Dr&nbsp;Jonathan Knowles' service as the Board chairman and the chairman of the Corporate Governance and Nominating Committee, and of Ian Laing's
service as a Director and member of the Audit and Remuneration Committees, up to 31&nbsp;December 2016, the vesting of 217,222 options held by Dr&nbsp;Knowles and of 144,000 options held by
Mr&nbsp;Laing was accelerated so that such options vested and became exercisable on 30&nbsp;December 2016. Any options held by Dr&nbsp;Knowles and Mr&nbsp;Laing that are not exercised on or
before 31&nbsp;December 2018 will lapse and cease to be exercisable. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
closing market price of our ADSs on 30&nbsp;December 2016 was $4.05. One ADS represents six Ordinary shares. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payments Made to Past Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended 31&nbsp;December 2016, we made no payments to former Directors of the Company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payments for Loss of Office  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended 31&nbsp;December 2016, we made no payments with respect to a Director's loss of office. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy on Payments for Loss of Office  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our approach to payments in the event of termination of an Executive Director is to take account of the individual circumstances including the
reason for termination, individual performance, contractual obligations and the terms of the long-term incentive plans in which the Executive Director participates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
March 2017, the Company entered into an amended service agreement with our Executive Director and adopted an executive severance policy that is applicable to our Executive
Director and senior executive officers. The amended service agreement and executive severance policy are compliant with our last approved Directors' Remuneration Policy. In particular, all employment
arrangements for any Executive Director(s) will continue to include a notice provision and continuing payment obligations for not more than a maximum period of one year following our termination of an
Executive Director. Payment obligations would include base salary, target bonus and benefits. In addition, the Board has discretion under our option scheme rules to allow some or all of the options
held by our Executive Director and senior executives to vest in the event of a change of control or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will comply with applicable disclosure and reporting requirements of the Securities and Exchange Commission with respect to remuneration arrangements with a departing Executive
Director. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=61,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=809796,FOLIO='A-6',FILE='DISK122:[17ZBH1.17ZBH78701]LE78701A.;8',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_le78701_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Illustration of Total Shareholder Return  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The information provided in this part of the Directors' Remuneration Report is not subject to audit.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following graph compares the cumulative total shareholder return on our ADSs, each representing six Ordinary shares, with that of the Nasdaq
Biotech Index for the period that our shares were publicly traded. We selected the Nasdaq Biotech Index because our ADSs trade on The NASDAQ Global Select Market and we believe this indicates our
relative performance against a group consisting of more similarly situated companies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g755814.jpg" ALT="GRAPHIC" WIDTH="634" HEIGHT="352">
  </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Chief Executive Officer Total Remuneration History  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below sets out total remuneration details for the Chief Executive Officer. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="97pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="116pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Period

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Single total figure<BR>
of remuneration &pound;(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Annual bonus payout<BR>
against maximum<BR>
opportunity(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Long term incentive<BR>
vesting rates against<BR>
maximum opportunity(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Year ended 31&nbsp;December 2016:</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>410,348</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Six months ended 31&nbsp;December 2015:</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>358,354</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Year ended 31&nbsp;December 2015:</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>516,708</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Single total figure of remuneration for the six months ended 31&nbsp;December 2015 includes the annual bonus payment for performance in the year ended
31&nbsp;December 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
bonus payout percentage amount for the year ended 31&nbsp;December 2016 relates to the total annual bonus payment for performance in the 12&nbsp;months ended
31&nbsp;December 2016. The bonus payout percentage amount for the six months ended 31&nbsp;December 2015 and for the year ended 31&nbsp;December 2015 relates to the total annual bonus payment
for performance in the 12&nbsp;months ended 31&nbsp;December 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amount shown represents the percentage of the options that actually vested during the period expressed as a percentage of the maximum number of options that
could have vested during the period. There were no performance obligations linked to these equity-based awards, other than service obligations, and therefore, all options that could have vested during
the period have actually vested.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=62,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=531730,FOLIO='A-7',FILE='DISK122:[17ZBH1.17ZBH78701]LE78701A.;8',USER='PJAMES',CD='26-APR-2017;19:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_lg78701_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Chief Executive Officer's Remuneration Compared to Other Employees  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Chief Executive Officer's average fixed salary of &pound;315,000 for the year ended 31&nbsp;December 2016 was 4.9 times the value of
the average fixed salary of the Group's employees for such period. His average fixed salary of &pound;150,000 for the six months ended 31&nbsp;December 2015 was 3.8 times the value of the
average fixed salary of the Group's employees for the six months ended 31&nbsp;December 2015. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows the percentage change in remuneration of the Chief Executive Officer and the average increase per employee between the year ended 31&nbsp;December 2016 and
the year ended 31&nbsp;December 2015. The figures for the six months ended 31&nbsp;December 2015 have been annualised. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=7 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage change in remuneration in the year ended 31&nbsp;December 2016<BR>
compared with remuneration in the year ended 31&nbsp;December 2015(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>CEO </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Average change<BR>
per employee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Annual bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#150;61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#150;8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Taxable benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#150;50%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
figures for the year ended 31&nbsp;December 2015 are based on figures for the six months ended 31&nbsp;December 2015 that have been annualised
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
significant percentage increase for base salary was driven by substantial growth in employee numbers in 2016. Employee numbers grew to an average of 266
full-time equivalent ("FTE") employees for the year ended 31&nbsp;December 2016 (compared to an average of 173 FTE employees for the year ended 31&nbsp;December 2015). The average increase per
employee is calculated on the basis of the average number of 266 FTE employees for the year ended 31&nbsp;December 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Taxable
benefits for the CEO and for employees comprise small amounts and, therefore, any change generates a significant percentage decrease or increase. For the
year ended 31&nbsp;December 2016, the CEO's taxable benefits totalled &pound;848 (year ended 31&nbsp;December 2015: &pound;1,708)&#151;for more details, please refer to the
table for '</FONT><FONT SIZE=2><I>Single Total Figure of Remuneration for each Director'</I></FONT><FONT SIZE=2> on page&nbsp;26.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Relative Importance of Spend on Pay  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the total amounts spent by the Company and its direct and indirect subsidiaries on remuneration for the year
ended 31&nbsp;December 2016 and the six months ended 31&nbsp;December 2015. Given that the Group remains in the early phases of its business life cycle, the comparator chosen to reflect the
relative importance of the Group's spend on pay is the Group's research and development expenses as shown in its consolidated income statement on page&nbsp;38 of its Annual Report and Financial
Statements for the year ended 31&nbsp;December 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Period:

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended<BR>
31&nbsp;December 2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six months ended<BR>
31&nbsp;December 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total spend on remuneration(1):</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>38,513,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,105,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expenses:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,514,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,342,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
total spend on remuneration includes the value of equity-based awards as recognised in the financial statements in accordance with International Financial
Reporting Standard&nbsp;2 "Share-Based Payments".  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=63,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=354740,FOLIO='A-8',FILE='DISK122:[17ZBH1.17ZBH78701]LG78701A.;4',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_lg78701_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Remuneration Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to 31&nbsp;December 2016, the Remuneration Committee was comprised of Mr&nbsp;David Mott (Chairman), Mr&nbsp;Ian Laing,
Dr&nbsp;Peter Thompson and Dr&nbsp;Tal Zaks, who joined the Committee upon his appointment to the Board on 14&nbsp;November 2016. Following the retirement of Mr&nbsp;Laing on
31&nbsp;December 2016, the Remuneration Committee is comprised of Mr&nbsp;Mott (Chairman), Dr&nbsp;Thompson and Dr&nbsp;Zaks. All members have continued to serve until the date of this Report
on
Remuneration. The charter of the Committee is set forth on our website at http://www.adaptimmune.com </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Advice Provided to the Remuneration Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Committee retained Radford, an Aon Hewitt company, and Willis Towers Watson to provide independent advice and consultation with respect to
remuneration arrangements for the Chief Executive Officer (being our sole Executive Director) and senior management. Radford and Willis Towers Watson are global remuneration consultants with
well-established reputations for the design and implementation of remuneration programmes, including the design and implementation of equity-based award programmes. In the year ended
31&nbsp;December 2016, the amounts paid to Radford totalled $27,152 and the amounts paid to Willis Towers Watson totalled $38,158. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to Radford and Willis Towers Watson, the Committee solicited and received input from the Chief Executive Officer concerning the remuneration of senior executives other than
himself. The Chief Executive Officer provided recommendations with respect to annual cash bonuses to be paid to these persons for service in the year ending 31&nbsp;December 2016 and base salary
awards effective from 1&nbsp;January 2017 and with respect to equity-based awards to be made to these persons in 2017. Finally, the Chief Executive Officer also provided input to the Committee
regarding the implementation of equity-based remuneration as an element of all other employees' remuneration. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Statement of Voting Results  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting at our shareholder meetings has generally been conducted by show of hands by shareholders who are in attendance at the meeting. At the
Annual General Meeting held on 16&nbsp;June 2016, all of the resolutions set out in the Notice of the Annual General Meeting sent to shareholders were duly proposed and passed by unanimous approval,
including the resolution proposing the approval of the Directors' Remuneration Report for the period ended 31&nbsp;December 2015. No votes were withheld. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Details
of the proxy votes received in relation to the resolution proposing the approval of the Directors' Remuneration Report for the period ended 31&nbsp;December 2015 were as
follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Resolution

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Votes For </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% of Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Votes<BR>
Against </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% of Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Votes<BR>
Withheld </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% of Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>To approve the Directors' Remuneration Report</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>364,228,920</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99.83</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>617,058</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>115,566</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.03</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Statement of Implementation of Remuneration Policy in the Period ended 31&nbsp;December 2016  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There have been no changes to the Directors' Remuneration Policy as approved at the Annual General Meeting of shareholders held on
17&nbsp;December 2015. In 2017, the Company intends to continue to adhere to the policy as approved. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=64,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=970348,FOLIO='A-9',FILE='DISK122:[17ZBH1.17ZBH78701]LG78701A.;4',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_lg78701_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Application of the Remuneration Policy to Executive Director Remuneration for the year ending
31&nbsp;December 2017  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides an illustration of the potential remuneration for the year ending 31&nbsp;December 2017 for the Chief Executive
Officer, as the sole Executive Director, computed in accordance with the last approved Remuneration Policy and by applying the following assumptions: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Minimum</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>The base salary for the Executive Director is assumed to be the base salary of &pound;407,830 per annum effective from 1&nbsp;January 2017.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The value of benefits receivable for the year ending 31&nbsp;December 2017 is assumed to be 5% of base salary for a pension allowance payment and the same rate of contribution for private health insurance as for
2016.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>No bonus is assumed for the Executive Director.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>In line with expectations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The same components for base salary and benefits as reflected for the minimum above.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The expected level of bonus is taken to be 50% of base salary, being the target level of bonus payment for the year ending 31&nbsp;December 2017.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Maximum</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The same components for base salary and benefits as reflected for the minimum above.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The maximum level of bonus is taken to be 100% of current base salary.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual bonus  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the year ending 31&nbsp;December 2017, the Chief Executive Officer is eligible for a target bonus award of 50% of his base salary of
&pound;407,830 (that is, &pound;203,915), subject to the achievement of objectives. These are linked to our business strategies, which include: the continued advancement of our clinical
trials for our AFP, MAGE-A10 and MAGE-A4 SPEAR T-cells, and as well as of our clinical studies with our NY-ESO SPEAR T-cell beyond the setting of synovial sarcoma where preliminary evidence of
efficacy and safety is established; continuing to use our SPEAR T-cell platform to generate SPEAR T-cells for cancers where existing therapeutic approaches are limited; continuing to understand,
further enhance and improve the
effectiveness and persistence of our SPEAR T-cell therapies; and the continued optimization and expansion of our process development and manufacturing capabilities to maintain our leadership position
in the TCR space and the continued expansion of our intellectual property portfolio. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is anticipated that the Board will meet in the first quarter of 2018 to assess the performance of the Chief Executive Officer for the year ended 31&nbsp;December 2017 against the
objectives. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board has considered whether it would be in the best interests of the Company and its shareholders to disclose the precise targets agreed for the performance measures in 2017. As the
specific objectives for a single year are based on the Group's long-term strategies, the Board has concluded that disclosing such targets would necessarily involve divulging competitively sensitive
information that we believe would be detrimental to our commercial performance going forward and, therefore, we are providing the categories of objectives, rather than the precise targets. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=65,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=18412,FOLIO='A-10',FILE='DISK122:[17ZBH1.17ZBH78701]LG78701A.;4',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_lg78701_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PART II&#151;DIRECTORS' REMUNERATION POLICY  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have set forth below a summary of the remuneration policy for the Executive Directors and for our Non-Executive Directors. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
full Directors' Remuneration Policy has been excluded from this Directors' Remuneration Report, as the last approved policy will continue to apply. That remuneration policy was
approved at the Annual General Meeting held on 17&nbsp;December 2015 and remains effective for a maximum of three years, until 16&nbsp;December 2018, or until a revised policy is approved by
shareholders. The last approved remuneration policy can be found in the Annual Report and Financial Statements of the Company for the year ended 30&nbsp;June 2015, which is available in the
Investors section of our website: http://www.adaptimmune.com </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary of remuneration policy&#151;Executive Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As Adaptimmune Therapeutics&nbsp;plc is a U.K. incorporated company listed on NASDAQ, the Committee considers it appropriate to examine and be
informed by compensation practices in both the U.K. and U.S., particularly in the matter of equity-based incentives. The Committee considers that the last approved Directors' Remuneration Policy
continues to be appropriate and fit for purpose, but the Committee is committed to reviewing the remuneration policy on an ongoing basis in order to ensure that it remains effective and competitive. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
last approved Directors' Remuneration Policy is used to determine the remuneration for our CEO, our sole Executive Director, as well as for our other senior executives, and would
also apply to other Executive Directors and senior executives that we appointed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
described in the last approved Directors' Remuneration Policy, the elements of remuneration for our Executive Director and senior executives comprise: base salary, pension, benefits
(currently, access to death-in-service life insurance, family private medical cover and ill-health income protection), annual bonus and long term equity incentives (currently, share option awards). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
remuneration of our CEO is determined by the Board after having considered recommendations from the Committee. The remuneration of other senior executives in the Group is determined
by the Committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2016, the Committee retained an independent remuneration consultant, Willis Towers Watson, to assist the Committee in ensuring that our remuneration arrangements for the Executive
Director and senior executives are competitive for the calendar year commencing 1&nbsp;January 2017. Willis Towers Watson provided data from comparable publicly traded biopharmaceutical companies
and otherwise assisted the Committee in its design of competitive remuneration for the Executive Director and senior executives. We expect to continue to use remuneration consultants to assist the
Committee in determining competitive levels of executive remuneration and specific design elements of our remuneration programme. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary of remuneration policy&#151;Non-Executive Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the last approved Directors' Remuneration policy, the Board has the discretion to pay fees to any or all Non-Executive Directors; and/or
to pay Non-Executive Directors in the form of a mixture of cash and share options. As anticipated in the Report on Remuneration for the period ended 31&nbsp;December 2015, we revised our
remuneration arrangements for Non-Executive Directors during 2016 to comprise an award of a fixed number of share options, plus an additional number of share options or cash payment at the Director's
election. The option awards and cash payments were established at competitive levels taking into account peer data from comparable companies provided in a benchmarking survey undertaken by Radford
consultants and are compliant with the last approved Directors' Remuneration policy. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=66,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=985042,FOLIO='A-11',FILE='DISK122:[17ZBH1.17ZBH78701]LG78701A.;4',USER='PJAMES',CD='26-APR-2017;19:27' -->
<A NAME="page_lg78701_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg78701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Non-Executive Directors do not receive any pension from the Company nor do they participate in any performance-related incentive plans. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Non-Executive Directors participate in the Group's long-term incentive plans on terms similar to those used for Executive Directors. In accordance with their Letters of Appointment,
all Non-Executive Directors (except for Barbara Duncan, Giles Kerr and Tal Zaks) were granted an annual award of share options on 11&nbsp;August 2016. Ms&nbsp;Duncan, Mr&nbsp;Kerr and
Dr&nbsp;Taks were awarded share options on joining the Board and relevant committees during 2016. Each Non-Executive Director is entitled to receive an annual award of share options, with such
number to be determined by the Board. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining option awards, the Board works within benchmarking guidelines provided by remuneration consultants. All options are granted with an exercise price that is no lower than
the fair market value on the trading date prior to the date of grant and options awarded to new Directors become exercisable over three years while options awarded annually are exercisable on the
first anniversary of the date of grant. Expected values are calculated in accordance with generally accepted methodologies based on Black-Scholes models. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Approval  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This report was approved by the Board of Directors on 10&nbsp;March 2017 and signed on its behalf by: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;text-align:left;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;DAVID M. MOTT<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> David M Mott<BR></FONT> <FONT SIZE=2><I>Director</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> 10&nbsp;March 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=67,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=158546,FOLIO='A-12',FILE='DISK122:[17ZBH1.17ZBH78701]LG78701A.;4',USER='PJAMES',CD='26-APR-2017;19:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Adaptimmune   Therapeutics plc All Correspondence to: Computershare Investor Services PLC   The Pavilions, Bridgwater Road, Bristol, BS99 6ZY MR A SAMPLE &lt;   DESIGNATION&gt; SAMPLE STREET SAMPLE TOWN SAMPLE CITY SAMPLE COUNTY AA11 1AA   Form of Proxy - Annual General Meeting to be held on 21 June 2017 at 11.00 am   (London Time) Control Number: 914353 Cast your Proxy online...It's fast, easy   and secure! www.investorcentre.co.uk/eproxy You will be asked to enter the   Control Number, Shareholder Reference Number (SRN) and PIN shown opposite and   agree to certain terms and conditions. C0000000000 1245 SRN: PIN: View the   Annual Report online: http://ir.adaptimmune.com/ Register at www.investorcentre.co.uk   - elect for electronic communications &amp; manage your shareholding online!   To be effective, all proxy appointments must be lodged with the Company&#146;s   Registrars at: Computershare Investor Services PLC, The Pavilions, Bridgwater   Road, Bristol BS99 6ZY by 19 June 2017 at 11.00 am (London Time). Explanatory   Notes: 1. Every holder has the right to appoint some other person(s) of their   choice, who need not be a shareholder, as his proxy to exercise all or any of   his rights, to attend, speak and vote on their behalf at the meeting. If you   wish to appoint a person other than the Chairman, please insert the name of   your chosen proxy holder in the space provided (see reverse). If the proxy is   being appointed in relation to less than your full voting entitlement, please   enter in the box next to the proxy holder's name (see reverse) the number of   shares in relation to which they are authorised to act as your proxy. If   returned without an indication as to how the proxy shall vote on any   particular matter, the proxy will exercise his discretion as to whether, and   if so how, he votes (or if this proxy form has been issued in respect of a   designated account for a shareholder, the proxy will exercise his discretion   as to whether, and if so how, he votes). To appoint more than one proxy, an   additional proxy form(s) may be obtained by contacting the Registrar's   helpline on 0370 702 0000 or you may photocopy this form. Please indicate in   the box next to the proxy holder's name (see reverse) the number of shares in   relation to which they are authorised to act as your proxy. Please also   indicate by marking the box provided if the proxy instruction is one of   multiple instructions being given. All forms must be signed and should be   returned together in the same envelope. The 'Vote Withheld' option overleaf   is provided to enable you to abstain on any particular resolution. However,   it should be noted that a 'Vote Withheld' is not a vote in law and will not   be counted in the calculation of the proportion of the votes 'For' and   'Against' a resolution. 4. Pursuant to Regulation 41 of the Uncertificated   Securities Regulations 2001, entitlement to attend and vote at the meeting   and the number of votes which may be cast thereat will be determined by   reference to the Register of Members of the Company at 11.00am (London Time)   on 19 June 2017. Changes to entries on the Register of Members after that   time shall be disregarded in determining the rights of any person to attend   and vote at the meeting. To appoint one or more proxies or to give an   instruction to a proxy (whether previously appointed or otherwise) via the   CREST system, CREST messages must be received by the issuer's agent (ID   number 3RA50) not later than 48 hours before the time appointed for holding   the meeting. For this purpose, the time of receipt will be taken to be the   time (as determined by the timestamp generated by the CREST system) from   which the issuer's agent is able to retrieve the message. The Company may   treat as invalid a proxy appointment sent by CREST in the circumstances set   out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.   The above is how your address appears on the Register of Members. If this   information is incorrect please ring the Registrar's helpline on 0370 702   0000 to request a change of address form or go to www.investorcentre.co.uk to   use the online Investor Centre service. Any alterations made to this form   should be initialled. The completion and return of this form will not   preclude a member from attending the meeting and voting in person. 5. 2. 6.   3. 7. 8. Kindly Note: This form is issued only to the addressee(s) and is   specific to the unique designated account printed hereon. This personalised   form is not transferable between different: (i) account holders; or (ii)   uniquely designated accounts. The Company and Computershare Investor Services   PLC accept no liability for any instruction that does not comply with these   conditions. MR A SAMPLE &lt; Designation&gt; Additional Holder 1 Additional   Holder 2 Additional Holder 3 Additional Holder 4 *00000101010000*   140527_133078_MAIL/000001/000001/SG151/i SG151 000001 Form of Proxy For   Ordinary Shareholders </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="816" height="1156" src="g111872bgi001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=68,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=199598,FOLIO='',FILE="DISK134:[17ZBH2.17ZBH78702]11187-2-BG_ZBH78702.CHC",USER="PJAMES",CD='Apr 28 21:42 2017' -->

<br clear="all" style="page-break-before:always;">
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Form of Proxy   Please complete this box only if you wish to appoint a third party proxy   other than the Chairman. Please leave this box blank if you want to select   the Chairman. Do not insert your own name(s). C0000000000 I/We hereby appoint   the Chairman of the Meeting OR the person indicated in the box above as   my/our proxy to attend, speak and vote in respect of my/our full voting   entitlement* on my/our behalf at the Annual General Meeting of Adaptimmune   Therapeutics plc to be held at 60 Jubilee Avenue, Milton Park, Abingdon,   Oxfordshire, OX14 4RX on 21 June 2017 at 11.00 am (London Time), and at any   adjourned meeting. * For the appointment of more than one proxy, please refer   to Explanatory Note 2 (see front). Please use a black pen. Mark with an X   inside the box as shown in this example. Please mark here to indicate that   this proxy appointment is one of multiple appointments being made. Vote   Withheld Ordinary Resolutions For Against 1. To re-elect as a director,   Barbara Duncan, who retires in accordance with the Articles of Association.   2. To re-elect as a director, Giles Kerr, who retires in accordance with the   Articles of Association. 3. To re-elect as a director, Tal Zaks, who retires   in accordance with the Articles of Association. 4. To re-elect as a director,   Ali Behbahani, who retires by rotation in accordance with the Articles of   Association. 5. To re-elect as a director, Peter Thompson, who retires by   rotation in accordance with the Articles of Association. 6. To re-appoint   KPMG LLP as our U.K. statutory auditors under the U.K. Companies Act 2006, to   hold office until the conclusion of the next general meeting of shareholders   at which the U.K. statutory accounts and reports are presented. 7. To   authorize the Audit Committee to determine our U.K. statutory auditors&#146;   remuneration for the fiscal year ended December 31, 2017. 8. To receive the   U.K. statutory annual accounts and reports for the fiscal year ended December   31, 2016 and to note that the Directors do not recommend the payment of any   dividend for the year ended December 31, 2016. 9. To receive and approve our   U.K. statutory directors&#146; remuneration report for the year ended December 31,   2016. 10. To authorise the Directors under Section 551 of the U.K. Companies   Act 2006 (the &quot;2006 Act&quot;) to allot ordinary shares or to grant   rights to subscribe for or to convert any security into ordinary shares. Special   Resolution 11. To authorise the Directors to allot ordinary shares or to   grant rights to subscribe for or convert any security into ordinary shares   under Section 570 of the 2006 Act as if Section 561(1) of the 2006 Act did   not apply to such allotment. I/We instruct my/our proxy as indicated on this   form. Unless otherwise instructed the proxy may vote as he or she sees fit or   abstain in relation to any business of the meeting. Signature Date In the   case of a corporation, this proxy must be given under its common seal or be   signed on its behalf by an attorney or officer duly authorised, stating their   capacity (e.g. director, secretary). H 7 4 5 0 3 A D T * </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="816" height="1156" src="g111872bgi002.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=69,EFW="2231999",CP="ADAPTIMMUNE THERAPEUTICS PLC",DN="1",CHK=509720,FOLIO='',FILE="DISK134:[17ZBH2.17ZBH78702]11187-2-BG_ZBH78702.CHC",USER="PJAMES",CD='Apr 28 21:42 2017' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g111872bgi001.gif
<DESCRIPTION>G111872BGI001.GIF
<TEXT>
begin 644 g111872bgi001.gif
M1TE&.#=A, .$!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M,&$%O#AY Z:$VA!G!:/I.6$*FPJD*@P9Z.  I@(!6- = X ZD $?\"K< 1!
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M34L<SW&%9P50<*#? B.!(EP]:GC:V[T#<$$.[H XMW7ZY)/_*7&2C0F*Z:3
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MW+(WV?O$ X&3HCH!?O_,GP 0MYZJ7]N0FP0, !BB99(HPA#0@V]LO=@PP0
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M6#[@KGK6U*8&NY'5 )"= ^'0ES@D"64DU1%D)E2# ZB(I%83QP'8*#,$X04
MC($FVISD@@"X@SZTDPVQ4/(C(K#)24"0KX%4@ 1EB@%_H'%3MK;5:#J*"B7=
M.E>ZT@T8VF(44?(Z%."9Q!-'6894M#64N];5L(?=V@'&A5C&-M:Q_X^%;&0E
M.UG*5M:RE\5L9C6[V8VIY  MNUUHF<*4;UR$*C*9W5VG08+ BO8@I04 ,.[
MD-&^EC06^<D#M+6,P3)E=[,;4V#9EI6LS$0F "!!.![ E.,R"AAY=1KP@%O8
MV*;6)>'0P;?F-[1&;.(!#*D=9\7K.OC1D#E6J8 /C**_HH@"KC(1&U"(>Q"X
M2@1.C *> .Z'1I4,UKV@">P_S $ 4;3VO4"96@4DV,1Q"< 8Z<O T,8[X=-5
M\0U\,< "'K#<!1Q@PPO00418P(</&(0#C4BF2D%1P0^CJP("P,%,N_2 EO$V
M:"LH 4=UL(P#\&)H8A.  %JFX8,LUP R=O_)!U9@S@I4,,3?0!<T2&"@ZP&
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M#0?P.E'PBT$$/2*"% B@%C[+=D4.L@RZ"* ,#[!B'#D@@XN(@Q<02 <.W/$
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M0P**!6@M.*J@BE,)'5E%7(1 A+3)OMG#QX@C"C(G2. %'4$D Y&'_,F 8SB
M"8"U%.0!..JS2,D AU(I1Q !.80Z<LR("L",#((?J3D -X($2WH#/5NIOY B
M ( !9TB%^ $B1[*TJ9*-3M&6U!N2QIL 2/@ V9(!^I@?*S*4F_1+O<&.@Z
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MB0O(JE#@AE\(3;[+B(I[ &X("58S/9=RJ7G@@,(PI!6X@'/Y"P$ (<?#RH.
M@1*,B'<TR'C3SQ7X@! \@0K00OQST%]"#PZ(  [ @UI*O3?@,P XAHOX 6[(
M !J@D0.@GHNKT"UUFSQLR*P[@'?XA_5PAB*K,O(CJO^0H $1P ,2@  W[3,5
MR !_*!GU#*8][$C:.X@:70 06*?Z[):.H+1OZT_]BK>%<(?Z_ RQZ<N!JZ5
M*[)MFP ^6#42L =@>))_F  \,*22.S\N!56NN8$_D3KO<X;X04^! !7]&B!7
M^C16<2D-L#D $(=C,!0[-:<JLB( * <;P(A:4(C.J]%K0(<%H  92(7O*DH0
MZ$H^8X&40![OJ+X!0IY.60!'N#:N6 !^.  LB)^.^($%@H!_V 9(L")S<L50
M55?)40$7,@HRBP$)2XX26]=ZI9RNE(IJ<(1KD !=)(X=LM> '9THS J!-=B#
M1=B$5=B%95BM^=2&A=B[0<G_GRA8^D*+C5R*B-58O1&%1N"%<*#7,7$:GU"!
M\^.#Q0*&=(BW;PDL#?N ?W@N)D R(7,7?X@QAJ"QE0W#V&"7C?79NVD53Z"5
M?!&R\#J(5& "<S20*_ )=?,A1;@P(Y*'J7R#/YN .Y!3!T@!.,&!/=L^'YH
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M$-9H/78'3L,M$5#'V!#H/142T,@-]42EAWS2RFBV!J$!<SF(7^B4\VA 50$
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MQ(@2)U*L:/$BQHP:-W+LZ/$CR) B1Y(L:?(DRI0J5[)LZ7!!PPDP'CSX &'
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M/JB0&E8^5/_ <(K *6U%I9A+U,"-"-P+#YQ(K_S?;7@"0JQ90U3C-$% #$Q
M696%&N:=#@W$'<9-?2I/SO0G@GJ:.0ZIFU84J#&!4%I<P=103=U- ;W.ZCC,
M _7*B/XD0IRHIH&D0W## %C2N@B /XA#AS8$-&[%=$[7?Y6,@.VH=C[$^;RI
MIA963S%$67A?YF6'K;A//H@ F##C+=8G=#5,ZV&&LL00K<'J0#B:K_T$E@(
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M) 2G],:4.40#7_\(_Z@O8R@%HMF/:]PP$_]2E^B,\@BLJ>R?#Y.7=*XPC *
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MB1XK1@R9D>-'D1I-D@2)<F3'DR5;IG2I\N5*F"QQWM1IDV=-GS2!SA2:4DR
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MZXZRSRZ"/+7"DX@F&HU1@P2,KX1:'+DME&T]V807-E4=_U=6X\KRAQ<KF@O
M'SW%0XB7 CG]EZP21/B!(%XNN,V[J'09@#T(QV(!RP?+1:V$*Q3Q\=RQQKR,
MK0%T\5>Q$F"HDP4"^R4(G@G_"D"%.O\MES[-/!C $R45J3< 3ZS@!9U4"%;J
MWE2NDS84:XVJ)8/X[AC@5J]@3OEA1T2X(Q01)A -$D?0>< *&&YC5SZ?XRH!
M%% (LJ)FJI'ES"A'8$WJ/M0V"643<&_8Y($$0>$%L/H"R#BXG^4SMSOXJ W3
MX;^CXL^_=[_RN5FGE"+PZ@ *!KW<%Y4MJB%1/6<)*A &4#PJ<&'- HL)"A2
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MRK),[2#R*P!XP4N,XM;RJ$7 I$20T"R*HM40XEZ*H6NVT!\J0!$Z90"@Z"A
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MA\_F%-36DCC[Y@O'B)[84PSJCC^D2C"?I0?1"#7&K=P>!DF?!2(U%5.A0G0
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M4&)X,8B!>$E*%L5<5S!%=0?_+Z>10O5[9 547Q?H$.ES1,>9'^LJPTG54&4
MT.$@I-!(C'56!Z N9(24Q?D3_XUO"8)V$DU&_U,%-,4 35)I,P]@=W, [ %V
MJNC+# ;-!J-$'E(,3;)"MA5=(+-%7L@ZU4MVTN&Z8.:T^H,V$=%)SFAA#' M
MDJK0KHN#),LL_^PA/H!@KH >XB@ T$$P^/6.DFC*U,P?0OIQ!B)ZIBQ7XBT
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M1JJH^.UMMO=V5Q SMX5.?%,!"SY-$4 !2**1<B-$:R.J#$3L0^?_\@%BP(0
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M,@_314Z*3D3%$N@F0!+Y5ER_.&(,)#?_$%3"+W4%<$$J_OPBPEI:F29@5Y[
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M&A.H$PA&[X<TO!L=?^@I&MY1AD-17T/XB#] [JLSJ=#, '3AMSXF,)!L%&0
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M"["?R[??NKL7*[9EJP)CJ[,2"[!V>[QYVZYD&[=I:[@-V[D1"[-H*P!@&[2
MJ[WEBRP<D/^7"Y !#P"PX0JT C# FWL !#RN M"T$!NN6)# 6GO !HS SD#
M =RN^( %>"# "5S EZO 68L%ZRJW_<H$0*L"'<ROY\JOZQJN^("N"LS!/XO
M&WS (HP%#9O"XWK"XUK"X-K#%+RN*US"?8O ![##8CO ZZK  G"O N ,.@RT
MZ,K!#VS!%:RU2#S%$9S 2AS$,*S%7RS%_+K (CS#/7P %@O%'OP/*H /_>JM
M!RP ZA"NT%O$")S#0.RM<OO"!?RS/<RO:-O&71S'<WRY9HS 4IN[^,#% 7O
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MU,H4=DXF"*64*],8W)*"D7IJADGQK&9!"J?"D4EE+<4,W4UNTT= YE2G WA
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MTX%+C1$<5*,(9[#$P$!$#OB)4.BC#$"'4TG'6^$!C+T54, *:5,\@0 %J#H
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MS!4(*)/F'8!40$&=9%CY!=O.$T-US-X%\(%;$0ZRY0 C>ZK/H]6IZ,6G.MS
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M!6PHT1#>V&E(1QPTF@9-3=P>@!AP2X/UL+#63<7K77"KH/(CPW^@<+&UQ E
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MN# <L1F(]H#O]AEY WB'QAV :CC!$DT!;%B WHB(39;D;VP?< 3SA(V!*X\
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M @.D@B[]P20,_V&C$+$,1"E%P66O0NB R=R@E1_PFP$FDPVE5, *ZX+F-/B
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MP0%FZ;<[<>,.@TMJ=Y,G%E!HR&0"2.:&8,8!%H0P!Y$AF3Y4T+CP_$,Z2.&
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MQ$;,!Z@Q:'DJ9$>$)+)^)K[\DYN6+$4Y US<JX;&QF ^4..YJ6<N:86:*$>
M[+(VY@O^@_1D:KN^K" :0,L2I=':J\$Z+'?\)E%)(V4<0VD"EU^00)R@2 ;Y
MZ],^!O"]R9VXJ;SJ*J#,6J5V5:*<J"<JZ\X,A6",AR-8"@UD2D7D1*&8$ 2\
MR638[:$$BC.,Q8R6R>/,2H_F#Q[ZYV/NR(?6&2C^*'M8VYQ96A>M+9:ZQY1:
MFGK^$TJ@1)8VZ)X4Z0%H3DO DI'.XX'B9EYVHR"2KD;<9)DN5>@VCN$BGT8(
M"\A@*?_%ZJ-VZA.*:FS(SF-A&(<?UBZ):H3DQ-'L[HQ:P(P=6=Z._-C9C(F3
M8DQM<6A;.BE4!J\@2@]+@6>XHM#DHHVE@:?QHM!0-$J =JGR,<KI0J'C'NN5
M5I69R$IAB$G]B.M</J7;>:+JFBCK*M4PMJ?;!:YZZFY3.4KY_MA35F^H>>\
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M<:D*U&(B%<&(HAHKS!O((P<U<< /RO%#;K4-!]-2YE\-L-8*\ *KT3F RB(
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M)Q2AL0P@(9[B'2[B_^*,F<2B#,[,![ @+,1"$6! .YQ-+#+ O#!"$38!TMZ
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M@,<T9B<XX :FYWLRP!,.H@(<85,R@"*@!RTGP@\GH!$XI11[QQ0U_\,>;$
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M-#LNA2S"6*]( @2>HB;?8%RH8B<R;% @P@$\(8PO)2HR\B0 Y0%( T,, "E
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M,.($M&X3!34#X*,F3>,B-D8#O!+AD-.VEM(@'O]"[KQH5V+ *K34DM8LYTA
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MCQ!@$!P]E@-A!:#+%C:Q'Z!<@/U! : $F&440>!!W:PM%N#EF>788N^D:UZ
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M47Z9Q>@?\V%PV@O)V72\/PFL^%#_7_LXT:JHJ]!0H*HRJE"7Q8ONUZ!&]7Z
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M'2?>W5!%VN/AV3*SMK$9,1QPHC4M.#_,]ZK QQ0-4*M6N\4?_JR@O__W(10
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M'! *(O$ #U =+B$C!Y4% + )<L$!0'@KYK$"'# W2<@!;*=-5X0R5L)FXB8
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M$X5'A--%QG-#!A- PE.6@T,GLU41SD"/G&,\.F)#(>-2/8J;-O 3_S <,?
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M% Z<62&# T1 J:$*JG'$P@P,6"&M(S=1Y$\'-'  2G$RN&&"-!T@:+@*;!A
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MI;" !"7I24[$,0"KG%!9_T#'N<3E)UZRY@I7K$I"#V=.SQSD>M9VZ)O;$NW
MJ'%-CHA!8AQ@(_2$4*.-\ QIJLT'DO &U@:)DT'$)'8':.XR7QX*"PQM> $^
M\S\_YFHZUJ13:_:%,D)#Z(FH2=3B"$2CL@[WY?D098K&Z#^0JPQ)!#V>J,%G
M/PG_*2D IM%[&3VF/"T=CY#A-/#H/YK"G0$X ;D@B>)PO=R8$ VY!I]:M0EL
MD%8;JLV("\BYJ@F@@!( D8_J% "HA?3X!0"H)P\! #&AG49+#U!@0?2  /U+
MCPF8JO)(B/]!D<'YAZ3I';7@0:!@LYA8"DQY  #! JT L)/( 2#4D*!@+7$
MA8,ZB%$*"@ZH"*+XBEN2B-:R"-ZQPI,HB.2X W>P*@=0 0Z "'?  0ZX@'
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M+:=4-9IP&PU&_0_"N< HZRKN.->Y(!RDG!#":5=I8]%32]2)50N$M-*G!#,
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M:R+IM^@0YPD/+(6/'["G:Q!@^VAA)6/,VQGG%N:&BDN=+!B6<E@ 7NCM3CH
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M,?0#R@L5[F2 R@T"01T760@(R=,&! XB#H#P :K"NP<5''WPY$"E P@_'$Q
MR,'1@;00) I@88"%B@,O%4<\H *?@'\H!3@30"+BO\6:(Y*5/)ERYH@"-C-A
MG#@=G\\"4@N,O/FR0!5\#J^>[%FRX0.P=3.&378R9 &)5^-A45H@GA73>+<6
M__U9LF[CO:<;2.W\MD3:^!8W<JP8>N3/OTET?JV8K./.*)UAI\[<. MUGE44
M#@X]]H'NNPLSP5(;I63R9<<<@;#Q\0\63 B 16J7N58@=62E!N!HG+4VVP'J
M'" &@>%1.-QL?.RV6V(&.$." P,X  "++8(RP ,MRLCB+P/(   ' X@ P!LB
M#/#CC], D &0/U8 P D#N /  P-D,*,!/QHP(P _/D6;B*+1QX=_6=5")9AA
MBCDFF66V6(%GO^&!&6T'O#'!DV;*.2>==>;X@&)8X.,98214EIE' JPP 2@X
M3&-/#HXT4@$H$QCP "@/B.#  17P(H%:$%PP@* &5/_00P8/8'-'#A)DL((S
M$X3W02T9@'*, 7> PH$&!V0# 2@B0.!J!A]$],,571G0E7&I2/2!##!,X(XC
M*QQ0T <]3% .#Q]DD XO/&#12 [S?(#-KC1 D,^SPQXPE#BN'E#:"HP.P-,;
M#8DP#0X0S%:! RC!H(, 3Z4@0 2M2H3-#7@YX(FC6$!@3@4"3%!O#/F&)M$;
MC767'6X*>NA9<Q?GUY@!*.D6641^/C@@Q2!#1]\_E<F&Q<082N2Q ?<5YMF$
ML@U86L4S0T<"R2RCU%IFZ&6A<G8DH_0;$^6AIQ]C&!-&87&K-;=<RDE/S2>;
M%H,,,H44JD/6=HWUO$)S68C_'#*73*CP#SY8X&%=SQ]+S4<Z-X?=L=?966?
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M@2&8B,$ 0(-__W44F9680.!):X1"Y.B&VZW'Q#B#QRS R,43Y4@&>>Q)FW"
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M@<VP ,YTX 36TGU0YF= !F%F37CMDH=XGLS_\ $V%N9$ON6#O!_8A*9]O2"
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MJ@,?L$?;-KEV75KC!J+>I:T,T@?Y8O0/-KEGZ)_&Z=Y^O!Z <&1S.G1V0,,
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M5T/PT<A'CU>!#\Q__I>1$4-*#(J4=@0;1RJ[AH"(_N8/\KP"&P8 $HX!!&3
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M=M,!&'AW=RT#@(1D 8CW=H.&=C7# )A@=W$W"Y@@'=Y@ :X7>PW@>&GW&PP
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MP+T[M%?[OO&AO/>;M/E !38\N_V;H@,\NFNZP+/[F[$[N_F ! 1\<1JCP/'
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MSJ=;TCG:R0'B@($#) 0*7#&PH $63%@(> C1(<&)"0TJ/"" CX!_$"'^4W%
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MI'!RY"[%;>O$DL,//69JZ::7"DIKJ2I&7 8#O [[!U4I]Y!(2ZGYP #BP7L
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M+5D1.@F)"/(SJA&.;$<[S*U2A;_9)?0 H+B>4;3T,X>XBVD:Y:,JEZ<1X(C
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M $:0;H  4E$&X.,(>HQ$@GPX G:;P.@$$M/T =! +0](?"KX^KH8? 847A]
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M 5:T0 M 13=@ -2'#E]U=@= #YAW#/46)>[@",93@\[FA09 16)6%EB@D0?
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M19H3X%48(1R7_X(HB<$G-.(=Z#%P)@<_AP4]J>(^%2!SM6BDEE%+/R%HDK(
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M%VP$&F/3(<O!&/]SHWG$(KVA&&H%"M? NRL- %=J&VJ233SGEQ/Y#]5S2#T
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M-#J@#Q.67J5U#-(P-B8A4POP6"?V#Y";W1_BI5'"#7%9#<QX7?\0E/ ! 0\
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M\%B;@**3LOZ$J \U#0+QX1%QJ75O5TEB$*&OPPVM.@"[1?\I !#I9 P8L,*
M#@@0%D@;D&%!A@$?#%08 (&$@!4B"'(0P(&@#@<-!6C\@ _4@!\'",I; 6&
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M8"\?"!^=)G0 #02%*#Z 0'6:<HW+V*4"$.# R.;!/#YP0(R7%$/%*M #&AP
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M9*'VLA]Z +#Y9:A]F_=W8"@!VQ>%X0(&^G"&VQ?^<_>';[!]8/"(J3> 1@"
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M"9*&@$3 )]W)#]@J?YJ$K<9'LCI%2C(%K8PKSOWF6'8&X[T$<.EJ9]"(=/B
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M'9O$]ZY1HAC$!]# ['+/Q+SJ\'Y2"=@R7RQR*/E Q+4R.4UK%?9NYY*%.AQ
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M"P,G<  @8, ' !DJ G@P@$/"!0]I C!@8\( "!$A.*@UX(&\ >H +!@ ZJ4
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M4QF7X*@UPH<T(C%=61#P;C8 ;M#D1A]DHCIV-@ : , 8$RC_@;]&=ZL#;&(
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M370PC_3FI9 'X#*D +""=_AZ'I3Y!2@<D .F3,4_>M+ CWOX!@C_W.'. 8,
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M&@0C0\QF/9AU=^\7?_/WHM("YJ[G;-C**FS7G3S+,Y#'_0K)'99D -CM)!Q
M6KQB,T1*IUIG,/9V9A=@:F&6EW)B*B ! -3$*B+"@Z<V)Z3A =(B%:#J5UQ%
M?UO8A5]X3J9"M\;B<6#'E9CF=-UUMEAB ,)A9N )K$BB10HD.5"" @YF) K)
M@F>&=6^W5*R@8VD+,!*"1D:#D8R$LL+BZ[("!H!A'F$8C,-8?Z]@ &Y +);A
MJO25,,CW5C#"764#M-8D(?^N23#"9(AO X+5(@M,ZSG0=HD%P[O8=5%F0EH
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M/-94D('T2DY.V+%M@IBX^QO>X !48,231 :\YSFX^PT<0RFXV28.(F6?0UC
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MN!N#3;E!5$ :=$#?8[M!:"(&E,+DIR$=TLL QM8? @6,W%T'2,;>8SL+E (
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MC>'X5Y**\S7DP "A '60 ]WQ]0X36QH6@WW;4F01#QQ8H>2![+;K[KOP@F6
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MX.,3TTUC+LS+I"8W"8"O]&0 _7F7_-(A -TXR!R;$,!O0*$(E"T0&)  2YB
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M1W/Y6 Z<%@\'6/!*%3>!!XP-0EDP &66%R5@-N@$\Y*2./$%- %X(HLR5#$
M&A%.A8D#D TQ0)2Z!XH[X)2=68TGH(P& ! L8!D2,4 7(<!(FL#W,_Z<!B3P
M80 6A-(>.1V;, %P7QM<%P]\&&>+?&"?:VC <*6<1TOF123'JL65,6-CL>Z
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MA/9B2@;XW"4$PAL ):"4DF1X7P,X @]/-\ *2B!G!_S<Y*&0#=KD; !S./4
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MP ,.4!]<V1(^5@8LT"+V\BI/N2X?D HP4 '+< $Q4#</L/\-> "9$"87[/D
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MH"!84%.[ ) .#E0PA>?6"Q2101%*8 Q.<I(RC-1:*3D130*I"V ,=@XQWB<
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M,4451P* EP\FD.V#ZA#*H*D*M@'E#L](7$ $$BK_)+$A 2;@13<1T)E@&JL
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MU@'P5PU4 48&8LD"Z< H C\>I <J) $_!&>%I!B*CS?%Z>L>T)!WB1 4*P
M'D!!(AU4PS4'\4'[4L(!=SP@_XW4<L )?C&-N51 %(!<SG(\ PW7[$V""R !
M6U(%%0.TSV("J$4%=F6H9%W,'3[XP#+$XP!SX><@'S# <G  "AJ 1RSUFH8!
MYE)61N4U+&GZ0)K^0P,.+, <H/A'2ABJ.Q](] $<>$,YNDJ8P0F  P?8VT\]
M(P_DI:1>(EW!NZXHP1,TQ!-"R>4'>BK8F&1#0@@1 +W.HE7/:%4<!K@" )+*
MJ-"1%2HLN !<!,#6Y7! 'KFM14/,@A!\@ (8#[A&*)8*B@=L8@'<H,$R/,$!
M8 P.!Q>ZJ[<F^($%G  +"&%"!4"1#AM4P!WH*=8EE82_%7Q  -KE@ ]NF]-\
M50<8^/_#ITJ&%5<=B.,NG4NK&);K&;+2B[W4J@#RN!$*/@" !=Q0L"A-JR2'
M*/7! CA!!4@4E@I XPX<$*H!@E*"<MSP+#LM+XL 8Z@#G!>O3@%%#B0XK)BX
M)AQXL.ER]J)9W&:0 RQP@*9VNC< KK@Z/_XLD/%I /S*H\3WFW!/V>M4%I5
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M/@!P*$1L0Z$Y"XBR*0C(PZ$(BG\Q"DM,"0, 0S+YAADQ"C]Z@(4 "\OCHP>
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M"& "#M"!?* !?9.-"?@. ( &5S&8:]@GW2DI<]0D$7D1W>$!$;@!G+%)=C2
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M^KVQL((#. !' (8+P*N+$ %I#9T,>(,!"(5LA1'S689%H<77V X1>  QH9M
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MHA2%"ATPH5T[$-(X $@ ANBY'MP%'ORXHF,#K^=U!NY2"4TRB _ @>I(!P@
M<ZN(( 0!@#=(B9-H*Y$ 0S"D "PXA@7PA^J9CR09@&O(@FS(/V \9LB!'W30
M""RAD?HH&O#^:^E2 7YHBC))#2"NPQKJ&A9.#Z70[7S0"'6 5*AP@(98<NGZ
MAU$]B#NX=/J(P^5!XH:@ 28PE64 TQW*\E%) ;:Y!ATQY>B! !9(WJ%J00*#
M &S_&)[^R>(W< 0_-Q\ $*9<P5%WL1,)2"H7%0"@<037LI2#B!ZTI:+ISHC$
M2@]U60Y/,)@3@ H:@(H)R.?'^(#7$IQC$Y$+04865!G7 &).I9O9=HBY> M<
MCXF%,0 )J! EJ0 < ,/?,V5T:0V#>""E<011+JO(J0I7S0'QN"(QJ)G/:.*C
M'"I7V8@.?P-0:.-'!X!->)'SNIUW\/5T;XVS(!=-2H]X$: ,,.8]8PNHR)X@
M&A,F.ECVF!$$7I+-P89M[Y%7NIYO=<(#-@BV>#7'(&=JV7@@41IT9>/P*8ED
M>8!RMO$3J<ML2 5IX(&&>!KSP2-E#XL!:(JB64^'$ $6_^C,@D"(3PHG@FX-
ML^Z17)(+NC]VQ@EK 9 !/ *JSG2$R]IR0S\B$PK$L."'(RH)A$P(T%3>_A0@
M3 ^%<E@9/'@'/,H"NC>+RC -/#"2UI@ "H@!8?]S1TD)'W .#G"$; "+_,@&
M1Z#$"R$-T#" ,O@,/!( ,OP%R*F #  &4$#1U9)'%,V!#"!(L! !% 6+4.@(
M1DGB/^&U?5H,9<<!$< C]QCK@M@$)0NY1ZGJ&)@66_<,\I]FA 3B+7Q_ Z86
M$: !YP"(;"HF0,B604R&!0 NX #@$%(Y$0XAD*CV;@(HAQHW<NSH\2/(C0Y@
M *!0#4 V,=BR8%,H !($"AP @/^:D.&!PP4P)A $!@%"!G1,1'#@D*$@ (E)
M 2S( ""'O!P.'GP ( #" H(9_BW 5@:; X<5CDY06*&'Q@]5LP(5P <"@%\9
M8F"5X9!7A@D5#$QPF&)!A0F.<+#-(,!A/A$'>/ \X-" B <3&@&HP.' W+X
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M1K/SX($>.4"2GQG&(2O8G$U\G)44&R YYZ'74>XPVKQDH<*0N"8PL" "NWQ
MPXUU"#[.DX-IQ"#7#MC$ "Y@ Q?C!!1'68!1(#'+XDP !-<$A9VQXA *_Q@(
M)@QWT(9I:;H#](4#K0;F,6( "N\LP!%':;,(2FYJ1F6 'B9VT)@%($T63"0#
M9I4'!!Y@X/^"\]N>H/%E;-+Q#QS#$09XP'X%P..HYB3(0Z:Q!!31%[89W@>)
M9R_+_KT1R0# !V,/2P0N4$L'L!'& ) &7%+1:Q\91@3I:+/Y*@ 7!WR@H#<(
MBV5HX)BQ4P#9#F@*LD_ZX%HDJ (,3E(%FI*D@*=]&7;1R);O (D%.,.H9>%
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M)WB9 *1&(N'$OU$ 3N0'UB2(8I3 H@3<&["? SC '1B%9B6$ &1#F_F##D@
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MQP'$)@1XI@A(PR9, '=H2D8L R0 EWLP8-DUA2B(0*THT@"H!2S*52KH6.P
M5R.<E%M:16_B! ?\  >@TV 69E.$@CP4AP5JQ%=J(0=P)@# @&/<Q 3H@'[M
MAXS(P)%,124NDB)Q&"C<6\%-C3XJ!0^P0'2RS8%D!?].3(U>BL5P9@%7(DD&
M+%A5L(EWZ 5X@F8J'$8ML=LJ&IH(G  \*1('G$"@*$5:1N4*:$8Q3JBW0$/6
M@$),1B*!24E:B<,'4,"1D"58/L>_12<O\)E#L(T&#$!88,8!>M;B9(6<',
M].<';,(50 !]UDLJ%(Y#@$(^:*E&2, !I((!_(!^TEX9")A"2 1OL(DH&(-6
MZE=)MEG>;<2%$L@&&I56FL--2&)(]LHJYL0\].E5(-X#< ,GC>9,L DWA(66
MFA+7[:+4U! -*!,.N$,%Y ,$V$!1V)$&>(=W*@?7<0 WZ!%X%A0 A ,)9HUA
MP"('A(+\1:@&_%I&9"4,%(7_'KG'8GP :(2#^,V$42W ;1'%+TC<:.'$5<@E
M /3 !Y#$>>$E-8U16FD$)#B$"AP 22R ;[S7&S@%,T6&JG+'A ( J1(G4XC
M'21(<A*@ ]A#8_%&67S@3(SFLB;':[Q(+8TE!_B ,R03ECX?16A$O:254EI&
M!"3H Z3 V"5(FX&C$7J+BHA #@2KC)0H4QP#<-$>TP$ #22'U "#4D#GO7*
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M##AJ68A [T##!,@ 7#S8&]A$@$D3*.A .&023NB "/B&NU9J^TE##F32KCT
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M%@30H^0W?*!LHN2CYT?\3%_$5A2U#=5L1"U04].\S2=UDR?$#^CW2J!@:OG
MQ0/H?4?\C.%LR 'T0.-//T'UT4YMNYPGB9X,BV1=R>%D 4 8, ! S/_ !0N
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M>""#"7H *4[ZJG'/-H\:RX"^L 8(:5$1^%@@AD&? H"#1>4\M"0'XLSA !D
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MK- !,CS+L4AB,0"D(P-W2(T 4L$!&+ 0 CHPQQ6PY -W'. " !"1(Q\WC3>
MCR,0\$@/<2"48]E ).VARP=N-90//, C6<"&/QJ1 19D3@P?JJ0 MB$S>Q6F
M;5N:%Y;>1Q>0N$0"$)/EA(CSISJ&Q8ZB 4 9TL0- -3B 6D!R:A&!@ 68,F5
MOZF.2T3D#!CH(%S'^M W5>#(WL"D)"4LX0)20"SB5. 7#AC(#[91@3O,$ #@
M-( (2@"9%<B2@A7( 0!N_U!/T""3@CA<0!O/ C[4,"$#7WD'5+3(IP/\ #)A
M"1]Q>$@P>X%&!"1P1PE:%3#[@.*?A70AR>Z0,P!0(), X(= '1G.V67A&.-L
MS,X6\(!PA>18%1#)!'"PC.><1@1<LM5^P+, 2,!/5+W[&<'<,Y2,ZE)S$#'&
MSPRP#$7<\X;A,\ )/V \T C&3QMY $0^< -01%4'.G7D--!4DL<-T0 IX%//
M ( %'$PU!W,DV*7D*8 V&D"!*A!)H-[PD5'.;@'8P,(Q_#%)IAX !  +J!Q]
M($L(N-4!)]@(^?PA)4@T ABILV0^^&E.U:[V3+78AA-%D+,U7:-.GIC #V#0
MN_^-N'( H*@ IWXC* A4( /M<0\'!,8!'&3@!!48 %YMDU@G2FJW /!$D#C@
M  @,=P(5(%($1.*1$QZ !]4UP !  PH<:(!< $ALI6@0JJ$  !_BR\ /3O"Q
M6OSJ+*F0A@[09$=1U6E;%/P8'HOKGD9,P+CNN=(!/#N 6E3 ?=5L+P1(L!^2
M70HD&!UN#$YP@GPLP $Q, 8OI/&!Q I 9E5ML2MQACB1H(8C61"1"'[@7#SD
MZP; >(# HCF!=(!WC]GPQP<@\(X3S'>O+KEF*D#S &EHV!.C4@M]J8DS/CT5
M5T]\@#R(PV( 9.Z;6F85L:K$VC.A$X4=;D0YRB""' 3_L;H?RAR-?2"/N9T
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M.0" !B!#F4CF!P3@B4Y@W1P)10#&!$6CZ)X%2S($'T !%++!)Y[(F>CL)%:
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MX!K6D<0\01W@$4U096M_2T ^P!W:ZP'HX9CK2!P:0ILYS%#(&>AR)AV<F0,
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M5?S. "8D^U*#&TK&';+ 7JKAG%G;-OSA!(+DRQB0 !N!%=>#6T;E T #!\I
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M(H#%ZBT#1($>@L+_6(7&VO^)F_S4N"I&,Z40?D^ .+:1![! I:Q2(3?+/0R
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M[*$/02B "9:'1$*$71'14Q?R0,8VA@& !L2S +^%9P$_6DH5U07 G05Q/24
M&'D.L *2A.<?TAC/!WAVQ-V(8AH,&> 9"W)%VT21/15(S@_OB,<\VM!9NEF
M*&ZC W?8$2Y[RDUM<O,++[+F&UUD#2_*:#KP1."/NX&?>&:C+ML(Q383X>-Y
M_I@M\SC@ Y9LH!A8,!X'=$H&APP/"0XEGU8.Q(_H4>5_[):A0Y:2(,"0Y6T
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M +H_XM]9/N &L&LX4'S$) Z<RP&+R<8&9SD!"/!"!@(H0\=4A1:8R* <H/A
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M&P$,$_ /(  ;7:$.J=!-);  !J@A/^%1 " M'<873+$ FV$3?%0+,05>_ZE
M)^"Q*4OR'XSA%+"##?[P#?#58:5S FEA96!U [Q ?T(XC?@G%CTQ2DBU3.24
M"DLBD#3 $!\ #5(A%7$RD0!R**_B .N#$3I &%[!*9Y1 =4  :4# 1'@"*JC
M%#$) -O@=-18 3= <PN #1,0AT4'.C^" \S! 0)!$A_9+@Q&''=A$.DB9B>1
MD&"W'@Y <^CQ>?[B?65X :GP',[$)<#P =N4&F\ "MG "P4Q#26!)ATA((04
M _D@"J"P31)B3B,S2]7B"0M@:J0'.R_R/V5P#?Y 1=G0*LO2 Z<9+A]  Q-
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M&3 /J< #W:0!V508CRJ2S9<#_""D'$ !R1$@8\H!?"!7ZH0#2>&96/8C.P$
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M$QIP% X+%_Q0 >%P*/07DCCPQ+1,8H61"NZ@,T=B#CD-@ \ BQS@"<IB3 ?
M"S:P %V: C-R ^( T,,G)/DD#3=P #*(*6A= 8F'$]):@!VS4#BP&J,D8,1T
M0 H=0@?@ / \0S/JVKC!,*)T-",DI>&U L2BVK;Q>>2$QO]J86Y4.TKM)Q$;
MU!/>!1P"=M/Y$",.^8QY"QO0!PQS-1#1^:,7Y\@:JW_AL!@.!0$8@]R5&!U
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MC:(]","";' '1S";T,LQ#K!!7B*!\T@1 (@!U_N7#-#_/,0CM[6: .H1K9Z
MI ]( 8K BP:1 4DBJA1H+$_8JU<RDY,A+(<)A3\A#1I $U$Q)P!Q!!FH@&5(
M!3,QOPF @&-8AG_( !"P 0   ;\J" T!09@  3,QLP'(@0, @6-8%@#@ <7Z
M@'1(@30",0%@ 3"\$^O(&>; *T5$AX)0$@J ! !:)!90CXF !,<X#P< A9KH
MD51)!TUB#A#,@#NXACL I*\ZGQ,P!I0P !'@A08Y!CY20PCXABBRHZD2$ A8
MLEU:@ '(B<I1CPQ(!P&0 4&T <XP 'H@JF3*DH:  !DPHTH3@&-80KV[)>C
M.+P HPS0 -,8  &X$"41%2;*_[/40,%:<*?F*),/F:<) (%@LJ<\7 \2,(94
M9!!]$"D2<C*!@,*_::^QD0J?X0QC.0!WN ;PH)AI2($%8)Z3X ,*X)5+%"Y(
M.H"-HI=DZ1TW\;'P$ !L2*0"Y"7F^(\?$".P,9M.8R*)\K!+88YO6!9L@#@F
M\AB+>YJHXY5&,H@KB#U0L ?5$H$!B$K.P+<!:"R[.4FG$[-J\ 11:(YC, "H
M29IZ/,"^$YR=?)DF= X**+V4FH"H3,&&' !'X(.7^3\12!\_[ D.R)EX] 0^
MW!$0$ #'8!+ $CH(F(HQ<8"_M!.7E$B[RP?*V02<6X%E6 $#R)=<1,D,R E8
MDHITI/\*%3@FO5@@4AJ/?YB7#! #'5BO>6C([>& M'1"V9Q-VFRHX&""<;N(
M^2 .K2*.LRRZA\"6ARB7X<@9C6@WC)@[V8P3$9"!,C"YF)L '0B',:DXL "+
M"O!$'?B "JM*MX3-1!J>!ORD@ZBCGH@HX)(!#K""6AF TX" '  %"OB YU !
MVM,1/O#. 0@)@4DF4(BG\'".+($$RP@IB_/.?N25DF$)B:@ ;OB.1!).L5FB
M-4&(!Z ''5&'DPF+*Q@ ;& !+F*F6ED86.K%DQ0%DQ2)$G@ #8!-"L$T"XL=
M@0%.7EFFCAS *Q"!')D / "!?5(51<DN?K#&G@" 1M  SMO_40. !'VH)"Q+
MQY^Y3F6Y3Q]0AR84#QK@!@0]G\G@$1VE@!1P@*_CI1&-@'G!"PA0!Z(:T7#@
M#"8PB=J,TZJ24SJ]B+.L"#S9H>(0SN&8&D8,%!.KTY$:(8NHH[U8B,@:$7)[
MCIDKTA9!)A;@ 7=H""XY@&,IMI[0J IED*DI"%0LB&V(+T4X#4DCB ^0!KFX
MS$0*U9?9K^R" &Z0$())EB 4KH)S"9Y*))A@C@4@4*>S#(ZTIVLX@$823(,X
M3'6J!6EH"%^D"+!*IHT2F$TT'ZG8HMC;$7SPA];B(F 0&"DK49+ 2E[JF0F3
MI%X%41YM$[ "0\A$B.;8Q$HCNV\0_P"H:Y # %&W.Q'F,)TQX85!\35N8[SS
MR2;KJ@#(5"QQH-66@SYWPS-C?;[5' L!(+L#^E0F*(%Y8;HMVAX&B5@!P$Q!
M#5F1#=D%<(:, *"170@C0H@B2]ELT8@3N@@!R('99-'#@\)/>@#)XX/#O(,)
MP =,P4[%,@=?G)K>*@I,<8"D+,E5M-2#J(_(4H$&*91$>@-1K(8,8 'G$3X!
M<(#) I[>$ID<V%9\:$)0F"Q>_1 '&  ]#8\@[!6P6*^[] OOXKRN'9$*" M(
MB( ("(7 F:M9^L23+!T.>$E/@)U>K<#ST(<6N8%\@(1I*%%2<9*&6 E:Z0D1
M (8BY9$<PO^O"/B7FN(&3UBBNA.)+=K$\U24"C@!:*@ %D@86K1 D_R'.6$.
M70(%):D44'  3Y@4 X)2BUO%Q\6YWG*$:BS0OMFKW36>E+ N>X4&8=&EO.B;
M>"L(11 3,5!;*.E!WW-9[_U>\ U?\1U?XFA:^O09&_ '<\C;9>&2AF""!] !
M'=N1AS& O'6LSOD X2&!W34*12T(_T M>=A<&E@& W"'"L@"/*"M9?B!+N,,
M[A2 U<TL^[T BG@ Y_.+3>@("G'?)#&(GC@^YQ#,I@4J4%@ZJ3B?!:B !2B'
MTO,98)"(_K4;)RT(%;B&_W Y"2@(? "%$[BK!UL 3Z@%NN3.[!+_O[J*"A_P
M&8I@ =1:80,PAQ,NO=#PCS0L"'4 CX.@D&^0I/_Q3V@H@2X6N!ZN (J0XF)"
M49_YF[@5/X'[Q/C AX9X@*.0AQ_@!K.Y7P\S"!W0@1P>XP;"@A$!"TV1"G?0
MXE7<$<K0$VSRF9\ B^\BW^)X-9 X#/Q)CG3I3;-:*VJY"#ZU373IJ9G B$MV
ME]YTJ$]VJ&FIY,A0CE,.6>@L"&R49(B   6DY?&SC17^7F=8JAJF96!F%B;0
M&F+VC2>#B#%-'8=((0/P@=H03*WQ#<A0R)$R6868UVG@,.$8TP/8(1S0YH<P
MF]OX7XV #.)$"'0X94 !AE X'P,0 PHR_PBII6;=:&?QU5G-(.=@_L0*>.61
M=8"YO8W0 -\Y<9)]/NC>Z.2"6($'"(<'XXRZ&.7+< ML<8L?F(:K<HAIY16J
M> AD846,"(F&Z2W52"B@&&6%[L^7;:B]4P@N\2KAV.B)R(<,^--S!B5H*6F$
M4&FK4JB$@ 2MV.3A>96%^(BPP#G4@@G@S =R+H%1C@V=$@RT &5U>H<1H8M#
M_2F$WFJN[FJO_NIK9M8=<3(!T(';J>$*S \=H#8?\(<%"(>QKC22X(4# (9_
M$8--H!X 4(</&#*#0+-J&+:Q[JT?"S(N86J!^( G.P!@Q)SI6H"G6@ L.(90
MB&8!" <ITYI-P/\!C H%'?B4:EB!V#C-L=83X. @J4@' -@&'< +O38 '4@6
M6O&!VM&!]., ZG'LF/U$G4V?_WF G# B%IBLES& FHR)U GL&"9L.YDKPDZF
M31@C'P@-'_B&-\B'T5@8/?D(#K#MU.@Q*W,&S/D79T@I)M@$NOR&[YJQ@N !
M"HYM/*RTP),*-ZD%BEB3^3@MZI%:J?@ %5@)$A" X"NX2@L-'8@T/D@6IAZR
MU$F_FC( =0!&_UJO"N2 1ACP=@%K#=]P#N]P.BV!AI$G]WN8*S P"\0N3*D
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M 9J1B. #$Q"'#0C3D<GQ0@00L$%R[,$#!Z0" !58"2@2>8VMZ80#$0%%TDH
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M P_(1TX8FZ6<"("$=N3 &PY0CDTPC -7.8 \CB2:'JTEM(S[J\=2PP&SU@L
MWVB5 $01QPO@J[(Y$)1 "'-,':7- ++=3#5H8!UIP$PT.% !6QSG !9$DU4F
MLZE$XN@# ]#) ?AZ2!P7L#W*>O,\X1UOV_YZ6+@B=D_X$H #_K&5E<EV6Q*Q
M@6H^NTK_!R#O 3FY0U\RD Z8'*"S@)V*64FP%2ST)10F2VN^.( I/%  3=ER
M6P5P((!T D $[Q'LHP"0!8UF !\D@ @'#$ " 6 JQ"/V#I^LY:L)#R0?63!
M<JR %@,?PV03$-)+7#*!-XDF+OCPB :.U#N8/&")/HG6/E="&%"@(\0A%H.2
MT"&L;!'90"DU"E&PD0$)O&E*?.+ #PRP'37YY"26 =U@LC$PEIP'*PO(@6 G
MX!,!>,^\JH)F2C731X[D8!DGMM)+/&DM^JX%%#?Y@)BO5!@L'*,T*0BA0"B
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M54",?="CI<DG0H0#_( BY%Q2R- BJ1/E*- T9, FI G:2(!+@0(3_]@),CV
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MVP"2*S'K P## MP L=I @4B#6BP +WRK5AF &2;*4NR3F4A&!!3B$FV&-7U
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M/ 3,UHR6$L8*Z")@Z8GW2@2?6).QP-*JO,2A<8 BJ,/=K$"C5-(JT1N>0)U
MX(%R.<!3-(5#^,08)Q4/N(Q,[%[_&0 DE$97"( !.$/V3@PT+  .$.):J!\
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MMV=^!\LDC6+(QL\Y6L5PGJ%@SF)T!76.2%*LIXBH-^PQ!FJEWASKR6*<V&L
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MQU):_]9"^1AJ#CR .[",0 ' DOW."KB##OA#Y_:.;PU2L11B/N>WVY#Z24"
M:UA)37W "1!&1@,:9,O'!TBYD]# 2T#-.@U&+*E,+/5%O$ VCR.F>F1+"B3%
MNO>%FT&V;"1%K0%H(;) 2+6&E&,,9;'>#X" M)C[RN@3G1#[=NS8!VCX=JP,
M4!?74#&4Z&3+-.AW:FS'[Y2[0$B#"/P"," 386@4?8F"FT&#& @*S5(7T!Y#
MC]\3C/;W88P<_"AA!2B"JB@B3+]-+G$4 +P#-!#B+P)Q*"PK$S,2=$S.%CH
M#V"1/ABB2S (+'G'Y*B;%U]0VCB$U4>FEII-!F CJ]D W_^9#0UHP%(ET(2)
M DBE2?\QS"?B&VA8?0S\(E:%PP38@!RGN4KHPR!;"PO(@ .P]*^@1-G["H.
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M ?A59&(YV5W-;>AR3K-L0$%AR@ =@ ) C!0T-( /"(J=H&JWIYG*F3(0JAF
M&)BKV@!'8!86\\PUWYSSSCW''*3/1=__.8>.1C\=]=2!32[SJ8%%QUS556<H
MA@L,ET;#"3[08=D*+I0:E HR3+HU14#1X#'X0@>4!PZ 6H ?470^UTV5S!U)
MYW<U.. 8GBI*"U^$5!(NK([V%A> [0%8J.4)>(#AX0E N0\ >0&K^2)'*I))
ME(, B"XH/\C04BIP(H1(X&1,2-<$E@0!P^@%(<WJWJB^ X W3*\UUVN* STC
M@>-M FD?J,O.LK(W#00%%,X WK2VQ@.W06!^)RH@ / Q'!Z@,$,6.5ZQ:@,
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M Q\8P;(3P#9$(8#B',!.-OA GA#R!@IO"$2# X S.(0E;P'*29.Y$0=N%&!
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M!3* !1Y@]&+B,3R#"=#"@]RF3,B# QSA6?!@X31$!I;!!NH(+;XJ(JKA '@
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M]L(?C%($IFHYD[.L B2G_(/UXF@IVP4S-P>&'F+\=N*N/*$"JD$:0$AB.@D
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MH&$ N&$"TJ%(4Z!(D>N*'*$G6"ZV[#$&)J"^,&("X+5:4P!T508;(.$ '&
MJF$M.V8!8L 88J!(*>!R;Z"BCDH&JL8!4L 2>V "@E>>CDH4%:@'/.0#6O<V
M0!=@)L 1>& </^*_BB-X);1C "4#*, !_.%R#^ $K,!Y)D &@&("4B$#> !T
M"2)X)Z R888^.'(^' $;0($S)L!T)84"* !!D<NHJO8C/.+_-AQ!'>#"=RF6
M:R@@>'OFF>B+ TR7(Y<D \+*XL[I1O  1.!#%+95X!2!.TI T!;@+JN5(\G2
MM10I?9/W ^ "=I>W8S)@/UT':A9+!(ZA52+8 <B*(V_#7_@V*/ @ T"!'T@
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MT&2LER1-EN0-\I6M]41=(Z4]90(A16P!*E//9N6(W&1)!"Y"+,@U#D1#4$P
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M H '#?$ X%51X$ ./R;\6 #@5[:! T5%=/#PP8.)$V@ P\DA@X-\'S@ H"$
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M8$ 'U+$P2N&?;313@0LLP!]\D!BZ*AA  \+H8GSXA;RV^*TA&F>2JK225PS
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M<!Y:8=#5!<2 J0=X0V4KJY8#_/4=.7#'5(27(5",<0 J@&PJ.!NB#(@!):"
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M$' #_) ]Z08Z_74R<.AT&7(9GG!8EF9P\94!)< /1T*'$9 YO. Z;P4 *7
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M >*J-@4&.T91HL?Y6XI8F^+X>#]4>P"09H[P (F7'-P' >J0=!!0#=AY!QF
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M?<:A \*!+G<\27>@ QSA)310'?GQS?ZGM*?XBCAQU*O6-K_@ZJL64Q00-!D
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MUSX8M@SB #@@UX8,KD#/3T&!!F'_A<7Y9MY4))L-91TH(,$1"* 10<X*;*1
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M&D)IB K>"()I &!8(@#CED8)@%#(PW['5(W>IF*GYF5 %#XAH/^2MG>4!:1
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M:,RT*&Q/Y1V8H;5S_R$ ;;YRNOSY@/P6L()%N8IH2$+B#TKU &GP#0#J(+4
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MB@$0B4M1,7SX $\4@5<IF*G@H2LX&X,:  ?B&I@ !1P)C!AH(RZ<AT\$!1Z
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MX&"(:<@.T\"#(\J\68$)#= !:2BJWD0*:3B.V?0' RBCAE"'1<0F!VBC"8B
M"OV5<7H) 3"'[P0 Z\ +&*.Z^OP,&/T(ZP$ V)R*J+A/TY2)]'1/^ @PVIC-
M"B&!V(B-X@0/J6B$1:&*_X:P 4\ #Z)Y#$BI%LJP#AG[F_=D 0Y@ 0C0@7#0
MCR9LCR/ZAM9T3P/(CMBTSQ$1"1S(O70(#X;8!/@:D0^ T #SD7;JM-A8"O.Z
M W/XA?8@S1&Q =1T4FP:"P<0!VFX 8Z(3I9XB?N$TN$D,@<@ =K0@49]JI=@
M#'O13NW,T?8\HELEU(P@ <:H4!9@"3)5#!=ET[)PE3 10D;MB!ZE$AA## <
MG2W%. ? A^_JM']PAG]P34?4GGPP$2$<#?CX1=^T"@.(50&X@5#@@\20!A(0
MB70X(E&X4C.BTGO%5YH8E@P!1<J"@)6S*"K%Q7PEV!B)(7^BK&E0F1'#+<M*
MA?_CY->"E=AZ'-@5X8,)H,0J=:[&G-@8F0:;Z]B0%5G+"HT,"="11=F4%8!L
M2 5'K*Q+4<=[U8%,3=F:/8#=J:P?.,/Y<@HG P4'99T8J]FA?1&Y>)%I6+PG
MG0D2H$<L2 VBK0D;\$JHI=JJ11<<J=JLU=JMY=J.!1W**KVN%=NL99"QA9&P
M-=NT5=NU9=NV==NWA=NXE=NYI=NZM=N[Q=N\U=N]Y=N^]=N_[5O: 97LV(23
MA1'&J(D0P:J:$!&9(!&:"$$5<%F9$(,I1:8R_0R:8"?+=3(.B%.8,+6GH+J8
MH,=]0XB.Q5*T,(W)M9]9C1%_,!DP*E@5H1W:, =0(1#_AG" <J ! 3BEAC")
MF/A0FG@#!X@ C$L,UHT)W/3/SVV1RQ@+I$@]FVC<F8BQ&'K#?G61[3P+H:V)
M.P 5/])>F^"#R8VA[8P1 9"';"305Q)!UYT&( 7<^;4?ROP $." ;'!>&/%>
MF'B-!_A:F8@SF4#< ,XC%H@>ZH6KRFHL^J,)_GBALFT1YH"1I-/7C . ;8L)
MT-E'?F.ZD:%@9 (%NL&P :8LV8.1S1S?>PU"3UP &BF*#]B&S?R :]HM2,G8
M=:R)7Z02VZBV%7F'QCFSD4D!G,@\\[!7 >Y?U\@OI*  0PI8%WF#_3J*)98)
M<1B2L[D6%PD%3PA;!D+<%!XP_[*IC9C+%1RI!6@ @!* &_IU8_H9X)A[M5DA
MD/UA"'S(WA$17^!XJO&H (P000C"*A5X0U&834E9AI%*##^B8!(AUP\N#VJA
M&$]H3S]J"& P !II.#W.QM[(B$ZS3OJJ9$HEBX/ANR?5Q^,%#4?4D@=PA&K
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MD <>F!Y0*,D14017@0!&P^51$@!Q:P@<H =@"Z[*WHB02"G_4 B9 +,"A)B
M%:B>J7B-NSF;@M( ZH$8>5B\XK@ '/GKU]!(!VB:-[*6F@H)"; ,C:* HG$&
M';"38*P&&'"W#. !SV4=DZD VM7%(R$.DZF%<) !#EBN0?D&)UJQ]_2E#Z@&
M1Z@-17FC(&KH;ZN%;0 5XY:5:GN#RM8!D. %WB46^DY)J;#CQ7N[( (%PX#J
M,L.- A(!&VAEI[(N#CB&Q @)",@'&C"/CK G4.C=W4%;@L6'5-@& 9 !<TJ,
M-Z*>8?N)I3J*F[J#(VFZAB@!'%'#EON)('^  ]"'4"@'P:1MUY"*:[@#P/"J
MZ_9MEIF-03IMZC&N2_&JNN: "T!'_X;<GV] $BA)9-"P JDXFZ+@,J80 .ZF
M'OI:)CIAK:\2-Y@IGWN)GA@33W\ %3QH23OA\F \ ?B",9-9;[!DBBK* "4?
MC@MOV0)ZC1PFCJO3R8IL")\ZI7'4ZTZW"7TDKI2"@'0HCD!F.?52$NN(H2&3
M\88X\#5ZE ($H&\JBP-@ ;9(@3>7C)^M(NOKJ%53K .P1FVL\%[/9%XA00#P
M*>QY"GS"D8:K(F/S#'=P(-";-Q0=D> 3HY3* 'S(@FOH-#2Z)W ' +/[B(]T
M/G3JNS C[!(3DA>'O'<X@$88P^/\R5_%)F>'JC>' %Z0GTT:(W%K!!Z@$D\P
MT"QA.9/-D/\[H(!&0%H&]15%8*$"&B1)"0=HQQ'Y21D^^ F)-P 2DS$P6BG)
MX!_;^"(W\8@Z!;VCXYL,F-$:@C&B @"S05,#" 6F24[_,(#VHH"1O8%G.X ;
M6 8=$"?YT0A@P), $R%1\ETSN;F&N-AO$P5/D%_%N@-SU)ON@*O@.R,.H $-
M-)D= P"]$+<LD/2&"#Y%X:<"XJ$%P(=T6&0N5/@4N(-=\3Y0A!+-42!3^P!Y
MP*R5N!8&*CF[@[TV09<5$ &P@(D;& !]$#(Q\ 1Q$ .]*22@(8N!P[=]+]>O
M*J#)TL.JA.]YCPF.\MS)JFQX7 $N\O35IPE[*Q8\X#L-L)/JTBC_!LILZID'
M&. PMZJFHPDE7BFZ2/,$?C@=Q7 5"NB!-K:^69,*@J>K!7B'LX$ Y1_&\C8:
M8VBG*7F*/\044"@4 *BC7@JV[2F=C%!]_G@#_;L7X2@_@[^Y0G<P?/,E] (%
M\*%$!\A4KX> />( :+ -% ,(:0\R0( !X4"&!0 6\H$PX,-"#M< +$AA@" H
M".$@5N  (,,W$?,,'E@(:@4  Z#T@3(@,N,!D3P@* 0@8N$ "!D%.'@P8<&'
M#!DK?("XH(*(%/Y>0A  H.G"H@\< ,"3RJ5.F@ $0%AX\^;3?QD 3)L X,&'
M"08 ?-A4 5O&#QT7GJ5:(B$%NGKW\NWK__>OWXMT#4SX$$XO5Z\'0%',( &4
M6<(+$W]<X" "71X'%E/$-C#C#[H9U@( =: G  [0#BY<, "4AH-F/QHH2@+"
M;1P5Z,:, <%&N!LN-<#L6AF OY*=#VAX#.%!#*=UMT(PD I NJX@ !P#, #&
M3 $'LM%[0-<<1%"[Y4V(;<[TV0\_\M55??%Q=!A,RO!A#$ &9_\!X$ &(JSU
M#46I4$69"!QH@--" 0(V(8456G@AAAEJN"&''6(XE5X0J#"!4QRPD,$T ,3
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M^@3 ,P60@]XAZ1<<B$!-"9N:;QH@M_)<*W:SJ]WM<C==HCAI+F_)%[,M1*"
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M@-YD@)640 44B!7Y6R4-@ U< /.)  E<1 K0! 3$WU40B QL0BTYP@2\ ?Q
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M', /H,F>Q,W<@!S_\4!JG,#3\/]#3?@'B8B   ##:(A"LK220+&,<73*350
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M< -.S@B=V-/'" K62)4&8,H=F,L+3?^-4Q2%;ZY)G\ ,#OC'8KQ2&=W40J3
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M1!PQWJG* F0#"0Q$"ERAUS2E(H" >2Q##S ?58#"&XX%#!R?XNB#/$(&!:@
MC93!:(!"-D32XF6#^%G2^ E)[F6 R!ZT6F!*#.P($V: "F3 -M=$$.E \3&?
MO,7$ $T /X25^T" BE&&RIB#(U" 1]2""D+ +7KS(V%#%@R$9PB %<@ E5T#
M\['(  QG6NP&,?=*"N"D !@?)$#&,:2#.XS?3Q#&H%BR% :1(2XG!Y#O$DT?
M/3.?KOP$-TO',U- -KB/"L2? -RFSU I#L: ,<! "IA%2+- /',&7P?I!,C
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M9 S\; 6(@T?FR3G5A@B$K\73RFCH!(YDU#&8Q@JGP@H$M*E':@985H,$Y<.
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MG4!YP)T[*I(F0@-R[.@C#6TZ((-&"'1@I6L^\&0:4#@@D:]_\,G@'_<:,<:
M!QB:"X /;A! A ?P2(4O 5BPDB&HP@(%E$8TB+*")[DT8*V;)FC$&9TJR $
M+S>IX %/"II )3ZV^T O $#X$R$8!(B(O@] X>:Q#ZX H!P_4UA@N0,&8.F!
M;4"IR0!*+04@)]M8;=755V'M[*%8::UU-G]LS357"8.C=!G-'A@, '<X^@"=
M1D")X3&$'I@ %$_P >6"Y#S*1C86JT%(' AZF 8A&ZB38 )>@-F+!XABBP$"
M%@"(%@ ;/@"+2R&3:[:6"_#_0*E<?ZZ9X(IS.9C@@A\JFJ ":-")]TL(M@.
MAO86"#BYO4"9@%(.U&V)2PA:"HSA!? HP^*A9%N@XFM8$Z ]%@RXYKUR"W9
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MR@(Z!0 FB  &&9@ #$2 I@R 0B&@$ ''(F<BP7RU+P  Q<]24*Y0#" 4U\@
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M-('$ :*#OVSD/7;O%W1@@W;G >3!2'Y@Q&Y@*&2 JS(B RI !DZE/5IBL!S
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M^.(KU$L-P4*9Q*PQ/*JT_X0$(:)2!KX'&I0U*O)(Y4A/V]:7-4C$#)N->7\
M6P' YV15T6PB-IRO( 8#271"5DDD:UI"S40@-AOC#@ &(U!B5?"5,TRX-H"$
MT?+056)-A.:.,TJ  E PB2F#%$^,4&L">."O)A2!:+Z%/BM1,JT,(F " ,1
M]-CU9_!4V!#B#IH"(EBP\:)K BA@ @!O 2[@&$ @ND3@6O,T&ZP 1_C K/R.
MQJ(29,]X+N9!9=Y!CPE%JAYM]K+KV.:B!PS "G7#/,2#Z, +$A*5-=9B -R!
M-4#/(' #CT<&B<)35&N!("P"/O1X678/IV;L)W:X-/P7(8Y71QKB*Y!()T!
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MT,LA UX$ /(!!J[!6UQW63P4T6U0)QBJC<!R+Q[C\:!A >[@T O\#XD)"W2
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M0(,(-F0067W0/'#!7Q 8D(I1"V@ "A.I5 "! WP,L-H #F20@0.0X %*!>Y
M8! 35E0P00:>!%8!-P \($\%04ZP4T\.]<A0*!-X6)@#H.P( %=2:L"3%:!<
MXP@PH)P0)  35! #5Q.)8 X$%7 P  T0E/,&ED0"H$(&'P3FR3$WD,A"CQ08
M ,,_ #C RXH/O&E%9#)LZ<AY6TYP$ 090'. (PY@DTX,UPB0BD'''(#C!P/0
M6,$"6\:0DI\&L2 "8JF4DZF>H"@BA@-V$@G!:B)X^($!/3K"AR?_(M1B&"AX
MPFK0 R"@NJ4(!OB Z4%2[KB "%?8^<"Q&60[TJ:%"8 ED%AR,$$6"Z2@K(?H
MB*-#O1G\P^H/$'P@JP.IB =AP08?O!\P""_,L,(,/XR@P_I)#''%"(-R!P#2
MZB7M :#HX$E=H)CC   <@'+?!)"A'(,!*AN$G@"<AGD IP<0^4#)>DGPP!M6
M&D!!"0(0Z< #)YHL;$I/I7!0#"55\  V/?T0V6I0A1DF5ADPP9";+$S04&"<
MAFO0&QH9( ,'1+K\@"=#_2DS= MXDE@HY4A[GK#.G#=I.A/T!,%2 &1 TX4B
MB.&0E3"H6%+1K:GS)P@U \#'V!G<P<,R_VQ7\/9!&91P3!8 ]("#/0IG0((Q
M#:6"QP<Z// # $.S-I0[#MQPD,<W V! F@"(D8U#3W,@M<95?_ -%HW\Q?7)
MCR:F\M\ W&D0-)L\Z0G4YWUP#0<"S/, Y_CT\,$F#B3&00_LSKF[RT)9W)^P
M1NGG@)6/]E20@+/?EYR P)0 ( X,ASX*$H T"N0  LXG0 ;007T >" !V& E
M]6%!:!34$@-PKD N<4G^]K,,4!0&0 H+14\H>)#^&61N$P#%_/3#'?C)$$!Z
M 8 .N*$7#E3@3N7(0"HFH('6F&R#!U'! "   1$T!B+S0X_'#"*")ZX 93G3
M&#X.  (1) 8 )/\(WA,=\ L:_"4"-&#7L1:0@4Y)!#V0F$"2(O 9"BBB9#+P
M!P5\0H*932 ?5G#C,9R'M8F XEPDXIS+T".[/RV@ @-0&31^,40>[$5*/4$/
M!$B #<0Y(#)IG!Z>W!@8@ZAO<*#,&0=(\*=]S6,H*$-CN=PX 40.S7,+ (%!
M-BFG>1B@D4D2 'JJ<<"A[6@"*?A2B737RDZZ#  M X G<F"/'Y+H,QG0AP/4
ME %'3" ')7.=FPP@ E!6+0/9<$0Y:E&2#]R  [5P@ ^N$,X)_$L'U!N: % &
M#$B\THTSW(^R_D&Q^S2J4U8:X7\JX #1V<>@_F%H?T!1$@=E83@$DM/_0@-X
MC17"!4& K \B%52T919(!]* 3G^^ ;H":8"B%UUA&2J #P_QIX83Z:=-[].#
MX>E%5A18P/E^]X^BF2RC'O6$  R0#;6Q2"+;X\.?HM@#5@(@ B6#04L \(\,
M-()WGN$#RAR0@W*(IQKUS(  F&:0,CBJ:!FXR_S^D@ZSRF !QRC(HCKYH9G=
M87<ED!,.(/ -9>D0 %F8 "]*Y@RT<%$ "Z"!)YZ)M)\\J0(\*(D\)M6[= #@
M&J$PB R, E%%&.0I/NF)](Y:CE PX:D'X(%4!Q>^T>H L8H=G"B4:#S1 H "
M))#34]!316$Z< %\$.IH,9;1>1F$1=\$@#PX_]"UHXZ'BST2H<M^43)IB&<"
M?6K(/^9'/>A ='NR4IDY$@.5#X1#>SB Z%.YL<$2.;1B%A*A Q11 0H: (F>
M""PHYO&A_8(B!0)PP#QBL !YQ !]2+0+$G7@#ZKT]F]J<^'),C#;8EG( 5A1
MF % 026'0, 3V5DD!&CPE KP[" ".$;0\@&!'KC(9(FYTS<J\J22B0-O$%!!
M"#_S@0*#6  5Z,D#R*+B!XA";7KAQ0!*"@JG+0,&V;@-DG3RI@5P0%@0F,8$
M1( %)%9 #%$^   5-JE89>$:$%"R0<*!@Z%\X "U4%-$T9B![62C @H% !,V
M"($%7" &L?IP-B(Z$?\>8<A?XAD:3<=3+ ,$%8ER62=)N&R4#Z0"&@:MXPXE
M<!T1:LPK6=[OP+;"J0H;P&-FC2,$*V" 15))% B-Y0%$<*&%B.5-6[WI#-7V
M 'V$HH8Q(!*[U":-&XA'A_[@7$$FX*@G@4(O99B? S8!#$>$[P0"T(!4JP@*
MIUZA&C/#@\V^&HI)<0 $7F(K.".*1.@:P$L[(8%!3E"!'("@EAIS (7.:A"5
MI0(]V"A!"G1P#3FA@TJ>&JS+T @O&!@$'X[ @0:@])>V<2 5T"TP#,J%V0_T
MX 'VX&0M?, /?^"[-X4!!3YL^)-]>6D:%0*%"%BPRB>BT952F@:)Y'F07)W_
MTP<96,8.;3" :8#B1 R1QK]*9L]WJ.T*QA59/@RI3)Z\+-_TUI9!E@[='%"I
MG-P$@+*_Z0 ><, 8- $ #AS!@6R$X@3I%(=#T!*H'(""!C8(\L_S\8\!/*"=
M"Y!!^.Q[4W;-N\A@,X@HYB$="@SM ?@8  L@P(T[#&"_/W#&!XJLE[_I'6IX
M2*/#I,4U)GP %"AGP:#V.X_>CK#- I#!-!2Q"3P8Q!\.*+((<(!0=EG)'])J
M! A($(X_R6X"MW6 R\"F 4YE( *P'D .!FLR4." )Q:BG034X6^_*4LNL1)!
M"6B%#Q" LR@T@/7/25 .&]Q 9140(RB H454<N<=_P4I3EM!$3X.$"A,)48
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M#@^@ S\I9.V)5@^':X(S. UQ)Y0I]Z@"$6KQ 6+%2E)"3Z!060!0=HF#2 9
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MJCF$-5C!!@0 ?[?_A:"BX 37&F_,!B !%(>(?R,NX#6APMP%CO%DFQ0.2,4
M] !@+2( \*M@N1L* F4>D1Z8H)&-<K@#E+YLXZ!!4,J)@3FZY'O -0=R &"!
M1EB;AX^W,J"!@PF<H: GF@3P1 0L*/B FU#PF& ! #9T9(%_*+R +!%^\>$7
M(G&4<DHJJ[3R2BRSU/)*ORKP9( %'#@@RI4.^V4IUQ;H:X$4R&QP E"F2T=!
M,0[D;BT>#)H@F^G0XP,4?[1B<*[#I'D@/ !J\0Z "5A(+["-9KN FXL @.$
M!WA!T+H%K#M @^D*^@__ '>&RZ9--1M99H(#T'O,.G]<B\ 3PMI\#8 W6!V)
M@Q.F6T%! _[*8,X,#&!".\)NX"9.!T#Y8"02EP*E.<?NY"!/WCZ,J$-0!%!D
M17K^$4& ;_KJKEA@CBP(!]D4'"R#IPSP:S!&#0 EE&P+XN<GR2"1"-[77./%
M@6FD4T&R5)A(L,,KH+'K@UJV(4R<@A(N 1L+-=H.F ENW6BDXPY+A:[!'/@
MP0>6O O>]%BXZJI@_V%MRX3N J <'\#:2#6-_,'F-7Q 42>%!B$H%H"NLG"3
M9J:;=OIIJ*.6NJ8/!E!D.!"J<0D"/"QC"CT=1!!AN(-*PJ$@#B#AAQ>X,ECF
M_P090* 7K@CAFFVR#"X A0_$2 ;@A@?XR@ ]&?SYAY\,'#/(-1E *0&""62
M=@ .8D#L&! .2)*RUB('% !/1B),!!G"40$]?-!S0 81[C  A Q &9(UUT21
M( .6 9!A F-F^PLW&<B60:*YE@%%A&P\6<#H8A>8(''Z*KCJ!Q$<*>JIP0&
MA*"(0.$G!0A6<.3YX9P*!01(Z -7HP/BGNT#$5* 3\)B*4"V(!I$F$"TCC.8
M[02Q'>   VB5#"!W /BDHB R($D,,I"-$C H''4+1_6<-:2=\49]%< =>AX@
M@MA]( :#^07E7F,T""S@@XD3@*",,8$8+"IJUDG< O_PX(C!B0*#O&';9!P
M0@.L0 206(KBIG9$)"91B4MDXA$)(J4G2NDP33Q(!DI Q9=\(P57E EVECC%
M#&*12E$48QG->$8TIE&-:00C%AG8$G]0$3/-6:-"0'$C@]RFCGOD8Q_]^$=
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M=^@W #"&!WB#?3DYZTBLJ+,>>#D Z1"K:L@\Q7B6:4B%X7J/ ]@$<_@:&OB
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M,PUEFFP95IJ(PM)AD6GP82#<2-#K<M!-8'  '6]@ C !P (.A.693.#D6@2
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MH 3\1DL..LV+!VA C O@-\;G43T1//+6:,'6/.RU@$J#HAKHP"W1%^ /?NL
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MS@7_*/A,-7Z>4-Q>9HC '91#?_*#!F'!"<S4 YC#X6C0)F#%!XPGFF0!C8C
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MW-.])WC"VK<]W@,MVT,#WM]].0"M)\@#T!9^!1Q^X4.#//"\)["])]!]Y-/
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MLZ!;8($/=%C  0/" L8 !_;BP"6O'H@@HP<.L*FK!6XDZX$/'!!'' X>Z B
M$X?K2I1I;MA1(6#_.CKRJP,$P%$A?SA0T2U_!#@ (K+$>(#*KF ,2T< 'GB#
MK07 5,B ');1[4.W]K))HP<*.DXO SA(2$_<XM(3  $<^""=DKPR8,JP!#
MT##1^L#1$+L20(0'IF044P/2R93110U88-$I0UU !4TYY731=$A%=-4IF3"@
M5$8W1971:4H5E=5723B55S'PR(*)!7;%%==9><54A05>G3+6+!A]]5A,F65U
M5&BCM1554%G%(]IL;]5VREV-Y95;59==X-=I-UWW5$^G&19<;<<]5=Q6X_44
MTWE-S918<-_M5E8#\!"66D0Q5>>!#"*5E.&N)J@ @ H&N%($++_R9X4!_P"
M )2PEIG 'C0SD 8L!R#0"X (3(; @0<F\$H>CVGH@<NN_(RS*QO!$N4#%=PB
M2 <'S!+@Y*](E$$L 5YVQ.*TU'E9(:*[@M*M#\9D" !0F%#K !X4(N$#N@2
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M:U2;PA>F*C<-;I%@&J,:U;=:*3 #- )8V1)FP0S@K,J]H97+Q%6RFA6M6RY
M'< :Y28[R<Q/1@N6K/J6IR+'J6EL2AUBD";!U-&(79GR6>?45+Q>B:E-9,!X
M^;2C"*!F@ $(( /VR,  #D"" 4Q !!H#!2@^H+$;X--[BA!!%MYA/A'(@)\J
M$($('.  163 $682@?O"YD\:..!E"IM  ..V@%28PP 9T,'P'J"/CD(B82L5
M@4TJD -/>")A7>F! $#A !MT* 4/* ,W;F"G X "H"ZSX 0^ $>%? ,")X6
M_S\[.@&BY:!C-B#> 42 !PZL]!T,3)@!)@"!!U3L VZ%*/DR\( *@*(1=9U
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MX 95!15!*W"R2BV H'OTR@<1 E'$1I=1O#D!.NP*O[K^P$SE $#:%*803W!
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M(6Z@#*8AJTY@BJX! OZA8QJ0.:?(9-R2 XP3 *X!WV#/+06@# IK ,(+1"?
M3_)"MZ2I4SBEN? O#Z^,J""@$42ER?B'_GR% V# ? [I Z[ MCX@5)YSM+*
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M^L@2!"QW&N!(2+>J+QRXL-P.!A1!;S) @_6F+ %H '1V4!5I8B;F!B9F 30
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MG(Y(8",'^!B!#%BH35Q#- \(%$33!P'T?< <'XA.0CDPQ8Y \'X.F*)=.B*
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M*7US <!X-SN];:%E5)- !=KG@Z(]I&K&R$H=PK:V"R0&,65;2++,$K_U39&
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M#@!*'" .5K@?"92)^Y$!!;<?A:&.4S$![:@F$54?^)$/]'*.3JB*'8%9(#
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M/@^0$TQ@= 5D+()"?>AC*@TT+%"JLJ%PN[F+&/+P "> *M4+:F]PH*"0G1*
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M&UG_4Z%"1)M4OO(#LF4F&/5UT'LV!X!9@<0_5*$Q*#7%+H@>*;2S2T1^2]1
MTY$2!M 2YN )U"4 G@0 ^> LE_H.?),!'AA($^"1!_ #;S8K'Z MP0Q1Y= =
MK(%#',QW:!9'1&L >'"\)&-;A&5 ]K'#H%#.H&:J%RH^9(4GFJ1VAU7) 8-<
MS-N<AON>B%LL*6!E & /COM  F@L,A *?6(,U$>D HBWB (!?<(+Y_' +OU:
MCJ*>F?A;4W%)'J3'/(V!&!V3%<4"]L ')C,8#H.D*3$J85@&U0 I*L /'?&O
MJ< !H445ZL.N%-$19XL.V?E;F7I;.VIE-S#%$Q *#"F]_P\C&+]0P[;!+P>
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M@:V,# ,+,7Z<"6!BQ90-'S@ *72D3!$ 4H4%L" #R 6@#$PP\ - AJ I$TZ
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M@ ]P284!U+86N'SE*6LYG4MLAR#_!044JTS'0UA %QMT,GCVP@<$])5$NAW
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MNPR!U3(%L:7L8 &K5-3>X1K"PPM5NEJ!NBS,?N;97]=^P0$8',- (GB=S'Q
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MTFU5+Q(&",\ 'FPTUB/AY'MJL??_;' # ;SC0L%[4G&->H"8FN4 _/#X -Z
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M;@"%7Z@;M],D ["";.B< 3  :*"_D,!0^T11]5A%@ER)$_"$">@@9Z".?W@
M>GBX7O&-!Z&!"7  Y^L;!\B&4%B 'P"%;&"!MR!# '"&1_('!T 3N-@@)Q69
M?U@?IDD(%1 !1Q EW'"* X@!&&B$ML@&!TB6%X4UG<"!,N@!)L@"+N4<:)@
M##HR4, &%M 61:B^!_ 'V_FJK\@&&)B&)2N#<TS10HT/Q\R*'"@A;5($%J@
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MF9MJ<(<<4$,NZ]!G)4/C<&V$$%/ZO&U)U-7Q-N_SYAS]#8WU.S,&TO_K1S$
M?3")DY9L3#6'Z]!,L+""A6@PEDV(&(!N(4%H*XFI3<"&B7"$#ZA5+)WO,)$!
MI["-!:"!$JTV\49O0*3M"]=PO]YG*!I*#-2'MO@8Z0$ 7H@MF<F"30L='AVQ
MV.*!H* '"%*+#'"$0:;IA/Z&6H@M>V'5?E0$2,"&,D*'8S &MB2H\"2! 1@
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M @S@2+4B+' "?8WY,*RW"_3JWP<?E(/<<L9VR8VR%610;4)#ABN1,_Z!HB(
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M< ,0T?\!YJ$#9Q +9AD(G+ J, U1@,*S@?.!.X8U <]FP!PJ()Q>*/2 2W(
M8L."@&>/,;X!U%8%LN* C* &B@ILI[71$E&T9+")E]Q4&J=%[K!X.P!0/ VT
M0 V% [ 1N"L,2P2>A< U.#"P%7UVM[/RS;".X=D)5. 7#I*(=BLPC^(1A&2U
M==NP,BO@ 1.F:=M(EFN+!S+2?L!MU_V !O33-=<"*+9ZI>T5\$ XJ>C6O+](
ME@8N_-P/1,LA4O$$\LR[#.X6Q;D#H,<#1DQ=Y%Z7%R$&@'FC!8H0OYB_']B&
M QPQ &Y 6"(Y'H &0/'A&P_ 'KMU "C@*Y'K#D "WX(8?@?_L-L*@"(<S8GR
MOAS@MAL3N,QF[LF# *0!SXK(&5VF[@"D(63L2KBUNPU<#FHA6]I^0!V$:\2$
M'Z"/UW)7Q ,PA@Y*_ 'CWC2Y"P#%-22RYF@I(L:'UL%+/A"*#T B<.'(KF>Y
M"XSV-N<#.9!IX*!LY/->^4$+:.\ Y!%E51>*U<ACLF>Y_ #2@AD;5P#PF8,M
M;)ND&<'1@K&;=5!J!P\YM;FE\"^N\5O:.L  &P; RQ82.-\:>D8EKC:VN*%M
M8'!71RZ&L8P!<%-S7+<:Y0WUTV!<:K?.%KNKCE:20Y$L_.ICM^6(LCF&1>54
MN -YH-ZMM#_P$@V0S!%B+O*P(R[Q_Y2$& <>\ZPB(G" K3(89BE ;82=XN+
M)6M8$N"SAAWP[ ?0(W"_ $4]NOT ;A#W ^E0-W+-^^AK!,?%T!V #,*1:;<^
M&-0ZYK%W28QJM[X[6NCMK:MA38-9"]S6]P44/:+%Y6I\F604:+"P)B[VL8?D
M00<^]ZY!H?#2?N"TFU[NLZ.E90Y(V] 9R/"URZ'E'',; )/^+(F)ZX"YH'C<
MA2:(9^E1C70W^KKAN/&1=RR*'L][Z6''L6?GT9A]8]W?#'? C:E,WU]X+,M;
MUL F>.W?A\^#[*Y_O6$!< >(>78^!P!%-4C[:P>\ [7+%?F0>5MR6_'9SY'%
MEI9;KM[# __WN0_X1<UOWFCSE@#2.OK[ST& :9Q7)'"\,/IV03'JI-,[< &_
M]P!X4/#[OEI$ YBZE&OM]&\] -=:Q[WJ!^!K8,.^_Q,/,=1Y5K^YV0=T7-N!
MG&I-F-Q% -W=6/,)GK6!6X>17#U,VXB5V V<CP-$@+8]FO@AGMQ9FC&L'8D=
M( >X&_H5&N41BUL)V0- W)%!P.9E%XP-P+\9P/G)WP"D0GJ5'J!HV0!< ^KQ
M07^%V9CY'Q(.VX/@P,MYEI.Y636\A#G # 7X'C0 '_2Y'"@T"0"<G*)IF#2\
M0: IGX-8X*4IFE1,GW)%&@BV%\W)P-K=5/?9VP\>':"0W]*1%_K_S4,%<,/+
ML9?[>0+539EG69G!X5?6#<#6Y=_7\5\2/B*!/4@^&-L ]-OMT0C;G1:1P9T"
M7I(/< "7V5VU75NVY1@'L,.P] ";!5X&9""VI-@ D!LHF%OB#=>,S)@)/EX*
M\IB\L6!X-1ODG=?F,5F_P8P&- *M49F5D=[!*:(&Z !2,-P 4,##D1DD7F-+
M]=Q_<,#?60$WW%[N <#NB1>=.<4)4-CP"0G*79MN*=_ F*%TT5P&?$ :YMP:
M2AJ;61H(1*$OUACXB1JI^>*<T5KD-0:6M9^_@<(T)*/5V9\BXMZS@%DC7AXV
M5B1+A=CLC5SQ:  ),AN= =J;7!(#"J$H_T9@&NX=R:&B1,S#*GX;=7&@BHE:
M&Z(;X.%BNS5=^'5>Y=7;Y1U9#\P@(NX6_(E#U45+#!2<#UX2PG59UPG>$5HD
M5)J3)$I./D+AL@49 @)?!/#6RYG<.JK<& 9.&<H<&N*<HUE?&U9:M!@#+[R$
M-'# #3R80^[8'?I8^3'='J87^\&:K!G OQ%BM)0!_='@_>U:$>X?14:E8DJ2
M)%*BO#TC4H"=)J:64X0DR=4= #S@W:4<AZ$D-S2@1*CB!0K>S16>><FB826>
MI=WBCM"8I^&DY*V@TO$D3FK>9])@0L8?E3U=!.#:4O+"LTBCP[D-# S(8AXG
M$SW("EP<I6D<1/^JVP"(0]$EX,@ACX6IHZ(9'Z!Y0O*))?-Y%J*593G88_7Q
M7!O^7-#-V!Q>GG8!)![66PX>F?JI&2 *Y2#JX#)>77[A7Q%.9( A)X .D=G1
MWK&E'29*)@+&G4B"HAF:&&YA&TI"W;"PY&@Z!'79EWE]0[G-Y.(- "2LG0VX
MY@G"YBQ6XB947N^]8#!&B^;I6W858SDP7 Z*7JN9GC-"8Q$ZQ%,&*(_R$$;F
M@(M902A 863"3.]AUQ4"P#G>&0?\P@EXY1>R8W=R@.2P UG67#TFUXJQ(?:)
MX/;)8=%EF8[%7$ JW<=Q@!YB7K3,)S?6YP (HFY:'6$^9#5$),D@YG__]JB>
MNE":$6@E;N0'$"&"^@!E=N( ?")F:N8H@ELI;AMFBB;@?9OTP:*&?N"Y=2AK
M7H&(ZJ*:;I<&3%XOSB8PHI\, DAV.9D-@@(R%J6TU%=OVJBT>9G?-5PU[JFM
M\BD ; .0.J$/0"%I3:$#5"&=Z45UIF.]U5S*K1P9?J?S;>4\2L5XGN4UT"*E
M65IZ<I\_BFGXC9]=+AU!PAO4N>G4+22K<LHAUN%#&J9$@EV>WJJ[;E!$"( S
M;((&",!R'0 >Z, V($MC0)D ;$,UZ(Z#L$!LR>L#\ ZQ@(*]R@,'B('TB"'$
M' "7L<#:J$S"VFL%;(.]HIA4Y !SR!H A$/Z_U1#O8+"!1P /BR7N?R' *S
MOPE /E@LEZ7LP1+$R;[$-AP TW6'Q;ZLVG&= # ,I-T>D2T -_2LPA+. PC
M 2 L=]$L+^PK %0'*(QG8S ,$H:4U@( .W5M24G$-^@(0@%#/9&M/5D'VKI3
MV K42;5MVDJ$/+WMV)9MV;JM.[TMWMZMWK[3W)[MWJK//HE4"8"MCG2M>-23
M/(74X+Z+<?9$X[K/X\(>/7)MM>V'LG" YI$ -]+ HVE #]3, MS <JC=?X!,
MZ>+*CH'"-W!9S>@ [SQ:9;+) VS#6JR(E\$ ]<02BYQ 4U3 #TQ#(U0 E #
M5*T(+WC5/RP#E/6N?O^0 .&,+G(L@PTX!7/0 $<R"Z1)!8L   OLV$OH+$5@
M;>UX%#&\@#($0%)T0@LHPQ9(41[(D_JV %( 0"=L ;ULQT=PD4A$KD3PKSW)
M$TCP[Q=QA !/1'#H[P![! !WQ (W[N,BL$KX[R,6SDLX0YZ0F#/\0 50A;$X
M@')8&]EV152IVZ,9 '^02+A<S L^@ [@@[901 :4 !\,0%P,SG]\P/%>S0.D
M KD)@+% 0,)8&XE)K%_= (#,XW]$0 PL@P2L@,H)"O%LB@&0& 3LQP'\@ @X
ME3ODU09[P@,  Q;4P@*,L%]=#1(?0**]CS_ 0QZ4P!:\   H0QY@$3,$@"C_
M*$,?2,0+!$ )Z @>V^^[!G)-L @)/-H&J^H"S ,$G, $:*\.]9=&^(RQ$ N2
MJ!N)/(CJ"@D J,/$9,1$5$ M2&P55P!-+0 .?(#T2(1J-0V5\ >4-0>G- 4$
M_, "G& M2T<%I ,F?X!R0( #J(,Z.("Q]$@/=$R5* L U((!#,[;&$OH<  P
M+,!F<9=++, =($<%X$'3O,\;PP,? T +3$0?NS$S2 0SY($RR-,6Y $\"+([
MPP0 .X  0$,% '$%J$,)W[ !0(#W9$-'%'/'@MM-_7 M(X=]51+^ L!XU@+K
M,D0&\$(^7 'Q2 0/+$,'[QN7.0:G","CN8,!<, F__P'[RC+@P!Q4$" .&#!
M/Q3+ AQ L2B$="ADT#+%%$.##CU/N/B#L<R%40% /B '2:NQ**SS"[2 *+R
M*)3 "S##_,*Q* C#4"N#1+#O.U=U2HS'/:L T:[ <FU*L;0)E1C +XBO"'?-
M*_? 5_= -1@+*0, 'RQ7^JBR"NR4.P0- $S#3-U -6SQ%0#U6B^ 6D.  /1
MB]Q>MR3+(R./ )A#9GX [_HRJ.P857UN!9A#&1#K-(A##0L+K@C6DW*ML8""
M.4  4JP /?Z&-:I/_4YU +2 7= O5 , ')= .P< ' - '@"R5>^V29!%53C%
M4B0("0" ,S"'STB%"BP%5?](A5)0Q0$(SP$ MW6H YLL!5:40%,8 !Z4R#34
M!7-$]XJ =TO_B-4(P+-,Q5P @!C4A1B.=U7,+Q-0A5PD2%:<!56\P0%014MO
MQ?DLQW!'LP%, W"KL6TK@S*\0 F(@?GF 3, ,C,,[@L00PO8KRBP,V]?>$Z,
M!],>@-6H1$LSQP[I[P+#Q( \K@1[1 &'A$>Y#P"[L6X/M6ZK]Q1M@1U+1 DL
M+H;GN$Y ,$ZDN([_.) 'N9 /.9$7N9$?.9(GN9(O.9,WN9,_.91'N91/.957
MN95?.99GN99O.9=WN9=_.9B'N9B/.9F7N9F?.9JGN9JO.9NWN9N_.9S'N9S/
*.9T%U_E?! 0 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g111872bgi002.gif
<DESCRIPTION>G111872BGI002.GIF
<TEXT>
begin 644 g111872bgi002.gif
M1TE&.#=A, .$!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M1$1,3$Q24E)/3T]965E)24E#0T-04%!%145+2TM45%186%A(2$A"0D)'1T=
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MP,H1X82C"":96#("-"34$TX[!1Q00C0&'- &+6[40H<C9O@XQ@$ L"("  C
M8T(Y)YR#@CC_ %,O$K800( 8E0B2Q#$C/ -..0D0D (Q"@"@Q"U#I%('+G/X
M:,>TN2QQP +2J #-",R 4 \X\#! P KT'G#'*G@P,4T3U(3#3@,'.!!,  <X
M,<P3Q"C!"A$^0@+N(D, 8, P4!P3134L /.//0\<T$(R$!P@A2YPC&&+$=:
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M/3+^8WL Z-[WP@>-\97O?.E;WP3:][[XS:]^]\N?'?T'0 '^@X  ," "%<A
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M]"8XG3I./YHSD-"KJB&OFE5W_S(RGB>D9R3O.<E\6A(M9 68Y(:;UIDD@@
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M$+##/2(!B%H1( CM2 $4[-&!+Q0C#12HQC,J@($%",-)C<A +42! 2 T@P!
M4 <(=! .!\S_81X%^$0V*!"*)WUA!/Q(@P?R,I [N. >3;A"/1Z@A&KP@0+*
M"$(/YG4 >_TC'0W8A!R>Z0H)T.-<W3! *^R1AE20X@"1P,<'XC!.4!!@&:"@
M0".H<840H&,@Y!!"+H"! %JH@@":0$8!P& / BRA'3RH@2PH( AJL& &Z<
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M1*N488,#6, (Q:@E*L#A!AEL@P*D ,<S L )<-#A &0P%CB^L *:$,$%SSC
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M0SB <Z!(V0L'6$  :+B''Y@#2U  +@C"LP&'<=B!)MA$0R !8!"+Y*,G/RB
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M+]B&J0,',*" /Z %'V@ ?_A+:: G+;B!=!@"#CC,Q%Q,"VC,QXS,CTF&5"
M5LC,S>0 ,(@'.[@&_')/Q'"_T90?TT1- @. U3RP!.,?!ON?!Q,@"2N@"CN@
M#%,@#FN@#X,@$9N@$K,@%,N@%5,/]D!."!RA&C,A''O.%>(Q%_JQ&!(R&C*R
M[,RA)>,A)_NA*!,B*BNB*T,B+>,R)@*S)VI:*9*2R*5!&PQ2'0R3?*@!"("
M+M@')U  #?  ^F@!!<@ 'U &:? !!4" T S)+6 8)9"':N" "5@ +_"'Q0L'
M2S-#_S04S$-A 7%HJ&0@AQ?@W"D(AUN@@ U AAU@73RXW-@J@3Q @4!<-E<:
M@P6H@ Q(A%KZ 010@+,Y!0N(F$B0!Q6  7<  1]@!XTPAQB@  /( 68 !@*H
M!7"0M6H:B!<P@(H8)6^9-0Q0GW! !;JB"4"X@(B!A'"@! JH@!Z@)XI,!Q1P
M@7U @@V8AW_X 3TPARV @ S8 %%(&&5H.,-*BG,0  .0A3F   (0 %W8B-<8
M@ ]P@ N(A%*! 0/  7JPAP,( 0JX@%V0!S)PG0%@A7]XF7"P &F1/7 PA06(
M@$H%AS.@  X0W7-P$AL@ $1 R*(C *9:FB@0 9IP!=2) ?\%D :*E $9R  (
MZ 1PL(+0]0 ;,*NB H<I<!JZFX!?4!]&S>$',"8*T 1P8(<K6),4 (986(!"
MR 4*D*Y%( #U*PQP^(0*(( **+E>6( '0(2E=  _2 <KX%PL2(<\J$K#F(,)
M, (M^";26P8WJ&(-T !SV &?,00"V-A_L(8%0(!%4 !C"-E[@!4(J('?V@AW
M\(+X?0#G^LM\:P0#:( .V(!X* $CH#[#PCY+0)LF.*P>\ 8&2  -J !%\ 0)
MV$P?D -E((!>8%K*U8BG]:^H/4W.. "JK;_6[(2LA4W]ZUK:]+_;#$"RW<T"
M1-O?3$"V'4X6,\X'E+&Y94X*#!#_O)7.#.1;Z^Q P 5!)NN.$?S.PSW!\5S<
M%73< V %)GC!R&U/=T8S;/@(BF2'5,#B=!B&9!@'<"B'1RB%9IB&<$"':; &
M++9I:ZB&5U2*:5B&<=B(<P"%9) '< "&:  '<T@%=W@'68@'/^B :Y@&I,@'
M6; H=M@&9VAJ?B &8N@'<IB&8EB;PAB'94"&9UB&?K@'4:@'>Y %<>"'8O@%
M;Z@2?Y %;5B$MAL(9DB%; @'??@%8WH&63#F?[B'9;"&<:OJ>)@78@"';?"&
M1XL!'I 'B@2'8YB*9Y@&]0&'?9$%3H2&PC:66E"$<I %V!L(;O@&<,B&;AB(
M95C:=^@&_U&8AV.1A73(266XW&>P!G;@AVKXA78P#'Q+A&IPAFQ0!0/X!FLH
MAW HF45(AF88B'XXAE\@EZWL.U  !N!CR7 HZ[4)AW<XA5/0AE^0XNN+AGJ(
M!NU>!UG -\LNAMD&!WY AFY@AV"(':TB@V,X!IJP!TF(A6:(!GY(!;\ AW.(
MAG7@AR)P  8M#$9EA6GX[E3@1G#P!\@>-V00A7?P!U"@!G!P!0,8[4E.ME30
M;G#H!V?X!FT A7&0AVF AO3NAF'P'6]8!GX84W8 A68HA@(Q!UEPAW1 !5AH
M[\<V)GJ0A7WP[&](!GSXA7?@AV'HNW%PAF58M$GN!VZP!I\ !_]I2 9P2(?7
M]H=7 (1U^ 5]<(:4Z 9E\/!H, MN +;:#@=L8(1K&(9FP =0\ =YV 9C$(=4
ML(=V=F=XAK_2G.<2L6?6/(U\?LW\X]K9[#^P_3^QS<T!--O>/$"U#<X%=-OB
MA%L0:NCEG$"[C>CHQ,"]K4X.Q$XD"]P0W&CO-%P3%$_%54'S9,$F*NF3;EIF
M4 ,UB!&59K\J&:5H<Q)FKQ*,P1@6A_9IC_:-8(,. &J"=))1V@AG5_9JC_9I
M/PQH'R5JG[I)+G=J'PAIN ("@ 0T-?>-2(,$< $[4G=M'^!MOW>"C.%M]VQR
MEW92,8"^&XB2,81]GRZ$)_>%3W=]O_?_9%4#=%/X<J""!? 9PV#495!X:*<)
M/OB '. \=%=WBFSX?N?V@.\\A6=QE,7W=&=QB>=W?-_XAW_VDD?VPF!TTI1:
M>H[TJ]4$2L>_K95-_OM:VP3 L=5- CQ;WT3 M15.!GS;XT1UY93 NG7.5K]
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M_,L(@-#O>?LS_:"/S=3W9TT':*3W=-@OZ*8'B!G$( !0LFM(JCJXYH#[9^<
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M61 &<((2)N +&M^!!1%X!Q!DIP0*Y( +!( S!38 A..)HP4K& ,$8/$+ J1
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MR$2U,UU-35IK4Q@D3&$YB:U.9</3V?:4-C]]N/_IT<$"7( "4, I? ,1:8(
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M&W1 Y<1.. P1*,: %<C! *Q#*1# G[R#!Z <;0C"!3 #/$C )Z##- C#&AQ
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M'0 RA,ZEQ?_%(IB.+4Q ,8!#-4Q 8X&#.2B! A" !B0#"3"G<\+#L:0" 6Q
M E# %!Q!"9 +.-"!+UI'Q$7+ :3"/R !%)2! 3S !AP *<3%/IS %7"'/;B"
M.0C"[\3#1\J2 ,C  8A#[("#$M! ./3@+Z0##JP!.)  $^R#'7C #RB .QX
M,?S#"BA!F\V%/CH5.^  %S1"XQC"!-A@0 HI.(! $,"" GA#.(C"! S#'?S
MAGJ3TF& &X!#(!# .UQ"!Q"  KP!)4R   B  =C!)'P 1Y1D8MR#!H"!#Y"/
M 41"9?P &<@=/KA#368#G3:+![P!=]R %*S# M2!"[0 $63 ,WS_@E>: P94
MUS_L 8RD)R4( PU\  YDY0R409EV #AD@@"(A 0D  2PP#800&K @@,0  3H
M03C< P'H@FS 9=O81V3DQQ'<"#& P &XCPN\@Y \P#H0P &(0%[&AO"- #2
MP#R$0SL4 #M%@P$< /+1@8APAQ[<",D@ #SD0#RX" JDS,TB@2V@K!@LY@C,
MD\ P!3$HP $HP2W4P<WD 7>@P8U(!(8Z2?[,$3S0[ K8+$FL AX$P30T 3>
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MI\Y#C,2%) 2 4Z4"! 2"(BC VLZ! !#+"+>J04X +SQ7  A#0^8J1/*JKTX
M.9S"-I2""$0 +BB *60#+3P#)"2 #4+K;92!#QA JV# $80#/#  )E0" T!#
M.6R 31[ +#3+"3B!/)C#![P!/_Q E14! [0 /WQ"!-2#O-*KO8I#>E["''@
M,(R:5@*LF0[L!W1#!F0",*A"-V #!5S#.]!"--P"%"  .-"#*I^#.6#_K,&
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M( UPG(("J2B.)R PSDTPH!@(ZD,!C!$.4RQ@%<I1Q0)* 0YU%" -"?(& ]@
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M! *RX8D D$8GQR# *[YA %6<I!\5< ,O)I ,#:F# (R AP$L$9APH( )X>"
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M SVGF$ UGE&!=&-$&A PA*))P991'+H<&P##BMLA@;:7  LK!D<*NL /,E@
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MH1^$ ;DQPAA2^1_( 1VD(1[8HAET&R/,6J)'X02:&;2#0;3IP0H\@6SUP1R
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M'^&@A"!1+MRH&3U*I:CWCQV.W,($.!O_A-,1)PRE<T(S>N0 @A# @)""+G@
M,LT*-,!01#^R[,#"#61\!5:))IZ(8HHJKLABBV!U<@8X1C033@S!;!((*F4
MM@\0@83C"A,(_A./!,BX P(RC;PACRA7B(*#.O>4,0D_N7@QS@+#O+-%+XSP
M$0X?AO@%"2?\V$)%.!&0LL\3@/@R@SG"1'E"*?Q@PH0P*E2# 3/E^%"/@"1&
M,!D"V*2CPC"?A#$.-C:($Q8X,MSD%SA"[+%/(G&H0T4Z]\20#"*81.(%._V$
MH H[#@ B#Q*ST'%+.(6$H4\&U*130C)@M=&'/+*TP X=J(2#TR]*A',$&.-
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MY-, PCQ"'\3ZAQ\L 8[_!&A !3I01^JQ@W$0(P;1R($]W+&"4D#B$.#8 R!
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M"^!0#&V <BI7#&'P4NT@!*9P0"X8%-E0!.-0 .H0#EZP"N#0!RVP"95" \L
M#J>P!>'P &ZH!X_@"U108BC _PPA$ S@L I4,'4%R% .!5'@(%%<!PITT ?A
M4 Y D(%A40DCD##XT #3  2ZP'9%P M=P _ZD )SMS5VAW>%>%,8L [@< B"
M1WA"%199,";>$ +G("R-]WB1]P]0A0TI( YS80K4 @GJ0 -]!'K:\&?@\ FK
MT C]R Y!, ]0T%9OA8JPEPAJ$ [JX!@=(0\E@ @X40\]L I522SLT .#('R+
M57S_ %EC]FZF61'/L /HL \[I 0A"0Q", X/0%I)( [RD 2RH <3-@\AL YM
M2'[F5UL%8A'RT ,IR0:^I0\G<)5LX 8YD []H 3X%PZ6, 7AL ],\ P]\&M]
M((#41?^ 5@<6"6@!"X@&H&8.0% .Z34#^C .)$ ,+! +M@<#1=,'.; +!K,*
M7, /YK #_I4UW_ "P; #\.4'WI8(-G 'X1 ,*) .X4 (O= 1\# #Z, /0H (
MG. *X: +7R"$1,@+1FABX? .-N "U\ ,,Z$-/S /X1 ):L *26!G$  .7G"%
M'2$"L_ /@3 &R."%X% %JL"2,& //W )#H .X  ,(= #!-414#:E8R(,KX,3
MR: "X] /,8"'0J"'>O ./; -X, *8!"(@[@.5E *_T )!U0BX- (H! .@[ '
M\, !YB /(B *01 (X* -1& -*^ /_+ %FW@'P( !<H437T#_"N%@"E&&BI3F
M"670#_@0FV&1#220 ONP"SI@IU[ ":3V#U/P".# #$1 'L#8#\+X#\0X:Y$
M#K90 Y_Z!LD@!/C #V6 "D0P""1E!<B 3^! "+& !Z56#%0@#- V5+8 #L0
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M<Q "W& ";2 %/] 'RI  ED .)@ '2D %_1!]#]R?_[ UUU6V^-81.6 $\K#
MX! $NW"]8] $ )M>$9 %7J $_B!5>Y "B\ -9HH+)4!:+.D :8 $'7 +C=
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M">&0#DB0!75P ^: !C60!C( #$6@ 6*P Z; #T& !60  ^L@#9P+ H;0#AA
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M#Z^P/H/0!_QP#!_U#^,P"Y3@W]( ",I@NJ:0:!VQ!:IP"3R6VA41#MQ@"*+
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M=@%R8Y1@%4,#!S96P(X4."H22;#%#9; CQ\4(A0-(,8B'F"(.3QA'CQXQ3U
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M 1R8 2!H4)=0 @>XAVZ@ &QP@ G2 #.8B'>HU]+I4//;!@)0/]7AAQ:8KP-
M4100!P$0@!1X@ 7 A0GX@110@#?0C4(@@"@H @1P GZ(A@60! 5@!58@@!UH
M@0PH EA0 &.XAQ^8 R>%A<?,@6.8@ 9( 08X2>/XAR,( B!@@068A2\]@# ]
M@#%EAF&8 %'XAV90 %B @$@(!S^H #EM #B( T7PA]8;@ (X '50 Q0H2R$X
M@ E@QI>0'P:8 3V0@0K_@(?N 85P:(,9& <R#(<#F(1_L(,(B <"6(2((H!C
MR $A"(=YB(!!F ,V 0=(, !Y((!-^ <PD( 'C;%9#0]P* ?QE2YI. 9>_0=?
M!59A)=9:,%9=\ &Q,(=B<-9H*H%HK0<>2 9LZH9P@%4HE<6-F8IGX(&R'(4H
M$%=R!<9_&(=S3=>&J-R!A -/$H)F (<9 *1T4)E\Y8)'VP-_M8%5"H)7T(%H
MP"9GZ(>$K9@U& -U. >=R;J);0AX"(%IZ >L7 :-+0B.%8J/78*2V@=B"!M^
MZ %), 53N().:(66W8>7C=F9K5D2" =^X %A:()$0(=M.,EQ P=7B(';\)L=
M_RB''X@'?K '9 #7IJV''J"&8_XTYG !7K@'0S!*ZQ$X%0@'&V"#3^@&7@H!
M90B'>TB&4;B"?@B'9L 'K0Q)/X#;8! !;*B"Q* #O)V+!$"'U?@!ORV(9I !
M7MB%6/" 8IB!YP4%+SB&Q@R'(PA,3TN'$S &;K[<S-W<SOU<< C=T2V3*G"4
M1.B#U/V''H"'%S#FINZ.V<V;?ZA<)-B%<!B'>>;=2T&%=.B%X=6 Q+ #1#B"
M5P@'>< &?WB!Y9$#Y,0"Z<6&$G .7T@&:5 '24C??WB&&G .+L"%P;F!)X*&
MTFZ((9B%='" R_"&H/X':<@5</""5B"!)_('9.8]^O_E@'Q  74XH&IXG&M8
M@;+\ P,E 5A(!UXH8 ] "##8@'JPX6<H@2E@A@( !(9( A'H!RM @@ZU@7 P
MA0SN! 9H!G=P@#[@A@].40=X@EMXA5KH!0-0!%M !:T3B"B@  NP@ RH@'5(
M-@?H 'T !0/XA%MP!6((8FAXAR)VTOA1@AS(A@7P@ULX!6O@!W^X'"D& D0@
M  EH!@) %RT6!B[.A0-@AFJ @$L AU\P %V @'M+8Z9@@2]8)8$8! 9H!5V@
M8S6  3RV@#]8 *#P!Z Q"$HP  FP@ N8Y&X@@)%I JY>Y$9^Y @XAP P&$J8
M@&I@ 2SHAVL(@$_X@P+XJ3C_$(!5+64PL(#+YJA53O2"X(<DB(1S&(,]D&6,
M\-4S, -QJ$0]Z(1WN)@I.(-SV(,[L%FII@'AD-8_F()R> 0DZ =&>\Q2J(4D
M.-R4>(<7H 1UT()$.!N,*-=_\ >(-=]_.$Q$V05_T((!_2M[:(0DX <,8(5O
MV(!9R)KL (8*D 5N< %FT 0OB ='N()]J.=:&(,^. <[$'1^KL>&:(8?: 9N
M\(%*&(856,A_:(-!L(>.38)M*(0MP(=0>(%T*(AJ" %]* A <()0X$:,#H<H
M&(9_H 0\P <?^(98J !O8 %:F <CV *U9+E[* $A^(5;\ (2D(<OP(1'%X-C
MJ *,_Y#6,Q ">_@$*N"'J?4'!W"&9EB!/&B:/&'G-7B 8^B&)@@'-PB#<X"$
M+T '#C %?%B!7@ $)D '&[@&/T ?RD7$41 &!W %\.F"<>>#.XC8@1@$+A@(
M(#@$.G@J(UB"9<B!>/@%"2@%1P@!8T"%^ZX"7I '$M"&%'@UOVZ#SPV'T V'
M?"B3)X $8Z"!/Y"&Q &''%B'/D#U1\CSCJ*#M,L;<%@;1M"">4 %';@'S0X!
M5H '*#B">S  6O"&'*@&3F !?(@%$&"'&"@$89B!3^"&&X@'YAP'&4B%4;R$
M%6@'5AA$SF, 6?B&&:"'P?F#,K '/N@#W0@#2] '*L $<O]H SH8BVPH &MP
M!AB8AS_@@G*PA%7'B%=0K/N4!R7P@W-X@SEXG'NP 5]@AA\8%(% @52 !R>8
M@G<8@' NB&Y  (!(LB*%OCT"O&10]F^A'P-2%K#Y1^1"(2P'IG4BP&0-A5[?
M"(QZLT,<$ V>4B"AQR"+)@2TP(%3MT$-OW"[#% "I^< $7#D'FAAA, 1+ 70
M[H68$Z]"DTH"<K";$2-0A$C#7$@#M]!(D%$$>M@C8 T>@5?"#I#:1< +/1H=
M^,# H0]")'!^*H1;^"]&E[S_P FJ4$L* 'IC7/@#!^0$N@1W]+F@M1!<%QSN
MPKEKD*0;@1*?*H )EX$0/P*(P-G_V;#O2@0^#@Y4BZ3 S98#@8@%B*$G YW2
MF\#)L1"NR!V_>H\C3ZY\.?/FSI]#CRY].;0J,I3$DZ8$9HUXLE"$,N&/E ]9
M18;-HR(C"KYU2,!!HQ(N' MU^H3(J!$,'(R:9%@QTX,9QNE%S H[Z)'.,'6$
M TX.X_PUC@GAL'-#@TM($XXP,M@#3''@E)/%#D@  PXE.UQ!AC6OL*'50NU(
M(8(+OH C3A@RK,"-@^^ @\<LU]P @QU20*-$,)4$ A,X_,B!PQ:1-').#66X
M6(L/NI  DQ#.C..&#"^(HI<G:KB(SPZHT!'./B: $P0V_[SB!S^$[.!%$-J8
M,D,+B"PA_\X)[TP6#CU"<-# '?C 5P4.7J@CC1<-=L<.$SBPD%4(-14B P^,
MU-%.%7X!HP4_K-"0SC=38":%#"(\ \XH/>Q@QS[*F(!($\],XD@XV3P1SBTG
M],#"*7^!HPT4.SQ1#SA&*LE$+N TJ$H2ZGRQ0QQ[R%.'#TF 48@C+*10PGZ?
M^/!,%?#$4$\X-ISSCQNVZ/)&.*;D@5D)X4Q# @AG2')-$@U>@8\^0.2WGU[@
M^-*'5O&PT. 3TKPSA@PT= ,.#>: D\L/.5BRQ#T1-+&#)>",(P8*+Z3BJPDT
MX/&*.5<4D8H>X8S20@B6]),&#B^ HM<S*,0 P[-LO))/%C@L<?^.DK@T$$TS
M6^QPA#UZ&6,$"S/4 LY]^2$#4SBMG,&//B3PXQ[2]3P313C8O)##';AX[<L/
M/5CR1#]U@.!7.(PT<,(O,37A "/\Z$5.%PYXX0XXU@P@P1L))"-)"TT$4(0_
MU0P031\KB$//%P[4D TXK:30 ![WP%2*![O Y,X)180CBP>Q-+A+#AR,\4XM
M#JSCCPI@[#-'!C  <44XR]#@ !#Y1!/ -TJVH<8Y':1!S@#=X/- *,T,H$LY
M->#@3396/*!"Q0XD @XD/ACW!1%^@7/-#P4\X< N:ZB0&!E;A(.)#-!<0!(+
MR4<*Y 6M/(1@%P,8 @-HH(Y_^  1X1C_P", $X)P4.,%/]A)-<QAA :L 0DO
M0<4,.E 'C W $O^(Q _"L00J\,-%TYDA#6MHPQM&!UHU@9;7O/:/&/ZC00WR
MVA"+V,,@SJ>'/(16@Y!#1",NZ6!"3*(0;7$$(2II/DE4HI)<Q,0A?E&)4,1B
M%K,(1AX&BHE+U*(,AZB7!L60BDO\BQ:1B$7CF'&+7Z0C')_(Q7#$$8UT].$:
MD\C',IX16NH 0SKVT056])"-:NQB%Z=(138Z(FQNO*,8N2C&':[1C- ZV"@7
M(D<M0G&2_O! /_+B1ZW,!XA)C.$D);F09ZP E*+\"[&VR,9 ;=&.E!SC%FDI
M29@@D8>&3&,>_X\S29B4@Q[SH:,\C-&/2!91CV3T)"@3Z4MA]@,8Z2CD?,9!
MA7B(4HY+%&48@YC%XTSS8.Q@1BN?V41 GF$7P"PC$YG!(S2",1SO ,(<F,&&
M )0(E=E,98- 42\9XC"B$ITH12MJT8F"8Q,RT 5$+^K1CX(TI!&5!Q=4P (J
M\,BCX,@D@43Z47#X8P!-]"@N6^K2F^(TI\I97"-LJM/GV&,(@)(H.-B   )
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MPB&0. $$NA&.(60 &UA(0#OZ<8L''$!T2\H" 01X,$@00 C@:((+'+$(%F3
M&\"(0!>6@0 ^W!BTH%4L3$)!@4;4 0'00(<:)N#HY+@" =I ++&:SL_!AB-<
ME(C ',31@B@0 0/DT,<:)E "??O!#U.@ "D22TE\3$A)['##!&*@%62TX "P
M. XR( "&'F0A''30P"$@P#J'_[OIR#$$#,01!!"XJ(D\)U87[]#"AO.2DO5P
MA"4(  1'..,;EA 'SQ<?!0,ZL?.=U;;.FXX%7.=;](PGY6:/P3]CT%*S1__<
M1S[^G?K!WD$5K!=]YS_0#W;X&/";C3?QBV_\>,.$'UB0@7/-$8(M5.,&;(A'
M#?!@!0)H0!'*4(()N%!P.Z A!I.HAA5H$(<# *,;6#"!%9Y7 "%$X0:E\(<)
M3L&.)OSA!LG@!0UJ4(K$R@,.Q( _A ,^9$ <:$@%\( !" (XT$,$S$#(P80I
M"  $F-Q"U,,'?(#*-0'_@ ,M3,!:B0$$@, &:(.Q=<,5T, G\(,I-((6L( I
M*,DVJ$$^;,,!@$(D2$ '0,&C*9TOK(!]($$@K$,34$(,7 $QA$,U.,$+?,(0
M\<,>U (_B$ 3E(,"N((L4  R5(($<,#7\5 6*,'_?H%6,RS!"WR!-I!! (3!
M$'7"!3B V_V#"[C !,R=7KQ" *P#'L@ .(B %.2# TP"#ZV#$>0 $A1#/23!
M)]B "/P"%ER!,"2>%>A!FR">*?D#(;R #9P"/TR#%KC"#:0A/]!""30!%OP
M.-3#'?1 $PP#.$A"&H !"9!!8GB-/DS (_P%*JA .71"'- !"!P"(KP )O #
M.K#B$&!,)6  BAT,)ZC #42"/ #"(50!$N@(*(C %HC09/C#&=R #O!"+U@
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M]<\"B$.\3H B@ ,C&, &'-DA#%<\%("I0<L/\,\\#$ &&,#_LQQLPH(#";3
M&3  %!1#@ZB!!:Q!"+0 +S2!"BR#"\B ,?Q%)AA !K0 .G34+!!!#/5"$0!"
M&OA$""#6,GR "-3>0KPLL92#-8"#*V2 -M0L.MSL-1Q +("#%^B M5J  "S
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M.'1P$LA@" =K7 O[L!<K,@S !93 !7Q ,/A##<S (U" (?SU*L@##T0 $EB
M%?1#%30!/_!#%UR $23  4A#"9@M",# .V 9.$3" KR#76*VKCS#!D!!%C"
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M82?)^( +.L ,$$A@$I/A@0Q2H $6,. 897B !J*@C@9X( XOB($'E+&3)&0
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MH0@5R(,&IQ!!&0*Q =.$]14R<$0;QL /%3BB!Y;01P=ZL8%NK",!O'A .4P
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M5ER@#A* P[KA&[4!+F>@$B9"# J #!Z@%=J@'='@!^!  (*A"*P !R8A')K
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MJF$7T$ 7=@ 3_L <=J$0SB$(VB 29N$/GO]!&.2@'8)@#/P %*[A#;Y!&L3
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M_$$)J&&'B?D<?@$<W(0,V-.48CD3 L ;E  %[B$I7N$ G,!_/5B+S^&#F>$
M>D"C2><;1J *RMJLSQJMJV +A&"\.-JMWQJNC:(4^. E>J$.2-H?V" )$J$?
MZ"$.M& .V,$4GD *MB(9E  (FJ'EQ@4VFD$2NO] E</A%;[@#4XS8+Q!")H
M#'+K'W#! NA@"QP5IN5!$UA "T;H%*I@"IIAMO"!"]8 A=/ #KX DIFA"+S
M&MQ!#-P@"H8#8EJ@!=@!'(J !;K!'.9 "^ @'@0!"*S@"Z@A&M3@'0;B#NQ!
M&)C 'VS!#L!@$ ( $<C@#I;@#LBA)T9!"J+@$N+!#L@@"D(!=]P!![;   QA
MFB?"JIW@0W!!!6 X'TR $"+GJ\-Z=*S!"H3A&0X<P1-<P6=A!-HZKA\<PM^Z
M%.H 'M9A"C1A#';A$NJ@&:0 %-; $8QA"7KA"K[!=XEP&DA!"80U'%!@,KK
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MZ,&)<("*2I1@!0YX@PI\( E^Q($$)F #/_C@A!IXH!6,R$ =%C0(/\3#!B*
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M GH.)S $4N $_: $"0H-(3 &32":[Z8%6I -+R $3Q!946&V+Y>V#/D"9-
M!L<"[& #0E L\R #:M %*) (_\Z0 (#@"R$@!BWP)/^@#AK0!WS3(/4 !%0P
M!B=0 _R  KV5);N@ ;@P M4 #H$@C>&F O]!!>-0(@$@ F60+TL:#N)0!4\
M!#10#EG ".]0 KP #NH0 3[E*53@!6U@ DE0#@A !4%0!>* "0F@!B2@,&/
M F0@ ]E@"WH5 6)Y"ZS0 ;D I0^)*'SC#C4P!4&@ ^( !_EL"E.P#S+0!A?1
M7<*  W,@ F<"."= !%W0!.- !)+*=O+ !%:@!B[@12*" F_  ^9(!R\*#KVP
MEK9 (FE[ST^@!1A #%$"#QA ",G0!-%0 %S0!&%P6+J@#C!P!U^@!*8(#NE
M T+ !/\ND ??P !9T 5,L ]QT %X$ *VP ]?0 5MD +T@ 7? *W@()?A0 5:
M8 \PX$/8"@XC' LRL 8Y< GG@ )0807$\ H[4 J:4 )IL ,5P:X_L <[H OA
M0 1(0 8[H W1.%I080/>8 LS0 <A@ 2@60=VTEON@ /W4 -,( 0I$ ;L$ -
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M#]SM!*5 "[]S!Y) "54:.;B "HA4"O80[&@;"B/$"?K@"P$/"^?<[>'@#(4
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MC?K_L &7H_J^+S:=$ 6FN/OE30ZIFAH"A/J]6>[*/_NI3S"[KR.MSR#E;?K
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MIY<YB+ &G%WB,,.5+**(Q@EZ;(A*A7JT]$0U<(J81J![9N"GC53 ^>23->\
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M7.8VU[G/A2YP0  )#[""%LG<Q!-0P0)F," 141@#9J,[7O*6U[SG/:4<.I
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M,#@ ?RV'!*B %+@  @ %7YB 7[#"-0@'A$T$6"" +PB"!1 W!_@"B! $ M
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MA$T>"$M@@QVXA'J8@R](A*B B' 0\FZ-BLN&92)0@E*($U"0 BZPAG[0@P4
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M2, !$["%'?P'43@"+@B9)-@%>I>"(/B&<)"'2GB"(YB%+,8&(%B"1]B'(YB
M)=#>H-B%%X %%O"+>>"#+R #I)F%(W@"2Z"U>:"#*$"#*A6&,/ "6$AY6EAK
M-T@"+@"%>(B!!X@$2)B&<)B'-T@",*C23- %(L@"5HCD\:('"0C+CU.K/0"
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M#1-LRXBN0 $DHE&(D5) 7>S8@&*7 @YDT" .N< "(50P#A#3-!=< $1V@.&
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M3T>*01Z%;MVJ\AVJP4AEK*LWJRE7_[@=X<85/9IT:=.G4:=6O9IU:\CT+!B
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M2TU@X!D\ 8=XR:L.<*BA"N+V@AJ"L8$8;((_] 6'#.P"#@& BR;^B(8BR""
M76A!%1^'!@K2,2M^_,$.!3E'!/21 7:  PB+ \=4PE$/7R ""RD8<38^XH#_
M>F@@R^#8QRTP(.X^=. SX=@"*^ 0!R@<HP3WZ#%YW3$6?;@^ T%YA!MF+H:"
M_&$3C2B!N(?PA)J<P@>Z* 4,&!&.0%#E'YA@PS_D, EL@&!/\N#'7W;A 7'_
MP0/WL($+W  *>60E$H0$1SX>0(X[<.(IX+ ' Q3A%HA@!+S" K:@$Z !',8
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M 11C#<9 (<; !M@!$)R@.+N!%GP1&(4Q< PB#V) #[Q!!F8 'IKQ'T2P&#!
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M$*+A"OB '\CB'[C! VBA%3I #6K!!7ZA%4X@!/QA!@(O(S=!!Y8!#W1@>^G
M&:)@0:-N [P@'(B@ ICA[6ZH P[A'<B"^)BJ$&Q@&B8!# K"##;A&3I@:DS
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M/]BH\&765Q$]0"9"<S0+!ENLNRE8"G72S>0%C4 ,.&FTP_3GAG\L)#T6'*!
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M$, '0ET*%^+'U0-HH=Y!L4%9CX0)!%A!GGR!*SBXX8%EO ,3*R#X/\;  FW
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M"*30!/0P .CP#]G0 AH(4N!@!:Z /+O8#PE0"]7 #3U #/30 .#0#*F7 M,
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MFK"I=[MZ%UOR.]-0 //* S?@#]] !1;@ 9[0$?/  5\B"&F*$_PP Q60  ]
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M72"WZJ ,6G$(3:!&BAD(_QJP_, WIH<O]) )PZ "U! "^O!;R7 /+4P/BI
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M#0U0#.B0!&S0"CD #^*@!LYJ8JE:A__@OQT!!F' 1R6@!;5@ NI@# V #8O
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ML: !#6 #<R $QU "WX(/#  ! >#H = *;"  .- %4B )>A<.V/  Q8 ''N
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ME(N  8R%"P=!#3P [O*PA.?" I)033)0"('@ 1SP [%P#E@P !K0!/% #DI
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M8!X<BL8)7F"**X7#'VPQCQ\T\8]W*!:=MT) )Q;Q9"A'&<J*@,(!6 ;: PA
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M@STHQ7! A7;0!^(:"7B8A7"0AU9X@6K0@%Y AV8X!Z@XAF5 BD8H@_[(!1W
MB5CXJ(OJ!AE(!W  @5O B!78AC@ @W#@!TJHAT#  W!( F\#AT_0 BXUL(.Q
M@S$(!UO @8LX13. *1FH@1JP@#&0!S!@.G#P@SXP!P8@)VE  ?0*!8P8 5C8
M!3[*AR5P!2$@!+E  EMPAHY+!S'8 V!X@'CXAVF@ 7#H1A#1A@?@ARSH@47X
M!17 APCXKV_( 6/  )'J!_\>J(7X((*"Z0<<2(;9Z %DR"]P"$AP<(%PLE&6
MD(0R2 492(5T4(:_:(A*:(*8X(0K> <3L(9SD(&PT8A;: $C[ !M X<ZZ -[
MP(!P@(=>, U2D#,& X<!L(<_*(*,B(8.\ <%$"9F\  !Z2DS"(.8*(-*D*Y7
MB EDR(!W\(!B (=ZN(13N *6L(5BB('4 P="" )32 &KX !K (P6V(5N@+%T
M< ,T$ 8,&(A?J %DX ">H 9;  .5 H=&V$.-2(83D(<JF(%86(4G" <96(=I
MZ#!3: %K @0F: LH@"066(5_V <7V(4&4"9ZR$@*:01]_84!$(=_0()"D(L7
M^X?_'+B&&GB%V7B$>ZBQ/N"#C! $.S@"./"&?:B&!P$'*) $C9@$+PB'!\@5
M<#@& =B'>W  4P"'*,@#8/"'8'@&#P@%<S"&<M"$(V");AB 7_ !AM@&4(!/
M>H!(>;B%% @'/SB$?UB#3\ $(V")+]P' _ &B;6 %'R5<F%07I$:=I&8":W!
M"JT5<7@!&OB%%?@!&%N.#OT'2$"#A@B''6 &J-"#2SBI!<" #NB "T"'&8 !
M'C #!+C>!T"H*UR# +C>#^B"(3B%YKV*()6+?4B$%4 !&7@!>9B#"L" .O"]
M?P#5$\"!#FB#IQ@$-VB(9N !&NV&$8B)!'B ZT6 4,@"_U+PCS4%!QKX!KG
M!K?CM.'@AQD@R"U8 &WCTV]+*(.*AB(H@ [   LH@WQ(@(R !QF@8(;[!S%(
MA&<@@A; @0W@!"%X!8UX@E(XASDX 1GP %%U@8PXAAM(U3.,KP;@!A@8A#&(
M!## AP9@"6\P@6IX@:X@ T5X"B)0VWV@@ %(806P!F155A>0W3.H@.L5@"\8
MAR!   X@@WR(BTH  Y:XAM*E SO0A1$P0KFXA20@" @HC470@W)PUWWX!!N0
M7QYDL'^823T86X=8@'NH@(P@AP$86&0P TUHB#1X!,M8!1'X@1!  'VP -7
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M%T '?B@"2 ""-^B'?O ",#"%*(@))+ $68^ 7:""T]('&QAF(_^';U"!>M"
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MF>_\9%^,@CG2)9S]@RQ0 3]8Y&=0@2P$R1'%9F@.CUOVXIHQIF@N!4=TI@/
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M"E#".D3P!%^-#QP"$[A /"!"!##!O8* %E, /7S"#&2"&%P -^""!S@!&3P
M(-R##F0!(3C ,G2# _P!$:C &(%#%*!".#S_ 0HP4P^@0P240QA0 3<@@@5$
M01E$P"5MA"A(@"/L P.D0"E?03@4@@P@PA; 02R9 @_<PPU8!SA@0 \402]
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M -!#(TS##"U!+N "#HP#/_@!'[ "#(A#.$P"+A1!)/"#/(Q \T3&)L1!..Q
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M.O\[X=JH<M5$)8K@AM% I@.++"^D]$4(5^E-.$1GX/HYE!+L W(T;8:#<"^
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M(I2>#PKYE!-TN+$A'!\F<45:8WB18LZ4YFG@24($24F,3^A A*)T#HILH3;
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M& F !"<<(/^)-^# '/>2+U!.J6%!4"1@\.@ '1SQ TB @P*/F>7",, /'31
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MX1#0 1CT@ AHX19R81@&@3$<X1^,00U4A")(@0C:X!BB1!J*X"/*P!DV$ [
MH1[T !)FX14H(A=X 3S  16FP!NVT#2"0*@>@0GH0)A2PA[@0!W  QW"(!C:
M0)K^81&88!V 0*@F@0D.01S(X8E4J@C@H&OZP1&   Y  8-, Q"80 __M"<?
MU"!-_& 7>@T2+F$>]L ([,"(;J$(A  5"$+ZY \NI.$.AB :]&^F0@$(QB ;
M#N$91M(/,,$7\4$,IJ 3Q $>9@3_P*$0%$'UIA(\MB2Y0DA,F OT3HA-HJOT
M6LA.J%(LX]']EH.X-$\E'(L@X()<XC$M12,MT0>*S-+]1$.9YE(MU1(OUY(@
MH(0?!@4SZO(N ],LS](N\W(O8^4=I& ?@((MHT2J4((O#U-DHJ0OR9(P#\FQ
M.C(N_T$'B.$PH8@R^:$CE8DGA$ #P2,T(]-T'&LGTA(S ^0N.[(T-;,P*Y,N
M4R(<YD 3TH0P-],L!Z4TR_(V'8LL'=,T?5.J_XB+,GFG-J6JUWB', $S.8$S
M./.E+%^S+#D3-N,1+MB2.-VOUP[1+LE3/)TS+_FR,'7S+6O3-WU3): (,$.3
M((13+R63-)6).GEG/DUS+*=R\Y0K*S_/A+YD]/!$NL#RA?Z301O401]T]:[!
M$2'TN%2 &#8H',[A#"F4@^2!!#Y &TR/0T>41$O41$^40@,4*T<(3YJ+*U,(
M0;_R2U /16O41FOT+F\T2Z;!'38H-W5T]:YC&0@%2(O42(\424M413MO0%MT
M*PVT*TF/A68T+)/42J]4ABKS2,=%@_P32\E%2[]43,>43,NT*C](0%G435P4
M2F'431*42A?43.>43O_KU$[O%$_S5$]+U"HY[TH\STD+5$VB-$:G%$MH=$\3
M55$7E5$;U5$?]4;[-$VU4E"OY$#?5$8/M4HAE5,[U5,_%51#U5'IP0(8 !_\
M 5535555U0V:=$T/H 'N855G-56/X #<E$S@A IDE59GE08.0$Y%55B'E5B+
MU5B/=2I)U0!<8 ::U5F?U5E3X -<E4RH@0 6( 6@55N=]0)NU2L9( 6R=5NA
M-0. %5G/%5W355W7=5CI00 ,@ (,0%[GE5[GE0+B-97PI!CN-5[KU5_E-5YQ
M04]Z@5__]5_O]1O956$7EF$;UF&+E"+&(1B*@6(KUF(OEF*IH1_=!!S>@1K_
M,!9D+S8?B/1+T.%C0Q9DJ8$:(O!A6]9E7Q9F8Q9#JY-FJQ-/)+-F<U9$>TUG
M:U9F?Q9H@U9H&S9,.79G>79/2/9+E%:\CG9HGQ9JHU9JIY9JJ]9JKQ9KLU9K
MMY9KN]9KOQ9LPU9LQY9LR]9LSQ9MTU9MUY9MV]9MWQ9NXU9NYY9NZ]9N[Q9O
M\U9O]Y9O^]9O_Q9P U=P!Y=P"]=P#Q=Q$U=Q%Y=Q&]=Q'Q=R(U=R)Y=R*]=R
M+Q=S,U=S-Y=S.]=S/Q=T0U=T1Y=T2]=T3Q=U4U=U5Y=U6]=U7Q=V8U=V9Y=V
M:]=V;Q=W<U=W=Y=W>]=W?Q=X@U=XAY=XB]=XCQ=Y_Y-7>9>7>9O7>9\7>J-7
M>B&5::?7>E^W:*]4'IK!&Y[!>[\7?,-7?,>7?,O7?,\7?=-7?=>7?=O7?=\7
M?N-7?N>7?NO7?N\7?_-7?_>7?_O7?_\7@ -8@)^A>\UO3-]A%5!%@3_E%!JX
M@1<851R8@1\8@BNX@BG8@C-8@S>8@R%8@CN8@S\8A$<8%1R8@DT8@R\XA15X
MA4E8A%NX@UL8@T68A&O8ADL8AB,8A7-X@BWEAD/8AW$XB%D8A2VXB'\XAGE8
MA1=XAS68AI&XAC^XB848BHEXB*M8A7WXB;'8B*_8@Y58BE?XB;>X@U=!'*X7
MC=-8C=>8C=O8C=\8CN-8CO_GF([K&&Y%1BTUSV:KET'-4DJ(]#F[,RZ)%"4X
MTTO/LS/C,SD?4_4$4S#'$X]#+WMU,X.\5/6^LS4!E(\M4YF6EI ))9([&3([
M>9.SM)3_6)1Y5I1K%I-UEI--ATI.N3M!V;EHUKH6^3WC\TNW5QAZV9=_&9A]
M>3QNUA^"V9B#F1UD&4KTX9B;^1JNX<CHE"*^X042X Q<1;Q@(0(L@)LM8$F<
M%O/ 81[X*%_T81#2A!D>@ L+P0>0P0RZN0/>0'ITX 8B$!QBX G@(AB^0  &
M@ A&-E;2 02^H=?J(+S2TA V@)L?@ M4 YR/"QSB8SD P0ODZQD>X#L'X0>N
M0;S_!N$@HV0> "%?3H?^'CI/DJ<+64$>(&'+PMD9M$!$P8$95B$<JB 8OB0B
M= $HY. UTG(,SBP<XN$&Q$ >6AH<1$$'-N ''$&9-^@$Y@&<D^$#;$%I12,3
M_@0HA&$$(H *M"$<U$$+/J )>&@?Z&  0& GP0$2-, '!*V#P"$4@BJ6TV#G
MJD0=LBH>,8'^JH05'& %>D$#MN +?L*XG@'Z5@ 8N$%L@,(<6+$-2.)*Q7D
M%("R*]NR+[NRK<AIP>$8$ "S/_NRH0^<>\&S0?NS/3MAYQ3D4F  :L  LO!*
MPF$>1H$52" 11F$;)AE,D_:4T?#,2%;(TL08%L!5IL$"_T(!',2@"UAA%%P!
M TX!''*  ;(A)8!! I @'-HA16RA%TH@"1XS'60@&7K-""8A'BN!!I@[%'8
M%8^S+?6X:2GB",R;(A0!"])$&& .'%@A JA:O'[.,CD!@N8$')3AQ. SEM$R
MEA<@'%!!&'RNI3M(P;%D&$0@5M '/*!DD<+A!H*UA\#A!$@!/-+@,L"#"#+M
M'NIL?#H(&R+@#TQA$#X@A6(ZP]_;2B!!-?!$#E @2+ 3' H@<703"?:@'=K
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M,;A$VX$:V/X#SA@].. 7.?JPX((-'"#C+3C:A*!"""AL8MX]2\@@P@/;7-+
M%D!H@ 0I55@C#QP^Z) "/@G7($,>\O@7BQ+8P3*$.0.<, ,#D03#_T,/O*3P
MC#,D_1../50X$ @7('" 00KHY'/##2THH6U:4$/MDP4,E%,6.'L L%1:U!"
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M/P:!AW"4( _^ ,8 F!&'U-D#!]>H23@,Y9!$+:H+%@"!.-X%#F90@'X!),8
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M8BC)P$4=3! .%T@#.TMP11D4\1!&A"$(CT (-7Q0.G#<8!L(@0$P7&<@5KI
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M"H_@!K:A4I[0!=A!"B- #3C #N&0#ZL0#D? "S8Q>W\W<P_Q8R5 "E@7"^U
M*&%0?/Q !==S38SR#_N ,2E3'#6A!'^'$)I0 JO  CS9 =H@6?^P#%=@&_K'
M5N"@2E[P"0.!!VX& [9Q##< #@W0#CEP"U@7"O/0"LP0#NW0 K)@'H"P E@7
M#D50_P?7@ ,'40QGT \%H&P.H0H#P T(H0\P4 W@X"?G8 2+8!PN, PLX"G@
M8 .F !<(04[X )CG<06HH%:4\!! @ MQ  ;8H0LM4&M?H @(H0=0R 9UT!#<
M, #"]@_$)A>H<!W@L J7P *Y@'6SL XJDX_@@ D8MP&V46D!5W=KV&W_$%/A
MP 2A8!ODQ@698!RIH QXF(@\L8?PUH=<\X<)^@^""#6%F!7\IJ 8^B[Y4"HC
M0 &Z@ P1( EQ48EZY KT4 >G(CB>N \-L GV4 9> #:<0 /,P TJD (%EP3X
MX BJ>0<H4 W=L$ZSX '3\ PU( ?TT ".U8O @ TAT W!V/]AX2 %"86,-Z&,
MYH "B@0*3A .QC  3# +O6 $!4 ->Y$.,B )O["FZ7 $<;"FJ8 /W(@3X8 +
M/6 ,QR "." -'= +Y# 'R*(O_C #<E .F] !XL '6) ,D0 !]1@IW" !<L *
MC" !/R4,B! ._IA>7X %_; (PU 3R* !MV /?! $_( !IR *GO$,3Z  XX *
M,9 -H=  LI +'O 'RI!,QY  H= .4F $_!"2""$. N "<@<.30 &Y[ *&V &
MS_ !L) *)  %^W "C6 /<'"30F0!MP /'K (]: '(X -D@,.8- $S! ,/Q"&
M#S$'B]JH3.F4_W (9@ -'* *T%#_ R/@#R;P!_9 !TC #T;@E80B"5;@#33
M-C^F"3;P#,3B#83""PS "*/0!Q*0#>"@"*X8EU]6 :P #9LPC#5!# 7@![+0
M"0R "^W@ 8Y #W$@2H))F(9)9C^0#=.  <3 !'Q #JV0 '-@#)#Y#Y()#HSU
M!RQ@#+;P =I0!T% #]W@ "?9!81@*;6  _9  YHP#UGP=Q:0"XP&#N/@ GB0
M"JDP#># !TH #T,P!.%P4LI@"2T@#HI@ M>P"@/@#O+P!^H@*2*P">2 !&V
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M#"( #M<)2A_@ W=(#U@0 3[P"35A#B'0A/H2#S(0#<7  QN0!?:@S(>C+\0
MPS%\@.6P!!% !>4E#VCP #D 6?V !@.P R?B#Q5 #>;Q#YKP ?K:!!&0 KU@
M$W1P"@_1!KQ0P =\!^R@#BD@MFLP #W !^2C+Y0@ QM@!$95!*7P#T>0"N39
MQ+Z  @\ !OMP#WJ0 !PPA#6Q!Q]P I@ !N@ B/.0 U_F '$0P=R !0:"#RG
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M> >Z["(."'AA%2_PP2?J<(5^%$$*RR!"&/BQB!/( A(F>,<Z*."-4_2)"C,
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M@!/$.,(3PM$ *CBB& X 1"EPX(S)4&$'LZA$!YIQ Q8X0AU<8,(PIC &?O
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M2(!<'( Y2 ESX #(\8*(H!P:. <D( +<_T*(<*@''0@ $DB$<7"^S<$9$^B
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MA@&P)5HP/!J@!H-P 6^0 COH!WZ0 C3P*GA@07!0A0OPAQ.XC76@@7; !#\
M!U'  @OVA2;(B5F0-W  A,FSPYRX!Q[0@&?(A 2@QWS]AUD0RRE8,Y3$AAV
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M9NNVG@F%F8(2( (?0(9L0($N> (?J ;D_8=?P()P_\@#$R@##%B&C@H'3_@
M*V@!!R &0F@ /E !+;B'(XV&_<0"%Z"'6BC?\_T'?U""$R@#!P@_*T4(9R@
M/6 ,F>A2I,J!.-" QLF)$.#??_!?67B (5 !*Y '5YB!="B&!+B&5]@ 03B(
M;V@ (B@!#P7H+0""#L@&094)=-B <+@$#+@#$R"#?C"!]B&''_B"(KB!#4"&
M(G!'D[L %GX#%P:'3.@ /8"!KXX&#Q""&'""FO$ &K $@_1A8@B&!@ "%8B
M$+P6&AB!(G@ 4O@'J#L(?T""$I@#%- $CI0)*WZY$RH!"6@&ZQM"()@!/=
M5;"9,OX'F4P&!S"")@@!9O^P!:MV@Q\@@QE(@'! !0^X@QZX@WZ(!#YVAQ>X
M C5P@(0QB'9X ".8 AK8@'9HA0CH@\>H QG0AV@P@%X -B20"4J&K'#P!0W0
M@QWH!'K@9$]NBDC G#B@NW^0RWKX@2B0@AUP:H<(!@Z0 1J(@#OHMC7@ W"P
MY7^@APCX!'88@.C\AW"H0"Z8@@:HAFNP "9XA0<8 R>@@1+HASS @5#X@A^
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MKL!1CA6XH(W_;GPC'%TP QA48D7*F$$<\^A&/%)/1:G HQX#>9U5@<,)!R
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M#2-!0P0%"$ 7MD.$AC@"#B4PP V P0$C9, !OP#'-UZ0 1G$(AQUT,$"(($
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MB(, M$ $X,-,20 #W(?_B>P!I*W(3_G ZG ! &P:BAQ5$ZR.#0! J;V*)52
M-%022+ :3%R#!Y"".\Q!%8Q#103!'*"#,?C +M""$/ :&= #!_"#,1A (RC#
M&%C!.X  &^B#*WA /0S!#7 #/B@ [[S6$8R!/"S!'K##)US!4YQA%?##+5#
M)2A#%,P!-\$".A#!#4V9$U"".F! ,/P#*" !OGF!.#R *Z"#$ "<!X"#-J!
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MY$$6F(,CP( X-( KZ$,;I$'_.&S!%1P#)F3 (+!" FC#&G0 -QA#"IS",C1
M,<!##MR".$P )E#&+-;BB>!BI*'(+O;B+ZZ(,!*C,<+*/MP %JC:JK7:/S@"
M%4Q$.WA .5'$,<1#.F3#".""-X)C/7! .!B#!E (,=R -'! /L#$#;1"$4S"
M<]@C3% "#)!#/#@ ,J #/L  4E1&-%1!*=% ?\ "$YB"": #.BQ##A!/.V!
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M**B !\! !_B"-Q+&(I!!/3B )G'2/QS##53NFMP!(!0!:? #P3Z# U //%#
M!FP V T&140L)6HM+C#!*BB .&] C=H-*D  #+B  -R /XB"R0JR%]0"%Q!&
M.M3>R\K E%5# Y@#8ZD#/(1!Q_EI!NB#!#2$);A!O7(2&V#".M'#/ZB!(21M
M+4P!.#0M/U@! T0 20N")B! .&\ 9U9$&70M!/0'.' "!5%$# Q#93!"T2
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MV.,X:$$>$(8XQL-CT8.8F;-@-40Z\\(5\ ,_O,/YV4T6D($LR,(J2$ PB,)
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M<.> <[!"<1_W_S\,)2O0 (J- T9# 6R7@P.L0CR\ PI,<(EZ@@'"%CC<0"F
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MJ.0[76@0QY\_*N G"SG2N04!8AI1(IUZ?D!DF!' (0.2<9:@PY]S6D %D#+
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M$3C/_ SP !$P 150]9+* @K 'H8&',3@\;PO9IP.'*;@ &BO:*S*]W!F!0X
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MTO)-LI=[M3=\K_\7>P7.:(*!#,27?,MW?*<E]T;# ":@!=;C_'@A!UJ@ F3
M!"8%V1*O9P#X.VH2G5R 'FI2&JDG'#!A#0&Q9?Q@"&0F&AK@4$*!!"2C'E+
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MY*&>_P +W$ F@D$(M/^@=\$A".HA")XK#KZA'>+ "B!!'B;C'K@@ \(@$O*
M#*S@?1++"** %ZS&,]YY(*(AGCUCGOL!#W@@'K01NJ; N^U!$C9@!:YA&J8
M">H &'X!!UR %P*!B/_A$%)!#0@ DVYA";3@$OJA'HK "V+ $NPB<WQ9'-B
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M U(X$(1#!A^#76(#,Q&L PX[/W##S@[ ]*:(-^"\8P4IJ/ 0-"%NP&/!.N&
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MF,$HP.&/&2##$R-@CAW^\(4N\0,+B7A$%H(&B3EPPP,2L\8%8"2CJM@C <"
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MQ24BD%$>S" <Q5"#%69 @7;,X7>410 /,AJ!5$@"O^" A!Q>$$)PL($18L!
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M"9<P#8[XQ6'\?I1 "-3@"IS9"WY@!G[P".W 0^;<"?50$-ZP"8B S+;0")(
M;MO "@5A"5MG"LM0#Z4P"XTP"M FQ50,#J[P<[CZ#J?PPZY4$)C@0N!0!<Z
M$-[ U69@!EW2#[W0"+I0GM PTSIS#)'@"3%AJ:9 "(8P#[J\L0V5#O=P"H2
M#91@/^' "X>0#\*@PK2%'YT ;F7D0ML@"!L-Q9] DLB@"?^0T RX"@[3T @I
MK)X?/0^(< C<, S=X*B'T!T'D0R"\ LS"P[0P G@( ZNP :JT*+PLJ,;'$\"
M<VL?C$]"*L+_(H@FS-[_,L:4!=Z4)=_P#5*A,]_WC=_YC4CU/=_YU3D<R$/Y
MM4.PMH'[7>#YG5_VC4A+,5/R7>#A( _JH -N"> *3N#YO8$)+M\:WM\%H3,<
MKM^4]>$B;M]9J. ,%^"APYFP9A ,3D@@CN -CN+W;3\F?N(>3M\V3G\=GN+S
M;:"J4 ,#?N ];N \ON$>#N,Y?N,M'N)$WN1/ON+[+=_\< 3N%.+*EA C[N V
M3M]$WM$#ON5#CN%,7N%)ON$L?N3_^ W>&6R'\(*'Y/VC_Q*D 3.DZEVD[8WG
M>:[G>\[G1_JF)B8.?2[H@SXNA/2(A-[G>2 !JH#HC4[H_) *CB[IDP[#]& !
M&GR'' SG'BSG(.R'^V3G)$SIHT[JI;[G!7$/ME"3IL[J ;4/S-#J@JX,T5#C
ML6[K]6+@MZ[K1NHME][FZO+F 5/>G7[>=)[>];+>NZ[LL3Z'K)[CG+GLM][L
MT5Z(U&[M$&+MV1XPO8[I;J[IPA[G]3+G %/GR'[GVL[K(2XPN2Y0A[Y(SR[M
M-+Z!S-YK83Z(_OTF]33M[U[4\/XF^&[KT\[D8N[O <7N\:W?="CB&>[A1=WO
M!([N$5_I_^W$H^,-[IPN[IZ.WJ!N[J(N\08/#N-0!0W  0V !-M0$%BP6@&C
M#KC@[N2"#CT'\M'@B,I>$"Q@: 7!#B2Y"V-0ZZ0>#<6 :W8B!#BP"[P>#740
M#C_PT%4Q!<0P)I]0-0+#!,F $/L0!S@03. ]#=00\R\_Z-K@?N^>!H<4.M+@
M R3_ VV0.V /+Z&Y[O3P!3@ !/' 0_[P!&!-A^OP!3[P!'AC#D&  TIPO_\P
M#H1_$-4P C* !C_X\8_/F6Q>\3Z*\? R[O]2[OMR[I#OZB[PP[E0!QX0W)H@
M>]W2Y1!2",^&[:9/YMWR#_D0?S:^3@L.(5' LESNX_,^\! "W_]CC/L)'TF3
M5!6LL"B\@(R\S_N8<:?"#> 73/NYW_L%_@5'#^V4=0RE6PXF[ORLK^]581'A
MX 8+AZN!("8\1 B$(.59R/I.4'[_L+^HT/:MSYE>H L=1;MODN\.OOK0/_#J
MS_HO#A#@!/X#1U @."*T_A&D5B%4*TXWHHP[N'#AP((',5XT:+"%MXP&-V($
MQR\($6%'R(0#MP_-!&T6+8(+]P3.M2%2PO6)(JU(D8+]P$Q@!DY?"T;.8)"2
MV=3I4ZA1I4ZE6M7J5:Q5P=&SP  9/;!AQ8H=<Z!1UG_4#G# -]8MV'E+#N0J
MB)44@2IO]?(X4 SM7\"!K^YS,8K@/2K_?<)A2V?LF:)J__)M0\82W+AAR?:A
MV_/D&;AYT8+Q P>MF:=CX+)%$T;:8KACV_ )X!>NGFB6%M7ENV:MG$!YQ*SE
M*VTCTSF+U)0]BM>OV#9]![U%4R=PG[-IYL#)>^;.VK-PTK[) Z?NW#7HZ:;A
M$SC.F>9P_9ZAVU:,-+AFUNS)6+?P7B8;JN'E"'BB,48@?J29ACB-FF%G&&KZ
MH2F>::8A!YQCYA%(&V"TT0<;;/:I9QMW"C)GF]' 8:>=VX I305$S+D(--'X
M26>1%*:1YZ)WB(G&Q7"$T6>9"-/9AKQ^DKGG(G^<<487+<*)!K;J2FNF&'/"
M,6>9;!J)9+MB_Y811R!OQ.G&&?+ :2<:?)"(1J![5O'!FG'Z.88Z@2!4))V%
MF&%A$V,2<*>^?E@J<)V!_NEG&G%8*N;"<EBC"9QUK!DF.FB>682:C,(Y9QMI
M!$*'GC6+ J<?:I:19@:6M(FF'8'"4<<:8Q)*3H*"P@%F@&[">= ^X(CIYAV:
MR)E&&8',J4<;"\?IIAF!6JAF&&XD!">?::1A*9MF BDJG'2NN 8<66@0J(P<
M).BO*8$&J(?2!][)H1MPF,'!'G#N:,&"HFZI81]P*#FE+L$*-OA@A/\2B*L#
M"G#X88@AOD !L]"BAH )+HAX8X<O6& N@NPB@((+-.8X8@,.."9AEO];CHHP
MPP@RI(9P3LA&#AP&\ .:&6C@H)%PQ'$BA1F4$(8$&0H9A0,;'.!CGS]R_F.2
M!JY(0)*ZP&G$ QU6^""<5)AV0(U]PED(#2<XP, %=>[Q0H8;9 @&%@]JB&RA
M&G#P8!0U<."!AG+^J:1N#HZY)PH4> @A&W(XH$&&#?# P0)-P.EC"Q\22 )S
M#^C91PL73$CBGG.81J& 3\#!I>X3+EC7GBH&T(07$SC (0)0PFE$ QMF@/:@
M&W2@H8,]Y &E 19FV*&>-_(()QPN"J&B"APDB,,$#T9X9YT>;O!!#GYVL0$'
M%"2(YI6Z[P;G%@=LT. -9J"(@ A]%CI'A1/_=)" EWLP8&&'"VR"' X(!GY"
M@)Q_C$,*/S@!#[0 #@3(@PY[>)X4%K&%:-3C!20(00L$(8\XH. %-K@0#K8
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M1!R^,((5_%&7/GN*<( $%R@'0;.,$O +1&.&?WB#BAL')9 #@E$U"JQ "[Q
M#,Q @V&U?P $%> '6#.B',*")$B"+_@%)L %C5@$-:@'#G F06B$/\@V-5$#
M#5  .D"U?\"%(& )=&B >G  R\ $-J@+,?@$@M"#2ZC_@X%IB0P(!RT8!8*A
M 6[XAT:  1/\ CL !; [B"EXHG_0AP@H!P\P&T20M6PX 7! @TX0B >XD((+
M A[X CH<A'-X@ W9 6\P <LX 8M[H $I"%0( T/P@2PL@\/R0X&8 T50A W(
M@2'H,7"H@TT@ TP ARN8!G P!GT"AYU# 2<HP20P!5L8/G#PA2 XNJ3[!WA
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MU5!#-ER(R/L')N0#\ F';\B&.Q2(=1!&#@ \=G" _A"(O.('7AC+?QC$5OC
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M$LK_/>"4<HL0A:0 !S1\(=/%%9H:(S<SX.#C"QN"\/./.T.<T,LI1;#2B2E
MLK/*)]EH!8\AQ^KS2#_J*%()?<B>(A.N0 <X5L&+.@AC-?NP!2-  :5N  ,6
MGS 8.+QA"51 8@_\>(8E*&$;@2U"$:J@ EL$$027@&,4&' '/T3!"%T<ZQ_!
M^ 0L9K>/6#!B&GS9AC$ (0EU<.-V_X#$&G#QB6H$BQR4& 0T6E*)5<2A''S)
M!AF@A <_@$\#1.B!9,#AC#! B1)#Z,8/6N(+)X2#'EK,03C,@0)@"$P153$5
MCN@A 09$2V)ZY,L> - (HE#C #[(W1ZSQ85,$:5332!D_R'Y8@, D(J.2 *'
M#J[ CTA%(DL.@=5.WA&%$JC! 8_PSQ@\4(57S"$%>7# +<!A" [P(023&,<2
M=  '&2"Q)U4X!3CT\0!XY*$%JVSE:D#!@384X0.W*$8'3I $ 22"'"9(@A$X
ML*Z%1"($;L""#.JA"1EL 0@.J,8PFCD&#+BB%Q%801[J 8,F$*$#H&!%#X#D
MASE4PP=%N,(2_+$I<O0 "G 8@"[2$8&6U(,#_%!! ZK #8:0C$$F8PC*7/&
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M#XQ#&&RJN?)".^P "]B!(CQF"90I1!"# ]PJ(>Q#$= "7WAF$I3"0A3"'MA
M&W3H-*#!>/[#-E"A:ZY&.7S *$B 'YAK(]A#"B@#7\B#*.# K5:'%,1"1'P
M3C#G)!P"7R2##=A!%;1A(S!, /C3U7S0,82 =\[@5[S &$0B*<1 2UA##J G
M%TG# TB1/#Q I/VG7LSGG/F1$^)9?D8AI_!G2?_\V=NNQR=X 3H4@@&8@C\(
M0SX<B:*A @LL9#9T@#HXZ-L0@P8\#S0<@CB,4YI @2$H+CAT R" :,O\P1?
M@#\X0P?XDS&TV&I<@7&&PQ$X8E_^@ZX>@OJ! R)P05.P ZRUD0: (NU.PA0L
M PRH1C>@0"UX 5_DP1N8T0LHY@^, "J  Q9TS%_:"U_TP:>" Z.QPP78!BOP
M()DZ!"9 022"@Q'@P6K\ \H("QZ<  %EE PE0CCP@R=0 3]T8QUT0DOL@0XB
M <:QP"@(3 (H@\?1 ,.  QZ, 2E(05/H @B$@',M1#GX@#?<RP-8ZC]L@&>
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M/7?!<2:H(=ZN6_IS]<"=Q[Y./7K[W[+/M[>^WOOM]^C7/VNA_+GN?JMN0/P
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MDDON(#)*P:E, 19,?GED%CXX )<X"8C 99A?9N!BCWW^&>B@A1[:S'#PD0"
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ME5N(( :D* @[]' #,@3.*MDHSBUZ8H5:%4;_#IT@0B["D8L8U, 73$E%%5B
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M,.FBO: +T03B!;*0PPOT88H0W (-*KB'.CAP"5H,0!OA:$,60'$%0<QY"*(
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M6D$",*,?:D &A( '6J <SF #I  +/N#V1H(/\I,@ZB$";F'_''R! \[!$MR
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M+R2,$_1@$PH" ;PJ"WI!'RS %?4A!(JA'MJA&E A 8 !!ZH!N#; '9(8%'R
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M@0SJP0'8 @9&XAAN(!E0[2KB@!.*0*;X00'"X1S4H $8H B:(0-40 =J0 =
M>"#6&AQV(0E& A>8 !8>0 =T0 6^X(#_ 7%'+0'(00 6\PM&8@)4/N>)80N.
M4CDX]Q\*WCA2 ?\+9-XXBJ$+-B !R)PD5$#]P,&S0P :!L(#RF$#O.H?RJ 6
MLF &<EX%.F$>&L UWN$;*%L>5.$!]*$ 1$;GK2$*=L&4MA<<B/L/#KP@QCX"
MH.NY!\*7,.%-"V(;;  SN)L@5($NKL(*?N$1W$ TD($$P($8:F D4H$*X. '
M=%X%XHX@UF ,,(\4>L#--K@!\*$8+N"_*^0+U&X@Y"$4EN&[4\4-)&$,#&$@
M%& EE& 6.%4Y:F 8S* #>H +(@ 8?$"H_^$#.AP6>"$!6%X'U'D:K$ "/$"D
M/TL'$(#$)F M+J 3E:,+2-@JL $%"L$X7N HP4$*7"$->HVGAZ 5<,#_.(Q!
M ^H%('A4 _<O!+1_&M3]^W<A708;-73H&+:PXC]PX,XY$7(/7!\TX<!1XC*J
M1DAC#] %H 9N'PEN"\%Y"W!APP4#U$QI"4G07P6"%3&6*&;1![PYGC""R[ O
MYJ .*;PXV-;IS+,4P4CP=%-)EA6@X(RTNF@N@3H-!"'UP9BM!C@'\]0X6ECD
M5383#:ILT5,. T9^5U1EH:04G# C"38("D>!X+L+_!!U:"'% S82P?X5*R Q
MHCMI2CYL@(3Q'R4]X4+J(";0XC^N_S:@ Q>NUI32KEV#HR>! ;G<P/_M = H
MN/%_U [X 'I\(1< N9H#CW6@"?/F-@ 0E<Z]_[OW[ZZO'?@$+M8$7/,*T.$)
M?(NUBYZZA,37@1[0'[C8A7."RQ>7D(*048\#X!@# T''W! ,#NY@M$(K=?W#
M#P+]+&,/.M,TT(L&[80SSC;^E!9-%>#LD@1!N#!12@G\A$-.,K0M1$1Q%UFB
MPSX"Y*/+%P1MD T_%>JC1"$7(>)-(X* <T,O%P5RA(GAB&,*/^48X@%N.FP#
M3CHR"&/00@.4\\,R(4512QB;I"8-//,T<)TP&'0(CCL"N., ,:DM@PX1Y($S
M2#"=V '."=(@$D1JT QP3@3L+-380N\\04Y(<6#BQC08O8($4'S,59$I)H1T
MSP_./.(&<\B0  XQ;O_]XU4:9[0HS$$+A7,)#3Q]LD5("P$B0DADW/#.1:X=
M@H0\"Q63P"X-E+-0%:N,8<A""O0#CA*SZ+,!.^"@L\,H&C@C#CH. .-#.PM]
MX$X8L*22 S_\N#,,.[_THPXB+?"#$30/8 -/.X> X$\#WV"T!SM=Z&(1/2T0
MHB\X3UR"T0F_)$)$2'3XX4P'UDJ# J__Q" +1E\FM- %X@Q03#C\;(-.;N",
M P06YF"TB!(AH;'&-0_HNPL-XN P##CWY%!-3)+$ ,^_(YC130OC@$.-)SY=
M]\\])F1C$0[P]#%&2-<DT-0__B3PBS[^G$"552D\TRQ&5<#B%7-E$()1-#__
MU(/6/X4L$1(H*[P5EZ=%T'+'&^?PHTD<\?B%T29<P,",4N.DX@\YJA3@SZ./
MH3- -.F\,\-EF0DCPSGAW&--.J/L8\\K#/"DB@HAN8."-*U9!)L,6O[#AA[\
M2+=;;[]Q-QR-WR6W7'?/10<>==9UE]UVX%5O_?77$$ >/A^<\,0$(]>0A]7@
M5&$-0<$,,(H^=M3@3T4<Q#).+0J\LDL'U1 #@X /!&,@@B5(1PL0\8Y:)  ?
M0W@%./I!(2V X1[*P$$QK@"&=\ "!C7#R#1 8(Q;G.@?*2J' &IQ#SK@3"E$
MR,,UI/$*#Q@"'#G:44BF4 =VR,(#^*A$#.PQC 9 _T,088C'&9!0#VB8P!%0
M0L<&2@$.7^P@'!5)PAR8D8D%>,D8!/% .? @!7-8(P.J\(4+H$$/$L""'FZR
MB#]T$(5A'(,/*AA'&[@@KPUH@Q,WB <U.'"-1' A'H1RA@>LP0XZ(&$?C+K(
MH_ZQCQN801RI<  W\J"%<@"C!)ZH2*>"8HX-G.(>E? !.DP%%FGL0!C.< LX
M9$&%6_A &>=0P2."<HT(; (9ND !(\"!C9'Y*B3J2 !Y4H$-YN"# WB0QC9X
M$(1TO$ 0XNA% IJAAQ?^ P'RN%8OV&$ 2/@C$2]HA@>JH0],3$ 8.&@'1M05
MAE/H(P&O\ <:J*"- 8"B'_^2L %/'&&#;/ZC&0Q0!ASB( Y4[( ?7NB$/BJ2
MABT$0QG*\,<E;#"/5J# '<K0 #::H0%BR ,&@1!'&<( Q9 P(2G@< $OY)$0
M@J"L"$)@AS4$  ^8[0(#HE!&-L@!# XL@QDHB 8_3% )=GPA$N @0Q;,<0H7
MO&PA6)A$3 )Q@W,TH!7I8,(9_!$ F%A$'3B@1TS^@8)>F*(#V' '')X 1;)9
M8!GO4 0%0!&H9[3@'<\4QRP2 (Q?W$ ;%?$%#KQACR6,X2P8:08'1($.+^"*
M X.3$2WJL =_4.,';8A'!P@"CFI$X K!N\@[4' *?NS" _N@ !0?XXX/..,=
M@S#_0#(P PY_@  1]W@$"<BA 57P8Q8#X$D[$E +<4"B!>G(747PX 9SW$%2
MWF@ +JP6''I8P#?=.5[UE$?=X#2O>M#K+G"F=[WRFI<[RB! (##BB U ( [[
M (<'E' =N)T/'/SPA 8$P .6 ,43#^B %<H@B'$\@0$_T,,9]$$"#70#!B$I
MQ@W"$0T3", '"AS"*A:( 'Y0HP4)P, ?^,&-'B0 ![/ 2&K@X0 2Q"()(4D1
M/T[!@0?<0!@\ 0<1*(  !"2@#U%+0#YL(1]P:(,&(0;$EHZ0  U((ARS*( :
MSI$% 21@#._P8$@,@8$'[" 6S(E& R3PA!H\(P18E&\Y_^)1A028( JSV$<<
MK!R&>^ CC4'Q!A(8P  :# 0?,1#  )+B#R&$N!.KO, 03H",<#"B PE8@33
M$8'9A&,!8,%&#A+@ $>$PQY42, #\B".BI#!$6 !!R]0(  8L (<EG!#6_\1
M#QBXH"0A\8H\Q"!J*90Z)N'@! XRL($\I",<??!".'Z)D4YL8!U<6 -SP"&*
M'F2@ %*(!SBZ<8($-( 2X5!#(3""S6O-@AT5B,(#8 "*?;SA QQH Q1(P;5U
MFJ,.L !'+3B0@!-D(QR=&,  9O +I1Q5*>&P@2;:L8('H( 5X=!$!A:Q$'TT
M@ (9Z+$RQ%&$!/B %R'IQ ,>X/^'D"1C!@E0 3YB @Y#M$%?=<A -!Q0#XPT
M!!XZ$( '4$T^(!B@QQE(!#@>X8$$V,%:VT!! K10,WMHX0$XV 50YC& S"SD
M&@S(!B\:\( MV*,?-9  /)BS#9-<)"1 0( U!%%T%M!*0HWX@ ..<(1%9()M
MX>"VMP'!#V9TX ;(8B0>$I" )L0C'AK@R2,ZX $F1"$<'*#'J25+#!P,@ =]
M0((Z.M#6<8!@$T$!!RZX[H-3@&,!^A+'!?K1![D'80FN $$P[@:#!.P@&N!8
MA0,>X(-<(!P6.!" "<['@V.X!A85D$,]0IV /01>.M;%KO&(LUWEB#<WWWU>
M=:[O&O+_GO?[X*](/^S1$=JXXQS(RLA30X^.;"K%'>2X!\C(<HY]^.,>C"2'
M/L;1$7&@/Q\8T0_F(%KZAQ'L$#7@0 Z.00[NH"_A\ [VP"VE@1'HD _CX XA
M,0X2B [Q5QCAH _D8 _D@ X.F#C[((&IPX!*L0_G@(&TD0_<L@_YD _9- ZS
M@1'PEPY*$1/Z4'_BP _YT"(9$1*7(P[OD$W]< XTB%_YH!N,E _G$"(8<0\J
MB!'RT((A$0[F@ [FT ^IX0[DAQ&3(H:A]PXC2#GG< [64A'Z@']C]8'DH(-7
MHP^II@\6V"#AL \-T@]0Z$\7H13IP( /\PZSX0\9! [R0 X:_R@.((,19DB#
M/&&&W/*!_A 2YV" )Q@!EZ.#B*B$_? .XQ"$8OB!XQ 2[$ .[_!^Y" .A9$/
M[Z,4[$"'5$B'"W0.;N@B(D@.Y)!-5Z@?2F$.HH@1XM"!+(</-\ ME\."0CB&
ME^,.Q*(;Z"""]F /J:B%^= /?QB(X_ /&4@.OK@0_$ .H44;BM@MY0@.[Z"&
MS"$'@Q!ZR:B%Y1@40$B#]W!_/PB Z'B&!%&!\F@.]4<;EYB%Z."#&<$/:+,0
M!P@.^D"-_: ?EP@I/4 -06&*WBB&*F8/"P2%_5"/7:ABPTB+W6(/(/F'[$"-
M&&$.SU<K^:"#XW .YA!:W!%]Q2,=VO\%'MS%/- !7MLG/=H1?C[YDT 9E$(Y
ME$19E$9YE$A97MH"DTG9E!>A!DSBE$&I#R.@$%(YE.#P#6=@ ^]SE44Y/-)'
MD]1GD]:'D\[S'>'%D]3CE6S9EF[YEG 9EW+Y???P'W,IE,8 >G=9/=UP";.V
ME]6C;SU0<(!Y7F YD\U1D\E3EMR1?6BYD]SA?84YF>;%?91YF9@YEY8I/!:!
M&YEY/9[YF<"Q@Z(I'7D8FJ5Y'(>976.YF,O3F#FI?=$3F3V9FIHI7J09>C"#
MFZCY';GI'86QF7^H8L*IFK0Q?T[YFW 9G,'1FQ6!G. Q@<49F,YIF]9YG=AI
M'*LY?<CC'3?_"9MGZ1UI29MKF9U7*8S!(0Q:HQNSD)+_P(C=A9Z@*0S*$)C&
M<#2_,(#"$P^D< W3V9SX57Y221N_)I?A0 K"")TQ$0S-,)KO\)>!F0SS  _?
M()3>,&GFF:$:FIW;*9;=V1W?*1V.*9Z0*1V2N:'4.9S2&7J<I13.H <3.)R'
M8 :\LH-"%A38< <UZIE-M D\2CZAR5F:0*/!F9L["!250 ?@H (%4Z2Z 0X\
M, ",0"Q&6A@LIZ)_: >F8*73%J-_>*726:7#.9R:X'N=R7)'BJ8QBAM'^J-=
M2J4Q4P#A\ MIP![/N!!B0![/2!"$T J<-9IIJJ(8<02\@ IP $5%_[JF@OJE
M:OH/DR '[$&:/SI63XJBEGJI0KD;%E  ]L =X*"8WJD<$&H<(]H=U*$%Q6D#
M!U">F.JI"/<7B7J</$$+0I"%2M$B:?BJ!)$CQ.D+0)!C\P<.2**K;)IC3CJD
M/&&L;<J-M,$/YN L-E!,Q(EPG4D!*%BD0IB%J=&B^(5P2;"E'IAJS$D;1;JM
MY.J!M:(47@@$OL"BB6JNQ!JNYYJH@DJ<7O@,X% (7^.D%V$/AXAP7! *P3EK
M+9JL++.M%T&HZ% /RAJNVRJ$_.J!D  &#3NP#U.OVSJJK;JQ'.NIUJ4 >V &
M(CNR)$NR*G  '\H=U$  %E"R+DNR+7  X?]IJ@?P R][LQVPJAW+'>N@!DR@
M"T@%!F8P ]L0#W:0!42 *68P"D! !,J #RO  9; 6:5 ""^ !K6@0,@ !T-@
M"YDD +T0!$5P#/2P @XP".G !ED0!]D %,20 BF@"N$0"E,@!*( ,N. "5D
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M!IW*C7  !;7P!QN0EQ^@!V;P ;/0"R\0(E(@,0!R!;5 !C\P#HT  J_P!$+
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M"#P$T&*JJOZYZI8'(,$$AD/"<,$>L3Y! 193.A!CC XB0^@1&3!1HX%Y,&E
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M(18,;0,-=D!K*DIQ$EW(0A[K5,0Z*C$..^SC)-+H QJ^ 210G $-OP!'/="
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MQ"*/"]B< !/X 3[P:9%:&$!!#$E'&!8!#C\<H!PQQWK6#9X+ DSA%5HX@"5
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M \@&4T #=D@&!5"$_P),B-4[@#6< !"(AWLP@1'PAT^@@&\P @S8A6:X!'6
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MK25P\(1VR"Z=:]IKN)62X I]30=-6,"D1;2<6 (GX-N^]=N_[5N*#=AF0 +
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M\-"3$(8D<( KP(9P4(.>+H1R\ (?$((3&(8H" 9F* (WD('_&A &<-@&$>"
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MX$681&YAC4&47+'=,T"U9 H\X)0#A2JT"*&4(V34XP XQ@Q0SC_;E* ,!NJ
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M&6?4(!R^J$$#8# !?S!!%1$)Q!&D\0-_M&10"O"!'_R1!DM$I R<*,82=M
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M-:,@&JC'W*:F5:7D#1!'J,PV_B:P@CC@K(O(ISYL,80.S,\3>:"' \X1D3M
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MI  M",H.F$)+P,'(]!,NM,$:\/\#,UR +1C"#Z #/[R!%-Q *H"#._@ -C0
M-\R>*AU=";X#!>P".&P#!FC#!H)#,,Q /%3=)?# .X0#(L2 /W!=2X3#-#B
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M.(3H]>A##8" %7  ,_0DQ"0 "& ,.#C#!GR!Z/P .QRE_X##.BP _"E%HVB
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M+,C !3B!<W&#"TC %M29.U2!!<Q -87#(F" !)P!/QV'/0S &Y@[+<P+%BF
M)!6! F#"BY,#%S   RR!<X&8-G3"J<F"N2.V-#3 Q7? V[A"!T@ '5Q1. @"
M(1A&*,A!9?!#&:!"3UD!O%LF,0S Q!=$.1 ".(0!+%1Y.VR!!,C VW!#"M@\
MSE>!!+A &X*#(P#]&L#_^C^0@P?,P=<V#3B(;IZ'0P]< Q@@ NQ*0$Z*265,
M0BJ[$3+PP+PS22^,0O;E$PM!-SC,@2*80A2PF#R(P>IC$3#,D<#?N+V+K9&+
M"9*349IW=!J!.$C__FC6"2*@P7&GMWT[.'K+]\&+B0->PC$ P@4(P^4S"=2"
M@R%<CWW+]PI$PBZ80C*(PRB8@BFHP0FP R8D@3L, JN==$N8 ""LBD&,084\
M)T#\$R@0W$"#[ER@RL<D#[\KD,Q-.1/.CQ=WF6SP"];!V344PPH2Y!5B1KJ!
M!4,F,66094B6 BN%DY?A%SEP!>=@V;:L"9%P!F\"!;>J2+A>\%R^)'@3G"D8
M_[9V[8H'S,,R8"%^_0NWJD*C?^#DB8 6KE^F!:YN2F$55"FX1D&R\1/X"PJX
M,*=0NDPJ, Z1?)QFL*MR"-T4,>'8/#'': 4_:1P]#F-)"H:+="A9?KD5;B\X
M$]>&40MZ\\+EI4I/NFCV\V1+S%]/2B/!FNW *;50UP8*NV4Z"YQ1&\RCR%24
MD&S=)0#^FJ!0W@(OQ=D;G'IUZ]>Q4P='3T( 6\O AQ<O?@J 1M.K4SN 8>=X
M]\NV(0&0*_O 6 =43'O_O@6 8O4!#%#  9=BAA-.F $'D3-^*>0;SLC)Q9%=
M]@''E5[PR&>?70JYYB9@ '$%J8+"*:>5F^B9!1Q6YO\YY97+PDFF$&RVL 8<
M?%#!11]PG $%#U-"&J4*?C@K A9PQM'%$&]N"F>90KKAQQ0!#DG'E7O :8:2
M5=S9KIIN"ED&N'_RD>&9VL Y!X51P+D!2'D\\.:D>%#AI!UP>/% D&8$4D8$
M(;PI A5>+FGF)CI?0<<E:)#P!YQ41F!&@RZ':4&>'D !YQT,@"%D#LXHX4:O
M,B*!(9HFD7'$%'F(R6$.? CJQYI"3ID'G TG',<E1\)Q! )%R"%H"UDXJT:'
M=,*!AA)2' 4GGU-0(2>?-FP0Q19\P/''%D>2X0<<:^CQY12;OE(P#*; R02.
M<,*!)1EP7M' "4)N$B6*?L#_V<0'%5#YZA8OQOS''UT6<8:?:I)8 DAPTEDC
MA5+J (30,\$I!Q4N:^M"5'\:&,:!?,"I5)X3?LD6@V8B(8-=3KAA*0Y!8! %
MU4)VD0>;'N:X4Z!PHBDDF!:N<>88</K9Q1!@"A"'J6_::842;6Y2YQ1.L!UE
M@$C886J<719)%!QNUJ%E7'"@R8852H0!)Q@2Z*%%'G#N064?@8HI(0YF]F%E
MD6V\+=<<7PSAQMM3E 8'D''DX3";</2Q8)U+0E%Z('E^<>24>, 9SA0M?O+&
M$%_8X8>2 A!4!I1"[7'%&B+[B<:1!_\QI1Y7:!''GB)BL)' W7D'<#L+#B#@
M@.&)_R^>>.$/.*\^<*@1G@#DC3?^^0-R80T[<$AYGH )HN]^^/]Z#U_\[&Z"
MQ@<IFN!@'41P2,&&#8B)!P0GZA!@$G 2P($'>]+8H8@.K"$,'Q@!"SB@!U.X
M80/.B ()X?  "$:@ 2:$HQ8)*$(+/A -;< @"370PCOD\  >)((UR(A )<Y!
MI'_P@PPN$ ('G $.23B@" [@Q"HL0 9W8* <T\" $EC0@W.\(@4P8($$=C&0
M=6!@#%# @SD&,@@GX"L!P  '/U20"H)LT E):$ P)/$!/1Q#(,1X01.P480=
MD  $'8B'/5)@A2W$0!\GX0PX$O$$8IP 2^JPP#@L #5YE/]@&EDHQ"4BD2"7
MZ ,'W*##IU;T "+LH ^L^ $7^/05-LC@#C<X@3O0T (X^, .UE. //Y  3G,
M@R!%< (WE,8N:?@@"SP PC[,\8(J8"$'VEA"#FIAA53LHP@P( (&!@&.%Y!
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M"\( ^ $,G, 9_  "HD$5_U#@%FJ! [ !5;=,&!Z "RA!$!)@%](!!?Z &JB
M#OK!".J &[+ 9&= $-#!5P7!+7U! +;A%8J@((PU)(+! PJ&"N+ 6WI %IC"
M$)Y1#ZB -GB! TC!*18!'+KU*][@")3!^ZIV%EBA V+!%GP@*P2"&02@#Z!E
M%\#!"(( &VP@$62(!)*A#98@'*BA U8A%S@@&Y@"$Y*@;^CA I)!#IR &NC@
M"L)!"<8 '@2B'## %8@!"!8 &V* #[*A$W[ )"ZV!@>"'_"  P[A$J+@"OS!
M$TS@%URA X"!&S2@%T@A ;Q!%4  %*Q %NP!!QJ!&[B@"?J!9@O"9LVL#)#
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M"EJ@"*PU"1+D'ZZ@' C"'#B\!M@8''9!!7A /05"$BIAQ-=E(.0@V<(A&$Y
M+@@BR9?\3A[;(,Z!"J) #'[Z#5*!'SSAOP/\FFV+P&= '>9A"G( #TYR'\#
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MD.E#OG %$30A'6B  0B>T80JY$ 5W-B!/M+0ATS((1S20 )&OB""$UC!"CF
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M, #_#>P0B0^1;9L0!_M ")EP"G$@#[" !/PP ^^P MS0#U/0"VD@#_$P ^'
M!,. #B7P#/M0![JP!+NP#U(@/0)A \L0#F)P")3P!..P"(\D$)RPA2T@"_YP
M NJ@!KK  \>P#VX@2/XP _S@!I\0#J&0!,*P _:P#Q99#AA #/7@ D?#<OCS
M#R^G [TP#CK@#38W!;40#HY@!])@ Q!Y"6*0"/S0"< 0,B3@#?M@!+ZP"(<
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M#VA+ R>&&"^@0&X0"^:YN0>1"V+0<Q@ ??5  W0 "%<Q"%0 "ZIPNNZ0"G.
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M"WH0#J5PNHTP!-^P!?[@#$X0#SP02@_AVO\ VS,@#M7@ T,0#JK@">!@!XT
M#KCP!.OP N=& N 0W%?Q#PEP#.)  L_P=OOP MC0#T3@"K90!8G@E. 0!3L
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M@9Y,,+@&E19XT,*<8$BX80M7/DKNA!6L.(=:<*Q-EI@$+O$Y.GK4L 65&7@
MKJ%[7 AGG1B:+N89*T9\G82@4Q G#J.!? >(#C 8 1]PG# &G":R >.58GB@
MH0=DY D"A!Q602:'$FJ _J-7<N"A"'&6$0 6$LX!!ZQM2 =!FU7( X<3W0FI
MF\-ZQ( ')/@&-DA @Q,(PS92P :"PI:'<T#A!2  13<2X H>V ,<T?!!#JB
MBWRH@ 8T:,<Z'K")5IB !ULH1S-*4 (G#,(ONA" +?]",!\<A&,7)KB!16P3
M@Q608 CW0 -2V*&$$O3 %K2  C\4H81PB$,#91'=%J"C WJ XP;-8 $-L'"%
M:IS(",WYASD&  IP/$,'-+"!,M)Q B*@0PD\F($A1O0/5>R !758 CJHP(,3
ME.4?X9 ..%C0CF\<L <*O,DH>K"")+A#$A'"FBER<(,OL&,/%HN$(<Q!A1O
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MAW#8!F=@AW4-6#D\LQDX !10@AL@@ MH!G!(@ K 3,TL@S50 +P,ARJ@ &H
MATH@ #: !@;X@&7 A0 X  'S@0,H V<P!0+_T(!H* ,"*,MP'9%Y$  +2(0_
MH( KX$.!A3]B(  'D(,S6 $"D %]V(8)0(%LL 0"B( #NP $4 -FF ("" -
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M]@*'24B"6H@".DB6?: !-,@$%V@&%Q"$2=@!;?@#&3@$?)"!)N $'*"&8G
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M@C=XQD5X&FB(&_B]?W#X?ZB#6/@'76""7E" #=B  &",?V@'$$B6)+T!#?
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M#SC2L0.YI4 B5\@&/FHP@#L((1R-2$ ' !&.-FQ 'B9IA10<\(-A@,,;-Q"
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M"K!")02!/T0#"]R#"QC"/4S!)8A"$8Q#/'S .$#;.V  LL1 ).Q#&J#!,*C
M.+1"$-#'*(3!.*B#!81#%JS!.)A!&ES6(QP"/X"""H0#"1"."]0#)S@!I@T
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M0SBXPS&L@)4, Q9$0Q>$@S5H051$ #@HP2_\0Q:PPDDT@@@\53^0@#'@Y#^
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M/%S#>B9+.;C /H3#.U #"TA$443#$LC&%SA$B2H!**0HBJ($"R"#1)1 ,Z3
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M&#"89*R@%5X0!"]Z4 UAS& 5F=# /++@!WM\(!Q=6 $L7O )>\S $F!0 '[
MH8\VT*$> WB"*S"P#'A@@!)V:$(XJ) ,2PR@$W0$ASI@$(@_U* 8,W@%(C3@
MCR"D0!4UL,0[0J"(2W#@&K=H@2^^@ 8T*,(7+Y!&)_@0CE0L(877.$$X_*&#
M/TBB!Y<2C"%8H H57*&'W4"!*HX0 7!@@1@C<((DSO\!@D,D@@?N<,4+0A&#
M1ARA#_9 PQ5(P0)"F$,!<PA%6$81 U(TX1/_F$(98.$":2""!;$ @2\N(8!.
M?&,%;+ $"."1AS+@XQ%4( 43BA".#10!%3.@!EQC\0X3U".JNWEJEKE<IJG:
MYB$*C%O]>O*@%,8P(1#<G^)\PI&6P.TV\JB%.?K1!S94XPIXG<<9'!&."-@C
M''#@11P>$8Y[@. 8,4C?,VS@"RMX@S_MV($YPO$(,*0A$].UP&!Z<05EU.,:
MRJA!M$P1#GL,@!UDH 4_-A!;_7%B#KXP G]SP%MPL&$0X,  \M1 "TWL@1_C
MH $PFCL(-=03'*?P0CC&P8C_;+ B'.5(P#N" (A_1&,%Y,!%.-+!@F$$81'_
M, 8@WNO <$C#!/X0@R<(PHL[A&,9-+@J&59Q$!&DSQ1;Z.$;_H>/!SR8&#%(
M!3A*@86K3D$73K!1-6KQ!A%J($79V$$^!*"@E;RB"<]HA\9WX(YP6*(/+>@&
M.*;!BDL,(1S1J,%5XY"+%H(C%=X(1RRLX.=+V2$2^Y !.<*1A&1T&3<TZ<&:
M@%YT+_$0-V%>7.-&TN8#WFWI8MJ)U,6,I=',G 88X,"=[PJ.%NQ9?!YH41E:
M\010#$0)T=A",?[QC!6@(PL*T($SN)&!"'Q  D4 @B["(8\?L+E!3$! "::1
MC5&G_]H'/U" /E3-CP^ HPO62/8< M$(P40!/P+!]3\:8+8\K"(. =C !C*P
M#"LD8Q#R24DG-$$0=HPA\0J@]C(,W8%]1"($#=A -YS C0>!P1/4>. _3I"-
M%%Q)(*B@0SAHH8 (;"  D,@/">#B#2J<,"5<@+8_7 #PM8-#$@B(0 0RL @3
M#.L?(0R'!01S#PSD0P9GJP@[E*" &F#C&^+'>QT^@.Q+["$<4$$!1B\ .N'E
MD*$)-. 'D$#7[N$?AF$$1$$+!$,)1,%KC.Z&4* 'Z(P?.M #/Q $0U $1Y $
M2] $3; ?^N$$5Y %6] %13 %5? %03 &9W %:_ %^Z$8!/^&JC!0)Y)F--S!
M!6+!'SJ!#8+A"E C!, N',3N']H@%(*@%GKG"ISA"G;&[>CA+,Z "H+A!=*"
M1]3 %?YA'#J S?XA'HQ!&]@@!J1AU"0A":"A'S" \5[!\2!O&OX!%O+ $-Q
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MX?-TH0?J_X$:?* <'%$EC,\8NJ$'UF ,Q*$2*$ <@H +Q($.[* 78H =3*$
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M!;* V3H &S:"^](B%'9  ^Q@']PN'-3!"C2@"1XHA%(B'/(  [Z@YIZ &[3
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MF4OJF($FAK#$<TL$<C+B@\\$SK*,0+X*S33_&'5+&";F@YRQ.86/89GKC4W
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MDJ %8*,3$0 5CL$:VB%P%?Q5>F$"IH$@'F$!F"$U]"%F 6$!=I7$/Z<3&?_
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+ABONN.26RV-  #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g1039423.jpg
<DESCRIPTION>G1039423.JPG
<TEXT>
begin 644 g1039423.jpg
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MSXH[7I$TBL*6$NN12<\02%R%\HQKOOPY1A/Z[\#/#R^7.%4F\>.,>'AG&?\
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MP]H/IG2'X<)06OD2<8L5Q+EQI,:+F#$?Q(D1WV&?.ZTXA.RV"SUNIPF25HL
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M*Y'I7G=(X.;5Y5AM'[-X[VP'4N07&J\R+K0'+&]B (,MS9 (F]$46^.*MCC
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MXT&;( DU)Q!,,0Y3HY^2W'>4B1D=;MR--M2OB=*XD,A*SMOP^(KU[%^%,BP
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*%<$)!(@*@@?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g755814.jpg
<DESCRIPTION>G755814.JPG
<TEXT>
begin 644 g755814.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ _1$E32S$R,CI;,3=:0D@Q+C$W6D)(
M-S@W,#$N3U544%5473$Q,3@W7S%?4$521D]235\T0U],24Y%+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MIJ;]8O-GQ1&8=*I&D*(/5,,;?GI,2I[)VN:>TM"UP)*/[$,LWL)AJ8 #>QF
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MXA>I5.UJQK?V]U!<C%9"2@JVW,4<U;IJ??Z[KZ\J@E%YU+3<XD\$?8]+58Y
M&O5]H(4SRC Z,Z@Y6I:9#'L2B$J</:A$O(Z"VCRA7;UQSKUIIT%M'E"NWKCG
M7K350TDY<NC:!S<K??ATCL68,&\/>%1U<5_0%1G-DL(K3:6TP=[G\@E?2/;9
M$<?3H*AF"(#U,6R0Q;$_<')$TU[69[FWN"06Y]%\IYM\W*7TPT-2,:N>?GO=
M%5!N.-M=HKO *6CU4WO!I!.ZL=Y5-5CZF61UVE:6.+F%!%W&/ER(V2]E0EMQ
MB-ID3DS(FU706T>4*[>N.=>M-.@MH\H5V]<<Z]::TCL+E=-LM=[A7G;\JB=^
MR;$7MR'[=9C=\0J=4[[=X;N5L-B;GV ;>I1:1STA3M=ER_N@B#&A.&T&0)EE
M$VBT?F$WC2Y>I"AUPV[\J+N$M_DH]\/*-S"DXQ74AI)-O@E5%5:]M[R0C71/
M:XURY#'6VQW-).WM3)7P^<P21L$[=XN9"&XIP1N3+'FD)+2GD[XB6U]!;1Y0
MKMZXYUZTTZ"VCRA7;UQSKUIKYH=P'+V;DZFM2W6MG(V+@:J6K[8+-VO;?.Y'
M9[+NUW8N&[6M(;-YG"MK38TR]Q1/DEBCE(S&1@ ;7LG1)35C+W6*4Z<Q2X#V
MXMSE.]]9D2WM;L-NU$[:'G9KR?\ ;%YUE9L1MJ9V@R[F;N1;3AF%;E9G6;A&
MFQ16-:H(^N2O;17C'-&^8.LS'%G1S=C(P4Y-#><B73=!;1Y0KMZXYUZTTZ"V
MCRA7;UQSKUIK7/<1RBE.[<X!MIGCM [RL\6[61M41I&%4O79,ZG\EDC]5+]<
M#(UG1PV0L>4(W",QY8F$L,5B;FIQ,+/?E;1'T[F^MVKC+RV&VZU 0^,TI#K_
M 'N=V/MWMV_4ASO1SD)AI)CIN9V%4]BCW&MITPC[S!%%96Q7ZZ*R]D[-V1Y6
M*VAOA;T\J7U">6B67]!;1Y0KMZXYUZTTZ"VCRA7;UQSKUIJMBCN6%JF<H]L,
M'<(/>=P63:% [/K5NRR-O.W28/='4>[[OH6W22KAV<E+ETOF=9ML\P<H?FEE
M"*R#H)$E"-UGTG3-:=6^BCY%RUU?5K#4)MLU[<]W3^1S+?\ JH\R;4-O[D\=
MIU?L;W"KJEG"V0LTCM=S4(G*+L)[6Y/$H&]I8Y,3F]U6L3?'W-WC4)7(EM'0
M6T>4*[>N.=>M-.@MH\H5V]<<Z]::K$EO+R[*8ZK;3V&-;D;-A1L7VJR*3VK6
M]*JWBL*Y7[TD$-?=N\,L65/$@8 QF8S>*SN.RLQ -&K;&-L6IFQX>4DJ<V2.
MNEKUQ6_7]"U+9=X6F_DQBM:B@\LL2>2$XHY2%GBL+:%KV_+0(T@#EBY02A0'
M]JMR(D]>X*A$(D9!RH\HH2)CG06T>4*[>N.=>M-.@MH\H5V]<<Z]::K[3<LA
M1&*N2SU^V][WH7-I)9=?515VWF:;9GV/WO=TIM&&N=B0T5/L:A^,@DO9SX(P
MR*429UZ1&\FN4+"M262"(O"EG;'3!IKR\&SV'5M!;+(KW=3,D4MKC<C9LEBL
M.HXQ5/J8:-G\OCD+W-M-XQ)\E+ OKA^IERD6%DM(<!*6K+6U+%+.\.ASE%TL
MA1+/>@MH\H5V]<<Z]::=!;1Y0KMZXYUZTU6:EY=+:2?%K%DBFL]V;2NKNS-K
M5;C@SS02]KL::%;T1O@=M,\K^%*I(!WDL+M#N==<-!7,13A(H3>Y[G"T;H8!
M#G'9[R^^SJN:@Z6Y%6>ZT@UBFUVU[;-:**;:&*Q*#E>WIHC<@L]FN+$NL"-P
M%C=FYAF,6>8VP1R>RN2V VO9*N!,LC+0/&6Y$M4Z"VCRA7;UQSKUIIT%M'E"
MNWKCG7K35:L[Y=3917ZNUCG9JOU=#J;J2A[@F5FLU1*5E?%-&Z&$QB:[=XHC
M=CG](XYL2W\2UKCD4AK@SMS@2^E.RE_&R11D=).E[1GER-HTVA$+>H3!MR<W
MM*;;@+!VV(MLD)J=OF.X9NL6I8@VV-:!KA&8Q-':&*HI"*W>&B=N,JCT^?VQ
MS8G),GC67Q^ K94R)91T%M'E"NWKCG7K33H+:/*%=O7'.O6FJ97+EC+78.1#
MB_*GG4*USBPY K+)4UO#,N37#69"KW*/5,)'Q[S*9,EEC8UA8FU")222I='H
MJ;/36WJ&E(S&.:EGVQ<>6!VR,EZM]&O\*W",H2;2K+;]85RG51[H[?Z7W*6[
M'F*0PO;K:]JL,C=FQDL\_$JBC$\'L2*2U['Y3)F6/O$\2+EF @1-Z>@MH\H5
MV]<<Z]::=!;1Y0KMZXYUZTU5QRC/*GVELQNV04Y!MNSI.4J'DZ]ZN\=!9CQA
MO'!T4RVTQ=M?8XRO@4,[97P4!(6GA:K35IFLF1MJN500$3PY)5\A<8_Z>&<O
M1M:+IB4SVZ()N J.?0.,;5G!76LNJ!5$I#;[MNX2.J6H%=!MTDE)1;_%IO)(
MO,$+0X3MX@Y[$WL"QQF.&5$E5+0(EK_06T>4*[>N.=>M-.@MH\H5V]<<Z]::
MU,@G*G[7K%V,V_O^C@Y\;4=!H+=';\0/CK1BUH-(Z..4%6)!72.I9.KC2F6-
M@22%2(+7,U\>>&]Q:W-MD"AO7%*-:QV1R_6R&H'>"LMG1S<5!%<FBL'L*= E
M54M[ IH2L[2LA96U66#=C2[31&_Q]GL)4D!+&=CBK1-9VQ0)<W2N=1"))%02
M0HEI_06T>4*[>N.=>M-.@MH\H5V]<<Z]::IQ4\NO7U*UA;EC[G*MGRY)"MXN
M_P"H>/F;>X>FD+,CJ?9/9.8HKL&=22PK"BL40R!R8%34NS&FF2G2>9N2A7FO
M8*XHVYQ AQW/+722<VGN3B4!K+$%K*I[7Y+F.U=<]A0Q9)VFS8/O^D\!2%F.
M,18[3C$AC+U*8U,RWNK'0XGL$<92U+W9D;*>VP$$=D2[#H+:/*%=O7'.O6FG
M06T>4*[>N.=>M-5TOG+@;)XG$$<UF6;:B+6F9]Y+Y8"1Z@K>)ZIM#L?LAHJ"
MV 6DT-,I=%3.OD-H2>'P2L&QDQ(5\SD<O8$@T[,!0K-1;*[&.41H7?\ -%IJ
M*B1SN)RVDY<RP^TJRM!HCK/.X>ME,923"'N:TN'RR=15<Q2V/*Q+F-R9Y6XX
M$:A=&UQ);G5L6(BD38'H+:/*%=O7'.O6FG06T>4*[>N.=>M-3?II$A#H+:/*
M%=O7'.O6FG06T>4*[>N.=>M-3?II$A#H+:/*%=O7'.O6FG06T>4*[>N.=>M-
M3?II$@\5%M. BSBPKMXXQG./_6.=?DQ_\TU71.76?,LVF#,VV[;Y#<TRF0-B
M @5C2(X1*) [*TJ4K)QRDPXW)9!18,F&F&&CSCG&#$/.19N%'[P7ZHOJSJGF
MSOQDV%^W$L^WG#2)OKL[_P K5!?NLB/V85K9/6MFSO\ RM4%^ZR(_9A6MD](
MC3332(TTTTB->FD3(EDK"]1U<8>4B?6AS9E9J418%):9U0J&]0-.,TLXL)X"
M5(Q$B,*, $S <C+&'&09]SII$T"C/)K[98_L+!R=BUC=Y-1:C;\@VYO[NZFL
M;;9$IA[8Q>XB)_?)/%F!@2&35*/!;VD>DK*F2I'THM<G;  YZ<R ZJY&VB:S
MS4JQ?<^X6R'^F]SU8[I8K(9FLI-F.,DU15+8E.PZ#K(]55)5I"2(+[@6=)GV
M1FM$8;9W+ID:1(I)-G$[M@A1;SII$JJF?)'T9)G&=3"-VQN!JNW9-O1E^^R'
M776\F@*"Q*>N6P*<B5#3AJKX,EK>4PQ=7,MK*)$L#]$+%B,Z N"[.:G*XM0!
MJ&V^\H/DHMN6W*45W+H%)KA7/-?;:+ZVTF+)C,&J4+IPAW+W4S[@+DMF>O"R
M,EO#W;TMLYK/>CGE*M;(LC3NZ]K0Q%.WIVA.V6<Z:1*87#D.-JKG3KO2BJP+
MYS&7KD]J=Y-Q8X@D4 "^XI2E+(DUH1B5EG9KC+;BSG&02IP3/[J-L,BJEJ(2
M)T$0;E #E1_K63D*=KK#>9MZ)+2OTUUQ96[&TT,74JZ5]R$TFWF51-JCN#+K
M+45*(;=G:5(PSQU6UX"RK+F8X J2M[6PC)C&%S&NNPTTB4W2OD0]JLOAM=PU
MPGVX%O#5&R.@=CU?26/3:+,4MB\5VRVW#KOIVX6MX103 2+MC-B06/NXG?*0
M<&<""5+<M@1R-6<5GTEB\A]2-H-]?.LLW/[RGBZX-TU(UVY*1SVH[!M^9QR^
MW9D>YO$'5+:%'SBJX;&&IRCK0LK5OJ"M*V,JA<F/<8"H9'%R=%2RZS32)I/N
M#V(5+N%HZG:4<I+9U=';=9?6%C4#;5:R=O;[:J2QZC9U4<B,WC[U*6"61I\=
M1QMT?H[(V^<1*4QV4,\C>TSTRJ1JBSB(=H;DI=ONWZQJ&MV-S.YI59E(N>[B
M5NDVGTJCC^_W?96]956ZJ[;1N14DAS02XR]7FK(HFC9$)30>*L+>F&WE1Q0E
M E GLZTTB51[@>1EV.[K[GW$WMN7@!UXSB_:MA-/M)MB$1I[2;?8A"(Q*&!,
M+;R/,=*=((_/+K+G6;O;\XN4C<!S$*)>V#;$"7#:.%WWD(MO[Z6D1CW*;QFY
MF=(]L\;K<C;=8=:9CFX&6[&2H4VT+:5O-KI4+F8X3Y#&J]B4:EAD261&*R]*
MRM3TZQ@4I:&I[1ZS\LERB-W[4=T48JF'[S8-LZK]=L(W [AVI\F%'Q*Y#;&O
MFK;(B+77%3M2=[2'.+>IL="X.<=RF0Y5+'@OLS+%$ )V[1UR1:=TQRMW*>63
MOZI.JK*.I^AUS[9>U2%RK9#+VF-M<OFE76UMKC-EVW:T2P>P2:_5TACDO?)&
MY1F1MC@V4E"T$*4UY:9Y<C"H>G!$WUO;_A_ZC.A>XV74;9UIK[JF-4\I$WT]
M%+)<JC1UFFLCE"JMG$1G!=C3*+4@W7+.V1,_RL!T=DEE6!8$MAK*44R-SBK8
M4V&91*4(Y#"HG+;K8=;7C?VZ&Q;6NBE]I%326WWVQX&_3>G(UM'ET:MRLH!1
MCIFI6R/I(7&[A9CY2)5/8E-9)+QF8.E[PZJC3CQU*UC)=Y.\W/\ P\E\[GMS
M;U:!FX6]+KO]5349J2LZUKU#(* VVV7:5:-+BG;6M0ID4C='ZN@HARE]5%-L
M<<Y>M?87&HXX-+2<7@V>6=Y0!)1=X68P;BH':UFD[$KZW$7=3C3MH:(0X\EO
MN-KRW('%J\HV9JG@EP72S$U(D4W@@X5<R1PL5Q<("=8[.Y$QA9A,<B?00@Y&
MK;@DGH[)56)>3M*5-L[W[G<E2Y\KXE,Z37?W3<8I6[#E*)KKAN3$-Z!ABZ9]
MA"%O+1%LTE7.!KCEX9A)&9)ZE^Y$W:Y(8/&H$LG=YDM$7VB;']F*!0ED4% X
M'UEL)OUIW$U(^K#3*]-3F3B23-G3-=AN1*8AD<XT,])'6",.8@.Q=8>]O>#R
MGFVZ>7=$X7O$B+P=M7H[DTYY(A/FU>LE37<DWWH;T)[M]F>%Z!"XH7:$PN-Q
MA>RJF]ACS\ID"S,(9 !F34M<):[R"#[RY4GE *?B\UV_N^ZM@36]7O*%;S-O
M+=N,<J.H&LTE@UC06V&F+KA#-('>QE:ZDX;-7"6W$!B216'5E8%GW*TL.&FO
M&%F>T3NZJT3Z &+DJ-OC#.VV?$2NV%3BW[[;]Y0$;8L?8MEI7VQN,J"3TM.X
M>K"FAR=Q!6B6+2MP61]M1."25HGHI(I62YP2 .0G:?M7_#R;6T<)<:]?-Q>\
MJ<1;&V0C:##6Z9V+5SF76-#MNX.IMQS!$H&6WTRT$)#6&8T]'&5,\OI+^[N4
M26+VQ]6.:E#&5L?JG<.56Y3&8T%8&Z:+;@(-#FK;MLFY(+<Q*:G)V]0.3,5Q
MS3><_O45N&/J).O-!)X7%#@-*E["FCJE4]MCMA G8WA@:D:]N==A93RJ&\1F
MOO?LACM\Q-^NNA9=O\B]1\EJ/:-*Y+*':KMMM9+)%0M_K[FB1C?-(^AMDQ,R
MV"2^S)4MK.RFZ2E4]6:-+/%;:\H42UC<!R->VW<)8UL7 ]SRY(C:5G[@ZSW*
MH)G%S:A>3*XL&M-O:+;,4AB$8M"HK%@SS#IA6:$!4UC%DQ:=)7)[$6ZMIK2-
M"W$I)7L;DS*5M'8HP<GS+)Y<JZDD*J F3)Y%)XZ*QK5;85939:CLPS^0]QX6
ML]FL>2-8$L\11F/1H"B/*EC#',1Q (@LC0?D+]\.Z?> GW"].5UU/N0B,0CM
M!22'3VO"H&D?8G.K$A3N\V14<N%4T99ZUP2RKT;8XQID/<5EKP%&M51^W2A/
M T!F*K4/*9[^[_KBYXB?N/)4V)9.R7E'+$W/[>ZSH5J@%E\DC.]O3#(E=11A
MUGR] Z2)S/M14WG54=TJIQS-W7JLV=5+RRD%M:E&B7<3?D&MC#RT[H(M52":
M;8Z\W;U!4]4VI6FW,JO8/!2W.EK7Q;$$MN.,#E7TC VVJC<Q'1MR=%HW.-N,
M6-$F41<+J'W7UFJ+D=ZC4I;VD<YW,;S+)W"7N946%^[1_MF)1:_ZX0T.^K)3
M5#%4BNKJS@%9PZ,1F3.3D_KXT96SLQ39S7'&3M#)"R41:2K'=3!YE1G_  R&
MUL=:79-JE' X/R>%F32=QAGC*1U-CEA7?2TJG2F0*#651[EM$3<+!53M^>DO
M:JZ0@AQB6>+7F/2.:(7B(]N>XC>'M]N^P[%JZ[4MHTC=_+T[NMKRW;ZZU]$W
M85F%R#;O)+=C=IL]V$J,O+$ND#]7<;;HE'X2W,M<IV^0&K,H7$HXD@*)]'^T
M_8I!]ISA?4V0V;<-Z75N7D,9DMSWA>KY#W&>S11 X=B"5\T&(*V@M:UZPL4,
MC.#&UI1QV#MB@_*I6N>5CJN.P>74ALQY )@BNSB'5'N_O2])O:.=E-P;.A1]
MALB(2*JMN,7W"O6'"Y56V7#E4+4[)7&7)6N-I N]E"GH&=L;2XZS(4$=(2MB
M?#^0NY1K>SO3N:7,VX:V*=LV)+=ML?M>9PB)L\28I_MAO-?92J/GU"Y,T CX
M!1B,J6#+HAQ"KWE3E?+0^PH]W,PY1=XRX J4ECWN2J8^YG1O53^P=O&\3_B'
MG"M'4L;HOR1MPONA.4\B+A#'A!D2SB56.X6EFYYATA2A3X3M5AUC#>PGX33$
M:,M$^JO<)R3^WC<C)Y[+II,[J8)%-]N6WK;HC=H)+F&-N,#2[7+Q==Q%-6I!
M7(407K&VU8U9KF4Z&.#F<\1)P0MB-L61 Q,:XX70E8G(@4A:""OG26;G]YCQ
M=<'Z:T:[<G))W4M@V],X[?;LR/<WB#JGM"CIQ5,-C#4Y1UG65H@J"M:V'52Y
M,>XP!0RN+FZ*EE'39NSN8?*[-W*D&PN_BMH4FWQN_)D$VJI707&TX_:U@M+M
MYC4K2\+ !8:25F;W6AWGBZ0N5:%PHB+K0H!RXMQS[D$8YM9E3!5/*JUPG)E,
M2W/7+.-^USP26.T;FNZZB^4[K)EE[Q8[H^*-XNWV4KIU0=I;/*P8 ,;*T/C,
M.#1DF&HZUE$) E>3%;:-$^G+=ELRD$XB.QU70J]&BFVQ'<K1ULP-LF3VO3(I
ME6\9CKU2MN05ZDX6]U4DO4AI&>3!>Q/2AM4Y63UH82G4U,UN;JI+TM6<C*=4
M"ZY[?I6Z[:NFXF&L+W@^QB';B[ ;,PC;.][CHLKB$T=%=@L<$S:<^9HR0[*2
MX>CF\BEBJ/P1'F'MF!/IJ.6)/GKY/B8[;8NAY)"<[6[!"BY0%!N<W R/E)%,
M7GDY=\LVQF)/^XM[N]QW61\;LY0YC;T,=:*R/K@^7M*!T,?"FG$0$)T&CSJ=
MN3LW+;MV'>TGW;2.M;^@S5RU,%W18JQZNI57O02=<$3!*;=Y/)JJ?#/8;^^-
MJ!1MV8C8._$63#X*%_D#B0:RC?V\)SEE$^DF:<E+2%@[)MH.R9\G%AM$6V9J
MZ"?JWFT70U^M<7J94!#U,29'N:0:VH1;54S)GD/ND[O+K#YG#),PIG=6B<6L
MM,XLK6L(T^FG_#E[19W4\8I*0WONS6UNPJKC.=(PXR2C94RR<-W6T^7%+5PF
M*;T!*H[7<V2R&0+V=GMFDV:KK7+BA;8RN4P<@,C.<BHGHZ_MJK!8_)#HJ1E=
M]HN6,LG<OMW:M_LSG4XM%N?G=8_R4<8WQ4INJCUC31,W(PN'97!RI.'JH*C2
M*4[%"S*A79 7EK5;8<N836;ORK->LMS6!LE@T(#R93RX,2C?T^74U5(=,![E
MI&B"9!"Z5L&OI 9:)3.,TW)AJQT'B,$.6$K8-8%.<4B?0;NVY,2BMWIFVO,H
MFMJ0)9M88I[&ZW'#5U=2<)\8LN#LU=29+(FN\*XM]J52 $=CR$J-68WMC7:4
M.<<N+C&)HUKG->:;[@/)L4J'9?MSV-CE]HF5=MG>MLCU!Y)[I10,^=U&U6Q(
MC9, (E;@"'=SJM,\NT,;&^89:HTS&KFM0O SG,:XU.M3_+I1&[[<S0E"0VSH
MK'E[=<L3Y#OD],R*Y+EK1UM&U8+#I9RAMV4]85]2A.%&TS6>5;5]1A67[!H0
M_)P!;XA[F/\ ,@*T2>2&+)(L'>'N7N$&U&8/6]]386WZ@^6WJRDZZWK5O6M>
M5/7V[6"33:_/I>)9)BP,[G7B\JL;:+=]M693$@HJ?G#M-"GI5'E4TBL<=6]$
MOQ<.1UVO/+FF7/DCMYW1E[A]_>X]<R*))&$S:[R?E&:YLFK[TBZTUOAR1S)A
MS/&;2D71X2W+T4A9'!.UJ7N02,"=00KA"-<@EMT:8=(X=*MR&\2U"G^F=J5
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M[EEEES)^=%;V$:>)ID1Z=L0PY,E1)@E_*GM_NO=:S5#3.X/;KO(<2; V]?\
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MX(RG)R3QYV1\>Q<SL?O\Y%[WWV<B]]W]?KA.0$W)^"B\'"Q@(C< #@T0<>
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M..=G/8Q"R#&<YSC&..>.Q6H%O7W]._OVKKZWK2)*P(C%>:'_ -FH_P"]Q_\
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MY\G_ !=PANRG:\PNQ)I#BFI6"K%1!Q?,.3&O304]]KC#CCS1$ <@DYP+.!\
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M>Y*"#709"-,C&N&C3E$!JC!!W9/R&2ME<$*E,ZYVLNMAX2*B30GISE#DJM1
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M,L0<G6O).QQ5N<4*)+,HI:B]W4UPACII:)6K**EK%,SP@(*2F'#[.F)6$_\
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MU?AFU]K@T1BT+8K8NQ"RQ&.L<9:4:">80HDS<PMB5K1DID93.(I,2$E*#("
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MK,C$#(/?RH#)9B)77Q(@.JN[&_7DZT?Y21^41[8YN14(QY"M=J].AR# <_\
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M,C>:P<I944)>K#8J<8(R1$(.MP>Y<U3 U,S8PGNSE'F%2 @YN5(#%YQYIX@
ML&Z/KM\OO\IX;Z=J=R"2DY)1!!19!))8"BB2@!+*)*+#@!9198,8  LH& @
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MPHK%)"9&\8[%@6%:=:8K4-JMO. ,A:G6"*%@(\%C!KK6/*L;-F.HJQ#+K86
MD">K8L.2]K0:?K$*:9-T+;%3K# OV6$QG63)2N+4I&]B3.RQ8N5AP7@[.1=D
M%9;YFCR#Q[BMY//Z/0ZG*9MY/27DS-U#6,W%T.4ZQ0LS KO5OSD;/0D&=(!7
MM=_*OUT$</N]=74W8,/-Z2\G3P'J>&<KU E>#I*HW& &-5GQ/H0]E1O:9W_?
M^/1[YJ^LNPGC;)M;DUM*9.R[B+I!B5-Y$%CK  $"J2/K;#DRD\]N6#,6%X5)
M6,@+>;S25)IP!&#!V$.!QU4\XW*;7+-K/959[[-6Z!N,M<JZH3<$.$1.001^
MB.69P>ZUBKZZ.AF''$_ 6VN,351T)I FHA"RG)0N#<>!7F;JLFDEW4;WH':J
MBG;KJ:OJ!V^S$MJ)N: *X4Y.MB7/(VEO&-HYRMR:G%$F@L;$=E4W.!BH@:PQ
M,M*(P,(!;3[TZ.<+]V]32(QDW*&QV'+;8M1/17>5,=KU\K#)(0N2#R:4 DQ6
MXI,LB@T><APA=E6!A$'/#7;^XS8$\CQ3KJ1>+1FM_2*VW9<GM;]>T,W66[,W
MT9Y.6SGWIS$3$:4!:VK(UI)7']#]SNKY-RFNK6C12,%4JJ'J<G%FQGHYAKT+
M]B&GH+W4C10@Y#C^:CH#:+(AW7R^PMO]%3>>RF^EC@<H;%$4AT7:JGA^7^<3
MZ5I%+/$8;'B +#3CW=Z=%!80X)(/$F1D+5QA(R4A@<^UVN;>KSJ3;K2U<*;B
M*C*^(UO&&ASCZ>O8R^DLKIA !4ZM);PN6%JG$#>X*5*/*LT .SB(R8$. "#K
M1O;+N0:.4-WHU<^/$.>&5JVK4:^RMRC<D-(,;2MP<F=HE&7"1(&9.::%*IBF
M>ZID85#V'W1)$0<O2HV\[ 18O9\&HGO8='CN+-X[J22NBYBNQUA(@+ZCL'HY
MF0*61#=+QM;L8WY>V%O!7P#]M\FRG$VH[VO1W<S19A2#.5S2$2K[0^:']#2=
MF(E5GJ6K*M=#5 .$V?,_W%"K7E;65Q.*14@<+V+5(%R8]&N3&U-#,E*$:LH:
M=409C*T>,@-3F&%B#D(L9"+.!!%C.<9T;Y/Z-VR@JJ;T2BN7N<5;7+CL.C/<
M4=?1I[.#'6=TQ(X.[87+U)2@Q*\161(%"0&<=B3EEB2$X["G (5M6<<<9QGP
M9[V=5UU"#$0Y1W=Q%DN,)4%F4IM[N(2$ @A(/?FI5,:V>G8! RRQ=M*$C8RD
M+CDHCBL]A3"6&84&E%@XN7?[CC^18B_A>?#V%?[_ +C!M##=?\AO'U]AEZ_F
MU![_ (]UU]+_ $.KP=E?RQ^SDM_V^C;D/95W_O=:^7E$??XJF'_OZO9CH^NW
MR^_RGAOI^G1]=OE]_E/#?3]3J<J3)A)P'GDDC5'=KI@&FEEC4']C,.["0$8@
MB.-[$4:;V(K S.QEF#YO, +./WU7_5_[?S_'_.3ONOS^?X_G_E_XR ^CZ[?+
M[_*>&^GZ='UV^7W^4\-]/U/FFD2 ^CZ[?+[_ "GAOI^G1]=OE]_E/#?3]3YK
M%IQ,F"NX9*Y]*EG:$:A<<>I2_+>;@8DS0PMRAT<#2R\B!V4T*9,9@DG L"..
MR62#//&'60 ;#!:Q(V,(0 !JR(S*Z$1$:]V1$5U555>[NZJIB9BL"89"  )&
M9E="(B-61$5W^*$:J[N[_%57NY%G1]=OE]_E/#?3].CZ[?+[_*>&^GZR:D;G
M@>X.KHA;]:N"AQA\T;A+VT:Y()O=$1R=4>@<FEX;C!F#;WAG<DJIN<T8C#0D
MJTYG83CR!%'F2MK-Z'9GNS:%,1HSM8EZ6C8-4Y1V#%, JH@,#$A,2JK$JNKK
MW4P2Y6A*M"& Y#U@Y+5E1K:I@T:V 8W=$!@5$)5=U=75U^) ?1]=OE]_E/#?
M3]:D;J-PLCVCFT^*R;R=#6VV;!Q"<NK?5L"*3Q!M*;Q*W2:/1*A:(]8Q,AQ[
M62YD-^,+"DZ\:T'/PDRG469ZK W 0&.;@=_554W-FTM_@\4V?W[*9,TFX":5
MS;=D4:JM.:#G=D E<?<U$[C;E>2L'I3R@*D@A'$X,3S'CN3!JZ5_U4',YN7%
MT-NP<[/J?:\V)YJ%3+JZ%AZOH ?E5A9%0G5C=U<5W].[-@JN:2@Z&G9@R93>
M%L2)Z-B0:30K\VL<WWD?QNCH1NQNBJKK;G$+N'.4N,;B$V<KN/:7"KH3GMS
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MKM\OO\IX;Z?K'6#>;MAD%1'7H3<L,::S1K%32ZOTG<>Y4YDD" !0U\7>F5_
M@?&Z4(LG%!.CQS?[J"[(4-.G/).)-,V-9W=LD#2UOS(O2NC,]-R%W:7-"<!0
MB<6QR2E+4"Y&H+SDL]*K2'DJ$YP,Y :48 8<YP+&HG1AVY+*M>33F^#F9B_<
M(:GXZ$_&W(O[ 'TY5&-L7?\ >%$-E5?*O<FC9CU?']MJS:/DI;Q^AZV^T-LJ
M4ZO@1>U,L2H&?\)6)4-W=7ZA3H^NWR^_RGAOI^G1]=OE]_E/#?3]3YKJ(80Y
M#@6<8R+.<!QGPBSC&1< X\(L\W&<\,8SGAC.>'#&<XY9TR!>CZ[?+[_*>&^G
MZ='UV^7W^4\-]/U/FFD2 ^CZ[?+[_*>&^GZ='UV^7W^4\-]/U/FFD2 ^CZ[?
M+[_*>&^GZ='UV^7W^4\-]/U/FFD2 ^CZ[?+[_*>&^GZ='UV^7W^4\-]/U/FF
MD2 ^CZ[?+[_*>&^GZ='UV^7W^4\-]/U/FFD2 ^CZ[?+[_*>&^GZ='UV^7W^4
M\-]/U/FFD2 ^CZ[?+[_*>&^GZ='UV^7W^4\-]/U/FFD2 ^CZ[?+[_*>&^GZ=
M'UV^7W^4\-]/U/FFD2 ^CZ[?+[_*>&^GZD.$,,S8B' N83KNX.4GD&(3^Y9H
MC'N<264(!Q'8FD\X"SLYN0F]E.R$97-[&#&0BSG6<Z:1.H_>"_5%]6=4\V=^
M,FPOVXEGV\X:N&'[P7ZHOJSJGFSOQDV%^W$L^WG#2)OKL[SC&UF@\YSPQBK(
MCG.<^#&/<LKOYU0?RWEA)I7=&WIO:))!KEI^"Q3<I$K+I=LY6NLN3D6QS<F6
MHIA36<P>GG-C127S"551'G1_..ART"QNC!4]9'AV:A&N:)N?+[]GO^5FA...
M..BN)=[AQX_^5E=[A^7CX.'Y?!KYC^48.N@_?]9K;#]M+3,Z0C[8ZJL)G?\
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M+,RD=6DY6)0@7INQJDIG$1)@<YSQE33PZVH>[,Y6C.TTO28M4U1$#%L"Z(3
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M5349IA2EWBD63=U*\D6# NDT>CCW^:.G9\8P)3A=)W1T.+4&<3#2,DY%PQC
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MO4<BT=8'>9.1;S+G1F96YL<90[DIPI"7.0K428E2\KRDH0IRE;B8H/+)QV,
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M1()[>W+>+%&_3NPO[=:_(@[<>E)+3I8C0Z9.2' "B$\VGQ))0,> !91=<!+
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M7#-AML*;E 3B,-888]OST2:GR6+*@2\;['V Q.<$[F!) F I 87D0C#"Q8P
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M9AB&0RF-P=B62E];&!*\S*9.A+'$HHV*'12E)72*3O2E.TL#,G&->[N1Y*%
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MX]4=/Y>QTS0L;FRQN,05+5)S^VQU<IBS<H;ETM7*"(=!68V8S*5"CD(B\?\
M<UK)V#I>,(XA4=7QA+7Z"K28] HDV%UNW/94G1P(Q(PHR3XF1)B@ !),L!N3
MFLR18#SGPX@]U$,P2T9IDG_]_/X-(C6NV[%JL)_V[VS'ZFMR/T+9+[%C&2&7
M1)SRBV>K7YX7H6]#.CTRD.4#RIC@CQN+5&74Q,S2QW(0Q=Y6H6MW6+", N3>
MI6E?1J$JZT0/>Y2;VG;$NHJLZZH)SKF3R.26A7S?,W*RV90ZS"PJ_KV-%50A
MK^8JK%/F<\C!3 J8#XZ<;W2+FUK55D[2@7KN:W-L%PVG3%=6G14UB:MAMZ?,
MRQ37)4"W3[.+'6D4\9:FSRV720SZE[WA*Z26A!)DQ1*P[VK]R71RI[)9YPG2
MLD8591.#-FMO;@[XM:62PZ+4?NW:J5E6W>^Y'*:!<[SV;;L*9N-B;X6R[DZ9
MB;S.XJDKN[546K9JA%APM?-'IZBZ"-HJJM>.6K5*6G[*?;OZFKMLJ&K:VJAE
M='M[9ZR@,-KYJ>I,M Y21W;85&VR,H'20.)9*<#@]KTK62K=EH$Y 52\Y0>$
MDH(\%AS_ !C&,\<8[^?#\O\ K\.?E\/RZ_%0J3) =D4GE$ YP0X&<8$L.1C%
MS0 P(>0AYY@O\)8./.,%_A!@6>]I$_;.<8QQS]_S8QW\YS^3&._G/>QJM#><
MP;F7"QDK[5+A6ER4LU4).X[?>PF1G)>[O=)#9])&QFD:Z$.[PY-++7\JA,,2
MOK7!3WL:V&VZ_P M<ZNGCA7J03#8C!JIR@F_9NF)TBVC4U'+9<9>MM=JA[O)
M(O8$$J.,VJAI:3U'-=R>WUGM4JU8[9U+JYQ#9PU;?62^7B-PZK 7]8L0I/I6
MC4IF3:Z$[F["V-Q5E6K8"G;G+:#BJU1657T[B\ O*S=%)ZBJ>M&)K)%=+W);
M'M:2+TC/9+M8B*!>[\L \+F,2B1.+8::^%261HFNNR;D^DL =]N5JL-ROTGH
MRI3;WMF@(S8E'.T$W3X4;M4(U<JCFYRV9A(<R^?@BR9W6E&,L@K.#V [R5F@
M[G;#[*I'6[<N<KF-,8X8X8_)_O\ ]<]_32(TTTTB=1^\%^J+ZLZIYL[\9-A?
MMQ+/MYPU<,/W@OU1?5G5/-G?C)L+]N)9]O.&D3?79W_E:H+]UD1^S"M;)9S@
M.,BSGAC&,YSGX,8[^<Y^3'Y=:V[._P#*U07[K(C]F%:_;=U3,BW"[:KGI:)R
M8F)R&Q8([1QK=5QCB4RG*5&2%'N#*!-&<.^89+"TID3FP&G/NH9$7Q[ W<5@
MB0B1-?\ E"+5WBU!5<+NK9JQ53:J6#39*NNJH9<R2)[F5FU4Y$B:5I=&N<3D
MK:I.M"+N1Q3^U0I,SR9\L4A,HC<.:GB8!9H=+Z1]GFTU?NEMZ^II4L/E>WO:
M]N,FE>;E),]P*9H)CMWOQ/*I<[2YPD5"V;6SU&7J';E=M>Y.N&2X:CL>3P"N
MYRW1*<R+;SN8HM:T0. )XUN!L0KO<$^W+3L:NVCYY"H55C'<MEV!1<NI2N*U
MVI[1]QJ.=HF"D&S8W):WC$<8K@BJ^O)/9YF)(K<;3,(2$M%HO+S45N21ZA[M
M?'&8C%(6A5MD/C,?BK:O>W^2KD$<9FUC1+)'*WA9(I0_JDK6F2D*'J2/[BO?
M'YU.+&N>'=<L<G ]0L4G'#1,#J*C*XI2"0V 0MF-&VPG#HJ;7B3.*Z7S%<_R
M(Y:LETO?YG)#G&2/TRFCFZ.KM+I0Y.!SO(7%T7GN"@P!^2@^QLZZ:AI5"P.=
MOV? :P;Y5(T,/C"R>RQCBA$CE;F6<<@C;$-[6H_==]5D)E*@AJ;\*%HTR90H
M[#@@@TP$FZK7Y1O:[=MX1B V5MGEPX[>%/G29H+8!2,R#&V72MI*X4EO>M(?
M:*1&N<Z1MN5Q2%($=7W:VI%AT*=LKVU64A:I.ND+"B0?RI0=L,H8'20.EF)H
M!N4H5E!'6J7-E-S_ '"1-LC.X5G?R#=OV[6K:[B\H)FNV/= A@I\3FM:3(#>
M>YKA0R5P9PC5BDUW(QYGL:V4N3.;MZW-W')+952>%[>$\?H3;Y;XF)_D>R]I
MO-EA<FN6F5%M>Y""S[D]P'"-QNNXV\6XX.4DCL,AZ%L>3GN5C<9(*<>3_J6T
M:FKRU6^Q(Y+8)')-=TBDM*5K9-HIKLMJM:>##X)'6:)V3;B203(4N=<RJ/S&
M0QM"IL*RSH+ 7Z*5\7.W1#&4C:S;Z>#P:1&<XQC.<][&,<<Y^#&-:BBWLT6F
MN274^[/2N-AA<E:ZZ=;.EHF")U&ON5X9([)T%&128R*1-JB:V\9&Y2S/)L0B
M#(]B3%'*6Y0N+?&]>U)]NO#X=4\[M^2QQ=-PV7<M33"LH\OOZFYO2%S0.]ZF
M7WA6R'%@ML-8'F^Z;CJ>;PL==7P;&:_A4=EJG*EQB-G-D)@1D@0,SW%,OCPB
M0K>%&&;P]SU1S>![0+T@D(N4B)%[G+3L!1#ZQJRY=O\ "1397!GF;PQ!8#=N
M+KC=]1LX:*_GNSVU6&'0^YJ]02TYK>93&HJ"6Q*/7%4-1$ VZ5XBKBO"'\QN
M ZODE?)!,I7(9]/)I,)2YGO,GF<\GTO<':5S25OKDH&:N?']S6*\)2D38DRE
M:FYO0I<]A$6+A,-B4.+>'N1 B<98(R7().M"YR1[+8&A&T@=W]R"41A>].84
M>%SLL"22%4X*%*C!1>#.9C*=(G&<XQCCG.,8^'.>&/\ KJI[E+MZVX?9%(MO
M4Y@T2V]R"@9<HM>-VTLNR<S.KG'%ALD+Q/*@A,/L>.,DY9XP\V>WQ6QHM%$T
MDK:4IIK:(8!6Z-7'G&:-[GCORLETW'M_JFNK1ASM84?I^.S-TS=K]5CO%XI(
M&PQPCJALJ ^PK#EL-L!#56W#%F+4 [_M)JB+L]P2,EM3X>7B(D2P!V$U:PK^
M4A9MSD'W#SXK ZEF=<4ZA6;5K"3/]#--D0CHSW017<)2,\>8EE^Q=$;D#O 6
MMW:YEB3!J1]@JIA9PN+9+GMSD")JK#:OW([[97"FF7U?8D$KF#V\FL1QF>\N
M"JH5N_H&J;3;ARFY]EJEA4UY8&W3>EMYOAC,1P +J=8JQ%!(6(F-W5!G&ZZ9
M@4D.N2VY[,J-VMN\T>:H85C6=+@IF=M;5"I(&-5O7K8_2.4,-2U-$F=M98O7
ME;,DDF$ID!;*PLY3D^/CVJ>)>]2-R(;U*/:L(0AX\W'#B(0L_*(6<BSG_7.<
MYSG7;2)Z59(F!"[MT>6/C.C?G@A8I:654Z(DSLZ)V\&#%Y[<W&G@7+249><#
M5G)"#@)09P,X1>.&=?+CN7CDRIVX[ZE,AMS9]&+?L&7[H&RK[Z;ZAF&^#>CN
M5;G];%W>*[#&BF7./L=>5'&8!"9-7%12FG4<IM)WL")Y-LF,1^HW.4S&?-^Y
M^^';A><=W>MNY"&-=R2&I;%B3-'[ L/:I%*VE&]FCY)6D3F3;7D0K%;9S:\!
M0;<[*?98;(+$;J^0CD95C(R4TZ2N5,3RPCVBSO9I#9Y"-K]*,UM0Z(02WU,$
M:)'<<=@S<Q,[$"WI: 4GLYS.0Q7C&L/[_-'5Y?)8<PJ'!E42AQ>#&ES<VP25
M<H1-2]D')J5)0U:PE1,8N\*79=M_?:N54%,7R.S^GZ)CU[JH[8.XZFX(4&.)
MG2PHU+K":T+7()O=4CMNQY/%HA&(\OG2M@0=J*;/6-D9XRRM$=C[8@9&!@;&
M]D9&=L3%(FUJ:6I(2WMC8WHR @(2(D*).G2(TQ( E$$%%DEA"  <8]KK\CR2
MU!)I!H><4<6,HP/$0><68'(# <X.<"#SP"$'G!S@0>/$.<"QC.$2LK>1:%";
ML=B>[N+UKN1KM(S9CSY4+G8+:K=)?"4UCKG!N;&:N'Q-#D3J[SIKGLE-;JUD
M$/@2222&8-\G<HC&VYV?W%*V'P#-8//]_<TVJP*VM@LLH9#M]L)WDE_/=UI*
M0G51'5ZZ5-*X+-]N=/GL,JE&+YK:^%+]'$#GE="XI#V2$1)%))JR1JV(Q$(6
MFB^J^3SW8TM?U7,S2^JIK!ZAN*K14[N85WO)HX1 MB5=P]HCRS9S--J"-)F"
M2Z<+BV+W*Q932B$US=^>&^_Y*\PVQH(SP]R^@4 ,!QCO8YV<8YV<8QQ%G&.'
M'.>&,Y_USI$C6H*:JN@H"RU=3%?1&L:_C_;@VF(PEC0Q]B2*7-8<XNJT*% 4
M6 UP=G)0I<75Q4Y/7N2]0>L7*5"DT9HLU?9"PQA )UDCTTL#8 Y.F&XO;DB:
M4 %"LX*=*0)8X'IDP3E)XP$IRA&X,/.&$HH(QBP'/N-58\JCMQNJZZPK^=T)
M'8W9%A4=)Y#)4E32]CA$I321IF<46020S*M&"T@CJ@_<?5C"Z.,JH0^TRAU\
MJDACK&90:WMTG,=$2)IYRG,FW#QFZ)/ ;/O';*^<GEN%KN,168U]=VWQ/9C#
MM[D;BY(H>V/M^KX%;]4V]$J!MJ:E%%1?=0VN#RUT'<A+*V2=HCK$-JGS1(VS
M[DNK<937QPWPV2&<KVJYHE.4#'4%T6:XU]N4:ZI#$':BK WD1&:0B,AG^X.H
MW:)Q^.KK%CZUO,O>.5]6KYN&Z399'"W$W9GD^(!.0LVXQ\L^(6<IBTYLEF8Z
MOE^ZB*PENW3V+3<:K>,H@M]Z8CC4C-?X_%K)=K09*J'/DI,U.@JK!L@;S25:
M)[?K,M(G&,8QWL?+G_?.>.<_[YSQSK )DN[H6J95[$+%;H39B^%O&6-U1E1R
M1R2$JW="K:V"= A3V,]([IV1Z.3."1(^(1L+PJ1A;%V34YYQ><_%CG!$'CG'
M.QG'''AQQQPXX^7'AQKYMMV&V#=M6.X3<S*JGBEK2QFO^/3B>TI8^W>%4S(I
MI+=P<N;(?%VG;QOJ>+73'/2S:E%FZ+)4<'3-:YJJH-</4J;YTLCUBP.J'9Q1
M-:'RI-K<GA=8;=G&F O7*-3:PXM Y;-Z]5R*V8[RC^WR<35 U;H;PM.[!+^;
M;6U27U@1/'.UT5HRLN6;/+N;H3%*X]R9XT[?'F>_15M;V953M.2O>8,ZV#+G
MM[C->5]W5V?+,RN0--4T\A>6NH*IC_:S<RLS%!*Y02*0"8VUO9BG)Q=I ^R6
M6N\EE+NX/1^Q$(C"&+Q*',2>.Q>-8B\498TA8H>B BB\;0MS6VHNYZ))L)$0
MD$7;O<],B9T($J,L#:@;@C2E"3E@*R_2)ZUY>6B.M#K() Z-S&Q,;<N>'IZ>
M%R5L:6AI;$IJYR='1R6FD(V]N;T1!ZM<N5G$I4B4DU0H-+)+&,.H=P6)LNW)
M;=R8_8,QKRZ*$W**E-91E-$GI1,D]J/Y0W)Q TUDKKXY;(W*;1Q9$W"2LKS
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MB!.<,+>_,[S%93*(/.H>\8RSSBO)9*X>Y#2D/7;R3!MF>TN8;>Y'=UA6"_U
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MU8J[19F1(A;4G;*L\Y4H[72E]F4'&GF\\TP8\Y-II$::::1.!!"+' 0<"Q\
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HM0K(L$07) ((IO*Q!$%:ER$0<OR_.!!S@[AG&<9QG&<=[.,\=(G_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
